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Abstract 
 The single mitochondrion of Plasmodium falciparum has some unusual functional features 
and unconventional biochemical properties. The electron transport chain (ETC) has critical roles in 
generating the mitochondrial membrane potential (Δψm) and driving pyrimidine biosynthesis. 
Enzymes of the respiratory chain became attractive targets for antimalarial drugs such as 
atovaquone, an inhibitor of the bc1 complex and lethal to malaria parasites. Although much 
progress has been made, there are a number of knowledge gaps in our understanding of the 
underlying biochemical mechanisms of the respiratory chain and some major components are still 
not completely characterised. In addition, recent studies have generated conflicting data and 
hypotheses with regards to mitochondrial function. This thesis, using a multidisciplinary approach, 
was undertaken to improve our understanding of the mitochondrion and its function and to 
clarify some of the confusing and contradictory data in this area.     
 Due to high sequence divergence, two ETC complexes remain to be clearly annotated in 
Plasmodium species: the succinate dehydrogenase (or complex II) and ATP synthase (or complex 
V). A pyramid-shaped bioinformatic strategy based on structural fingerprints and motif patterns 
was applied to identify candidate genes encoding the membrane anchors of complex II (SdhC and 
SdhD) and the ATP synthase F0 sector (subunits a and b). In order to validate the genes predicted, 
2D (non-)gradient BNE/SDS-Page approaches were established to separate respiratory chain 
complexes from solubilised P. falciparum membranes and identify their subunits via NanoLC-
MS/MS analysis. Although the proteomic strategy was validated with bovine mitochondrial 
preparation, no positive identification of the genes of interest could be obtained with P. 
falciparum extract due to low-expression of target proteins and difficulties in the preparation of 
isolated mitochondria of high purity. 
 For the first time, the direct activities (or ubiquinone reduction activity) of the five 
dehydrogenases delivering ubiquinol to the bc1 complex were compared. Due to a higher rate of 
turnover, the type II NADH dehydrogenase (PfNdh2) appears to be the main enzyme for feeding 
the electron transport chain with activity two to three times greater than the other 
dehydrogenases (dihydroorotate dehydrogenase, malate quinone oxidoreductase, glycerol-3-
phosphate dehydrogenase). Additionally, spatiotemporal confocal imaging of parasite 
mitochondria revealed that loss of PfNDH2 function provoked a collapse of the mitochondrial 
transmembrane potential (Δψm). This observation reinforced the interest of targeting PfNdh2 as a 
chemotherapeutic strategy for drug development. The catalytic properties of the P. falciparum 
complex II were also examined using various electron donors and acceptors. Although complex II 
has been previously considered as a succinate dehydrogenase, results obtained indicate that 
complex II functions as a ubiquinol-fumarate reductase (QFR) forming succinate from fumarate in 
the asexual stages of P. falciparum. The capacity of menaquinone, an alternative electron carrier 
of anaerobic species and recently detected in malaria parasites was also evaluated to replace 
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ubiquinone within the respiratory chain in anaerobic conditions. Data obtained demonstrated 
that the menaquinone pool is not involved in the ETC and only the ubiquinone pool interacts with 
the different enzymes. 
 Artemisinin and its derivatives are frontline drugs employed in the treatment of 
uncomplicated malaria usually in the form of combination therapies. The ETC has been previously 
implicated in the mode of action of artemisinin and its derivatives. In this chapter, this hypothesis 
was tested using a single-cell imaging and enzyme-assay based approach. Data presented reveal 
that endoperoxide drugs provoke a rapid collapse of mitochondrial and plasma membrane 
potentials, both essential for parasite survival. Addition of the iron chelator desferrioxamine or 
the superoxide scavenger Tiron drastically reduces the depolarization highlighting the role of 
ferrous ions and oxidant stress in the artemisinins activation process and membrane damaging 
activity. Deoxyartemisinin, which lacks the endoperoxide bridge, has no effect on membrane 
potential indicating that this peroxide functionality is the key pharmacophore responsible for the 
pharmacological activity of this class of compound. Thus, the results presented, suggest that 
artemisinin and its derivatives act as a generator of additional reactive oxygen species that 
overcome the oxidative defenses of the malaria parasite and cause a widespread and rapid 
membrane potential depolarization leading to mitochondrial dysfunction and parasite death. 
Atovaquone is a bc1 inhibitor used in combination with proguanil (e.g. Malarone
TM) for the 
curative and prophylactic treatment of malaria. However, resistance to atovaquone associated 
with point mutations have been detected in the field. In this thesis, the first description of the 
effect of the Y268S mutation (harbored by the atovaquone-resistant field isolate TM902CB) on 
parasite bc1 catalytic turnover and stability has been reported. This mutation was shown to confer 
a 270-fold shift of the inhibitory constant (Ki) for atovaquone with a concomitant reduction in the 
Vmax of the bc1 complex of 40% and a 3-fold increase in the observed Km for ubiquinol. Western 
blotting analyses revealed a reduced iron-sulfur protein content in Y268S bc1 suggestive of a 
weakened interaction between this subunit and the cytochrome b. It was concluded that the 
reduced enzyme activity affects protein stability and should incur a fitness penalty to the parasite, 
features that were not fully discernable using the yeast model alone. 
 Due to a small mitochondrial genome (mtDNA), the great majority of mitochondrial 
proteins, including those composing the ETC, are imported post-translationally from the cytosol 
into the organelle. Thus, it is essential to understand the import and processing machinery of 
mitochondrial proteins in malaria parasites. However, the description of the apicomplexan model 
including P. falciparum is fragmented across different studies and no general overview, including 
recent insights, has been proposed. An updated picture of the whole protein import and 
processing machinery in apicomplexa is presented.  Novel putative components are revealed by 
comparison with five other apicomplexan species (Toxoplasma gondii, Cryptosporidium muris, 
Theileria parva, Babesia bovis and Neospora caninum). Aspects of the apicomplexan model are 
highly divergent from that seen in yeast, mammalians or plants. 
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Introduction 
1.1. Malaria 
1.1.1. The history of malaria - key discoveries 
Traces of human malaria parasites have been found in the mummified remains of individuals 
who lived in ancient Egypt between 3200 BC and 1304 BC (Miller et al., 1994b). The early Greeks, 
including Homer (c. 850 BC) and Hippocrates (c. 400 BC), were well aware of the characteristic poor 
health, malarial fevers and enlarged spleens seen in people living in marshy places (Cox, 2010). In the 
seventh century, Italians named the disease associated to with the swamps around Rome “mal aria”, 
meaning “bad air”. Alphonse Laveran, a French army physician and Nobel Prize winner in 1907, was 
the first to discover the causative agent of malaria in 1880 in Algeria by noticing the presence of 
parasites in the blood of infected patients (Laveran, 1881). This discovery was subsequently 
confirmed by Ettore Marchiafava and Angelo Celli in 1884 who named the protozoan observed 
Plasmodium (Smith and Sanford, 1985). 
Sir Ronald Ross, a British physician in the Indian Medical Service and Nobel Prize winner in 
1902, identified in 1897 the avian malaria vector by observing Plasmodium parasites within the 
Anopheles mosquitoes which had been previously fed on malaria-infected blood from birds (Ross, 
1898). In 1898, the Italian malariologists Giovanni Battista Grassi, Amico Bignami, Giuseppe 
Bastianelli, Angelo Celli, Camillo Golgi and Ettore Marchiafava demonstrated conclusively that human 
malaria was transmitted by only female Anopheles mosquitoes and described the whole blood-
mosquito life cycles of P. vivax, P. falciparum and P. malariae (Grassi, 1900). In 1948, Henry Shortt 
and Cyril Garnham completed the Plasmodium life cycle by showing that a phase of division in the 
liver preceded parasite development in the blood (Shortt and Garnham, 1948). The final mystery, the 
long period between infection and appearance and reappearance of parasites in the blood, was 
established by Wojciech Krotoski in 1982 who demonstrated the presence of dormant stages in the 
liver (Krotoski et al., 1982). 
1.1.2. Malaria epidemiology 
Approximately 200 species of Plasmodium parasites have been identified to date and have 
been shown to infect reptiles, rodents, birds and mammals (Perkins and Austin, 2009). Human beings 
are the natural hosts for five Plasmodium species: 
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 P. falciparum: the most virulent species and cause of the most severe form of 
malaria. Pre-dominantly found in sub-Saharan Africa, it causes 90% of malaria 
deaths. 
 P. vivax: the second most widespread species, notably in South America and Asia, 
and the most frequent cause of recurring malaria. It infects an estimated 70 - 80 
million people annually but is generally non fatal (Mu et al., 2005). 
 P. malariae: distributed across the globe but rarely causes fatality. 
 P. ovale: restricted to West Africa and some Pacific regions (Philippines and 
Indonesia). Due to low prevalence rates and its relatively mild and chronic nature it 
is, alongside P. malariae, considered one of the minor parasites of the five human 
malaria species. 
 P. knowlesi: the cause of primate malaria, however recent findings have established 
it to be responsible for human malaria cases in South East Asia (Singh et al., 2004). 
Malaria is one of the most important infectious diseases and a major public health problem. 
According to the World Malaria Report 2010, malaria is endemic in tropical and subtropical areas of 
over 106 countries (Fig. 1.1) (WHO, 2010). Almost one half of the world’s population lives under 
constant threat of malaria and an estimated 225 million cases led to 781,000 deaths in 2009. The 
impact of the disease on gross domestic product is important and can reach 1.3% in countries with 
high malaria rates (Sachs and Malaney, 2002). 
 
 
Figure 1.1. The spatial distribution of Plasmodium falciparum malaria endemicity for 2007 (Hay et al., 2009). 
The malariometric indice used is the P. falciparum parasite rate PfPR2-10 (the percentage of a 2 to 10 years age 
population with parasites detectable in their blood) displayed as a continuum of yellow to red from 0%–100% 
(see map legend). The rest of the land area was defined as unstable risk (medium grey areas) or no risk (light 
grey). 
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About 90% of malaria deaths occur in sub-Saharan Africa and the majority of them are children under 
5 years whilst pregnant women are the main adult risk group. A child dies of malaria every 30 
seconds in Africa (WHO, 2010). 
1.1.3. The malaria parasite  
1.1.3.1. A protozoan parasite 
The malaria parasite is a unicellular protozoan of genus Plasmodium, member of the 
Apicomplexa phylum (Fig. 1.2). By definition, the malaria parasite is a protozoan that has adapted to 
invade and live in cells and tissues of other organisms. Protozoan parasites are scattered in three 
different kingdoms according to the Simpsons and Roger classification of eukaryotes (Simpson and 
Roger, 2004). As for malaria, other genera of parasitic protozoans are agents of human and 
veterinary diseases such as leishmaniasis (caused by Leishmania genus), Chagas disease (caused by 
Trypanosoma cruzi), sleeping sickness (caused by Trypanosoma brucei), amebiasis (caused by 
Entamoeba histolytica), trichomoniasis (caused by Trichomonas vaginalis), giardiasis, toxoplasmosis 
(caused by Toxoplasma gondii), cryptosporidiosis (caused by Cryptosporidium genus), theileriosis 
(caused by Theileria genus), or babesiosis (caused by Babesia genus)(de Souza, 2008). 
 
Figure 1.2. Classification of infectious parasitic protozoans based on Simpsons and Roger’s eukaryote tree 
(Simpson and Roger, 2004). 
 
1.1.3.2. Life cycle of human malaria parasites 
Among the protozoan parasites, Plasmodium species have one of the most complex and 
multistage life cycle.  As illustrated in Figure 1.3, human malaria parasites are heteroxenous parasites 
alternating between two hosts: a vertebrate (human) and invertebrate (female mosquito of genus 
Anopheles). The asexual life cycle of the malaria parasite begins during the blood meal of an infected 
female mosquito when sporozoites from her salivary glands are introduced into the human. These 
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sporozoites are carried to the parenchymal cells of the liver via the circulatory system. After invasion 
into the hepatocytes, parasites start an asexual replication process called exoerythrocytic schizogony 
where they divide to form tens of thousands of merozoites (Cowman and Crabb, 2006). The 
completion of this pre-erythrocytic stage varies between Plasmodium species (Table 1.1). In the case 
of P. vivax and P. ovale, dormant stage parasites called hypnozoites can persist in the liver and cause 
relapses by invading the bloodstream months or years later (Krotoski et al., 1982). After release into 
the circulatory system, merozoites (1-2 µm in diameter) rapidly adhere to and invade erythrocytes 
(Barnwell and Galinski, 1998).  
Figure 1.3. Life cycle of the parasite Plasmodium falciparum in the human host and female Anopheles 
mosquito (Wirth, 2002). (a) The asexual life cycle in the human host. (b) The sexual life cycle in the Anopheles 
mosquito. (Permission licence # 3144911355100). 
Once inside the red blood cell, the parasite undergoes a 48 hours (or 72 hours for P. 
malariae) asexual multiplication cycle called erythrocytic schizogony. This blood-phase of the life 
cycle consists of the merozoite developing into a ring stage over the first twelve hours post-invasion. 
Then, it develops into a trophozoite and remains at this stage for 14 hours. Finally, the matured 
trophozoite is marked by multiple rounds of nuclear division resulting in the formation of merozoites 
into a schizont. When the red blood cell burst, each mature schizont releases about 8-32 merozoites 
which are ready to invade new erythrocytes (Gregson and Plowe, 2005). 
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Table 1.1. Characteristics of 4 species of human malaria (Looareesuwan et al., 1990). The pre-erythrocytic 
stage is the period between the time of infection and merozoite release. The pre-patent period is the interval 
between the date of infection until the first appearance of the trophozoites in erythrocytes. The incubation 
period refers to the first appearance of clinical symptoms of the disease. The relapse is a renewed clinical 
manifestation of the infection started by hypnozoites. 
 P. falciparum P. vivax P. ovale P. malariae 
Pre-erythrocytic stage (days) 5.5 8 9 14-15 
Presence of hypnotizes - + + - 
Pre-patent period (days) 8-25 8-27 9-27 15-30 
Incubation period (days) 12 (9-14) 15 (12-17) 17 (16-18) 28 (18-40) 
Erythrocytic cycle (hours) 48 48 48 72 
Enlargement of host erythrocyte - ++ + - 
Primary attack 
Severe in non-
immune 
Mild to severe Mild Mild 
Relapse - ++ ++ - 
Period of recurrence Short Variable Variable Very long 
Duration of untreated infection 
(years) 
1-2 2-5 2-5 3-50 
 
Instead of invasion, a small proportion of merozoites will go on to develop into sexual forms, 
which are microgametocyte (male) and macrogametocyte (female). Gametocytes go through five 
morphological stages to reach full maturity within approximately 12 to 14 days (Fivelman et al., 2007; 
Hawking et al., 1971). If a mosquito bites an infected individual, gametocytes are taken into its 
midgut where they can continue their differentiation to form macrogametes and microgametes. 
Once matured, a single male and female gamete fusion leads to fertilization forming a diploid zygote. 
It will continuously divide to develop a motile ookinete which traverses the gut wall of the mosquito 
where it matures into an oocyst containing 4 meiotic products which replicate asexually into haploid 
sporozoites. They remain inside the maturing oocyst for 4-15 days before release to the mosquito’s 
salivary glands to be passed on to another individual thus perpetuating the malaria life cycle (Sinden 
and Billingsley, 2001). 
1.1.3.3. Ultrastructure of the asexual parasite 
 The work presented in this thesis is based on the asexual stage of the malaria parasite, and in 
particular trophozoites. The invading parasite contains several intracellular organelles, most of which 
are found in eukaryotic cells, for example a nucleus, a rudimentary Golgi, an endoplasmic reticulum 
and a single mitochondrion (Fig. 1.4) (Hanssen et al., 2010). Additionally, the malaria parasite 
possesses others organelles including a vestigial plastid (apicoplast) and a modified lysosome 
(digestive vacuole). In the erythrocyte, the parasite is surrounded by the parasitophorous vacuolar 
membrane (PVM), which serves as an interface between the parasite and host cell cytoplasm 
(Lingelbach and Joiner, 1998). To survive and uptake nutrients, the trophozoite ingests host cell 
cytoplasm across its plasma membrane via endocytic structures named cytostomes (Aikawa et al., 
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1966). Malaria parasites use haemoglobin as a source of amino acids but its degradation by 
proteases liberates toxic heme. The free heme is polymerized into hemozoin and stored within the 
digestive vacuole (Dorn et al., 1995; Rosenthal and Meshnick, 1996). The apicoplast is a non-
photosynthetic plastid homologous to the chloroplasts of plants with a circular genome. Its functions 
are still being explored but it plays an important role in the biosynthesis of fatty acid, isopentenyl 
diphosphate or heme in the cooperation with the mitochondrion (McFadden, 2011).  
 
Figure 1.4. Diagram of an intraerythrocytic parasite, highlighting major organelles and cellular structures 
(adapted from(Greenwood et al., 2008). (Permission licence # 3144921093501). 
 Depending on the asexual stage, the shape and size of each organelle may vary and stage-
specific features may appear (Bannister et al., 2000). For example, during the invasion of host cells 
merozoites have specific apical organelles composed of rhoptries, dense granules, micronemes and 
monomenes (Bannister and Mitchell, 2009). 
1.1.4. Malaria prevention 
1.1.4.1. Pathogenesis and clinical features of malaria 
 Clinical manifestations of Plasmodium spp. infection are caused by the asexual stages of the 
parasite that develop inside red blood cells. Drastic morphological, biochemical and rheological 
changes of the infected erythrocyte are central to the pathology of severe malaria (Maier et al., 
2009). These modifications cause cytoadherence, rosette formation and knob protrusions (Miller et 
al., 2002). The iRBC's (infected red blood cells) ability to adhere to the lining of small blood vessels 
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leads the obstruction of tissue perfusion. Additionally, the release of malaria antigens, pigment and 
toxins contribute to a cascade of pathological events (Mendis and Carter, 1995; Miller et al., 1994a). 
 
 Most of the morbidity and mortality attributable to malaria are caused by P. falciparum. Mild 
or uncomplicated malaria are associated with fever and nonspecific symptoms such as headache, 
chills and sweats, vomiting or diarrhoea (Laishram et al., 2012). The clinical pattern of severe malaria 
is different between non-immune adults and semi-immune African children. Death in non-immunes 
is often associated with high fever, multi-organ damage including renal failure, pulmonary oedema, 
and disseminated intravascular coagulation whereas death in children is usually due either to 
malarial anaemia, cerebral malaria or respiratory distress (Greenwood et al., 2008; Miller et al., 
1994a). 
 
 Genetic factors, age of the patient and intensity of transmission affect susceptibility to 
severe anaemia or cerebral malaria (Kwiatkowski, 2005; Reyburn et al., 2005). Cerebral malaria is the 
most common form of severe malaria due to the cytoadherence of iRBCs to the endothelium of 
cerebral capillaries and venules, causing their sequestration and tight packing in these vessels 
(Wilairatana and Krudsood, 2009). Severe anaemia is due to direct destruction and phagocytosis of 
infected RBCs and unparasitized RBCs by immune responses (Ekvall, 2003). Additionally, other 
infectious diseases such as HIV, Salmonella spp or helminth infections can interact with malaria and 
modify the susceptibility and/or severity (Graham et al., 2000; Hartgers and Yazdanbakhsh, 2006; 
Korenromp et al., 2005). 
1.1.4.2. Vector control 
 The objective of vector control is to reduce transmission of malaria by preventing human-
vector contact, eliminating breeding sites, killing the mosquito larvae or reducing the longevity of 
adult mosquitoes. The different strategies applied are insecticides, larval and environment control. 
 
 Insecticides have been the most common form of mosquito control. From 1955 and 1969, 
the use of effective and inexpensive dichlorodiphenyltrichloroethane (DDT) sprayed on the inside 
walls of houses resulted in successful campaigns against the malaria vector and eliminated the 
disease in North America, Europe and parts of Asia, and tamped it down in other regions (Gravitz, 
2012). The appearance of Anopheline resistance to DDT was responsible for the declining political 
and financial support for the Global Malaria Eradication Campaign launched by the World Health 
Organization (Sadasivaiah et al., 2007; van den Berg, 2009). A mix of diverse insecticides used for 
indoor spraying and treating bed nets (termed insecticide treated bed nets - ITNs) have been tried 
and showed a reduction in overall child mortality or severe pregnancy associated anaemia (Gosoniu 
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et al., 2008; Lengeler, 2000; ter Kuile et al., 2003). However, mosquitoes evolved resistance to 
effective pesticides such as pyrethroids and there is now a requirement for new insecticides (Takken 
and Knols, 2009). Additionally, new alternatives associated with, or replacing, insecticide-based 
vector control must be developed. 
 
 The larval control of Anopheles mosquitoes is another preventive method. Chemical and 
biological agents can be used to kill larvae in breeding sites. Larvivorous fishes or bacterial pathogens 
such as Bacillus thuringiensis israelensis are examples of biological solutions that attack the larval 
stages of the mosquito (Walker and Lynch, 2007). The elimination of breeding sites by drainage or by 
applying locally grown plants are environmental methods to prevent malaria.  
 
1.1.4.3. Malaria vaccines 
 Vaccine development is a long process that takes years of clinical testing and trials until 
licensing and public availability are reached. P. falciparum is the main target of the vaccine trials of 
the different initiatives and programs. To develop malaria vaccines, different stages of the parasite 
development have been targeted such as pre-erythrocyte asexual or sexual stages. 
 
 Pre-erythrocyte vaccines provide humoral immunity by extracting antibodies that target 
sporozoites to prevent their invasion into the liver. The most developed pre-erythrocyte vaccine 
RTS,S/AS02A is based from the circumsporozoite protein (CSP), a cell surface protein located on 
sporozoites and infected hepatocytes (Girard et al., 2007). This vaccine showed promising protection 
levels in phase IIb trials with high immunogenicity for anti-CSP and anti-HBsAg antibodies for children 
younger than 24 months (Aide et al., 2011; Alonso et al., 2004; Bejon et al., 2008). Initial results of 
phase III trials presented reduction of malaria by half in children from 5 to 17 months of age during 
the 12 months after vaccination and the vaccine may have an important effect on malaria in young 
African children (Agnandji et al., 2011). Other vaccines based on the CSP antigen such as plasmid 
DNA vaccines and live recombinant vaccines that use the attenuated modified vaccinia Ankara (MVA) 
strain or the fowlpox virus (FPV) have undergone clinical trials but didn't show evidence of protective 
efficacy against invading sporozoites (Walther et al., 2006). For example, results of several phase I 
studies testing DNA/MVA vaccines have been disappointing even though they are safe and have 
strong immunogenicity (Moorthy et al., 2004a; Moorthy et al., 2004b). 
 
 Asexual blood stage vaccines are developed to primarily protect against severe malaria by 
eliminating or reducing the number of erythrocytic stage parasites. Development of blood-stage 
vaccines have been mainly focused on antigens taking part in erythrocyte invasion (Greenwood et al., 
2008). The SPf66 developed in Colombia was the first asexual blood stage vaccine tested in phase III 
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(Patarroyo et al., 1992). However, the efficacy of this synthetic and multi-epitope vaccine candidate 
has been reported to be low in several clinical studies (Alonso et al., 1994; Alonso et al., 1996; Beck 
et al., 1997). To date, the most advanced vaccines in this class are based on antigens from merozoite 
surface proteins 1 (MSP-1), 2 (MSP-2) and 3 (MSP-3), the glutamate-rich protein (GLURP) and the 
apical membrane antigen 1 (AMA-1) (Girard et al., 2007). All were, or are, undergoing phase I trials in 
different countries (Genton et al., 2002; Hermsen et al., 2007; Malkin et al., 2005a; Stoute et al., 
2007). Additional antigens from merozoite surface antigens such as MSP-4, -5, -8, -9, serine repeat 
antigen (SERA) or the erythrocyte protein 1 (PfEMP1) are under development as vaccine candidates 
(Girard et al., 2007). 
 Sexual vaccines, also termed transmission-blocking vaccines, are designed to produce 
antibodies against the sexual stages to prevent sporozoite development in Anopheles mosquitoes 
(Carter et al., 2000). Transmission-blocking vaccine candidates based on ookinete surface antigens 
S25 and S28 from P. falciparum or P. vivax are currently being developed and undergoing phase I 
trials (Arakawa et al., 2005; Hisaeda et al., 2000). For example, clinical trials of a vaccine based on 
PvS25 reported safety and modest immunogenicity (Malkin et al., 2005b). Another sexual stage 
antigen PfS230 are studying for being a possible sexual vaccine candidate (Bustamante et al., 2000). 
1.1.4.4. Malaria chemotherapy 
 In the absence of effective malaria vaccine, chemotherapy remains the mainstay of malaria 
control by clearing the parasites from mammalian (human). Antimalarials can be classified according 
to their chemical structures and biological activities into five main groups (Table 1.2). They can 
disrupt processes or metabolic pathways within different subcellular organelles of the malaria 
parasite. 
 
 To date, malaria parasites have developed partial resistance to nearly every antimalarial drug 
due to overuse, environmental factors, spontaneous genetic mutations in the parasites, etc. (Ekland 
and Fidock, 2008; Wongsrichanalai et al., 2002). To reduce the risk of resistance and increase 
treatment efficacy, the use of combination antimalarial drug therapy using two or three compounds 
with different modes of action and molecular targets has been recommended as the best option 
(Kremsner and Krishna, 2004).  
 1 
 
Table 1.2. Antimalarial drug classes, their target locations, parasite stages and their possible combinations. For the target location, 'C' indicates the cytosol, 'M': the 
mitochondrion, 'DV': the digestive vacuole and 'A': the apicoplast. For the parasite stage, 'AS' indicates the asexual stage, 'LS': the liver stage, GS: the gametocytes or sexual 
stage; 'HS': hypnozoites stage, 'SS': sporozoites stage. 
Drug 
Target location Parasite stage 
Combination References 
C M DV A AS LS GS HS SS 
Quinoline related compounds  
Quinine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP); + Tetracycline; + Clindamycin; + Doxycycline 
(Sullivan, 2012) 
(O’Neill et al., 2012) 
(Waters and Edstein, 2012) 
((Nosten et al., 2012) 
Chloroquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP) 
Amodiaquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP) 
Piperaquine   ●  ●     + Dihydroartemisinin 
Primaquine   ●   ● ● ●   
Tafenoquine   ●   ● ●    
Mefloquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (Fansimef®) 
Halofantrine   ●  ●      
Lumefantrine   ●  ●     + Artemether (Coartem®, Riamet®) 
Antifolates  
Pyrimethamine ●    ● ●   ● + Sulfadoxine (SP) 
(Nzila, 2012) 
(Friesen et al., 2011) 
 
Sulfadoxine ●    ●     + Pyrimethamine (SP) 
Proguanil ●    ● ●   ● + Atovaquone (Malarone®) 
Chlorproguanil ●    ●     + Dapsone + Artesunate (Dacart®); + Dapsone (LapDap®) 
Dapsone ●    ●     + Artesunate + Chloroproguanil (Dacart®); + Chloroproguanil (LapDap®) 
Hydroxynapthaquinones  
Atovaquone  ●   ●    ● + Proguanil (Malarone®) (Vaidya, 2012) 
Antibiotics  
Doxycycline    ● ●     + Quinine 
(Krishna and Staines, 2012) 
Clindamycin    ● ●     + Quinine 
Endoperoxide compounds  
Artemisinin ● ●? ●  ●  ●?    
(Karunajeewa, 2012) 
Artemether ● ●? ●  ●  ●?   + Lumefantrine (Coartem®, Riamet®) 
Artesunate ● ●? ●  ●  ●?   
+ Dapsone + Chloroproguanil (Dacart®); + amadioquine (ASAQ); + Mefloquine 
(ASMQ); + Sulfadoxine-pyrimethamine (SP) 
Dihydroartemisinin ● ●? ●  ●  ●?   + Piperaquine 
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1.1.4.4.1. Quinoline related compounds 
 The quinoline-containing drugs include some of the most common antimalarials:  
 Cinchona alkaloids such as quinine, quinidine, cinchonidine and cinchonine. 
 4-aminoquinolines such as chloroquine, amodiaquine, piperaquine and 
pyronaridine. 
 8-aminoquinolines such as primaquine and tafenoquine. 
 Quinoline methanol derivatives such as mefloquine, halofantrine and 
lumefantrine. 
 Quinine, an extract from Cinchona bark, is one of the oldest antimalarial drugs, having been 
used by the native population of Peru for centuries to treat fevers and chills (Ridley, 2002).  In the 
19th century, active components of the cinchoma alkaloids were isolated including quinine, 
cinchonidin and cinchonine. With remarkable antimalarial properties, quinine is often the first 
therapeutic choice for the treatment of severe malaria (Pasvol, 2005). The elucidation of quinine 
structure and then the identification of quinoline ring as key pharmacophore led to the development 
of synthetic 4-aminoquinolines (Fig. 1.5. A). Chloroquine became for several decades the first choice 
of malaria treatment and prophylaxis because it was highly effective, safe and inexpensive (Hyde, 
2007a). 8-aminoquinolines were synthesized to eradicate malaria hypnozoites from the liver and 
have been used for malaria prophylaxis (Tschan et al., 2012). In order to respond to an increase in 
drug resistance, a new generation of quinoline related antimalarials emerged with such as 
mefloquine (a quinoline methanol), lumefantrine and halofantrine (Schlitzer, 2007). 
 The widely accepted mechanism of action for this class of compounds is the inhibition of 
haemozin formation in the parasite digestive vacuole (DV) (Muller and Hyde, 2010) (Fig. 1.5. B). The 
malaria parasite survival and development is dependent on host cell haemoglobin degradation as a 
source of amino acids (reviewed in(Francis et al., 1997). Up to 80% of haemoglobin in the host cell is 
degraded by the parasite during its 48 h asexual cycle. However, haemoglobin digestion in the DV 
releases a large amount of toxic free heme also called ferriprotoporphyrin IX (FPPIX). Toxic heme 
monomers are suggested to generate oxidative radicals provoking parasite membrane 
permeabilization and leading to parasite death (Zhang et al., 1999).  The FPPIX is biocrystallized to 
form inert crystals of hemozoin (the malaria pigment), which is not toxic to the malaria parasite 
(Pagola et al., 2000). 4-aminoquinolines act by binding to heme molecules in the DV and interfere 
with their process of detoxification (Fitch, 2004). 
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Figure 1.5. Chemical structures of quinoline containing drugs and their mode of action. (A) Chemical 
structures of quinine, chloroquine, primaquine and mefloquine. The quinoline ring is highlighted in red. (B) 
Schematic diagram for the mechanism of action of quinoline derivatives. 
 
 Resistance to quinolines emerged approximately 10 years after its introduction, along the 
Thai-Cambodian border in 1957, the Colombia-Venezuela border in 1970s and all sub-Saharan Africa 
in 1980s (Mita et al., 2009). Several studies have demonstrated resistance due to point mutations in 
P. falciparum chloroquine resistance transporter (PfCRT) and P. falciparum multidrug resistance 
transporter 1 (PfMDR1), both located in the membrane of the food vacuole. Other mutations 
occurring in two plasma membrane transporters, the P. falciparum multidrug resistance-associated 
protein (PfMRP) and P. falciparum Na+/H+ exchanger 1 (PfNHE1) were also found to be related to 
quinoline antimalarial drug resistance. The involvement of PfCRT polymorphisms, in particular the 
K76T mutation, has been established for chloroquine and 4-aminoquinoline resistances (Fidock et al., 
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2000; Lakshmanan et al., 2005; Martin et al., 2009). This chloroquine resistance could allow the 
active efflux of diprotonated chloroquine out of the digestive vacuole (Martin and Kirk, 2004). 
PfMDR1 has been linked to the altered susceptibility of parasites to mefloquine, halofantrine and 
quinine but their association remains unclear and other genetic factors may be involved such as 
PfCRT. PfMDR1 is a homolog of the multidrug resistance (MDR) transporter family, which is 
associated with drug resistance in mammalian tumor cells (Foote et al., 1989; Wilson et al., 1989). 
Mutations in MDR-like proteins in mammalian cancer cells lead to an increased drug efflux and 
decreased intracellular drug accumulation (Peel, 2001). Although PfMDR1 is not essential in asexual 
stages, mutations lead to increased parasite susceptibility to chloroquine, quinine, piperaquine and 
primaquine (Mu et al., 2003; Raj et al., 2009). The function of PfNHE1 located in the plasma 
membrane remains unclear but it is speculated to actively efflux protons to maintain a pH around 7.4 
within the parasite (Bosia et al., 1993). The association of PfNHE1 mutations with quinine resistance 
has been proposed but remains controversial (Andriantsoanirina et al., 2010; Briolant et al., 2011; 
Henry et al., 2009; Okombo et al., 2010).  
1.1.4.4.2. Antifolate drugs 
 Antifolate antimalarial drugs are classified into two classes:  
 Class I or inhibitors of the dihydropteroate synthase (DHPS) such as sulfadoxine 
and dapsone 
 Class II or inhibitors of dihydrofolate reductase (DHFR) such as proguanil and 
pyrimethamine 
Antifolates are widely used in fixed-ratio combinations, most commonly sulfadoxine-pyrimethamine 
(SP, FansidarTM), in first-line treatment for uncomplicated P. falciparum infection in chloroquine-
resistant regions of Africa (Winstanley and Ward, 2006).  Antifolate combinations are also used as 
intermittent preventive malaria therapies in pregnant women and infants in malaria endemic areas 
or in countries without supplies of Artemisinin Combination Therapy (ACT) (Gutman et al., 2012). 
 Growth of malaria parasites requires folate derivatives (folic acid or folinic acid) which are 
important cellular cofactors for the production of deoxythymidylate (dTMP) and thus DNA synthesis 
(Fig. 1.6). The folate synthesis is essential for the malaria parasite survival which relies on de novo 
dTMP synthesis because of its incapacity to salvage pyrimidine from the exogenous medium (Hyde, 
2007b). Both DHFR and DHPS catalyze two steps in the folate pathway. DHFR is present in both 
parasite and human host and is an essential enzyme for synthesis of the reduced form of folate 
(tetrahydrofolate, THF) while DHPS is only found in malaria parasites with a function of de novo 
synthesis of folate coenzymes. 
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Unfortunately, antifolate resistance emerged rapidly after extensive administration of 
sulphadoxine/pyrimethamine (SP) combinations due to point mutations in both targeted enzymes 
(Mita et al., 2009; Uhlemann and Krishna, 2005). The "quintuple mutant" consisting of three DHFR 
point mutations (S108N, N51I and C51R) and two DHPS substitutions (A437G and K540E) has been 
strongly associated with treatment failure (Kublin et al., 2002). PfMRP1 is also proposed to affect 
intracellular folate homeostasis in parasites. Its point mutation K1446R has been proposed to 
increase exogenous folate efflux, decrease the competition with the incoming drugs for their targets 
and contribute to antifolate resistance (Dahlstrom et al., 2009).  
 
 
 
Figure 1.6. Chemical structures of antifolate drugs and their mode of action. (A) Chemical structures of 
sulfadoxine, dapsone, proguanil and pyrimethamine. (B) Folate biochemical pathway in P. falciparum and 
mechanisms of action for antifolate antimalarial drugs. Abbreviations: DHF, dihydrofolate; DHP, 
dihydropteroate; THF, tetrahydrofolate; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; GTP, 
guanosine triphosphate; mTHF, methylene-THF-Glu(n); dUMP, deoxy-urinidine monophosphate; HMP-PP, 
hydroxymethyl-pteridine-PP; dTMP, thymidine monophosphate. 
 
 
1.1.4.4.3. Hydroxynapthoquinones (atovaquone) 
 Hydroxynapthoquinone compounds have been known as competitive inhibitors of the 
coenzyme ubiquinone (CoQ) and have been investigated as antimalarials since 1940s (Wendel, 1946). 
However, the enthusiasm for these compounds as potential antimalarial drugs has been inhibited 
due to their toxicity, poor bioavailability and lack of metabolic stability (Hudson et al., 1991).  
Atovaquone, a novel hydroxynaphthoquinone (2-[trans-4-(4’-chlorophenyl)cyclohexyl]-3-hydroxy-
1.4-napthoquinone), was therefore developed and showed excellent antiparasite activity (Fig. 1.7. A) 
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(Hudson et al., 1991; Hudson et al., 1985). Additionally, atovaquone was found to be well tolerated 
and metabolically stable (Srivastava and Vaidya, 1999). However, it presented 30 % treatment failure 
against P. falciparum malaria in clinical trials and exhibited rapid emergence of resistant parasites 
(Chiodini et al., 1995; Looareesuwan et al., 1996). To minimise resistance and clinical failures, 
atovaquone is combined with the antifolate proguanil which displayed synergistic effects in vitro and 
in clinical trials (Canfield et al., 1995; Looareesuwan et al., 1996; Radloff et al., 1996). The 
combination of atovaquone-proguanil when given in a fixed dose tablet drug combination 
(MalaroneTM) produces a near 100% curative rate but due to its costly production this drug is used 
mainly as chemoprophylaxis for travellers visiting malaria endemic areas (Kessl et al., 2007; 
Looareesuwan et al., 1999). 
 
  
Figure 1.7. Chemical structure of atovaquone and its mode of action. (A) Chemical structure of atovaquone 
and its analogue, the coenzyme ubiquinone. (B) Schematic diagram of bc1 complex reactions and its inhibition 
with atovaquone (ATQ). Abbreviations: Q, ubiquinone; QH2, ubiquinol; bL, heme bL binding site; bH, heme bH 
binding site; Fe-S, iron-sulfur cluster; cyt c, cytochrome c; c1, cytochrome c binding site. 
 
 Atovaquone is an inhibitor of the ubiquinol oxidation site (Qo) of the P. falciparum bc1 
complex (Fig. 1.7. B). The mechanism of action and emergence of resistances are comprehensively 
described in Chapter 6. To summarize, atovaquone inhibits the catalytic turnover of bc1 complex, 
collapsing the mitochondrial membrane potential and resulting in the loss of essential mitochondrial 
function such as pyrimidine biosynthesis (Painter et al., 2007). In combination with atovaquone, 
proguanil has been suggested to inhibit the mitochondrial phosphate transporter and thereby 
synergises with the inhibition of bc1 complex activity but this hypothesis remains to be supported by 
biological proofs (Painter et al., 2007). Different point mutations at the Qo site associated with 
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MalaroneTM failure have been reported (Berry et al., 2006; Korsinczky et al., 2000; Musset et al., 
2006).  Y268S, and less frequently Y268N, are the most common mutations observed, increasing the 
atovaquone IC50 by several hundred fold compared to sensitive parasite strains (Barton et al., 2010). 
1.1.4.4.4. Artemisinin and endoperoxide derivatives 
 Artemisinin is a sesquiterpene lactone extracted from the chinese plant Artemisia annua 
which kills asexual stage parasites but also affects sexual stage gametocytes of Plasmodium 
falciparum (Chen et al., 1994; ter Kuile et al., 1993). A first generation of semi-synthetic derivatives 
(known as dihydroartemisinin, artesunate and artemether) were synthesized with higher antimalarial 
activity and better solubility in order to replace original artemisinin as treatment of malaria (O'Neill 
and Posner, 2004). Initially used as monotherapies, dihydroartemisinin (DHA), artesunate or 
artemether are employed in combination with a longer half-life drugs such as mefloquine (in 
combination with artesunate - ASMQ) or lumefantrine (in combination with artemether - Coartem®) 
for treatment of uncomplicated malaria (White, 2008). These artemisinin-based combination 
therapies (ACTs) are also widely used to treat drug-resistant malaria strains with a high efficiency, 
rapid clearance and minimal toxicity in humans (Nosten and White, 2007; White, 2008). The 
discovery of the activation mode of artemisinins opened the way for the development of novel 
endoperoxide bridge-based drugs displaying superior activities than artemisinins against malaria 
parasites and leading to the identification of a promising 1,2,4,5-tetraoxane drug candidate (RKA-
182) (O'Neill et al., 2010a).  
Several insights into artemisinin resistance have been reported recently. A reduced efficacy 
of artemisinin derivatives as monotherapy was observed recently along the Thai-Cambodian border 
(Dondorp et al., 2009). Several mutations in PfATPase6 (sarco/endoplasmic reticulum Ca2+ -ATPase) 
have been associated with decreased artemether susceptibility in field isolates from French Guyana 
and PfMDR1 amplification can significantly reduce parasite susceptibility to artemisinins (Chavchich 
et al., 2010; Jambou et al., 2005; Sidhu et al., 2006). Because the mode of action of artemisinin 
derivatives remains unclear, resistant mechanisms are also not well understood and further studies 
have to be performed to support genetic and biochemical evidence (Eastman and Fidock, 2009). The  
structure of artemisinin and its derivatives, their modes of activation and action are described in the 
Chapter 5. 
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1.2. The mitochondrion of the malaria parasite 
The mitochondrion of Plasmodium species has unusual structural and functional features that 
distinguish it from mammalian mitochondria. Because it is essential for parasite survival, the 
mitochondrion has been successfully targeted with malaria chemotherapies and contains promising 
targets for the development of new antimalarial drugs. However, our knowledge regarding this 
organelle is limited with functions such as the tricarboxylic acid cycle or the election transport chain 
remaining unclear. This introduction aims to present an overview of the recent data on the structure, 
genome and functions of the mitochondrion. 
1.2.1. Morphology of the mitochondrion in asexual and sexual stages  
In the 1960s, electron microscopy studies identified a single mitochondrion with a double 
membrane located in the cytoplasm of Plasmodium parasites (Aikawa, 1966; Rudzinska, 1969). The 
evolution of microscopic techniques permitted a better observation of the morphology, the size and 
the number of mitochondria which vary between asexual and sexual stages. 
As shown in Figure 1.8, in the ring and early trophozoite stages of the asexual parasites the 
mitochondrion is a single organelle. Before the transition between mature trophozoite and shizont, it 
evolves to a wider, branched and elongated structure (van Dooren et al., 2005). During shizogony, 
the mitochondrion becomes highly branched before the start of cytokinesis. When cytokinesis starts 
the branched mitochondrion is divided by fission into multiple organelles and the divided 
mitochondria move into newly formed merozoites. Mitochondrion of gametocytes undergoes 
morphological development throughout gametocytogenesis (Okamoto et al., 2009). In stages II and 
III the mitochondrion is elongated and branched, then it becomes clustered towards the center of 
the cell (stages IV) and finally forms a denser cluster with short, round branches when the 
gametocytes mature to stage V. The mitochondrion retains closely association with the apicoplast 
throughout the whole gametocyte developmental process (Okamoto et al., 2009). During the sexual 
stage, gametocyte mitochondria also develop the tubular mitochondrial cristae that are largely 
absent in the asexual stages but are required for full mitochondrial function (Krungkrai et al., 2000). 
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Figure 1.8. Mitochondrial morphology during asexual and sexual stages of Plasmodium falciparum (adapted 
from(van Dooren et al., 2006)and(Okamoto et al., 2009). (Permission licence # 3144930064779). 
1.2.2. The mitochondrial genome 
 Malaria parasites have a 6 kb linear mitochondrial DNA (mtDNA) which is the smallest one 
known among eukaryotes. The mitochondrial genome is highly conserved between Plasmodium spp. 
with more than 90% of sequence similarities between human Plasmodium species (Table 1.3) 
(Hikosaka et al., 2011). The mtDNA is present as multiple copies with about 30 in P. falciparum to 
about 150 in P. yoelli and these sequences are tandemly arranged in head-to-tail configurations 
(Vaidya and Arasu, 1987). The mitochondrial genetic material is exclusively transmitted by the 
female gamete of malaria parasites during mating with male gametocyte in the mosquito gut (Vaidya 
et al., 1993).  
 
Table 1.3. Sequence identity of intergenic regions in the mitochondrial DNA of the five human Plasmodium 
species (Hikosaka et al., 2011). 
 P. falciparum P. vivax P. malariae P. ovale P. knowlesi 
P. falciparum      
P. vivax 91.7%     
P. malariae 91.2% 96.2%    
P. ovale 92.2% 96.0% 96.8%   
P. knowlesi 90.6% 96.8% 94.5% 94.3%  
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 As shown in Figure 2.2, it contains three Open Reading Frames (ORFs) encoding for three 
subunits of the mitochondrial electron transport chain (ETC): the subunits I and III (Cox1 and  Cox3) 
of the cytochrome c oxidase (or Complex IV) and the cytochrome b (Cytb) subunit of the 
ubiquinol:cytochrome c reductase (or Complex III) (Aldritt et al., 1989; Feagin, 1992; Vaidya et al., 
1989). Other subunits of complexes comprising the mtETC, which are encoded usually by the mtDNA 
in other organisms like the subunit II of the cytochrome c oxidase (Cox2), are encoded in the nuclear 
DNA. Because the conventional NADH dehydrogenase (or Complex I) is absent in Plasmodium 
species, and is replaced by a type II NADH dehydrogenase, some of its subunits are not encoded in 
the parasite mtDNA like in eukaryotes (Feagin and Drew, 1995). 
 
 The mtDNA also encodes fragmented ribosomal RNAs which are able to associate to 
reconstitute functional ribosomal subunits (Feagin et al., 1997). They are scattered across the entire 
genome on both strands of the DNA (Fig. 1.9). Specific identities to large and small subunits of rRNA 
have been previously identified on a basis of 23 small transcripts. Based on sequence and structural 
conservation, thirteen have similarities to regions in the large subunit rRNA (lsrRNA) and seven have 
been identified with specific regions in the small subunit rRNA (ssrRNA) (Feagin, 2000; Feagin et al., 
1997). The transcript mtR-26 has been recently suggested to be a fragment of the LSU rRNA gene 
(Raabe et al., 2010). Functions of the unassigned rRNA fragments could not be identified because of 
their poor sequence conservation. In malaria parasites, functional ribosomes have an unusual 
assembly composed of the small and large subunits rRNA structures formed by mitochondrial rRNA 
fragments and with imported ribosomal proteins (Feagin et al., 1992). 
 
 
Figure 1.9. Genomic view of the linear Plasmodium falciparum mitochondrial DNA (adapted from(Feagin, 
2000; Hikosaka et al., 2011; Raabe et al., 2010). Genes above the line are transcribed from left to right and 
those below from right to left. The three genes encoding for Cox1, Cox3 and Cytb are indicated in blue. 
Fragments of ribosomal RNA genes are shown in coloured boxes: those with similarity to the large subunit 
rRNA (lsrRNA) in green, those with similarity to the small subunit rRNA (ssrRNA) in red and those which are 
currently not assigned in purple. (Permission licence # 3144930784297). 
 
 Unlike higher eukaryotes, transfer RNA (tRNA) are not encoded in the mtDNA but probably in 
the nuclear DNA or apicoplast (Esseiva et al., 2004). Necessary for the protein synthesis, the entire 
set of tRNA is imported into the mitochondrion from the cytoplasm like the majority of 
mitochondrial proteins (Mi-Ichi et al., 2003). 
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1.2.3. Mitochondrial imported proteins 
 All proteins required for mitochondrial functions, with the exceptions of COX I, COX II and 
Cytb, are encoded by the nuclear chromosomes and imported into the mitochondrion. After 
synthesis in the cytoplasm, mitochondrial proteins are imported into the mitochondrion via different 
pathways. In Chapter 7, the current state of art and new insights with regards to import and 
processing pathways of mitochondrial proteins, in apicomplexans including P. falciparum, is 
reviewed. 
 With PlasMit (gecco.org.chemie.uni-frankfurt.de/plasmit) - a neural network approach for 
the prediction of mitochondrial transit peptides (mTPs) from P. falciparum - 381 annotated genes of 
the P. falciparum genome have been predicted to have mitochondrial targeting signals (Fig 1.10) 
(Bender et al., 2003). These predicted proteins are involved in different metabolic pathways but the 
function of the majority remains unknown. 
 
 
 
Figure 1.10. Functional distribution of 341 proteins with a mitochondrial signal peptide (Torrentino-Madamet 
et al., 2010). Different cellular processes implicated in the physiology of the mitochondrion have been 
identified through 341 putative mitochondrial proteins predicted with PlasMit (Bender et al., 2003). 
 
 
1.2.4. Physiology of the mitochondrion 
1.2.4.1. The TCA cycle 
 In higher eukaryotes, the mitochondrion is a source of cellular energy in the form of ATP. The 
role and contribution of the tricarboxylic acid (TCA) cycle to the bioenergetics of blood stage malaria 
parasites have been debated for many years (Vaidya and Mather, 2009). In higher eukaryotes, the 
TCA cycle occurs under aerobic conditions and is a series of chemical reactions that generate energy 
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by consuming acetyl-CoA. The Plasmodium genome encodes all the necessary enzymes for TCA cycle 
which are actively synthesized during the asexual stages and possess putative mitochondrial signal 
sequences (Bozdech et al., 2003; Gardner et al., 2002). However, the lack of a mitochondrial pyruvate 
dehydrogenase suggests that the TCA cycle in malaria parasite is different from pathways in other 
eukaryotes (Foth et al., 2005). In line with this, a bifurcated TCA pathway, one part being oxidative 
and the other reductive, has been suggested before to be recently retracted (Olszewski et al., 2010). 
 After entrance into the parasite, the molecule of glucose is metabolised into two molecules 
of pyruvate via the glycolysis pathway. In higher eukaryotic organisms, the molecule of pyruvate is 
transported into the mitochondrion where it is converted to acetyl-CoA which integrates with the 
TCA cycle. Deficient of pyruvate dehydrogenase into the mitochondrion, the malaria parasite cannot 
generate acetyl-CoA from pyruvate which is fermented into lactate yielding only two molecules of 
ATP for each glucose molecule consumed (Foth et al., 2005). Depending on the atmospheric culture 
conditions used, the glycolysis pathway is estimated to consume 60 to 70% of glucose imported in P. 
falciparum (Jensen et al., 1983). In absence of a mitochondrial pyruvate dehydrogenase, the acetyl-
CoA source cannot result  directly from glycolysis. The acetyl-CoA is only produced from 
phosphoenolpyruvate in the apicoplast in order to synthesize amino sugars in the endoplasmic 
reticulum (Foth et al., 2005). In future, it will be essential to clarify the source of mitochondrial 
acetyl-CoA in order to understand the TCA metabolism in blood-stage P. falciparum. 
1.2.4.2. De novo pyrimidine synthesis 
 In P. falciparum parasites, many metabolomic pathways are absent, with essential 
metabolites salvaged from the host (Gardner et al., 2002; Ginger, 2006). However, the salvage 
pathway of pyrimidines is missing which renders its biosynthesis essential for nucleic acid synthesis 
(Gutteridge et al., 1979). Formation of uridine monophosphate (UMP), a pyrimidine derivative, is 
catalysed via a pathway including six enzymes (Fig. 1.11). One of them, the dihydroorotate 
dehydrogenase (DHODH), is a component of the electron transport chain (ETC) localised in the inner 
mitochondrial membrane. DHODH, a flavin-dependent enzyme, catalyzes the oxidation of 
dihydroorotate to orotate and couples the de novo pyrimidine biosynthesis to the respiratory chain 
by reducing the coenzyme ubiquinone (CoQ) to ubiquinol (Krungkrai, 1995; Malmquist et al., 2008). 
The main role of the P. falciparum ETC has been proposed to regenerate CoQ required as an electron 
acceptor for DHODH and to maintain the mitochondrial electrochemical gradient or membrane 
potential (Δψm) (Malmquist et al., 2008; Painter et al., 2007). Thus, inhibition of pyrimidine 
biosynthesis is suggested to be the consequence of atovaquone leading to parasite death via 
inhibition of the bc1 complex and collapse of the Δψm.  Transgenic P. falciparum parasites expressing 
DHODH from yeast, which is not linked with mitochondria and utilizes fumarate rather than 
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ubiquinone as electron acceptor, became resistant to bc1 inhibitors by synthesis of pyrimidine 
independent to the ETC (Painter et al., 2007). This result highlights the essential role of the DHODH, 
which became an attractive drug target for the development of novel antimalarials (Baldwin et al., 
2005; Patel et al., 2008; Phillips et al., 2008). Recently, a drug discovery study developed substituted 
triazolopyrimidine compounds that are highly selective to DHODH, exhibiting high antimalarial 
activity (EC50s below 20 nM against P. falciparum 3D7) and metabolic stability (Coteron et al., 2011; 
Gujjar et al., 2011).  
 
Figure 1.11. Pyrimidine biosynthesis pathway in P. falciparum. Enzymes involved in the de novo pyrimidine 
biosynthesis are indicated in red boxes. Abbreviations: CPSII, Carbomoyl phosphate synthatase II; ACT, 
Aspartate carbamoyl transferase; DHO, Dihydroorotase; DHODH, Dihydroorotate dehydrogenase; OPS, Orotate 
phosphoribosyltransferase; OMPD, Orotidine 5'-monophosphate decarboxylase; ATQ, atovaquone inhibitor; 
TZP, triazolopyrimidine compound. 
 
1.2.4.3. The electron transport chain (ETC) 
 Plasmodium spp. have a functional respiratory chain and an oxygen-requiring system that is 
important for parasite growth and survival. Based on the oxygen consumption of P. falciparum and P. 
yoelii yoelii free parasites, the ETC was detected to be functional during the asexual and sexual stages 
(Krungkrai et al., 1999; Krungkrai et al., 2000; Uyemura et al., 2004). The Plasmodium respiratory 
chain is composed of five dehydrogenases namely type II NADH dehydrogenase (PfNDH2 or 
rotenone-insensitive complex 1), succinate:quinone oxidoreductase (SDH or complex II), 
malate:quinone oxidoreductase (MQO), dihydroorotate dehydrogenase (DHODH) and glycerol-3-
phosphate dehydrogenase (G3PDH) (Fig. 1.12 and Table 1.4). Each dehydrogenase can potentially 
donate electrons to the ETC via redox reactions involving the oxidation of substrates coupled to the 
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reduction of coenzyme ubiquinone (Q) to ubiquinol (QH2). Downstream oxidation reactions by 
ubiquinol:cytochrome c oxidoreductase (cytochrome bc1 or complex III), and cytochrome c oxidase 
(complex IV) are coupled to the vectorial translocation of protons (H+), generating a transmembrane 
electrochemical potential (Δψm). The transmembrane proton gradient is utilized by an ATP synthase 
(complex V) to synthesize ATP but its contribution to the whole ATP synthesis remains minimal 
(Balabaskaran Nina et al., 2011). In P. falciparum, the native ubiquinone is CoQ8 but due to its 
hydrophobic nature, it cannot be used as an exogenous substrate for enzymatic assays (Biagini et al., 
2006). 
 In most of eukaryotic species, the resulting membrane potential generated by the respiratory 
chain across the inner membrane is the central energy provider in the form of ATP. However, in 
blood stages of malaria parasites, glycolysis metabolism is favoured over the oxidative 
phosphorylation pathway for ATP generation (Vander Jagt et al., 1990). Although the apparent low 
expression levels and activities of the respiratory enzymes in the asexual stages, the respiratory chain 
is the primary source of mitochondrial membrane potential generation which is essential to parasite 
survival (Fry and Beesley, 1991; Krungkrai et al., 1993; Krungkrai et al., 1997; Painter et al., 2007). 
Indeed, the sensitivity of Plasmodium parasites to ETC inhibitors such as atovaquone, a bc1 inhibitor, 
demonstrates an indispensible role (Srivastava et al., 1997).  
 
 
Figure 1.12. Mitochondrial electron transport chain (ETC) of malaria parasites. The enzyme complexes of the 
ETC are embedded in the inner membrane of the mitochondrion. Enzymes are drawn as ribbon diagrams of the 
crystal structures known or from orthologues available in the Protein Data Bank. Abbreviations: IMS, 
Intermembrane space; QH2, ubiquinol. Proton movements are indicative only and do not represent H
+
/e
-
 ratios 
for the respective complexes. 
 1 
Table 1.4. Genes composing the mitochondrial electron transport chain in P. falciparum. Abbreviation: MW, molecular weight.
Enzyme Subunit PlasmoDB entry MW (Da) Chromosome PlasmoDB description 
Type II NADH: quinone oxidoreductase - PF3D7_0915000 61,671 9 Type II NADH:quinone oxidoreductase 
Glycerol-3-phosphate dehydrogenase - PF3D7_1462800 36,636 14 Glycerol-3-phosphate dehydrogenase, putative 
Malate:quinone oxidoreductase - PF3D7_0616800 59,508 6 Malate:quinone oxidoreductase, putative 
Dihydroorotate dehydrogenase - PF3D7_0603300 65,559 6 Dihydroorotate dehydrogenase, mitochondrial precursor 
Succinate dehydrogenase 
SDHA PF3D7_1034400 70,696 10 Flavoprotein subunit of succinate dehydrogenase 
SDHB PF3D7_1212800 37,752 12 Iron-sulfur subunit of succinate dehydrogenase 
SDHC Unknown - - - 
SDHD Unknown - - - 
bc1 protein 
Cyt b mal_mito_3 43,377 mtDNA Ubiquinol-cytochrome c reductase complex subunit, putative 
Rieske FeS PF3D7_1439400 40,982 14 Ubiquinol-cytochrome c reductase iron-sulfur subunit, putative 
Cyt c1 PF3D7_1462700 46,187 14 Cytochrome c1 precursor, putative 
Hinge (QCR6) PF3D7_1426900 10,587 14 Ubiquinol-cytochrome c reductase hinge protein, putative 
Core 1 PF3D7_0523100 61,774 5 Mitochondrial processing peptidase alpha subunit, putative 
Core 2 PF3D7_0933600 55,736 9 Organelle processing peptidase, putative 
QPK (QCR7) PF3D7_1012300 23,020 10 Ubiquinol-cytochrome c reductase complex subunit, putative 
Cytochrome c 
- PF3D7_1404100 12,894 14 Cytochrome c, putative 
- PF3D7_1311700 17,965 13 Cytochrome c2 precursor, putative 
Cytochrome c oxidase 
COX I mal_mito_2 52,973 mtDNA Cytochrome c oxidase I, putative 
COX IIa (N-term) PF3D7_1361700 27,262 13 Cytochrome c oxidase subunit 2, putative 
COX IIb (C-term) PF3D7_1430900 19,786 14 Cytochrome c oxidase subunit II precursor, putative 
COX III mal_mito_1 28,809 mtDNA Cytochrome c oxdase III, putative 
COX Vb PF3D7_0927800 32,364 9 Cytochrome c oxidase subunit, putative 
ATP synthase 
ATP1 (α) PF3D7_0217100 61,771 2 ATP synthase F1, alpha subunit, putative 
ATP2 (β) PF3D7_1235700 58,395 12 ATP synthase beta chain, mitochondrial precursor, putative 
ATP3 (γ) PF3D7_1311300 35,756 13 ATP synthase gamma chain, mitochondrial precursor, putative 
ATP4 (b) Unknown - - - 
ATP5 (OSCP) PF3D7_1310000 30,199 13 Mitochondrial ATP synthase delta subunit, putative 
ATP6 (a) Unknown - - - 
ATP9 (c) PF3D7_0705900 18,559 7 ATP synthase subunit C, putative 
ATP15 (ε) PF3D7_0715500 8,496 7 Mitochondrial ATP synthase F1, epsilon subunit, putative 
ATP16 (δ) PF3D7_1147700 17,617 11 Mitochondrial ATP synthase delta subunit, putative 
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1.2.4.3.1. Type II NADH: quinone oxidoreductase (PfNDH2) 
 Plasmodium spp. lost the conventional large multisubunit complex I found in most 
mammalian mitochondria. However, they acquired a single-subunit non-proton pumping NADH 
dehydrogenase similar to the yeast alternative complex I (or Type II NADH:quinone 
oxidoreductase). Also termed PfNDH2, this flavoenzyme is found in a broad range of organisms 
including fungi, bacteria, protozoa and plants. PfNDH2 catalyze the oxidation of NADH and NADPH 
coupled with reduction of quinone (Q) (Equation 1). Type II NADH:quinone oxidoreductases from 
anaerobic species such as Mycobacterium tuberculosis use menaquione (MQ) instead of 
ubiquinone as electron acceptor (Weinstein et al., 2005). The type II NADH dehydrogenases can 
either orient to the intermembrane space or to the matrix, oxidizing cytosolic or matrix NADH 
respectively (Kerscher, 2000). The observation that exogenous NAD(P)H could stimulate the 
electron transport in P. yoelii yoelii suggests that Plasmodium NDH2 is located on the external 
face of the inner membrane to recycle cytosolic NAD(P)H (Uyemura et al., 2004). 
 
NAD(P)H + Q → NAD + QH2    (Equation 1) 
 
 The first crystal structure of a type-II mitochondrial NADH dehydrogenase was newly 
solved in yeast (Feng et al., 2012). Because such crystal structure information was unavailable 
until recently, structure-function relationships have been determined with modelling studies 
based on sequence and structure similarities of others flavoenzymes with X-ray crystallography 
data available such as the NADH (per)oxidases, NADH-dependent ferredoxin reductase, and 
lipoamide dehydrogenases (Kerscher, 2000; Mattevi et al., 1992; Schmid and Gerloff, 2004). 
PfNDH2 structure and membrane-bound orientation have been predicted by homology modelling 
as well as its anchoring region and NADH-, flavin- and quinone-binding sites (Fig. 1.13) (Fisher et 
al., 2007). The quinone binding site was predicted to be formed by two short antiparallel β sheets 
- relatively well conserved across type II dehydrogenases - close to the surface of the membrane 
with sufficient distance with NAD(P)H- and flavin-binding domains for rapid electron transfer. This 
proximity with the membrane surface lipid bilayer facilitates quinone access to the "quinone 
pool" contained in the inner membrane. 
 
 Although PfNDH2 is not directly involved in proton pumping, its inhibition has been 
demonstrated to collapse the mitochondrial membrane potential by starving the bc1 of the 
reduced form of quinone (Biagini et al., 2006). Indeed, NADH-dependent respiration represents 
the major contributor to the Plasmodium respiratory chain by generating to ∼50% of the quinol 
flux to the bc1 complex at maximal capacity (compared to only 1% by DHODH) (Fisher et al., 2007; 
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Fry and Beesley, 1991). Additionally, the PfNDH2 inhibition by the flavin antagonist DPI 
(diphenylene iodonium chloride) or the alternative NADH dehydrogenases inhibitor HDQ (1-
hydroxy-2-dodecyl-4(1H)quinolone) leads in a loss of membrane potential causing parasite death. 
Based on these observations and due to the emergence of atovaquone resistance, as well as the 
cost of MalaroneTM treatment, PfNDH2 has been highlighted as an attractive target for new cost-
effective antimalarial drugs. Recently, Biagini et al. undertook a hit-to-lead study and identified a 
promising class of compounds inhibiting both PfNDH2 and bc1 complex (Biagini et al., 2012; Leung 
et al., 2012). One of the leading compounds, CK-2-68, shows antimalarial activity in the 
nanomolar range (IC50 = 31 ± 3 nM against P. falciparum 3D7 parasite growth) and specific PfNDH2 
inhibition (IC50 = 16 ± 2 nM). Furthermore, with nanomolar activity against the atovaquone-
resistant strain TM902CB (IC50 = 184 ± 16 nM against P. falciparum TM902CB parasite growth 
compared to 12 ± 1.6 µM with atovaquone), CK-2-68 is a proof-of-concept inhibitor.  
 
 Recently, the type II NADH dehydrogenase has been shown to be dispensable for the 
sexual blood stage of P. berghei parasites, which rely on the glycolysis pathway as the main ATP 
generator (Boysen and Matuschewski, 2011). However, PbNDH2-depleted rodent parasites fail to 
develop into mature oocysts in the mosquito midgut. Thus it is proposed that the PbNDH2 gene is 
only essential in a glucose-deprived environment such as in the mosquito. Although non-
overlapping functions of paralogous genes may appear across Plasmodium species, it is suspected 
by the authors that the NDH2 enzyme is not a promising drug target. 
 
Figure 1.13. Predicted structure of PfNDH2 and its membrane orientation (Fisher et al., 2007). FAD is 
indicated in yellow, NADH is cyan, the predicted Q-site location is circled and the predicted C-terminal 
amphipathic helix is represented by a green cylinder at the membrane surface. 
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1.2.4.3.2. Succinate: quinone oxidoreductase (complex II) 
 The succinate:quinone oxidoreductase (termed also succinate dehydrogenase or complex 
II) converts succinate to fumarate by reducing FAD in the process (Equation 2).  
 
Succinate + Q → Fumarate + QH2    (Equation 2) 
 
 Succinate dehydrogenases are generally composed of four subunits: a flavoprotein 
(SDHA), an iron-sulfur protein (SDHB) and two membrane anchor subunits (SDHC and SDHD). In P. 
falciparum, two major catalytic subunits SDHA and SDHB composing the soluble part have been 
identified, cloned and characterised (Takeo et al., 2000). However, the membrane anchor b-type 
cytochrome heterodimer is highly divergent across species and remains unannotated in current 
databases. An attempt to solve this knowledge gap is addressed in Chapter 3. 
 Complex II activities have been measured in P. falciparum and P. yoelii yoelii and kinetic 
properties obtained are similar to mammalian succinate dehydrogenases (Fry and Beesley, 1991; 
Kawahara et al., 2009; Suraveratum et al., 2000).  
 
 
1.2.4.3.3. Malata:quinone oxidoreductase (MQO) 
 The malate:quinone oxidoreductase (MQO) is a peripheral membrane-bound flavoprotein 
which catalyses the oxidation of malate to oxaloacetate (Equation 3) (Molenaar et al., 1998). 
 
Malate + Q → Oxaloacetate + QH2    (Equation 3) 
 
 MQOs can be subdivided into two major families: the MQO-1 family including mainly 
bacterial MQOs and the MQO-2 group containing actinobacterial MQOs (Ɛ-proteobacteria) and 
those from apicomplexan species (P. falciparum, Toxoplasma gondii, Babesia bovis) (Mogi et al., 
2009).  PfMQO is involved in the TCA cycle by being a substitute of mitochondrial malate 
dehydrogenase (MDH) (Uyemura et al., 2004; van Dooren et al., 2006). The contribution of MQO 
in the mitochondrial ETC has been supported by measuring oxygen consumption and membrane 
potential ΔΨm generation induced by malate in P. yoelii yoelii (Uyemura et al., 2000; Uyemura et 
al., 2004). To date, no crystal structure of Plasmodium MQO is available. 
 
1.2.4.3.4. Dihydroorotate dehydrogenase (DHODH) 
 The Plasmodium DHODH is a flavin-containing enzyme that catalyzes the conversion of 
dihydroorotate to orotate using the flavin cofactor FMN (Equation 4).  
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Dihydroorotate + Q → Orotate + QH2     (Equation 4) 
 
 DHODH activity has been measured in parasite extracts and its gene has been identified in 
every parasite genome (Fry and Beesley, 1991; Gardner et al., 2002). The enzyme has been 
purified and characterized from the parasite mitochondria (Ittarat et al., 1994; Krungkrai, 1995; 
Krungkrai et al., 1992). Two types of DHODHs exist: the cytosolic DHODHs-1 use different soluble 
molecules as electron acceptors whereas the inner membrane DHODHs-2 (including Plasmodium 
DHODH) with the active site facing the mitochondrial intermembrane space use quinone as 
cofactor. The X-ray structure of a N-terminal truncated PfDHODH has been solved bound with two 
inhibitors (Hurt et al., 2006). 
 As mentioned previously (see section: 1.2.4.2. De novo pyrimidine synthesis), Plasmodium 
DHODH is the fourth and only redox reaction of the essential de novo pyrimidine biosynthesis 
pathway. It also regenerates ubiquinone in the respiratory chain (Fig. 1.14). Thus, Plasmodium 
DHODH became a potential target for drug discovery efforts (Baldwin et al., 2005; Coteron et al., 
2011; Gujjar et al., 2011; Phillips et al., 2008; Skerlj et al., 2011). Several drug discovery programs 
identified promising compounds but the mechanism of inhibitions remains poorly defined.  
Indeed, the quinone binding site has only been predicted and not proven even on the basis of 
crystallographic data. However, the different inhibitors developed by different research groups 
share an overlapping binding site.  
 
 
Figure 1.14. Overall structure of the N-terminal truncated P. falciparum dihydroorotate dehydrogenase 
(PfDHODH). The dihydroorotate binding site is inside the barrel (purple). Dihydroorotate (red) is stacked 
against the internal FMN (green) (PDB entry 1TV5). The quinone binding site has been predicted via the 
binding site of atovaquone (orange) in aligned human DHODH structure (PDB entry 1D3G). 
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1.2.4.3.5. Glycerol-3-phosphate dehydrogenase (G3PDH) 
 The P. falciparum genome encodes two glycerol-3-phoshapte dehydrogenases (G3PDH), 
one being NAD-dependent (G3PDH-1) and the other FAD-dependent (G3PDH-2) (Fig. 1.15) (van 
Dooren et al., 2006). The NAD-dependent G3PDH (PlasmoDB entry PF3D7_1216200 in P. 
falciparum) is a cytosolic enzyme converting dihydroxyacetone phosphate (DHAP) into glycerol-3-
phosphate (G3P) coupled with oxidation of NADH. G3PDH-1 is involved in the lipid biosynthesis 
pathway and plays an important role in the transport of reducing equivalents from the cytosol to 
the mitochondria (Mitamura and Palacpac, 2003). For the latter function it acts in association with 
the mitochondrial G3PDH-2 localized in the outer surface of the inner mitochondrial membrane. 
The G3P produced can integrate the lipid synthesis pathway or passes through the permeable 
outer mitochondrial membrane where it is re-oxidized to DHAP by the FAD-dependent G3PDH 
(Equation 5).  
Glycerol-3-phosphate + Q → Dihydroxyacetone phosphate + QH2   (Equation 5) 
 
 Both enzymes perform the glycerol-3-phosphate shuttling function at the central junction 
of glycolysis, phospholipid biosynthesis and oxidative phosphorylation. This shuttle provides an 
alternative way to transport electrons from the cytosolic NADH to the mitochondrial quinone (van 
Dooren et al., 2006). 
 
Figure 1.15. Involvement of glycerol-3-phosphate dehydrogenase-1 and -2 in three pathways. 
Abbreviations: G3P, Glycerol-3-phosphate; DHAP, dihydroxyacetone phosphate; LysoPA, lysophosphatidic 
acid; F1,6BP, fructose-1,6-bisphosphate; GADP, glyceraldehyde-3-phosphate. 
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1.2.4.3.6. The bc1 complex (complex III) and Q cycle 
 The coenzyme ubiquinone reduced to ubiquinol by five different dehydrogenases donates 
electrons to the cytochrome bc1 complex (also termed ubiquinol:cytochrome c oxidoreductase or 
complex III) (Fig. 1.16). Eukaryotic bc1 is a dimeric enzyme complex inserted into the 
mitochondrial inner membrane and composed of 11 non-redundant subunits (Iwata et al., 1998; 
Lange and Hunte, 2002; Xia et al., 1997). Crystal structures have been determined for yeast, 
chicken, and bovine bc1 complexes but remain unsolved in Plasmodium spp (Iwata et al., 1998; 
Lange and Hunte, 2002; Zhang et al., 1998). So far, seven subunits have been shown to form the 
Plasmodium bc1 complex including the cytochrome b encoded by the 6 kDa mitochondrial DNA 
(Table 1.4) (Petmitr and Krungkrai, 1995). The catalytic core participating directly in the electron 
transfer pathway is composed of three subunits: cytochrome b, cytochrome c1 and the Rieske 
iron–sulfur protein (Zara et al., 2009). The bc1 complex catalyses the electron transfer from 
ubiquinol to cytochrome c, coupled with the vectorial translocation of protons thus generates the 
transmembrane electrochemical gradient (ΔΨm). The catalytic mechanisms of bc1 complex is 
known as the Q cycle which was first postulated by Mitchell (Mitchell, 1975). 
 
Figure 1.16. Schematic drawing of the Q cycle in the mitochondrial bc1 complex. Abbreviations: PfNDH2, 
type II NADH dehydrogenase; DHODH, dihydroorotate dehydrogenase; MQO, malate:quinone 
oxidoreductase; G3PDH, Glycerol-3-Phosphate dehydrogenase; SDH, succinate dehydrogenase; Q, 
ubiquinone; QH2, ubiquinol; bL, heme bL binding site; bH, heme bH binding site; Fe-S, iron-sulfur cluster; cyt c, 
cytochrome c; c1, cytochrome c binding site. 
 
 The mitochondrial Q cycle necessitates two different quinone-binding sites: Qo, the quinol 
oxidation site and Qi, the quinone reduction site. Qo and Qi binding sites are located on opposite 
sides of the inner membrane and are linked by a transmembrane pathway through two b-type 
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hemes, bL and bH (reviewed in(Barton et al., 2010). The ubiquinol (QH2) generated by 
dehydrogenases binds the Qo binding sites to be oxidised to ubiquinone (Q) releasing two protons 
in the intermembrane space and two electrons per QH2 molecule. One electron is transferred via 
the iron-sulfur cluster of the Rieske subunit to the cytochrome c, the electron donor to 
cytochrome c oxidase. In a bifurcated reaction, the other electron reduces the heme bL. 
Afterwards, the heme bL is oxidised by neighbouring heme bH that recycles the electron by 
reducing ubiquinone to ubiquinol at the reduction site Qi. To resume, during a complete cycle two 
molecules of QH2 are oxidised to ubiquinone at Qo site, one quinone molecule is reduced at Qi site 
and four protons are translocated to the intermembrane space. During the Q cycle, electrons are 
transferred from ubiquinol to feed the mitochondrial respiratory chain and to regenerate 
ubiquinone to supply the ubiquinone pool (Q-pool) in the lipid bilayer. 
 
 The cytochrome bc1 complex is an essential enzyme of the oxidative phosphorylation 
pathway in many organisms (Rich, 2003).  Several quinol antagonists are complex III inhibitors 
known to collapse the mitochondrial membrane potential and inhibit mitochondrial respiration. 
For example, myxothiazole and stigmatellin binds the Qo site while antimycin A is a potent 
inhibitor of the Qi site. However, these compounds are often highly toxic to mammals and are not 
suitable for antimalarial use. Previously it has been demonstrated that the parasite bc1 complex 
could be inhibited by atovaquone, a Qo site inhibitor, at a 1000-fold lower concentration than the 
similar complex in mammalian species (Hudson et al., 1991) (see section 1.1.4.4.3. 
Hydroxynapthoquinones (atovaquone)). The malaria parasite sensitivity to atovaquone indicates 
that complex III and its contribution to membrane potential as well as Q-pool regeneration is 
indispensible to the parasites. Unfortunately, atovaquone resistance emerged and is correlated 
with a mutation in the Qo site of the cytochrome b. Details of atovaquone resistance are described 
in Chapter 6. 
 
1.2.4.3.7. Cytochrome c oxidase (complex IV) 
 The cytochrome c oxidase (also termed complex IV) is the terminal oxidation step in the 
mitochondrial respiratory chain. This enzyme receives electrons from reduced cytochrome c and 
passes them on to oxygen via two a-type hemes, a and a3, and two copper centers, cua and cub. 
Four electrons are transferred per molecule of oxygen giving water as a product (Fig. 1.17). For 
each pair of electrons passing through the complex IV, two protons are translocated across the 
mitochondrial inner membrane and contribute to the electrochemical gradient. Its presence in 
malaria parasites has been confirmed in different stages in P. berghei (Howells, 1970; Howells et 
al., 1969; Theakston et al., 1969), P. falciparum (Scheibel and Pflaum, 1970) or P. yoelii yoelii (Fry 
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and Beesley, 1991). Afterwards, the enzyme has been partially purified and characterized from P. 
berghei mitochondria (Krungkrai et al., 1993). The enzyme has also been purified from P. 
falciparum mitochondrial extracts and was found to be sensitive to cyanide inhibition causing a 
reduction of the oxygen consumption and a depolarization of the membrane potential (Krungkrai 
et al., 1999; Krungkrai et al., 1997).  
 
 In mammals, complex IV is composed of 13 subunits (Richter and Ludwig, 2003; van 
Dooren et al., 2006). To date, five proteins have been clearly identified as components of 
Plasmodium complex IV (Table 1.4). Subunits COX I, COX II and COX III form the catalytic centre of 
the enzyme. With the bc1 cytochrome b subunit, COX I and COX III are the two other proteins 
encoded in the malaria parasite mtDNA. COX II is split into two nuclear-encoded subunits known 
as COX IIa and COX IIb while it is encoded by a single gene in most other organisms. Because COX 
II is a highly hydrophobic subunit, the splitting of its gene may reduce its overall hydrophobicity 
and facilitate its importation into the mitochondrion (van Dooren et al., 2006). P. falciparum also 
has a nuclear-encoded COX Vb subunit which may have the function to regulate the flow of 
electrons between the different reactions centres of the enzyme (Burke and Poyton, 1998). 
 
 
Figure 1.17. Schematic drawing of the mitochondrial cytochrome c oxidase (complex IV). Abbreviations: a, 
a-type heme a; a3, a-type a3; cuA, copper center cuA ; cuB, copper center cuB; cyt c, cytochrome c. 
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1.2.4.3.8. ATP synthase (complex V) 
 F1Fo-ATP synthase (also termed complex V), is a rotary machine that couples ATP 
synthesis to the proton gradient generated across the inner mitochondrial membrane (Boyer, 
1997; Capaldi and Aggeler, 2002; von Ballmoos et al., 2008). ATP synthesis requires a regular 
supply of inorganic phosphate (Pi) and ADP imported via the membrane potential-dependent 
ATP/ADP carrier (van Dooren et al., 2006). In eukaryotic species, the complex V drives the ATP 
synthesis in the mitochondrial matrix (a process also called oxidative phosphorylation) but the 
role of this enzyme in Plasmodium spp. is subject to debate (Vaidya and Mather, 2009). The 
oxidative phosphorylation integrity in the malaria parasite has been discussed for many years, 
supported by opposing data. Because the glycolysis pathway is the major source of ATP during the 
asexual stage, it was suggested that malaria parasites lost their ability to carry out oxidative 
phosphorylation. Biochemical studies using mitochondrial extracts from asexual and sexual blood 
stages proposed that oxidative phosphorylation was absent in P. falciparum (Fry and Beesley, 
1991; Fry et al., 1990; Krungkrai et al., 1999). However by indirect measurement of respiratory 
control, Uyemura et al. showed evidence of functional oxidative phosphorylation in P. berghei and 
P. yoelii yoelii (Uyemura et al., 2000; Uyemura et al., 2004). Additionally, they reported an 
inhibition of phosphorylating respiration with oligomycin, a known ATP synthase inhibitor, 
supporting the presence of an operational enzyme. This observation is in contrast to previous 
findings that oligomycin does not appear to inhibit mitochondrial ATP hydrolase activity, the 
reverse action of the ATP synthase which maintains for a certain period the disrupted membrane 
potential by pumping protons into the intermembrane space (Fry et al., 1990; Vaidya and Mather, 
2009). Evidence for the direct activity of ATP synthase is lacking and therefore the question of 
oxidative phosphorylation in Plasmodium parasites remains confused. 
 Moreover, the absence of ATP synthesis in the parasite mitochondrion has been 
corroborated with the lack of two essential subunits normally required for enzyme activity. 
Indeed, both subunits a and b of the F0 sector are not yet annotated in the parasite genome due 
to their high divergence between species (Mogi and Kita, 2009). Thus, it has been proposed that 
subunits a and b are probably absent which explains why the malaria parasite lost the capacity for 
ATP synthesis and hydrolysis (Mather and Vaidya, 2008). Recently, attempts to disrupt both genes 
encoding α and β subunits of the P. falciparum ATP synthase were unsuccessful (Balabaskaran 
Nina et al., 2011). Additionally, P. falciparum ATP synthase was showed to be partly assembled in 
a dimeric complex. These results suggest that ATP synthase plays an essential role in blood stages 
of malaria parasite and confirm the presence of both key subunits a and b despite them 
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remaining unidentified. In Chapter 3 of this thesis, the identification of these two subunits was 
attempted by using bioinformatic and proteomic strategies. 
. 
 
1.2.4.3.9. Uncoupled protein (UCP) complex? 
 Under some conditions, protons can be translocated into the mitochondrial matrix 
without contributing to ATP synthesis by a process called "mitochondrial uncoupling" or "proton 
leak" (Ledesma et al., 2002). This alternative flow of protons back to the matrix is supported by 
enzymes or transporters located in the inner membrane and termed uncoupled proteins (UCPs). 
Uyemera et al. reported the first evidence of UCPs located in P. falciparum in the form of 
immunoblots using anti-UCP antibodies (Uyemura et al., 2004). Because a doubt remains about 
the ATP synthase functionality in Plasmodium spp, the presence of UCPs may be sufficient to 
complete the ETC circuit and generate a stable mitochondrial membrane potential. However, the 
presence and role of UCPs in the malaria parasite have to be clarified. 
1.2.4.3.10.   The ETC components as drug targets 
 Unique features of the Plasmodium mitochondrion suggest that enzymes composing the 
respiratory chain could be exploited as antimalarial drug targets (Kita et al., 2001; Mather et al., 
2007; Monzote and Gille, 2010; Vaidya, 2004; Vaidya and Mather, 2009). Despite ATP being 
obtained via the glycolysis pathway in the asexual stage, a functional mitochondrial ETC and its 
related components have been shown to be a valid drug target.  
 
As described earlier, the cytochrome bc1 and atovaquone (a constituent of Malarone
TM) 
are the "proof-of-concept" of this strategy. Due to the expense of atovaquone and the emergence 
of resistant strains, attempts to develop alternative compounds have been initiated including (i) 
acridines and acridinediones (Biagini et al., 2008), (ii) quinolones (Biagini et al., 2012; Winter et 
al., 2008) (iii) and pyridones, analogues of the clopidol (Xiang et al., 2006; Yeates et al., 2008). 
New insights regarding the mechanism of atovaquone resistance in the parasite bc1 are useful 
information for development of novel bc1 inhibitors. This knowledge gap has been studied in 
Chapter 6 of this thesis which describes the molecular and biochemical characterisation of an 
atovaquone resistant P. falciparum isolate (TM902CB). 
 The Plasmodium ETC contains two untypical components, PfNDH2 and MQO, which have 
no homologues in higher eukaryotic species including mammals. The absence of both 
dehydrogenases in the human host has led several research groups to suggest that they may be 
promising drug targets for the development of new antimalarials. In order to perform high-
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throughput screens (HTS) or in silico rational-drug design, the generation of functional enzyme 
either purified or from enriched heterologous expression have been performed. In the case of 
PfNDH2, a recombinant enzyme has been reported and its validation as a potential drug target 
demonstrated (Biagini et al., 2006; Fisher et al., 2007). The first results of a drug discovery project 
developing PfNDH2 inhibitors were recently published (Biagini et al., 2012). Concerning MQO, no 
recombinant protein is yet available and to date attempts to generate a functional recombinant 
MQO have been unsuccessful (Biagini personal communication). 
 
 Due to the crucial role of the pyrimidine synthesis, the Plasmodium DHODH has also been 
validated as a possible drug target. Different studies have been performed to generate novel 
DHODH inhibitors by exploiting small differences in the active site of Plasmodium and human 
DHODH (Baldwin et al., 2005; Booker et al., 2010; Coteron et al., 2011; Phillips et al., 2008; Skerlj 
et al., 2011). To date, one of these projects has advanced to the late pre-clinical phase with the 
compound DSM265 (Coteron et al., 2011). 
 
 Downstream of the cytochrome bc1 complex, the cytochrome c oxidase complex appears 
to be simpler than in higher organisms or yeast with a restricted subunit composition and an 
unusual split of COX II. These differences might be exploitable for a future drug development 
program. 
 
1.3. Research aims 
The general objective of the thesis was to take a multidisciplinary approach to study 
different aspects of the Plasmodium falciparum respiratory chain biochemistry, physiology and 
pharmacology. 
The first results chapter of the thesis, Chapter 3, focuses upon the identification of 
missing ETC subunits to answer two knowledge gaps: the two anchor subunits SDH3 and SDH4 of 
the succinate dehydrogenase and subunit a and b of the ATP synthase. By using a bioinformatic 
approach, the detection of potential candidate genes is attempted and validation of the 
predictions is attempted using a proteomic strategy. 
Chapter 4 presents for the first time the direct quinone reductase activity of all 
dehydrogenases composing the ETC in order to estimate their real contribution to the 
mitochondrial membrane potential generation. Additionally, the physiological consequence of 
inhibiting dehydrogenase activities on the mitochondrial electrochemical gradient (Δψm) has been 
determined with real-time single-cell imaging assays. Moreover, menaquinone, a mitochondrial 
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electron carrier of anaerobic species, has been recently identified in malaria parasites and its 
capacity to replace ubiquinone within the ETC system in anaerobic conditions has been evaluated 
in this chapter. 
In the Chapter 5, the previously held hypothesis that artemisinins target the parasite ETC 
is tested. In addition, single-cell imaging is used to measure the effect of endoperoxides against 
plasma (ΔΨp) and mitochondrial membrane potential (ΔΨm), and use this end-point measure to 
elucidate upstream mechanisms of activation.  
 In the Chapter 6, atovaquone sensitive and resistant parasites are compared at the 
biochemical level with the aim of uncovering the complex mechanisms underpinning atovaquone 
resistance, both at the enzyme level and at the pathway/cellular level. 
 Chapter 7 presents an updated picture of the mitochondrial importation and processing 
machinery for nuclear-encoded proteins in Plasmodium falciparum. Using comparative genomics 
and Hidden Markov Model approach, potentially new components involved in these mechanisms 
are presented. 
  
 
 
 
 
 
 
 
 
 
 
 1 
Chapter 2 
General Material & Methods 
2.1. In vitro parasite culture 
 In vitro P. falciparum strains 3D7 and TM90 were maintained in continuous culture using 
standard methods (Bray et al., 2006; Trager and Jensen, 1976). Parasites were grown in 2% O+ 
erythrocytes (supplied by the Blood Transfusion Centre, Liverpool, UK) in RPMI 1640 medium with 
L-glutamine and sodium bicarbonate (R8758, Sigma-Aldrich, St. Louis, USA) supplemented with 
25 mM HEPES pH 7.4, 20 μg/ml gentamicin sulphate and 10% human serum (or 0.5% Albumax 
(Invitrogen, Carlsbad, USA), 40 µM hypoxanthine). Cultures were grown under a gaseous 
headspace of 3% CO2, 4% O2 and 93% N2 (BOC, Guilford, UK) (Scheibel et al., 1979). Parasites were 
synchrony maintained by treatment with 5% sorbitol at ring stages (Lambros and Vanderberg, 
1979). The parasitaemia was monitored daily by Giemsa-stained blood smears and observed 
under a light microscope (100 x magnification). 
2.2. Drug sensitivity assays 
 Drug susceptibilities were determined with an inoculum size of 0.5% parasitemia (ring 
stage) and 1% hematocrit and were assessed by the measurement of fluorescence after the 
addition of SYBR Green I as described in (Smilkstein et al., 2004). Drug IC50 (50% inhibitory 
concentration) values were calculated from the log of the dose/response relationship, as fitted 
with Grafit software (Erithacus Software, Horley, United Kingdom). Results are given as the means 
of at least three separate experiments. 
2.3. Cell-free parasite extract 
 Prior to Western blot and kinetic studies, malaria parasites were extracted from the 
erythrocytes. The synchronised parasites (5-10% trophoziotes) were collected by centrifugation at 
3,000 g for 5 minutes. The pellet was resuspended in 5 volumes of 0,15% saponin in phosphate-
buffered saline (PBS) for 30 sec, followed by three washes by centrifugation (2,500 g for 5 min) in 
ice-cold intracellular buffer (110 mM KCl, 30 mM NaCl, 2 mM MgCl2, 20 mM glucose and 5 mM 
HEPES pH 7.4). The samples were checked microscopically to ensure lysis of all erythrocytes, and 
stored at -80 °C. 
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2.4.  Protein quantification 
 The Bradford assay (Bradford, 1976) was carried out to determine the protein 
concentration used for SDS gel electrophoresis and to quantify the specific enzyme activity from 
free parasites preparation. The reaction was set up using the Bradford assay reagent (Bio-Rad, 
Hercules, USA). A standard curve was generated using bovine serum albumin (Sigma Aldrich, 
Saint-Louis, USA) at concentrations ranging from 0.2-0.9 mg/ml. Briefly, 200 μl Bradford reagent 
was added to 5 μl of sample and incubated for 5 min at room temperature. The assay was 
quantified spectrophotometrically at 595 nm (VarioscanTM, Thermo Fisher Scientific, Waltham, 
USA). All assays were performed in triplicate and data are presented as the mean ± standard 
deviation. 
2.5. Cell-free parasite membranes preparation 
Cell-free parasites were disrupted with a sonicating probe in lysis buffer (50 mM Tris-HCl, 
150 mM NaCl, 2 mM EDTA, pH 7.4) in the presence of protease inhibitor mixture (Complete Mini, 
Roche Applied Science, Germany). The lysate was centrifuged at 17,000 g for 30 min at 4 °C to 
pellet the membrane fraction. The supernatant was saved for analysis as the cytosolic fraction. 
2.6.  Bovine mitochondrial membranes preparation 
 Mitochondrial cytochrome bc1 complex was isolated from bovine heart muscle by the 
method described by Kuboyama and colleagues (Kuboyama et al., 1972). All steps were 
performed at 0-4 ºC. First, bovine mitochondrial membranes (also called Keilin-Hartree particles) 
were prepared: 660 g of fresh lean beef heart muscle was diced and washed with water to 
remove haemoglobin prior to placing in a blender with 2 L of 50 mM sodium bicine pH 8.0.  20 ml 
of 2 M sodium bicine pH 9.0 was added prior to blending for 30 seconds at low speed, 30 seconds 
at medium speed then 45 seconds at high speed with the blender vessel briefly cooled by 
plunging into ice between each step.  The pH was then adjusted to 8.0 with 2 M sodium bicine pH 
9.0 and the sample pressed through a layer of muslin prior to centrifugation at 3,000 g for 40 
minutes. The supernatant was passed through 2 layers of muslin then centrifuged at 20,000 g for 
1 hour. The resulting pellet was resuspended with a Dounce homogeniser to 100 ml with 0.1 M 
sodium borate (orthoborate, BO3
3-), 0.1 M sodium phosphate at pH 8.5. The resulting 100 ml 
suspension was diluted to 1 L in 0.1 M sodium borate, 0.1 M sodium phosphate pH 8.5 and 
centrifuged at 20,000 g for 1 hour.  The supernatant was discarded to leave a pellet of Keilin-
Hartree (KH) particles that were resuspended in approximately 100 ml 0.1 M sodium borate, 0.1 
M sodium phosphate pH 8.5. The total concentration of protein was estimated from cytochrome c 
oxidase concentration, determined spectrophotometrically from a sodium dithionite-reduced 
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minus potassium ferricyanide-oxidised difference spectrum (ε606-630nm = 25.7 mM
-1.cm-1). 
Mitochondrial protein concentration was estimated from this value using a figure of 0.4 nmoles 
cytochrome c oxidase/mg mitochondrial protein. Typically, a two batch preparation, processed in 
a single day, yielded around 100 ml of ~ 45 mg of protein/ml resuspended KH particles. These 
were stored at -80 °C until required. 
2.7. Yeast mitochondrial membranes preparation 
 Wild type and mutant yeast strains were grown to stationary phase (48 h) in yeast extract 
peptone dextrose (YPD) at 28°C. Cells were harvested by centrifugation at 4,000 g for 5 minutes. 
The cells were washed with approximately 10 pellet volumes of 50 mM potassium phosphate (pH 
7.5), 2 mM EDTA. The resuspended cells were centrifuged again at 4,000 g for 5 minutes and the 
pellet collected (it can be frozen at this stage with a few ml of glycerol for storage at -80°C if need 
be). The washed cells were resuspended in a total volume of 10 - 15 ml in 50 mM potassium 
phosphate (pH 7.5), 2 mM EDTA by using an hand homogeniser. The disrupted cells were 
centrifuged at 10,000 g for 20 min at 4°C to pellet debris. The supernatant was collected and 
centrifuged at 100,000 g for 1 h at 4°C to pellet the crude mitochondrial membranes. The pelleted 
membrane were resuspended in 1 ml 50 mM potassium phosphate (pH 7.5), 2mM EDTA with an 
hand homogeniser. 50% (v/v) glycerol (cryoprotectant) were added to the membranes 
preparation before to be aliquoted and stored at -80°C. 
2.8.  SDS-Polyacrylamide gel electrophoresis (PAGE) electrophoresis 
 SDS-Page were run according to the Laemmli method (Laemmli, 1970). A Laemmli sample 
buffer (62.5 mM Tris-HCl pH 6.8, 0.01% (w/v) bromophenol blue, 10% (v/v) glycerol, 2% (w/v) SDS, 
5% (v/v) 2-mercaptoethanol) was added to each sample (1 : 2, v/v). Protein samples (containing 
between 10 to 50 µg of total protein) were then heated for 5 min at 95°C before to be 
electrophoresed on SDS/polyacrylamide gels (between 5 to 15% resolving and 4% stacking 
polyacrylamide gels) via the mini-gel electrophoresis system Mini-PROTEAN® II (Biorad, Hercules, 
USA) using Laemmli running buffer (25 mM Tris, 0.192 mM Glycine, 0.1% SDS, pH 8.8) at a 
constant current of 30 mA per mini-gel. The SpectraTM Multicolor Broad Range Protein Ladder 
(Fermentas, USA) was then used to estimate the resulting protein band. 
 For vizualization, proteins patterns were stained by Coomassie blue staining or by silver 
staining. For Coomassie Blue staining, proteins were stained in a one-step procedure by 
incubating the entire gel in Coomassie-based Instant BlueTM (Expedeon, Cambridge, UK) for 1h at 
room remperature. The gel was finally rinsed with distilled water to visualize protein bands 
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according to manufacturer instructions. For silver staining, proteins in gel were fixed with 10% 
(v/v) acetic acid, 40% (v/v) ethanol for 1 h, then oxidized in 1.72 mM sodium hydrosulfite for 2 
min, washed with water and treated with ice-cold silver nitrate solution (11,8 mM silver nitrate, 
0,025% (v/v) formaldehyde) for 30 min. After being washed several times with water, the gel was 
developed in 283 mM sodium carbonate, 63.2 µM sodium thiosulfate, 0,025% (v/v) 
formaldehyde. Color development was stopped with 412 mM Tris, 2% (v/v) acetic acid when the 
desired  staining intensity has been achieved. 
2.9. Western Blot analysis 
 After SDS-Page, proteins resolved in the gel were electrophoretically transferred to 
Hybond ECL nitrocellulose membrane (GE Healthcare, UK) using the wet blotting system Mini 
Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad, Hercules, USA) in a Towbin buffer (25 mM Tris, 
192 mM glycine, 20% (v/v) methanol) at the constant current of 250 mA for 1h at 4°C, The 
membrane was blocked with 5% skim milk in TBS-T (137 mM NaCl, 20 mM Tris, 0.1% (v/v) Tween-
20) for 1h at room temperature or overnight at 4 °C. Then, the membrane was incubated with 
appropriate dilutions of primary polyclonal antibody in blocking buffer at room temperature for 2 
hours or overnight at 4°C. After being washed in TBS-T, the membrane was incubated with 
1/10000 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody 
for 1 hour at room temperature. Membrane was then washed in TBS-T, immersed in ECLTM 
Western blotting detection reagent kit (Amersham Pharmacia Biosciences, Amersham, UK) for 5 
min in the dark and visualized on X-ray BioMax MR film (Kodak, New York, USA). 
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Chapter 3 
 
Bioinformatic and proteomic identification of Plasmodium 
falciparum succinate dehydrogenase and ATP synthase 
 
3.1. Introduction 
 The mitochondrial proteome from Plasmodium falciparum has been intensively 
characterized by sequence homology searching since the mapping of their genomes. Several 
mitochondrial proteins are part of complexes composing the electron transport chain (ETC; see 
Chapter 1, section 1.2.4.3) and only those having conserved amino acid sequences across species or 
being highly abundant have been characterized. However, a small number of ETC proteins, especially 
those of high hydrophobicity and/or low abundance, remain to be identified in Plasmodium spp. Due 
to high sequence divergence, the membrane anchor subunits of succinate dehydrogenase (SdhC and 
SdhD) and ATP synthase (subunit a and b) are still not annotated in Plasmodium databases. Their 
identification is crucial to validate the functionality and integrity of both enzymes. In this chapter, 
candidate genes encoding for these four missing subunits were determined based on a bioinformatic 
approach.  The identification of the subunits was then attempted using classical proteomic 
approaches involving protein separation by two-dimensional (2D) blue native/SDS-polyacrylamide gel 
electrophoresis coupled with liquid chromatography tandem mass spectrometry (LC-MS/MS). 
 
3.1.1. Identification of succinate dehydrogenase SdhC and SdhD subunits 
3.1.1.1.   The eukaryotic succinate dehydrogenase 
 As mentioned previously (see Chapter 1, section 1.2.4.3.2), the succinate:quinone 
oxidoreductase (also referred to as SDH, SQR or Complex II - EC 1.3.5.1) is a membrane protein 
complex that couples the two-electron oxidation of succinate to fumarate (equation 1) to the 
reduction of quinone to quinol (equation 2) (Hagerhall, 1997; Massey and Singer, 1957).  
 
succinate ⇌ fumarate + 2 H+ + 2 e-             (equation 1) 
quinone + 2 H+ + 2 e- ⇌ quinol        (equation 2) 
 
 In aerobic metabolism, eukaryotic SQRs play two roles. They are involved in the respiratory 
chain and constitute the only membrane-bound enzymes of the tricarboxylic acid cycle (TCA) 
(Saraste, 1999).  Generally, eukaryotic complex II contains four subunits (Fig. 3.1): two hydrophilic 
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subunits SdhA and SdhB attached to the inner membrane by one large or two small hydrophobic 
membrane-intrinsic subunits SdhC and SdhD (Horsefield et al., 2004). SdhA is a flavoprotein 
containing a flavin adenine dinucleotide (FAD) covalently attached to a histidine residue, and a 
succinate binding site (Robinson and Lemire, 1996). Succinate oxidation to fumarate releases 
electrons via FAD reduction. Electrons tunnel along an iron-sulfur relay constituted of three clusters 
[2Fe-2S], [4Fe-4S] and [3Fe-4S] located in the iron-sulfur subunit SdhB.  Electrons are transferred to a 
ubiquinone molecule in a binding site at the interface of SdhB, SdhC and SdhD. SdhC and SdhD are 
two small, highly helical, membrane anchor subunits with a low spin heme b556 coordinated by two 
histidine residues (Vibat et al., 1998).  
 
 
Figure 3.1. Overview and structure of the mammalian succinate dehydrogenase. The Protein Database (PDB) 
accession number used for the Complex II structure shown is 1ZPO (Sus scrofa).  
 
 SQRs crystal structures are currently available from bacteria (Escherichia coli - PDB entry 
1NEK), pig (Sus scrofa, 1ZOY) and chicken (Gallus gallus, 2H88) (Huang et al., 2006; Sun F Fau - Huo et 
al.; Yankovskaya et al., 2003). Across species, the hydrophilic subunits SdhA and SdhB have high 
amino acid sequence identities while those of the hydrophobic subunits SdhC and SdhD are poor 
homologous. 
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 Among nematode parasites, complex II has only been characterized in Ascaris suum, 
Trypanosoma and Leishmania species (Morales et al., 2009; Saruta et al., 1995). A. suum has a 
conventional four subunit SQR whereas its homologue in kinetoplastid species exhibits unusual 
features by being composed of 12 subunits. 
 
3.1.1.2. Succinate dehydrogenase in Plasmodium spp. 
 In malaria parasites, subunits SdhA and SdhB were easily identified due to sequence 
similarities with other species whereas SdhC and SdhD remain unannotated in the current database. 
Both SdhA and SdhB subunits are encoded by single open reading frames (ORF) located on 
chromosomes 10 and 12, respectively. 
 
 Although the Plasmodium SQR integrity is not fully established by gene identification, an 
accumulation of evidence published in several studies suggests to the presence of a functional 
enzyme. Early, Fry and Beesley measured reduction of cytochrome c after induction with succinate in 
P. falciparum and P. yoelii yoelii mitochondrial fractions (Fry and Beesley, 1991). In their work, the 
conviction to assay the SQR enzyme has been reinforced by inhibiting the succinate:cytochrome c 
reductase activity detected with known eukaryotic complex II inhibitors such as 
Thenoyltrifluoroacetone (TTFA) or Malonate. Afterwards, other complex II activities have been 
reported in several studies using two types of assay: oxygen consumption or reduction of 2,6-
dichloroindophenol (DCPIP), both induced by succinate (Krungkrai et al., 2000; Mather et al., 2010; 
Suraveratum et al., 2000). However, those SQR activities reported are variable and dependent on the 
yield and quality of the parasite preparation, as well as the type of assay performed (Table 3.1). 
 
Table 3.1. Complex II activities measured with mitochondrial extracts from Plasmodium spp. 
Reference 
Type of complex II assay 
(Plasmodium species used) 
Specific activity measured (nmoles/min/mg 
protein) 
(Fry and Beesley, 
1991) 
Cytochrome c reduction activity induced 
by succinate (P. falciparum and P. yoelii 
yoelii) 
Pf: 112 ± 13; Py: 150 ± 24 
Pf: 68 ± 9; Py: 69 ± 10 (with 20 µM TTFA) 
Pf: 77 ± 10; Py: 72 ± 8  (with 5 mM Malonate) 
(Suraveratum et 
al., 2000) 
DCPIP reduction activity induced by 
succinate (P. falciparum) 
33.13
1
 
(Krungkrai et al., 
2000) 
Oxygen consumption induced by 
succinate 
(P. falciparum) 
1.45 
(Kawahara et al., 
2009) 
DCPIP reduction activity induced by 
succinate 
(P. yoelii yoelii) 
2.66 ± 0.02 
(Mather et al., 
2010) 
DCPIP reduction activity induced by 
succinate (P. falciparum) 
9.73 
5.79 (with 10 mM Malonate) 
1
 Activity monitored on the isolated complex II. Pf indicates P. falciparum and Py, P. yoelii yoelii. 
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 The Krungkrai group was the first to isolate the P. falciparum complex II but containing only 
the SdhA and SdhB subunits with molecular weights of 55 and 35 kDa, respectively (Suraveratum et 
al., 2000). It has been concluded that the interaction between the hydrophobic part and the 
anchoring section is weak and can be easily broken during a purification process. P. falciparum SdhA 
and SdhB genes have also been cloned and characterized (Takeo et al., 2000). The genes encode 
subunits of 69.2 kDa (SdhA) and 37.8 kDa (SdhB), and have a presequence essential for the import 
into the mitochondrion. Evidence supporting the presence of SdhC and SdhD was provided by a study 
performed in P. yoelii yoelii (Fig. 3.2) (Kawahara et al., 2009). The molecular weight of the whole 
enzyme was estimated to be near 135 kDa in P. yoelii yoelii which is comparable to 130 kDa in 
mammals. A two dimensional approach identified two putative membrane anchor subunits SdhC and 
SdhD with molecular masses of 16 and 14 kDa respectively. However, both protein bands speculated 
as the two anchor subunits have not been identified by mass spectrometry.  
 
 
Figure 3.2. Analysis of complex II in Plasmodium yoelii yoelii (adapted from(Kawahara et al., 2009). (A) High 
resolution clear native electrophoresis of mitochondrial extract in bovine (Bos taurus) and Plasmodium yoelii 
yoelii. Both SQRs were visualized by succinate dehydrogenase activity staining. (B) SDS-Page followed by silver 
staining of the 135 kDa band corresponding to P. yoelii yoelii complex II. Putative complex II subunits are 
indicated with arrows. (Permission licence # 3144931157373). 
  
3.1.1.3. The membrane anchor subunits SdhC and SdhD 
 A first look at the primary structure among different species confirms the low sequence 
conservation for subunits SdhC and SdhD (Table 3.2). Except subunits from animals (S. scrofa and G. 
gallus) which are significantly conserved (>58% similarities), sequence identities between other 
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species remain low (between 3% and 24%). Therefore, homology searching by conventional BLAST 
analysis or Hidden Markov Model (HMM) approach with eukaryotic or bacterial sequences used as 
templates failed to determine either subunit in apicomplexans including Plasmodium spp. 
 
Table 3.2: Amino acid sequence identities between subunits SdhC and SdhD from representative species in 
mammals (Sus scrofa), aves (Gallus gallus), bacteria (Escherichia coli), yeast (Saccharomyces cerevisiae), 
plant (Arabidopsis thaliana) and protists (T. cruzi). The primary structure identities score was determined by 
amino acid alignment with ClustalW 2.0 (www.ebi.ac.uk/Tools/msa/clustalw2). Percentages of identity for 
SdhC and SdhD are highlighted in red and black respectively. 
 S. scrofa G. gallus E. coli S. cerevisiae A. thaliana T. cruzi 
S. scrofa  70% - 58% 19% - 8% 22% - 13% 12% - 5% 4% - 7% 
G. gallus   20% - 6% 24% - 15% 17% - 6% 3% - 5% 
E. coli    13% - 4% 9% - 8% 3% - 12% 
S. cerevisiae     12% - 6% 5% - 8% 
A. thaliana      7% - 13% 
T. cruzi       
UniprotKB entry (SdhC, SdhD) are for S. scrofa (P35720, A5GZW8), E. coli (P69054, P0AC44), G. gallus 
(D0VWW3, Q5ZIS0), S. cerevisiae (P33421, P37298), A. thaliana (A8MSF5, Q941A0) and T. cruzi (Q4D4V5, 
Q4D1F3). 
 
 Despite low sequence identities, high similarities were observed by aligning the anchoring 
section of SQR crystal structures available from bacteria, mammalian and avian species (Fig. 3.3). For 
example, pig and bacterial SdhD show only 8% of sequence identities but share 62.7% of structural 
homologies. Under those observations, the hypothesis that structural features of the anchor 
membrane subunits are highly conserved to accomplish an analogous function can be proposed.  
 
 
 
 B 
SQR 
Subunit 
Species 
A 
Species 
B 
Sequence 
identities 
Structure 
identities 
SdhC 
Ss Gg 70% 96,3% 
Ss Ec 19% 70,8% 
Ec Gg 20% 69,9% 
SdhD 
Ss Gg 58% 98,5% 
Ss Ec 8% 62,7% 
Ec Gg 6% 62,8% 
 
Figure 3.3. Crystal structure alignment of SdhC and SdhD in three different species. (A) Structures alignment 
has been performed with PyMol (www.pymol.org) with membrane anchor section in Sus scrofa (PDB entry 
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1ZOY), Escherichia coli (1NEK) and Gallus gallus (2H88), highlighted in blue, green and pink, respectively. (B) 
Comparison of sequence and structure identities among three species. Sequence identities were determined 
with ClustalW 2.0 (www.ebi.ac.uk/Tools/msa/clustalw2). Structure identities score was calculated via crystal 
structure alignment with the TM-align algorithm (zhanglab.ccmb.med.umich.edu/TM-align). 
 
3.1.2. Identification of ATP synthase subunits a and b 
3.1.2.1.   Eukaryotic ATP synthase  
 In eukaryotes, inner membrane-bound ATP synthases (F1F0-type ATPases, EC 3.6.3.14) 
catalyse two important physiological functions with the synthesis of ATP from ADP and inorganic 
phosphate in the mitochondrial matrix or the reverse reaction, the hydrolysis of ATP, to generate a 
transmembrane electrochemical gradient under conditions of low driving force (Devenish et al., 
2008). The enzyme is composed of two domains: a water-soluble F1 sector which contains the active 
site and consists of subunits α3, β3, δ, ε and γ, and the membrane-associated F0 part made up of 
subunits c8-12, a and b (Fig. 3.4). The F0 domain can be associated with additional subunits such as 
OSCP, d or F6 (Walker and Dickson, 2006). During ATP synthesis, protons from the intermembrane 
space are translocated to the matrix via two aqueous half-channels formed by the transmembrane 
domains of the subunit a; with one channel leading to the matrix and the other to the 
intermembrane space (Angevine et al., 2007).  
 
 
Figure 3.4. Structure and subunits composition of the F1F0-type ATP synthase in E. coli. The picture shown 
here is a composite of four different X-ray and NMR structures of E. coli F1F0 ATPase (PDB entry 1C17, 1E79, 
2AZU and 1L2P). Abbreviations: M, matrix; IM; inner membrane; IMS, intermembrane space. 
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 The proton flow causes rotation of the oligomeric ring formed by several subunits c and 
subsequently the central stalk composed by subunits ε, δ, γ which enforces each catalytic site in F1 to 
synthesize ATP. For the reverse reaction, ATP hydrolysis in the hexameric α3β3 drives reverse rotation 
of the central stalk and then c-ring which causes proton efflux via F0. During translocation, the proton 
binding and release takes place via a carboxyl group of a strictly conserved acidic residue (Asp61 in E. 
coli or Glu59 in S. cerevisiae) located within the second transmembrane helix of the subunit c 
(Deckers-Hebestreit et al., 2000) (Fig. 3.5 A and B). This aspartate or glutamate residue acts as the 
proton acceptor and donor at the subunit a/ring-c interface. The arginine conserved in subunit a 
(Arg210 in bacteria or Arg176 in yeast) is suspected to play the crucial mechanistic function to 
coordinate protonation and deprotonation events (Fig. 3.5 C and D) (Symersky et al., 2012). 
 
 
Figure 3.5. Structure of subunits c and a, and hypothetical rotary mechanism of the c-ring from F1F0 ATP 
synthase. (A) Cartoon representation of the c-ring (cyan and greencyan) and subunit a (red) structure viewed 
from the mitochondrial matrix  (ATP synthase in E. coli; PDB entry 1C17). (B) Same as in A, viewed along the 
plane of the inner membrane. Highly conserved residues Asp61 (pink; Glu59 in yeast) and Arg210 (yellow; 
Arg176 in yeast) residues are represented with spheres. (C) Counterclockwise rotary mechanism of the ATP 
synthesis suggested by Symersky et al. and viewed from the mitochondrial matrix (Symersky et al., 2012). 
When facing the membrane, c-ring Glu59 are protonated (orange, state 0). By entering at the interface with the 
subunit a, Glu59 adopt an open conformation and release a proton into the half-channel leading to the matrix 
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(state 1). Glu59 in the adjacent subunit c interact with Arg176 (state 2) but becomes free when Arg176 switch 
the interaction with the newly deprotonated Glu59. (D) The release of the interaction enables the unengaged 
Glu59 residue to load another proton coming from the intermembrane space via the second water-half channel 
before to re-enter in the inner membrane. (Permission licence # 3144940923456) 
 
 To allow the rotational movement of the central stalk, a second structural link between F0 
and F1 is necessary for the stabilization of the whole complex. Thus, an extended hydrophilic 
structure, the "second stalk" (referred also as "stator stalk") is located at the periphery and holds the 
α3β3 hexamer in place during the movement of the central stalk (Wilkens and Capaldi, 1998). The 
stator stalk composition varies among species. In bacteria, it consists of one subunit δ (also termed 
OSCP, Oligomycin Sensitivity-Conferring Protein, for eukaryotes) and a dimer of subunit b. In 
cyanobacteria and other photosynthetic bacteria, two different but homologous subunits b and b' 
replace the dimeric structure. In the mitochondrial eukaryotic enzyme, only one subunit b is 
associated with two mitochondrial-specific subunits d and F6. Both subunits are wrapped around the 
single subunit b in a way to replace the function of the second subunit b in the bacterial enzyme 
(Weber, 2007). Although a complete structure of F1F0-ATP synthase in eukaryotes is still not 
available, an x-ray structure of the stator stalk from bovine heart mitochondria has been solved with 
large portions of subunits b, d and F6 (Fig. 3.6) (Dickson et al., 2006). 
 
 
Figure. 3.6. Partial structure of the stator stalk in the ATP synthase from bovine heart mitochondria (Dickson 
et al., 2006). (A) X-ray structure of the stator stalk with the subunits b (magenta), d (orange) and F6 (green) 
(PDB entry 2CLY). (B) Suggested location of the stator stalk in the ATP synthase (Dickson et al., 2006). The N-
terminal domain of the OSCP (cyan), the stator stalk structure and the F1-c10 subcomplex (grey) were 
introduced by eye into an electron density map of an intact bovine ATP synthase complex determined by 
electron cryo-microscopy. (Permission licence # 3144940689940). 
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3.1.2.2.   ATP synthase in Plasmodium spp. 
 It has been assumed for a long time that Plasmodium mitochondria cannot perform oxidative 
phosphorylation due to the lack of both ATP synthase subunits a and b  (Fry and Beesley, 1991; 
Gardner et al., 2002). However, the capacity for oxidative phosphorylation in rodent parasites and P. 
yoelii yoelii was demonstrated supporting the presence of both key subunits (Uyemura et al., 2000; 
Uyemura et al., 2004). As mentioned previously, both subunits have major roles in H+ translocation or 
maintaining stability of the whole complex. It suggests that a conventional H+-ATP synthase lacking 
both subunits cannot be correctly assembled and functional. Recently, attempts to delete the genes 
encoding the subunit β and γ have been unsuccessful (Balabaskaran Nina et al., 2011). Therefore, the 
mitochondrial ATP synthase is suspected to play an important role in blood stage parasites by (i) 
maintaining the crucial membrane potential via ATP hydrolysis, (ii) producing ATP for local 
physiological processes, or (iii) contributing in mitochondrial morphogenesis. Additionally, P. 
falciparum ATP synthase has been found to be partly assembled in a dimeric complex by using a blue 
native gel approach (Fig. 3.7) (Balabaskaran Nina et al., 2011). Like in most eukaryotic organisms 
(Arnold et al., 1998), the dimeric ATP synthase seems to be the predominant form in P. falciparum 
parasites. The interaction between two ATP synthase monomers is mediated by the F0 sector and 
probably by the subunit a which has the most important basis for dimerization due to its high 
number of transmembrane helices (Wittig and Schagger, 2008). Additionally to subunit a, subunit b 
and accessory subunits (e and A6L) can also stabilize the monomer-monomer interface (Bisetto et al., 
2008; Wittig et al., 2010). 
 
 
Figure 3.7. Dimeric formation of P. falciparum ATP synthase (Balabaskaran Nina et al., 2011). (A) Blue native 
gel of P. falciparum mitochondria extract stained with coomassie blue. (B) Blue native gel with mitochondria 
from parasites probed with anti-β antiserum.  
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3.1.2.3.   Evidence of Plasmodium subunits a and b existence 
 Both subunits a and b are highly divergent and could not be identified by conventional 
bioinformatic tools like BLAST or HMM algorithms (Table 3.3). Recently, candidates of both subunits 
have been identified in the protozoan Tetrahymena thermophilia showing poor similarities with 
eukaryotic homologues (Balabaskaran Nina et al., 2010). To date, only one crystal structure of the 
subunit a (in E. coli) has been solved as well as a single structure of the subunit b (in B. taurus). Thus, 
their degree of structural similarities with homologues could not be predicted. However, the overall 
structure of ATP synthase remains highly conserved across species. Therefore, both subunits a and b 
in Plasmodium species can be speculated to have similar structural profiles with their homologues in 
bacteria or mammals.  
 
Table 3.3. Amino acid sequence identities between subunits a and b from representative species in mammals 
(H. sapiens), bacteria (E. coli), yeast (S. cerevisiae), nematode (A. suum) and protist (T. brucei). The primary 
structure identities score was determined by amino acid alignment with ClustalW 2.0 
(www.ebi.ac.uk/Tools/msa/clustalw2). Percentage of identities for ATP synthase subunit a and b are 
highlighted in red and black respectively. 
 H. sapiens E. coli S. cerevisiae A. suum T. brucei 
H. sapiens  20% - 9% 34% - 15% 17% - 20% 10% - 5% 
E. coli   16% - 13% 15% - 11% 20% - 8% 
S. cerevisiae    17% - 15% 16% - 3% 
A. suum     19% - 7% 
T. brucei      
UniprotKB entry (subunits a, b) are for H. sapiens (P00846, P24539), E. coli (P0AB98, P0ABA0), S. cerevisiae 
(P00854, P05626), A. suum (P24876, F1L7V5) and T. cruzi (P24499, Q57ZP0). 
 
 Only two components of the F0 sector have been identified in malaria parasites: subunits c 
and OSCP. Plasmodium subunit c shows important identities with mammals, yeast and bacteria 
homologues and exhibits a glutamate residue located within its second transmembrane domain 
essential for protons translocation (Fig. 3.8). Hence, Plasmodium subunit c displays necessary 
features to operate a functional rotary mechanism, supporting the presence of subunit a as partner. 
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Figure 3.8. Sequence alignment of the C-terminal section from ATP synthase subunit c in different species 
and location of their transmembrane domains. (A) The sequences were aligned with ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2). Residues are displayed with dark boxes for full conservation and grey 
boxes for strong similarities. In red is highlighted the Asp or Glu residue implicated in proton translocation and 
interaction with the Arg residue conserved in subunit a. The subunit c sequences used were from Bos taurus 
(UniprotKB entry P32876), Saccharomyces cerevisiae (P61829), Escherichia coli (P68699) and Plasmodium 
falciparum (C0H4L0). (B) Transmembrane helices indicated by green 'TM helix' boxes were predicted using 
THMMH algorithm (www.cbs.dtu.dk/services/TMHMM). The Asp or Glu essential residue is indicated in red. 
 
3.1.3. Bioinformatic strategy 
A pyramid-shaped filter was established with a series of structural fingerprints such as the 
molecular weight, number of transmembrane domains, secondary structure profile, conserved 
motifs, protein function and presence of a mitochondrial signal peptide (Fig. 3.9). For each subunit 
searched, fingerprint cut-offs were determined by studying homologous proteins from prokaryotes, 
animals, yeasts or plants. Thus, candidate genes were identified by passing all the available P. 
falciparum encoding genes in the PlasmoDB database through those different filters. 
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Figure 3.9. Pyramid-shaped strategy applied to identify potential candidate genes for succinate 
dehydrogenase and ATP synthase lacking subunits.  
 
3.1.4. Proteomic approach 
Two-dimensional (2D) blue native electrophoresis (BNE)/SDS-Page is a gel-based approach 
mainly used to study mitochondrial complexes (Klodmann et al., 2010; Taylor et al., 2002). In contrast 
to the conventional 2D isoelectric focusing/SDS-Page system, 2D BNE/SDS-Page is more adapted to 
characterize hydrophobic proteins even if the resolution of resulting gels is slightly reduced. The first 
dimension is a blue native gel electrophoresis to separate respiratory chain complexes from 
solubilised mitochondrial membranes. Digitonin, dodecyl-β-D-maltoside (DDM) or triton X-100 are 
nonionic detergents with strong delipidating properties suitable for isolation of membrane 
complexes. Following solubilisation, the ionic dye coomassie blue nonspecifically binds all proteins 
and charges them negatively. Thus, the electrophoretic mobility of complexes in the first dimension 
gradient gel depends on the size and shape of complexes. Separated by native gels, enzymatic 
complexes are still biochemically active and specific staining methods based on in-gel activity or 
fluorescent assays can be used to localize them on the gel (Heinemeyer et al., 2007).  Subsequently, 
complexes are resolved from a BNE strip into their composing subunits on a second gel dimension in 
the presence of sodium dodecyl sulfate (SDS). Following the second dimension, gels can be stained 
for immediate visualization with coomassie or silver stain, as well as electroblotted for protein 
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detection with specific antibodies (Fig. 3.10). Finally, mass spectrometry analysis can be a 
straightforward and sensitive approach to identify proteins from gel spots of interest. 
 
 
Figure 3.10. Separation of mitochondrial complexes separated by 2D BNE/SDS-Page (Wittig et al., 2006). (A) 
Gradient blue native gel of solubilised bovine heart mitochondrial complexes I to V, pyruvate dehydrogenase 
complex (P) and oxoglutarate dehydrogenase complex (O). (B) Silver staining of a two dimensional SDS-Page gel 
with subunits of each complex aligned vertically. (Permission licence # 3144940036515). 
 
 
 In this chapter, a conventional gradient BNE/SDS-Page approach was performed to identify 
lacking subunits in P. falciparum succinate dehydrogenase and ATP synthase (Fig. 3.11). The major 
obstacle of this strategy is the isolation of mitochondria from other components of malaria parasites 
as well as the low expression level of some mitochondrial proteins. Several studies on mitochondrial 
physiology have been handicapped by the difficulty in obtaining a clean preparation with sufficient 
yield of mitochondrial enzymes due to the numerous internal membrane compartments, presence of 
hemozoin particles, or their poor expression. To adapt the BNE/SDS-Page strategy for mitochondrial 
proteins, an enrichment method was added in upstream. Density gradients with sucrose, Percoll® or 
Ficoll are common methods to isolate subcellular fractions containing mitochondria (Tran et al., 
2006). Hence, a sucrose gradient centrifugation was performed on solubilised membrane proteins. 
Commonly used as an alternative to BNE as first dimension, cell fractionation based on sucrose 
gradient density allows concentration and separation of mitochondrial complexes.  
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 To identify our proteins of interest, two identical 2D non-gradient BN/SDS-Page gels were 
performed from the same protein sample. Then, one gel was stained with silver whereas the other 
was immunoblotted with a specific polyclonal antibody against a subunit known from P. falciparum 
complex II or V. Signals obtained from the western blot are compared with spots on the silver-stained 
pattern in order to localize the mitochondrial complex targeted. Spots aligned on the same vertical 
axis are excised, digested by trypsin and analysed by NanoLC-MS/MS to be identified.  
 
 
Figure 3.11 Flowchart of the proteomic approach applied for P. falciparum mitochondrial subunits 
identification. Abbreviation: pAb, polyclonal antibody. 
 
3.2. Material & Methods 
3.2.1. Bioinformatics tools 
 The presence of structural fingerprints in Plasmodium genes was determined manually from 
the PlasmoDB database (www.plasmodb.org). The possibility to add in a series of different structural 
queries with the "PlasmoDB strategy" allows filtering of the overwhelming number of encoding 
sequences in the Plasmodium genome to get only a few genes exhibiting the characteristics sought. 
For each structural fingerprint, the cut-off was defined by using specific bioinformatic tools and 
studying homologous genes from  bacteria, yeast, mammal, plant and protist species (Table 3.4). 
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Table 3.4. List of structural fingerprints chosen and bioinformatics tools used. 
Filtering 
order 
Structural fingerprint Bioinformatic tools to determine cut-off fingerprint 
1 Molecular weight Compute pI/Mw (web.expasy.org/compute_pi) 
2 
Number of transmembrane 
domains 
TMHMM v2.0 (www.cbs.dtu.dk/services/TMHMM) 
PSIPRED (MENSAT3 & MENSAT-SVM options, 
www.bioinf.cs.ucl.ac.uk/psipred) 
3 Secondary structure 
PSIPRED (PRIPRED v3.0 option, 
www.bioinf.cs.ucl.ac.uk/psipred) 
4 Specific motif pattern ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2) 
5 Protein function PlasmoDB description 
6 Mitochondrial signal peptide 
PlasMit (gecco.org.chemie.uni-frankfurt.de/plasmit) 
PFMPred (www.imtech.res.in/raghava/pfmpred) 
MitoProt II (ihg.gsf.de/ihg/mitoprot.html) 
 
3.2.2. Proteomics approach 
3.2.2.1.  Synthesis of anti-Sdha and anti-ATPase subunit α polyclonal antibodies 
 The peptide 573AHARDDFPERDDKN586 of the SdhA subunit (PlasmoDB entry PF3D7_1034400) 
was selected (Fig. 3.12. A), synthesized, and used for immunization in the rabbit to generate an 
affinity-purified polyclonal antibody (GenScript Corp., Piscataway, NJ). In the same manner, two 
polyclonal antibodies were produced by targeting both peptides 520EVEDQIKESIFQKFL533 (Fig. 3.12. B) 
and 162TKERRKIEIKAPGI175 of the ATP synthase subunit α (PlasmoDB entry PF3D7_1034400) (shortly 
termed anti-ATPα antibodies). Rabbit anti-SdhA and anti-ATPα antibodies were lyophilized in 
phosphate-buffered saline (pH 7.4) with 0.02% sodium azide as preservative. Lyophilized antibodies 
were reconstituted with MilliQ water, and aliquots were stored at -20 °C until use. 
 
Figure 3.12. Position of the peptide chosen for polyclonal antibodies synthesis in P. falciparum and 
comparison with homologues in bacteria, yeast and bovine. (A) Sequence alignments of C-terminal section of 
SdhA from P. falciparum (PlasmoDB entry PF3D7_1034400), E. coli (UniprotKB entry P0AC41), S. cerevisiae 
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(Q00711) and Bos Taurus (P31039). (B) Sequence alignments of C-terminal section of ATP synthase subunit α 
from P. falciparum (PlasmoDB entry PF3D7_0217100), E. coli (UniprotKB entry P0ABB0), S. cerevisiae (P07251) 
and Bos Taurus (P19483). In red is highlighted both peptides 
573
AHARDDFPERDDKN
586 
and 
520
EVEDQIKESIQKFL
533 
chosen for antibody synthesis. Residues are displayed with dark boxes for full 
conservation and grey boxes for strong similarities. 
3.2.2.2.  E. coli crude mitochondrial membranes preparation 
 Wild type Escherichia coli cells were prepared from LB broth containing 50 µg/ml ampicillin 
and 25 µg/ml chloramphenicol. A 10 ml culture of bacterial cells was grown overnight at 37 °C with 
shaking at 200 rpm. The following day these cultures were propagated in 400 ml LB broth containing 
appropriate antibiotics and grown at 37°C (200 rpm shaking). The cells were harvested by 
centrifugation at 4,000 x g for 20 min. Cells were resuspended in a ice-cold buffer containing 50 mM 
potassium phosphate pH 7.4, 2 mM EDTA and protease inhibitors (Roche). This was followed by cell 
disruption using a French press at a pressure of 25,000 psi. The cell lysate was centrifuged at 4,000 x 
g for 20 min at 4°C to remove unbroken cells. Membranes were recovered from the supernatant 
after ultracentrifugation during 1 h at 100,000 x g and 4°C. The membranes were resuspended in 500 
µl of ice-cold buffer with 50 mM KPi pH 7.4, 2 mM EDTA and protease inhibitors. Membranes were 
aliquoted and stored at -80°C. 
3.2.2.3.  Immunoprecipitation and immunobloting 
For immunoprecipitation studies, E. coli membrane proteins were boiled (5 min at 95 °C) in 
denaturing lysis buffer (50 mMTris-HCl, 5 mM EDTA, 2% (w/v) SDS, 10 mM DTT) and diluted (10-fold) 
with non-denaturing lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 
pH 7.5). Following centrifugation (17,000 x g for 30 min), denatured proteins were collected in the 
supernatant and incubated overnight with 2 µg of anti-SdhA antibody, rotating at 4°C, followed by 50 
µl of protein A-sepharose slurry for 3 h at 4 °C. Immunoprecipitates were washed, gently eluted with 
an acidic buffer (pH 2.8), and then separated by 7.5% (w/v) SDS-Page gel electrophoresis before 
proceeding to immunoblotting with the anti-SdhA polyclonal antibody as primary incubation as 
described in General Material & Methods (section 2.6 and 2.7). 
3.2.2.4.  Sucrose gradient density centrifugation 
Parasite membrane proteins and bovine mitochondrial membranes were centrifuged 30 min 
at 17,000 x g and 4°C. Both pellets obtained were resuspended in ice-cold sucrose gradient buffer (50 
mM Tris-HCl, 1 mM EDTA, 0.05% dodecyl-β-D-maltoside, pH 7.5) and solubilised with 1% dodecyl-β-
D-maltoside for 30 min on ice with frequent mixing. Samples were centrifuged 30 min at 17,000 x g 
and 4°C. Supernatants were subjected to sucrose gradient centrifugation. The gradient consisted of 
1.5 ml step-fractions of 35%, 32.5%, 30%, 27.5%, 25%, 22.5%, 20%, 17.5%, 15%, 12.5% 10%, (7.5%) 
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and 5% sucrose in ice-cold sucrose gradient buffer. 1.5 ml of solubilised membranes (supernatants) 
from beef heart or parasites were loaded onto the gradient and centrifuged at 100,000 x g for 16h30 
at 4°C. The gradient was collected from the top in 1.5 ml fractions. In order to localize the presence 
of complex II in sucrose density fractions, they were assessed by 7.5% SDS-Page and Western analysis 
using an anti-SdhA primary antibody as described in Material & Methods (section 2.6 and 2.7).  
3.2.2.5.  First dimension blue native electrophoresis (BNE) 
 Fractions enriched in complex II were pooled and concentrated within 50 kDa cutoff Amicon 
centrifugal concentrators (Millipore, USA) and brought up to a final volume of 200 μl with 0.5% 
dodecyl-β-D-maltoside in BN sample buffer (50 mM imidazole, 50 mM NaCl, 2 mM 6-aminocaproic 
acid, 1 mM EDTA, pH 7.0). The protein sample concentration was determined using Bradford assays 
as described in General Material & Methods (section 2.2). Finally, 2.5 μl 5% Coomassie in 500 mM 6-
aminocaproic acid pH 7.0 was added per 50 μg of membrane proteins. BNE were cast and performed 
according to published protocols (Swamy, 2006; Wittig et al., 2006). A stock solution containing 48% 
(w/v) acrylamide and 1.5% (w/v) bisacrylamide was prepared in deionized distilled water, filtered and 
used for both stacking and resolving gels. BNE resolving gels were cast in a large format (0.10 x 14 x 
14 cm) with a 4-15% acrylamide gradient for only solubilised membranes supernatant or an 8% non-
gradient uniform acrylamide concentration for enriched complex II preparation. Gel buffer was 
comprised of 500 mM 6-aminocaproic acid and 25 mM imidazole, pH 7.0. The final concentration of 
the stacking gel was 4% and BNE gels were stored at 4°C overnight. BNE were performed at 2-4°C by 
using a Hoefer® SE600 Cooled Vertical Electrophoresis Unit. Cathode buffer contained 50 mM Tricine, 
7.5 mM imidazole, 0.02% coomassie blue G-250 (w/v) and 2 mM 6-aminocaproic acid, pH 7.0 while 
anode buffer contained only 25 mM imidazole, pH 7.0. Between 40 to 60 µg of membrane proteins 
were loaded. Gel was run at 150 V / 15 mA until the front line had crossed one-third of the gel, 
where the cathode buffer was replaced by one with only 0.002% coomassie blue G-250. Gel running 
was then continued at 500 V / 15 mA until complete. 
3.2.2.6. Second dimension SDS-Page 
For a second dimension SDS-Page, individual lanes of the first dimension gel were excised 
with a razor blade and incubated 1 h at 37°C with 2X loading buffer (0.125M Tris-HCl pH 6.8, 4% SDS, 
20% glycerol, 0.02% Bromophenol blue, 10% 2-mercaptoethanol). The BN-Page gel strips were then 
rinsed briefly with SDS-Page running buffer (25 mM Tris, 0.192 mM Glycine, 0.1% SDS, pH 8.8). SDS-
Page resolving gels were performed using 15% non-gradient acrylamide. The excised lanes were then 
placed into the top of the resolving gel (0.15 x 14 x 14 cm) and sealed with 4% stacking gel solution. A 
pre-stained broad range protein marker (SpectraTM Multicolor Broad Range Protein Ladder, Thermo 
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Scientific, USA) was loaded alongside the strip. Electrophoresis was performed at 10°C with SDS-Page 
running buffer at 200 V / 50 mA until the front passed into the separation gel and then continued at 
500 V / 50 mA. Two identical SDS-Page were performed with two identical BNE strips from bovine 
mitochondrial membranes or parasite membrane proteins. One 2D gel was visualized using a 
standard silver staining protocol (see General Material & Methods, section 2.6.4) while the other was 
used for immunoblotting. For 2D immunoblots, 2D gels were transferred electrophoretically to 
Hybond ECL nitrocellulose (Amersham GE Healthcare, UK) using a Biorad® Trans-Blot Cell (Biorad 
Laboratories, USA) for 3 h at 400 mA and 4°C. Blocking and antibody incubation was carried out as 
described in General and Methods (section 2.7.2). For SdhA immunobloting, the customized anti-
SdhA antibody described in this chapter was used. For bc1 rieske subunit, another customized 
polyclonal antibody was used described in Chapter 6 (section 6.2.1). For SdhB and ATP synthase 
subunit α, the commercial monoclonal antibodies ab14714 and ab110273 (Abcam, UK), only specific 
to bovine proteins, were used respectively. 
3.2.2.7. In-gel trypsin digestion, mass spectrometry and database searches 
 For immunoprecipitation procedure, protein spots corresponding to the signal from the anti-
SdhA immunoblot were excised on the silver-stained SDS-Page. For 2D gels, proteins spots located on 
the same vertical that signals obtained with specific primary antibodies were excised on the similar 
silver-stained 2D SDS-Page. 
 Each sample was reduced with 10 mM DTT at 56 °C for 30 min and alkylated with 55 mM 
iodoacetamide at 37 °C for 30 min. Proteins contained within these gel spots were proteolyzed by 
addition of 190 ng of sequencing grade trypsin (Sigma) and incubated overnight at 37 °C. The 
resulting tryptic peptides were then dried and rehydrated in 5% (v/v) formic acid in 50% (v/v) 
acetonitrile. NanoLC-MS/MS analyses were performed on a Dual Gradient Ultimate 3000 
chromatographic system (Dionex). A 20 µl aliquot of sample was placed into a well on a 96-well plate, 
of which 10 µl of sample was injected onto a C18 pre-column (Acclaim PepMap C18; 2-cm length x 
100-µm inner diameter x 5-µm particle size; 100 Å porosity; Dionex). After desalting for 6 min with 
buffer A (water/acetonitrile/formic acid, 97.5/2.5/0.1 v/v/v) peptide separation was carried out on a 
C18 capillary column (Acclaim PepMap C18; 15-cm length x 75-µm inner diameter x 2-µm particle 
size; 100 Å porosity; Dionex) with a gradient method starting at 100% buffer A, ramping up to 50% 
buffer B (water/acetonitrile/formic acid, 10/90/0.1 v/v/v) over 90 min. This was then increased to 
100% buffer B over 0.1 min, which was then held at 100% buffer B for 10 min. Finally, this was 
decreased to 0% over 0.1 min, and buffer A was increased to 100%. The column was finally re-
equilibrated with 100% buffer A for 15 min. The LC eluent was nano-sprayed into the MS instrument 
with a glass emitter tip (Pico-tip, FS360–50-15-CE-20-C10.5; New Objective Woburn). The LTQ 
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Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Germany) was operated in positive 
ionization mode. Raw data files were processed using the software Proteome Discoverer 1.0.0 
(Thermo Fisher Scientific, Germany) incorporating Sequest search algorithm. The proteins were 
identified by screening LC-MS sequence data against a PlasmoDB database (version 8.0). A parent 
mass tolerance of 1.5 Da and fragment mass tolerance of 1 Da were used, allowing for one missed 
cleavage. Carbamidomethylation of cysteine and oxidation of methionine were the fixed and variable 
modifications, respectively. 
 
3.3. Results 
3.3.1. Candidate gene identification for subunits SdhC and SdhD 
 First, the molecular weight (MW) of each complex II anchor subunits was estimated. Previous 
proteomic studies have predicted a size for each subunit between 13 to 20 kDa in P. falciparum and 
P. yoelii yoelii (Table 3.5). The theoretical MW from homologue subunits in nineteen diverse species 
were calculated and determined to be between 9 and 22 kDa (Tables 3.6 and 3.7). Thus, a cut-off of 
9 to 25 kDa for the molecular weight of each subunit has been arbitrarily determined. 
 
Table 3.5. Molecular weight of four complex II subunits experimentally estimated and bioinformatically 
predicted (PlasmoDB) for P. falciparum and P. yoelii yoelii.  
Complex II 
Suraveratum et al., 
1999 
(P. falciparum) 
Kawahara et al., 2008 
(P. yoelii yoelii) 
PlasmoDB 
prediction 
(P. falciparum) 
PlasmoDB 
prediction 
(P. yoelli yoelli) 
Whole Complex 90 ± 8kDa 135 kDa - - 
Subunit a (SdhA) 55 ± 6 kDa 70 kDa 70696 Da 70327 Da 
Subunit b (SdhB) 35 ± 4 kDa 35 kDa 37752 Da 37655 Da 
Subunit c (SdhC) 15-20 kDa 16 kDa - - 
Subunit d (SdhD) 13-16 kDa 14kDa - - 
 
 Subsequently, the number of transmembrane domains (TMs) was predicted from homologue 
genes and shown to be between 1 to 3 TMs depending on the prediction algorithm used (Tables 3.6 
and 3.7). In consequence, a cut-off of 1 to 3 TMs was chosen. The secondary structure profile was 
also estimated from the same set of ShdC and SdhD homologues (Tables 3.6 and 3.7). Both subunits 
are mainly helical with 40 to 85% α-helix for SdhC and 28 to 85% for SdhD, as well as less than 15 and 
22% β-strands, respectively. This observation is confirmed by the complex II X-ray structure obtained 
from E. coli, G. gallus and S. scrofa showing three transmembrane α-helices per subunit (Huang et al., 
2006; Sun F Fau - Huo et al.; Yankovskaya et al., 2003). The part of coil secondary structure is variable 
with a percentage from 15 to 48% in SdhC and from 10 to 66% for SdhD. 
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Table 3.6. Structural fingerprints (molecular weight, number of transmembrane domains and secondary structure profile) of SdhC in 19 species representing five 
different kingdoms.  
 
  Molecular weight Transmembrane domains Secondary structure 
 Organisms UniPort Acc # Length MW (kDa) PDB THMMH M-SVM M-V3 
% 
α-helix 
% 
β-strand 
% 
Coil 
Animals 
Homo sapiens Q99643 169 18.6 - 3 3 3 76.3 0.0 23.7 
Mus musculus Q9CZB0 169 18.4 - 3 3 3 76.3 0.0 23.7 
Gallus gallus D0VWW3 140 15.4 3 3 3 3 74.3 0.0 25.7 
Sus scrofa D0VWV4 169 18.5 3 3 3 3 39.3 0.0 12.2 
Drosophila menalogaster Q9VGS3 171 18.5 - 3 3 3 67.3 0.0 32.7 
Xenopus tropicalis A9UM72 167 18.5 - 3 3 3 76.9 0.0 23.1 
Ascaris suum P92506 188 21.1 - 3 3 3 67.6 0.0 32.4 
Protozoans 
Reclinomonas  americana P80481 144 16.7 - 3 3 3 77.1 0.0 22.9 
Dictyostelium discoideum Q8T2T5 192 21.4 - 2 3 3 63.5 0.0 36.5 
Cyanidioschyzon merolae Q9ZZR3 137 16.7 - 3 3 3 81.0 0.0 19.0 
Trypanosoma cruzi Q4D4V5 106 12.2 - 1 1 1 45.3 11.3 43.4 
Leishmania major Q4Q708 104 11.8 - 1 1 1 48.1 11.5 40.4 
Yeast 
Alternaria alternata B8XSR3 177 19.6 - 3 3 3 74.0 0.0 26.0 
Saccharomyces cerevisiae P33421 198 22 - 3 3 3 72.7 0.0 27.3 
Plants 
Nicotiana tabacum Q5M9U9 108 12.6 - 2 3 2 73.1 0.0 26.9 
Chlamydomonas 
reinhardtii 
A8HPU2 203 21.7 - 2 3 3 57.6 1.0 41.4 
Bacteria 
Escherichia coli P69054 129 14.3 3 3 3 3 76.7 0.0 23.3 
Enterobacter cloacae D5CHF2 159 17.8 - 3 3 3 67.9 0.0 32.1 
Paracoccus denitrificans Q59659 130 14.3 - 3 3 3 77.7 0.0 22.3 
            
Minimum  106 12.2  1 1 1 45.3 0.0 19.0 
Maximum  213 22  3 3 3 81.0 11.5 43.4 
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Table 3.7. Structural fingerprints (molecular weight, number of transmembrane domains and secondary structure profile) of SdhD in 19 species representing five 
different kingdoms. 
  Molecular weight Transmembrane domains Secondary structure 
 Organisms UniPort Acc # Length MW (kDa) PDB THMMH M-SVM M-V3 
% 
α-helix 
% 
β-strand 
% 
Coil 
Animals 
Homo sapiens O14521 159 17.0 - 3 3 3 48.4 6.3 45.3 
Mus musculus Q9CXV1 159 17.0 - 2 3 3 49.1 5.7 45.3 
Gallus gallus Q5ZIS0 157 16.4 3 2 3 3 52.9 5.1 42.0 
Sus scrofa A5GZW8 159 17.0 3 3 3 3 47.2 6.9 45.9 
Drosophila menalogaster Q9VCI5 182 19.3 - 2 3 2 51.6 5.5 42.9 
Xenopus tropicalis Q6P355 152 16.4 - 2 3 3 53.9 5.3 40.8 
Ascaris suum Q8WSR2 141 15.7 - 3 3 3 52.5 5.7% 41.8 
Protozoans 
Reclinomonas  americana P80482 120 14.2 - 3 3 3 68.3 3.3 28.3 
Dictyostelium discoideum Q54YN1 179 19.1 - 3 3 3 33.0 5.6 61.5 
Cyanidioschyzon merolae Q9ZZN2 79 9.6 - 2 2 1 78.5 6.3 15.2 
Trypanosoma cruzi Q4D1F3 127 13.9 - 2 2 2 55.9 17.3 26.8 
Leishmania major Q4Q474 147 15.7 - 2 2 2 51.4 13.3 35.3 
Yeast 
Alternaria alternata B8XSR4 193 21.1 - 1 3 2 60.6 6.7 32.6 
Saccharomyces cerevisiae P37298 181 20.2 - 2 3 2 51.9 5.0 43.1 
Plants 
Nicotiana tabacum Q5M9V6 125 14.6 - 3 3 2 72.0 2.4 25.6 
Chlamydomonas 
reinhardtii 
A8HPU1 87 9.3 - 2 1 2 35.6 3.4 60.9 
Bacteria 
Escherichia coli P0AC44 115 12.8 3 3 3 3 80.0 0.0 20.0 
Enterobacter cloacae D5CHF1 115 12.8 - 3 3 3 80.0 0.0 20.0 
Paracoccus denitrificans Q59660 129 13.9 - 3 3 3 68.2 3.9 27.9 
            
Minimum  79 9.3  1 1 1 33.0 0.0 15.2 
Maximum  226 21.1  3 3 3 80.0 17.3 61.5 
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  Highly conserved residues were identified by amino acid sequence alignment of 19 
homologues and subunit-specific motifs were determined. At first sight, alignments confirmed the 
high divergence of those subunits across species with only a few residues conserved.  The role of 
each residue conserved could be determined by studying the crystal structures of complex II. For 
SdhC, the arginine residue R31 (in E. coli sequence annotation) is fully conserved and forms a salt 
bridge with a heme b propionate moiety. This residue is also involved in the ubiquinone binding site 
by interacting with the conserved tyrosine Y83 of SdhD (Fig. 3.13 and 3.15). The serine residue S27, 
(replaced by another nucleophilic residue threonine in protozoan Leishmania and Trypanosoma) is 
also conserved by contributing to the formation of a hydrophobic environment surrounding the 
quinone-binding pocket. Finally, the histidine residue H84 (replaced by an aspartate in Leishmania and 
Trypanosoma species) plays an important role by participating in heme b axial ligation. Thus, 
"[ST]x3Rx45-70[HD]" was identified as a specific motif for the subunit c.  
For SdhD, the histidine H71 (replaced by a tyrosine in yeast) is an essential residue for 
stabilizing heme b into the enzyme (Fig. 3.14 and 3.15). Moreover, two residues, aspartate D82 and 
tyrosine Y83, are fully conserved due to their key role in the quinone binding site. Thus, the conserved 
motif "[YH]x10DY" was determined for SdhD. 
 
Figure 3.13. Alignment of partial SdhC sequences from 19 species. The sequences were aligned with ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2). Residues are displayed with dark boxes for full conservation and grey 
boxes for strong similarities. In yellow are highlighted residues used for the SdhC motif pattern. 
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Figure 3.14. Alignment of partial SdhD sequences from 19 species. The sequences were aligned with 
ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2). Residues are displayed with dark boxes for full conservation 
and grey boxes for strong similarities. In yellow are highlighted residues used for the SdhD motif pattern. 
 
 
 
Figure 3.15. Interactions for ubiquinone-binding and heme b ligation in E. coli complex II. (A) Residues 
involved in ubiquinone (UQ, pink) binding are shown in stick and polar interactions are indicated with black 
dots. Transmembrane helices of SdhB, SdhC and SdhD are coloured in green, red, yellow, respectively. (B) Both 
histidine residues for heme b ligation are displayed in sticks. Polar interactions between the arginine residue 
and heme b molecule are displayed by black dots. PDB entry 1NEK.  
 
 Among 5538 P. falciparum genes annotated in the PlasmoDB database, 16.7% of them were 
shown to have the molecular weight searched and 4.0% of them displayed a number of 
transmembrane domains between one and three (Table 3.8). Afterwards, the secondary structure 
profile and presence of conserved sequence motifs allowed identifyication of 18 and 5 genes with 
unknown functions for SdhC and SdhD, respectively. By using three different algorithms, the 
presence of a mitochondrial signal peptide at their N-terminal section was predicted. Five putative 
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genes for SdhC and two for SdhD displayed a mitochondrial peptide predicted by at least one 
algorithm (Table 3.9).  
Table 3.8. Filtering of PlasmoDB annotated genes via successive SdhC- and SdhD-specific structural 
fingerprints. Abbreviations: PlasMit (PM), PFMPred (PP) and MitoProt II (MP). 
 Subunit c (SdhC, CybL) Subunit d (SdhD, CybS) 
Type of filtering Value of filtering Genes Value of filtering Genes 
Molecular weight 9 - 25 kDa 925 9 - 25 kDa 925 
Number of transmembrane 
domains 
1 - 3 221 1 - 3 221 
Secondary structure 
%Helix: 40% - 85% 
%Strand: 0% - 15% 
%Coil : 15% - 48% 
99 
%Helix: 28% - 85% 
%Strand: 0% - 22% 
%Coil : 10% - 66% 
167 
Motif pattern [ST]x3Rx45-70[HD] 27 [YH]X10DY 7 
Protein function Unknown 18 Unknown 5 
Mitochondrial signal 
peptide 
PM (strict score) 
PP > 0.5 
MP > 0.5 
5 
PM (strict score) 
PP > 0.5 
MP > 0.5 
2 
Candidate gene Manually 1 Manually 1 
 
 
Table 3.9. Prediction of mitochondrial signal peptide for SdhC and SdhD gene candidates. Three different 
webservers are used for prediction:  PlasMit (PM, strict cut-off), PFMPred (PP, cut-off > 0.5) and MitoProt II 
(cut-off > 0.5). Abbreviation: CG, our final candidate gene. 
 PlasmoDB entry Function 
MW 
(kDa) 
PM PP MP CG 
Sd
h
C
 
PF3D7_1371900 Plasmodium exported protein, unknown function 23.6 No No Yes  
PF3D7_1476100 transcribed membrane protein 14.2 20.7 No No No  
PF3D7_1310200 conserved Plasmodium protein, unknown function 16.7 No No No  
PF3D7_0702400 conserved Plasmodium protein, unknown function 14.1 No No No  
PF3D7_1303000 conserved Plasmodium protein, unknown function 13.7 Yes Yes Yes  
PF3D7_1362300 conserved protein, unknown function 22.0 No No No  
PF3D7_1243200 conserved Plasmodium protein, unknown function 9.8 No No No  
PF3D7_0107400 hypothetical protein conserved in P. falciparum 18.7 No No No  
PF3D7_0310800 conserved Plasmodium protein, unknown function 12.7 No No No  
PF3D7_0506400 conserved Plasmodium protein, unknown function 14.0 No No No  
PF3D7_1301900 Plasmodium exported protein, unknown function 15.1 No Yes Yes  
PF3D7_1319800 probable protein, unknown function 16.7 No No No  
PF3D7_0112100 conserved Plasmodium protein, unknown function 19.2 No No No  
PF3D7_1223000 conserved Plasmodium protein, unknown function 16.0 No No Yes  
PF3D7_0220200 Plasmodium exported protein, unknown function 21.4 No No No  
PF3D7_1212600.2 conserved Plasmodium protein, unknown function 11.1 No Yes No X 
PF3D7_1239300 conserved Plasmodium protein, unknown function 24.2 No No No  
PF3D7_1356500 conserved Plasmodium protein, unknown function 22.8 Yes Yes Yes  
Sd
h
D
 
PF3D7_0515200 conserved Plasmodium protein, unknown function 17.0 No No No  
PF3D7_0611100 succinate dehydrogenase subunit 3, putative (SDH3) 9.5 Yes Yes Yes X 
PF3D7_1317500 conserved Plasmodium protein, unknown function 10.4 No No No  
PF3D7_1325600 conserved Plasmodium protein, unknown function 16.1 No No No  
PF3D7_1458200 conserved Plasmodium protein, unknown function 13.4 No Yes No  
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 Subsequently, each gene predicted from mitochondria was analysed manually. A potential 
candidate for subunits c (PF3D7_1212600.2) and d (PF3D7_0611100) were identified with three and 
two putative transmembrane helices, respectively. Their sequence identities against counterparts in 
H. sapiens and E. coli are 9.0% and 4.0% for PF3D7_1212600.2 respectively, and 4.0% and 8.0% for 
PF3D7_0611100 respectively. It confirms the high divergence of these subunits with other 
mitochondrial homologues. Orthologs of both candidate genes are present in others Plasmodium 
species such as P. vivax, P. chabaudi, P. knowlesi or P. berghei. 
   For PF3D7_1212600.2, the motif Sx3R, essential for ubiquinone and heme b binding, is 
located near the N-terminal region (Fig. 3.16). However, this motif is not predicted to be in the first 
transmembrane helix of SdhC subunits in other species, but in the hydrophilic N-terminal tail as per 
SdhC in Trypanosoma and Leishmania spp.. Additionally, the conserved histidine residue (H84) is 
substituted with a tyrosine located in the second transmembrane helix.  
 The SdhD candidate gene PF3D7_0611100 contains the conserved motif Yx10DY which is 
partially included in the second transmembrane domain (TM) (Fig. 3.17). In E. coli, the motif is 
located at the second TM extremity to interact with ubiquinone. Maybe due to limitations in 
prediction accuracy, residues D and Y in P. falciparum are not localized into the second TM. Like in S. 
cerevisiae, the heme ligand histidine (H71) is substituted by a tyrosine residue in the malaria parasite. 
The encoded gene PF3D7_0611100 has been suggested by Mogi and Kita to be the best candidate for 
SdhC subunit (Mogi and Kita, 2009) whereas this work identifies it as a gene candidate for SdhD. 
Using similar filtering based on structural fingerprints, Kita and Mogi identified the motif Sx2HF in P. 
falciparum and Sx2HY in other Plasmodium spp. as a substituted of the H/Yx10DY pattern.  
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Figure 3.16. Sequence alignment of the candidate gene PF3D7_1212600.2 with SdhC homologues in other 
species. Transmembrane regions predicted are highlighted in orange. Transmembrane helices found in E. coli 
SdhC from the crystal structure are boxed in orange (PDB entry 1NEK). Residues are displayed with dark boxes 
for full conservation and grey boxes for strong similarities.  
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Figure 3.17. Sequence alignment of the candidate gene PF3D7_0611100 with SdhD homologues in other 
species. Transmembrane regions predicted are highlighted in orange. Transmembrane helices found in E. coli 
SdhD from the crystal structure are boxed in orange (PDB entry 1NEK). Residues are displayed with dark boxes 
for full conservation and grey boxes for strong similarities.  
 
3.3.2. Candidate gene identification for ATP synthase subunits a and b 
 To identify ATP synthase subunits a and b, a similar in silico approach was applied. Structural 
fingerprints were established with 19 ATPase subunits a from diverse species and 15 eukaryotic 
subunits b (Tables 3.10 and 3.11).  
 
 The high number of transmembrane segments is a specific feature of the subunit a across 
species. In the P. falciparum genome, only 96 encoded genes are predicted to exhibit between 4 and 
8 TMs with a molecular weight comprised between 20 to 45 kDa. Among them, genes with high 
helical secondary structure (> 52% helices) were filtered. On the other hand, the subunit b contains a 
single or two TM α-helices localized into the N-terminal section in order to anchor to the lipid bilayer. 
The 15 secondary structure predictions of  subunit b selected have shown α-helical predominance 
which is consistent with the bovine subunit b crystal structure almost entirely composed of an 
extended α-helix. Therefore, genes with a molecular mass between 15 to 41 kDa as well as a helical 
percentage comprised between 38 and 95% were selected. Through three structural fingerprints 
(molecular weight, number of TMs and secondary structure profile), 0.4% and 5.9% of encoded 
proteins were selected for subunit a and b respectively. 
 
  For ATP synthase subunit a, a specific motif was identified by sequence alignment of the 19 
references (Fig. 3.18). It shows that arginine R210 is fully conserved across species. As described 
previously, the residue R210 has an essential role to coordinate protonation and deprotonation events 
by interacting with the aspartic acid D61 of each subunit c composing the ring (Fig. 3.19). Thus, 
[AVFPMILW]R[AVFPMILW] was established as a subunit a motif with a residue arginine surrounded 
by two small amino acids. Mutants lacking the conserved arginine R210 were shown to not synthesize 
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ATP at significant rates (Ishmukhametov et al., 2008). Moreover, the fully conserved glutamine 
residue Q252, located further downstream of R210, may have a role into the proton translocation 
pathway. To confirm Q252 as a key component, Hatch et al. showed the maintenance of a functional 
rotary mechanism for F0 by switching the conserved residues R210 and Q252 in a double mutant (Hatch 
et al., 1995). Unfortunately, no residue was fully conserved and thus no clear motif could be 
identified for the subunit b due to high sequence divergence across species. 
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Table 3.10. Structural fingerprints (molecular weight, number of transmembrane domains and secondary structure profile) of ATP synthase subunit a in 19 species 
representing five different kingdoms.  
 
 
 
  Molecular weight Transmembrane domains Secondary structure 
 Organisms UniPort Acc # Length MW (kDa) THMMH M-SVM M-V3 %Helix %Strand %Coil 
Animals 
Homo sapiens P00846 226 24.8 6 5 6 73.0% 0.0% 27.0% 
Mus musculus Q3V2U3 226 25.1 6 5 6 72.6% 0.0% 27.4% 
Gallus gallus E5DF83 227 24.8 6 5 6 68.3% 0.0% 31.7% 
Sus scrofa B6EDK0 226 25.0 5 5 6 73.5% 0.0% 26.5% 
Drosophila menalogaster P00850 224 25.2 6 4 6 74.1% 0.0% 25.9% 
Xenopus laevis P00849 226 24.9 6 4 6 74.8% 0.0% 25.2% 
Ascaris suum P24876 199 23.0 5 7 6 78.4% 2.5% 19.1% 
Protozoans 
Reclinomonas  americana O21289 249 27.4 7 7 8 73.1% 0.0% 26.9% 
Dictyostelium discoideum Q27559 244 27.8 7 6 8 73.0% 0.0% 27.0% 
Cyanidioschyzon merolae Q9ZZP8 255 28.9 6 7 8 71.4% 0.8% 27.8% 
Trypanosoma brucei P24499 229 28.3 7 7 7 96.9% 0.0% 3.1% 
Leishmania tarentolae Q33561 232 28.4 7 7 8 94.4% 0.9% 4.7% 
Yeast 
Candida albicans Q9B8D4 246 26.5 7 8 8 72.8% 0.0% 27.2% 
Saccharomyces cerevisiae P00854 256 29.1 6 6 8 72.2% 0.0% 27.8% 
Plants 
Nicotiana tabacum Q5MA53 382 42.2 7 7 6 59.9% 1.0% 39.0% 
Chlamydomonas reinhardtii Q8H2C1 340 35.4 5 6 8 57.1% 0.0% 42.9% 
Bacteria 
Escherichia coli P0AB98 271 30.3 5 6 5 68.6% 1.5% 29.9% 
Enterobacter cloacae D6DPP5 271 30.5 5 6 5 69.4% 1.1% 29.5% 
Paracoccus denitrificans A1B619 248 26.7 6 6 7 69.8% 0.0% 30.2% 
           
Minimum  199 23.0 5 5 5 57.1% 0.0% 3.1% 
Maximum  382 42.2 7 8 8 96.9% 2.5% 42.9% 
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Table 3.11. Structural fingerprints (molecular weight, number of transmembrane domains and secondary structure profile) of ATP synthase subunit b in 
15 eukaryotic species.  
 
 
 
  Molecular weight Transmembrane domains Secondary structure 
 Organisms UniPort Acc # Length MW (kDa) THMMH M-SVM M-V3 %Helix %Strand %Coil 
Animals 
Homo sapiens P24539 256 28.9 2 2 1 70.3% 2.0% 27.7% 
Mus musculus Q5I0W0 256 28.9 2 2 1 72.2% 1.5% 26.3% 
Gallus gallus F1NSC1 228 25.9 2 2 2 75.9% 2.2% 21.9% 
Sus scrofa F1SBN7 256 28.6 2 2 1 73.0% 2.0% 25.0% 
Bos taurus P13619 258 28.8 2 2 1 72.7% 1.6% 25.8% 
Xenopus laevis Q9IAJ7 250 28.2 2 2 1 73.6% 2.0% 24.4% 
Ascaris suum F1L7V5 315 36.8 2 2 2 55.2% 3.5% 41.3% 
Protozoans 
Reclinomonas  americana O21290 197 22.4 2 1 2 89.3% 2.0% 8.6% 
Dictyostelium discoideum A9CLV8 137 14.9 1 1 1 43.8% 13.9% 42.3% 
Cyanidioschyzon merolae Q9ZZQ7 171 20.1 1 1 1 72.5% 6.4% 21.1% 
Trypanosoma brucei Q57ZP0 188 21.2 1 1 1 51.6% 4.8% 43.6% 
Leishmania major Q4QFF2 187 21.3 1 1 1 54.0% 3.2% 42.8% 
Yeast 
Plants 
Candida albicans Q59ZE0 233 25.8 2 2 2 77.3% 2.1% 20.6% 
Saccharomyces cerevisiae P05626 244 26.9 2 2 1 74.6% 2.0% 23.4% 
Schizosaccharomyces pombe O94373 244 26.7 1 2 1 76.2% 2.0% 21.7% 
           
Minimum  137 20.1 1 1 1 43.8% 1.5% 8.6% 
Maximum  315 36.8 2 2 2 89.3% 13.9% 43.6% 
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Figure 3.18. Alignment of C-terminal sections from ATP synthase subunits a from 19 species. The sequences 
were aligned with ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2). Residues are displayed with dark boxes for 
full conservation and grey boxes for strong similarities. In yellow are highlighted residues used for the subunit a 
motif pattern. 
 
Figure 3.19. Interactions between arginine R210 (subunit a) and aspartate D61 (subunit c) in E. coli. 
Transmembrane helices of subunit a and subunit c are coloured in red and green respectively (PDB entry 1C17). 
Residues in the R210 environment are displayed as sticks. Polar interactions are indicated with black dots.  
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 Among 5538 P. falciparum genes in the current PlasmoDB database, 8 and 56 candidate 
genes with unknown function were identified for subunit a and b respectively (Table 3.12). Only 
three subunit a candidates were estimated to be mitochondrial by at least one targeting program 
whereas 24 genes for the subunit b were predicted to exhibit a mitochondrial signal peptide (Table 
3.13).  
Table 3.12. Filtering of PlasmoDB annotated genes via successive ATP synthase subunit a- and subunit b- 
specific structural fingerprints. Abbreviations: PlasMit (PM), PFMPred (PP) and MitoProt II (MP). 
 Subunit a (ATP4) Subunit b (ATP6) 
Type of filtering Value of filtering Genes Value of filtering Genes 
Molecular weight 20 - 45 kDa 1724 15 - 41 kDa 1768 
Number of transmembrane 
domains 
4 - 8 96 1- 2 477 
Secondary structure 
%Helix: 52% - 100% 
%Strand: 0% - 8% 
%Coil : 0% - 48% 
20 
%Helix: 38% - 95% 
%Strand: 0% - 19% 
%Coil : 3% - 48% 
328 
Motif pattern [AVFPMILW]R[AVFPMILW] 13 No motif 328 
Protein function Unknown 8 Unknown 56 
Mitochondrial signal 
peptide 
PM (strict score) 
PP > 0.5 
MP > 0.5 
3 
PM (strict score) 
PP > 0.5 
MP > 0.5 
24 
Candidate gene Manually 1 Manually 5 
 
 After manual observation of each mitochondrial candidate for subunit a, PF3D7_0611000 is 
the gene displaying all features required.  First, the encoded protein possesses six transmembrane 
domains essential for insertion into the inner membrane. Moreover, it exhibits an arginine residue 
predicted to be embedded in the fourth TM (Fig 3.20). For functional proton translocation through 
the FO subcomplex, both Plasmodium residues arginine (subunit a) and glutamate (subunit c) have to 
be integrated into transmembrane domains. In PF3D7_0611000, the second site suppressor 
glutamine (Q252 in E. coli) is also conserved and located in the last TM. Like in other species such as E. 
coli or A. suum, both conserved arginine and aspartic acid in P. falciparum are found in adjacent 
transmembrane helices at a similar depth and with a slight lateral displacement relative to each 
other. 
 
Without conserved motifs detected, identification of clear subunit b candidates was more 
complicated. Among mitochondrial candidates filtered, only five exhibited the presence of a single or 
two transmembrane domains on their N-terminal section. With the absence of other structural 
fingerprints to refine the identification, those five selected genes can be regarded as potential 
subunit b. 
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Table 3.13. Prediction of mitochondrial signal peptide for subunit a and b gene candidates. Three different 
webserver are used for prediction:  PlasMit (PM, strict cutoff), PFMPred (PP, cutoff>0.5) and MitoProt II 
(Cutoff>0.5). Abbreviation: CG, final candidate gene(s). 
 PlasmoDB entry Function 
MW 
(kDa) 
PM PP MP CG 
Su
b
u
n
it
 a
 
PF3D7_0405600 conserved Plasmodium membrane protein, unknown function 37.8 No No No  
PF3D7_0514500 conserved Plasmodium membrane protein, unknown function 25.2 No No No  
PF3D7_0611000 conserved Plasmodium membrane protein, unknown function 33.3 Yes Yes No X 
PF3D7_0917200 conserved Plasmodium membrane protein, unknown function 38.7 Yes No No  
PF3D7_1146900 conserved Plasmodium membrane protein, unknown function 21.8 No No No  
PF3D7_1237700 conserved Plasmodium membrane protein, unknown function 23.6 No No Yes  
PF3D7_1318000 conserved Plasmodium membrane protein, unknown function 22.0 No No No  
PF3D7_1347300 conserved Plasmodium membrane protein, unknown function 26.0 No No No  
Su
b
u
n
it
 b
 
PF3D7_0105400.1 conserved Plasmodium protein, unknown function 16.8 No No No  
PF3D7_0107400 conserved Plasmodium protein, unknown function 18.7 Yes Yes Yes X 
PF3D7_0108600 conserved Plasmodium protein, unknown function 37.6 Yes Yes No  
PF3D7_0110000 conserved Plasmodium protein, unknown function 27.8 No No No  
PF3D7_0112100 conserved Plasmodium protein, unknown function 19.2 No No No  
PF3D7_0204200 conserved Plasmodium protein, unknown function 33.4 No No No  
PF3D7_0213200 conserved Plasmodium protein, unknown function 15.3 Yes Yes No  
PF3D7_0219300 conserved Plasmodium protein, unknown function 16.9 Yes No No  
PF3D7_0305900 conserved Plasmodium protein, unknown function 21.3 Yes Yes Yes  
PF3D7_0306000 conserved Plasmodium protein, unknown function 17.0 Yes Yes Yes  
PF3D7_0306500 conserved Plasmodium protein, unknown function 36.3 No Yes Yes  
PF3D7_0316000 conserved Plasmodium protein, unknown function 37.1 Yes No No  
PF3D7_0403300 conserved Plasmodium protein, unknown function 18.3 No No No  
PF3D7_0504500 conserved Plasmodium protein, unknown function 31.8 No No No  
PF3D7_0506000 conserved Plasmodium protein, unknown function 29.6 No No No  
PF3D7_0513900 conserved Plasmodium protein, unknown function 29.7 No No No  
PF3D7_0515200 conserved Plasmodium protein, unknown function 17.0 No No No  
PF3D7_0604400 conserved Plasmodium protein, unknown function 21.6 No No No  
PF3D7_0620200 conserved Plasmodium protein, unknown function 39.0 No No No  
PF3D7_0703100 conserved Plasmodium protein, unknown function 21.2 No Yes No  
PF3D7_0710500 conserved Plasmodium protein, unknown function 30.2 No No Yes  
PF3D7_0718900 conserved Plasmodium protein, unknown function 27.7 No No No  
PF3D7_0719100 conserved Plasmodium protein, unknown function 21.1 No Yes Yes  
PF3D7_0827400 conserved Plasmodium protein, unknown function 26.1 No No No  
PF3D7_0830400 conserved Plasmodium protein, unknown function 15.9 No No No  
PF3D7_0904200 conserved Plasmodium protein, unknown function 33.9 No No No  
PF3D7_0908400 conserved Plasmodium protein, unknown function 24.0 No Yes No  
PF3D7_0929900 conserved Plasmodium protein, unknown function 23.0 No No Yes  
PF3D7_0931500 conserved Plasmodium protein, unknown function 27.0 No No Yes X 
PF3D7_0933400 conserved Plasmodium protein, unknown function 32.0 Yes Yes Yes X 
PF3D7_0934300 conserved Plasmodium protein, unknown function 16.8 Yes No Yes  
PF3D7_1037900 conserved Plasmodium protein, unknown function 21.4 Yes No No  
PF3D7_1105800 conserved Plasmodium protein, unknown function 30.6 No No No  
PF3D7_1122700 conserved Plasmodium protein, unknown function 30.5 Yes No Yes  
PF3D7_1129800 conserved Plasmodium protein, unknown function 33.6 No No No  
PF3D7_1146200 conserved Plasmodium protein, unknown function 19.9 No No No  
PF3D7_1147900 conserved Plasmodium protein, unknown function 24.9 No No No  
PF3D7_1214000 conserved Plasmodium protein, unknown function 17.6 Yes Yes Yes X 
PF3D7_1223000 conserved Plasmodium protein, unknown function 16.0 No No Yes X 
PF3D7_1232800 conserved Plasmodium protein, unknown function 17.6 Yes Yes Yes  
PF3D7_1239300 conserved Plasmodium protein, unknown function 24.2 No No No  
PF3D7_1303600 conserved Plasmodium protein, unknown function 15.2 No No No  
PF3D7_1310200 conserved Plasmodium protein, unknown function 16.7 No No No  
PF3D7_1315500 conserved Plasmodium protein, unknown function 21.4 No No No  
PF3D7_1325600 conserved Plasmodium protein, unknown function 16.1 No No No  
PF3D7_1330100 conserved Plasmodium protein, unknown function 22.7 No No No  
PF3D7_1339400 conserved Plasmodium protein, unknown function 17.7 No Yes Yes  
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PF3D7_1347400 conserved Plasmodium protein, unknown function 16.8 No Yes No  
PF3D7_1358400 conserved Plasmodium protein, unknown function 16.6 No Yes No  
PF3D7_1362300 conserved protein, unknown function 22.0 No No No  
PF3D7_1366200 conserved Plasmodium protein, unknown function 17.8 No No Yes  
PF3D7_1407200 conserved Plasmodium protein, unknown function 34.4 No No No  
PF3D7_1416000 conserved Plasmodium protein, unknown function 26.0 No No No  
PF3D7_1429600 conserved Plasmodium protein, unknown function (GEXP03) 26.1 No No No  
PF3D7_1435400 conserved protein, unknown function 21.8 No Yes No  
PF3D7_1469100 conserved Plasmodium protein, unknown function 31.3 No No No  
 
 
 
Figure 3.20. Sequence alignment and prediction of transmembrane domains in Ascaris suum synthase 
subunit a and the candidate gene PF3D7_0611000. (A) A. suum ATPase subunit a (P24876) and 
PF3D7_0611000 sequences were aligned with ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2). Residues are 
displayed with dark boxes for full conservation and grey boxes for strong similarities. In red is highlighted the 
essential arginine (R210 in E. coli) and in pink, the conserved glutamine (Q252 in E. coli). (B) The helical wheel 
diagram of predicted segments has been carried out with SOSUI (bp.nuap.nagoya-u.ac.jp/sosui/). In red is 
circled the essential arginine and in pink the conserved glutamine. According the SOSUI nomenclature, in dark 
green are indicated primary helices while secondary helices are shown in light green. 
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3.3.3. Characterization of the anti-SdhA polyclonal antibody 
 To localize the parasite complex II into two dimensional gels, a custom polyclonal antibody 
against the SdhA subunit of the P. falciparum succinate dehydrogenase was raised using a 
commercial supplier (GenScript Corp., USA). The peptide 573AHARDDFPERDDKN586 located near the C-
terminal of the P. falciparum SdhA has been chosen for antibody generation. The anti-SdhA 
polyclonal antibody was raised by immunizing rabbits with the specific peptide (as peptide–KLH 
conjugate) and purified by affinity. This customized anti-SdhA polyclonal antibody showed a 
significant immunoreactivity against a 70 kDa protein, consistent with the size of the SdhA subunit in 
the malaria parasite, across species including Escherichia coli, Bos taurus and P. falciparum (soluble 
and membrane fractions) (Fig. 3.21).  
 
 
Figure 3.21. Immunobloting of the SdhA customized polyclonal antibody with bacteria, yeast, bovine and 
malaria parasite membrane extracts. Membrane extracts from Escherichia coli, S. cerevisiae, B. taurus, and P. 
falciparum 3D7 were resolved by SDS-Page and blotted to nitrocellulose. Blots were probed with anti-SdhA 
antibody (1:500), 2h at room temperature. Arrows on right side point to SdhA (70 kDa) immunoreactive band.  
 
  Antibody antigens were analysed by NanoLC-MS/MS to validate its specificity to SdhA. First, 
immunoprecipitation experiments were attempted on the membrane proteins from 3D7 free-
parasite extracts, bovine and E. coli mitochondrial membranes. The immunocapture obtained in 
denaturing conditions with E. coli crude membranes revealed a protein captured around 70 kDa on 
both immunoblot and silver stained gel (Fig. 3.22). The band corresponding to the protein was 
excised from the silver-stained gel, digested with trypsin, and analyzed by NanoLC-MS/MS to obtain 
the peptide sequence data. The SdhA subunit was identified by 19 peptide mass fingerprints with a 
sequence coverage of 19.22% (Table 3.14). Despite several attempts, the antibody characterization 
did not succeed with malaria parasite extracts or bovine mitochondria due to the low expression of 
complex II in P. falciparum and the low affinity of the antibody for the bovine SdhA. 
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 Immunofluorescence localization of the complex II inside the parasite-infected erythrocytes 
has been attempted with the anti-SdhA antibody. However, no clear localization into the 
mitochondria has been observed which suggests the ability of the polyclonal antibody to bind the 
subunit in an unfolded state under denaturing conditions only.  
 
 Attempts to generate polyclonal antibodies specific to the P. falciparum ATP synthase were 
unsuccessful. Two different anti-ATPα antibodies have been raised based on two different highly 
immunogenic peptides but none showed immunoreactivity for a protein expected around 62 kDa. 
Hence, the proteomic strategy established has been performed only for the identification of complex 
II subunits.  
 
 
Figure 3.22. Western Blot and silver staining of the SdhA subunit (70 kDa) immunocapture from E. coli 
membrane. Arrows on right side point to SdhA (70 kDa) immunoreactive band and HC indicate the heavy chain 
(50 kDa) of the polyclonal antibody used for the immunoprecipitation. 
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Table 3.14. List of 10 first hits obtained by NanoLC-MS/MS analysis and Sequest algorithm search of the immunoprecipitated 70 kDa band. In yellow is highlighted the 
most significant hit.  
 
a
 The list of 19 peptides identified are indicated in Appendix 1.  
 
 
 
 
Hits 
UnitProtKB 
entry 
Coverage # Peptides # AAs 
MW 
(kDa) 
calc. 
pI 
Score Description 
1 P0AC43 19.22% 19
a
 588 64.4 6.27 37.32 
Succinate dehydrogenase flavoprotein subunit OS=Escherichia coli O157:H7 
GN=sdhA PE=3 SV=1 - [DHSA_ECO57] 
2 P49064 15.30% 17 608 68.6 5.66 30.41 Serum albumin OS=Felis catus GN=ALB PE=1 SV=1 - [ALBU_FELCA] 
3 P49822 13.82% 19 608 68.6 5.69 25.14 Serum albumin OS=Canis familiaris GN=ALB PE=1 SV=3 - [ALBU_CANFA] 
4 A1AJ51 22.45% 10 548 57.3 4.94 7.58 
60 kDa chaperonin 1 OS=Escherichia coli O1:K1 / APEC GN=groL1 PE=3 SV=1 
- [CH601_ECOK1] 
5 P0C193 14.68% 14 545 57.3 5.06 7.58 60 kDa chaperonin OS=Sodalis glossinidius GN=groL PE=3 SV=1 - [CH60_SODGL] 
6 Q9ANR9 19.60% 25 546 57.6 5.29 7.58 
60 kDa chaperonin OS=Wigglesworthia glossinidia brevipalpis GN=groL PE=3 
SV=1 - [CH60_WIGBR] 
7 A7ZUE0 3.39% 2 502 56.2 5.50 5.43 
Glycerol kinase OS=Escherichia coli O139:H28 (strain E24377A / ETEC) 
GN=glpK PE=3 SV=1 - [GLPK_ECO24] 
8 B7LAN4 10.40% 4 548 60.2 6.99 2.48 
Probable malate:quinone oxidoreductase OS=Escherichia coli (strain 55989 / EAEC) 
GN=mqo PE=3 SV=1 - [MQO_ECO55] 
9 P0AG69 7.90% 4 557 61.1 4.98 2.35 
30S ribosomal protein S1 OS=Escherichia coli O157:H7 GN=rpsA PE=3 SV=1 - 
[RS1_ECO57] 
10 P25553 5.43% 2 479 52.2 5.15 2.31 
Lactaldehyde dehydrogenase OS=Escherichia coli (strain K12) GN=aldA PE=1 SV=2 - 
[ALDA_ECOLI] 
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3.3.4. The gradient BNE/SDS-Page approach  
 An initial proteomic approach using gradient BNE/SDS-Page was carried out to solve 
complex II subunits from solubilised membranes.  First, the method was validated with solubilised 
membranes from a beef heart mitochondrial preparation. Bovine mitochondrial proteins were 
analysed with a 4 to 15% gradient BNE followed by a 15% SDS-Page as the second dimension. As 
shown in Figure 3.23 A, complex I to V were isolated and clearly visible on the first dimension. 
Complex II appears with an unexpected size of ~200 kDa instead of ~130 kDa but protein 
separations on blue native gels do not exactly reflect calculated molecular masses and have to be 
considered with caution. Complexes were distinctly identified upon resolution of their subunits 
with both second dimension gels stained with silver nitrate and immunoblotted with different 
antibodies specific to SdhA (complex II), Rieske subunit (bc1 complex), SdhB (complex II) and ATP 
synthase (subunit α) (Fig. 3.23 B and C).  Additionally, seven spots representing different subunits 
of complexes I to V were digested by trypsin and analysed by NanoLC-MS/MS. MS-based protein 
identifications confirmed the localization of each complex. Among complex II subunits, bands 
corresponding to SdhA, SdhB and SdhC were clearly visible and were identified with sequence 
coverage of 55.19%, 53.21% and 12.43%, respectively. 
 
Chapter 3 
79 
 
 
Figure 3.23. Separation of solubilised bovine mitochondrial membranes by 2D gradient BNE/SDS-Page. 
(A) Dodecyl-β-D-maltoside solubilised bovine mitochondrial membranes were separated according to their 
molecular weight on a gradient 4-15% blue native gel (BNE). Gels were stained with Coomassie blue. 
Complexes I to V are identified with arrows and their masses indicated. An unstained native protein marker 
(NativeMark
TM
, Invitrogen, USA) was used as the protein ladder. (B) Subunits of the native complexes were 
separated by 15% SDS-Page and silver stained. Arrows mark the vertical alignment of subunits for each 
complex. A pre-stained broad range protein marker (Spectra
TM
 Multicolor Broad Range Protein Ladder, 
Thermo Scientific, USA) were loaded side to the strip. Several spots indicated by dotted circles have been 
excised, digested by trypsin and analyzed by NanoLC-MS/MS. The protein identification was performed by 
database searching (UniprotKB entry, % sequence coverage): spot 1, complex I 75 kDa subunit (P15690, 
74.28%); spot 2, ATP synthase subunit α (P19483, 71.79%); spot 3, complex III Rieske subunit (P13272, 
28.47%); spot 4, complex IV subunit 4 (P00423, 44.38%); spot 5, complex II subunit A (P31039, 55.19%), 
spot 6, complex II subunit B (Q3T189, 53.21%); spot 7, complex II subunit C (P35720, 12.43%). (C) 
Immunoblot with an identical 2D gel were performed with different antibodies: our customized anti-SdhA 
(1/2000 dilution, antibody synthesis described in section 3.3.3) and anti-Rieske (bc1 complex, 1/500 dilution, 
antibody synthesis described in section 6.2.1) polyclonal antibodies, SdhB (#ab14714, Abcam, UK) and ATP 
synthase subunit α (#ab110273, Abcam, UK) monoclonal antibodies. Arrows indicate localization of signals. 
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A similar strategy was attempted with P. falciparum membrane protein solubilised by 1% 
dodecyl-β-D-maltoside. In the first dimension, ETC complexes were not visible as with bovine 
extract due to the low expression of those enzymes in malaria parasites and limitations of 
mitochondria isolation. The second dimension gel revealed high background staining (by silver 
nitrate) due to the large amount of proteins solved (Fig. 3.24 A). Although no clear ETC pattern 
could be detected on the silver stained gel, the immunoblot with anti-SdhA and anti-Rieske 
antibodies confirmed the presence of P. falciparum complex II and bc1. Superimposition of this 
immunoblot onto the silver stained gel allowed determining the vertical row where complex II 
and III appear to be localized. However, only the SdhA subunit could be identified by NanoLC-
MS/MS (13.65% sequence coverage) while no bc1 subunits were detected. On the same vertical 
row of the SdhA, all spots between 10 to 20 kDa, range of molecular sizes for SdhC and SdhD, 
were analysed. Several attempts concluded to similar results: among all protein hits identified, no 
gene candidates predicted by the bioinformatic strategy for SdhC and SdhD were detected. The 
more noticeable identification is the unknown protein PF3D7_1117300 (27.34% sequence 
coverage) excised between 10 and 17 kDa. This enzyme is predicted to have 3 transmembrane 
domains with a molecular weight of 15.3 kDa. Nevertheless, the PF3D7_1117300 sequence 
doesn’t exhibit any SdhC or SdhD conserved motifs nor mitochondrial signal peptides.  
Although the resolution of P. falciparum complex II by this approach seems conceivable, 
its low expression in the blood stages and the limited protein loading capacity of BNE gels 
(maximum of 50 µg total proteins / well) is translated by non- or poorly visible spots after staining 
with silver nitrate which is known to be highly sensitive for protein detection in the low nanogram 
range. In line with this, the immunoblot with anti-SdhA and anti-Rieske antibodies revealed spots 
with weak intensity signals (Fig. 3.24 B). Moreover, the low amount of peptides digested from 
SdhC and SdhD and/or obscured by others from the protein background noise can also limit the 
detection by mass spectrometry of clear peptide ion signals from both complex II subunits. 
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Figure 3.24. Separation of solubilised P. falciparum membrane proteins by 2D gradient BNE/SDS-Page. (A) 
Dodecyl-β-D-maltoside solubilised native membrane proteins were separated on a gradient 4-15% blue 
native gel (BNE) followed by a second dimension 15% SDS-Page and silver stained. Spots excised and 
digested by trypsin were identified by NanoLC-MS/MS and database searching (PlasmoDB entry, % 
sequence coverage): dotted circle 1, complex II subunit A (PF3D7_1034400, 13.65%); dotted circle 2, 
protein with unknown function (PF3D7_1117300, 27.34%). (B) Immunoblot with an identical 2D gel was 
performed with our customized anti-SdhA and anti-Rieske antibodies. Arrows indicate signal localization. 
 By superimposing both bovine and malaria parasite immunoblots, Rieske and SdhA 
subunits were observed to be at a very similar vertical position (Fig. 3.25). This would suggest that 
both complexes migrated onto the blue native gel at a same distance from each other in both 
species. The bovine bc1, composed of 11 subunits, has a total molecular weight (MW) of 248 kDa 
(Xia et al., 1997) and was visible as a dimer higher to 480 kDa on the BNE. To date, the P. 
falciparum bc1 is composed of 7 subunits with a MW estimated of 281 kDa and appeared with a 
mass higher to 480 kDa on the BNE, suggesting a possible dimerization. By supposing that bc1 
complexes from P. falciparum and beef mitochondria are almost similar in size, their complex II 
should be equivalent too. Thus, the malaria parasite complex II is suspected to have a molecular 
weight near 130 kDa as predicted previously (Kawahara et al., 2009), which confirms the presence 
of both membrane anchor subunits. It also suggests that complex II from malaria parasites is not 
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unconventional like in Trypanosoma cruzi which possesses 12 subunits for a MW of 287 kDa 
(Morales et al., 2009). 
 
Figure 3.25. Superposition of P. falciparum and bovine two dimensional immunoblots. Both immunoblots 
were performed with both anti-SdhA and anti-Rieske polyclonal antibodies and superimposed thanks to the 
protein ladder. Positions of both subunits for each species are indicated with arrows. Both SdhA subunits 
have a molecular weight around 70 kDa in both species while the Rieske subunit (bc1 complex) is heavier in 
P. falciparum than beef. 
3.3.5. Enrichment of complex II by sucrose gradient.  
 The separation of ETC complexes and their assembly in supercomplexes using sucrose 
density gradients were shown with mitochondria from human heart, yeast or Arabidopsis thaliana 
(Heinemeyer et al., 2007; Klodmann et al., 2010; Taylor et al., 2002). Due to difficulties in isolating 
P. falciparum mitochondria as well as low expression of the complex II in trophozoite stage 
parasites, a sucrose gradient approach was used to substantially enrich the complex II from P. 
falciparum membranes. 
 P. falciparum membrane proteins were first solubilised with 1% dodecyl-β-D-maltoside 
followed by fractionation with a 5 to 35% sucrose step gradient. Fractions of the density gradient 
were collected and concentrated. Aliquots of each concentrated fraction were resolved on a 10% 
SDS-Page and immunoblotted with both anti-SdhA and anti-Rieske polyclonal antibodies. 
Immunoblot analysis showed that sucrose gradient fractions 20%, 22.5% and 25% were highly 
enriched in Plasmodium complex II (Fig. 3.26 B). Because the sedimentation rate in sucrose 
Chapter 3 
83 
 
gradient is dependent on the molecular weight, the bc1 complex, twice as big as complex II, is 
concentrated in the last fraction (35%) at the bottom of the ultracentrifugation tube. The same 
experiment with bovine mitochondrial membranes showed complex II sedimentation in similar 
fractions (from 20% to 27.5%) (Fig. 3.26 A). Subsequently, fractions enriched in complex II were 
pooled, dialyzed and concentrated before being resolved on a first dimension non-gradient blue 
native gel. 
 
 
Figure 3.26. Enrichment of complex II by sucrose gradient centrifugation analysis. (A) Bovine mitochondria 
membranes were fractionated on a 5-35% sucrose step gradient. After concentration (with 50 kDa Amicon), 
an aliquot of each fraction was run on 10% SDS-Page gels followed by Western blot analysis with the anti-
SdhA (70 kDa) polyclonal antibody. (B) In a similar manner, P. falciparum membranes were fractionated and 
aliquots separated by 10% SDS-Page. Immunoblots were performed with customized anti-SdhA (1/2000 
dilution) and anti-bc1 polyclonal antibodies (1/500 dilution). Arrows along the bottom indicate localization 
of complex II and bc1 complex in the sucrose gradient fractions.  
3.3.6. Non-gradient BNE/SDS-Page with enriched complex II preparation 
 To maximize the gel resolution between 100 kDa to 400 kDa, the previous BNE/SDS-Page 
approach was modified by performing a non-gradient blue native gel as first dimension instead of 
a conventional gradient. The suitability of using sucrose gradient fractions for non-gradient 
BNE/SDS-Page was firstly tested with enriched bovine complex II fractions. The enriched sample 
was migrated into an 8% non-gradient BNE followed by a 15% SDS-Page as a second dimension. 
The non-gradient BNE from bovine mitochondria showed a large band corresponding to complex 
II at a similar migration position to the gradient BNE (Fig. 3.27 A). On the second dimension, 
complex II subunits became distinctly visible on the silver stained gel, except for ShdA which was 
confused with a strong protein background (Fig. 3.27 B). Immunoblot performed with anti-SdhA 
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antibody confirmed the vertical row where complex II subunits are localized (Fig. 3.27 C). Unlike 
gradient BNE, the SdhA signal around 70 kDa is widely spread due to sucrose gradient enrichment 
and a better gel resolution. The four subunits SdhA, SdhB, SdhC and SdhD were successfully 
identified by NanoLC-MS/MS analysis with sequence coverages of 53.68%, 28.21%, 21.10% and 
13.25% respectively.  Both bovine SdhC and SdhD with estimated molecular weight of 18.4 and 
17.1 kDa respectively appeared with apparent lower sizes on the second dimension gel.  
Figure 3.27. Separation of enriched bovine complex II fractions by non-gradient BNE/SDS-Page. (A) 
Sucrose gradient fraction (25% and 27.5% sucrose) enriched in bovine complex II were pooled, dialyzed, 
concentrated and separated by a non-gradient 8% blue native gel (BNE). Gel were stained with Coomassie 
blue. Complex II is indicated by an arrow. An unstained native protein marker (NativeMark
TM
, Invitrogen, 
USA) was used as a protein ladder. (B) Native proteins were separated by 15% SDS-Page and silver stained. 
Arrows mark the vertical alignment of complex II subunits. A pre-stained broad range protein marker 
(Spectra
TM
 Multicolor Broad Range Protein Ladder, Thermo Scientific, USA) was loaded alongside the strip. 
Several spots indicated by dotted circles have been excised, digested by trypsin and analyzed by NanoLC-
MS/MS. The protein identification was performed by database searching (UniprotKB entry, % sequence 
coverage): spot 1, complex II subunit A (P31039, 53.68%), spot 2, complex II subunit B (Q3T189, 28.21%); 
spot 3, complex II subunit C (P35720, 21.10%); spot 4; complex II subunit D (Q95123, 13.25%). (C) 
Immunoblot with an identical 2D gel was performed with our customized anti-SdhA polyclonal antibody. An 
arrow indicates signal localization. 
 An identical non-gradient BNE/SDS-Page approach was carried out with P. falciparum 
enriched complex II fractions. In the same manner of gradient BNE, a strong protein background 
prevented the observation of a distinct complex II on the non-gradient blue native gel despite the 
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enzyme enrichment via sucrose gradient. The second dimension gel, stained with silver nitrate, 
confirmed the presence of significant background noise with no complex II subunits 
distinguishable by eye (Fig. 3.28). However, the similar gel immunobloted using anti-SdhA 
antibodies confirmed the presence of the subunit with a clear signal. Thanks to the sucrose 
gradient enrichment and a better gel resolution, the SdhA signal appears more intense and wider 
than with gradient BNE/SDS-Page. Despite several attempts, P. falciparum SdhA and SdhB could 
not be identified by mass spectrometry after excision and digestion of several spots around 70 
kDa (box 1) and 26 kDa (box 2) respectively. Although the sucrose gradient ultracentrifugation 
followed by non-gradient BNE/SDS-Page seems more appropriate to separate and visualize 
complex II subunits like demonstrated with bovine mitochondria, the enzyme enrichment is 
coupled with a concentration of other membrane proteins and complexes with similar molecular 
weight and probably with higher expression level. In consequence, the protein background is 
increased on the stained gel which makes difficult the visualization and the identification of low-
expressed proteins such as Complex II subunits  
 
Figure 3.28. Separation of P. falciparum enriched complex II by 2D non-gradient BNE/SDS-Page. (A) 
Sucrose gradient fraction (20%, 22.5% and 25% sucrose) enriched in P. falciparum complex II were pooled, 
dialyzed, concentrated and separated by a non-gradient 8% blue native gel (BNE) followed by a second 
dimension 15% SDS-Page and silver stained. (B) Immunoblot with an identical 2D gel was performed with 
our customized anti-SdhA polyclonal antibody. The arrow indicates signal localization. 
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3.4. Discussion 
 The main objective of this chapter was to identify the genes encoding the membrane 
anchor subunits SdhC and SdhD of the complex II, as well as the a and b subunits of the ATP 
synthase in Plasmodium species. Because both enzymes are believed to be functional in malaria 
parasites, it suggests that those key subunits are probably not absent. 
3.4.1. Proposed candidate genes by a bioinformatic approach 
 Because these membrane anchor subunits are highly divergent across species and difficult 
to identify with conventional BLAST programs, a bioinformatic strategy using structural 
fingerprints has been set up. PF3D7_1212600.2 and PF3D7_0611100 were identified as 
candidates for P. falciparum SdhC and SdhD respectively.  The SdhC and SdhD candidate genes 
have the quinone/heme-binding motifs “Sx3Rx48H" in front of the predicted transmembrane helix I 
and “Yx10DY" following the helix II. In the same manner as for E. coli complex II, both residues 
W228 in SdhB and Y72 in the SdhD "Yx10DY" motif could hydrogen bond to the O-1 atom of 
ubiquinone and contribute to the binding affinity (Yankovskaya et al., 2003). The arginine in the 
SdhC “Sx3Rx48H" motif and D71 in the SdhD "Yx10DY" motif may be in close proximity to 
ubiquinone and could interact with Y72 (Tran et al., 2006). The serine in the SdhC “Sx3Rx48H" 
motif, demonstrated essential in E. coli (Horsefield et al., 2006), may also participate in quinone 
binding via hydrogen bonding to the O-4 atom of ubiquinone in malaria parasites. As in E. coli, a 
heme molecule could be ligated by the histidine in the SdhC “Sx3Rx48H" motif and the first 
tyrosine residue in the SdhD "Yx10DY" motif. It is noted that the SdhD candidate identified here, 
lacks a third transmembrane domain unlike its mammalian and bacterial counterparts. Mogi and 
Kita, recently proposed candidates for these two missing subunits but without proteomic data 
and motif conservation with homologues in other species to support these choices, and for this 
reason, they are unlikely candidates (Mogi and Kita, 2009) (Table 3.15). The main difference 
between the study presented here and this previous work is the conserved motifs employed as 
subunit fingerprint. The SdhC and SdhD motifs used in this thesis are simpler and less specific due 
to a higher number of homologous genes used to refine both patterns. Clearly however, the 
bioinformatics strategy adopted here needs to be confirmed genetically or using a proteomics 
approach. 
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Table 3.15. Putative candidates of SdhC, SdhD and ATP synthase subunits a and b in Plasmodium 
falciparum proposed by Mogi and Kita, and our study. 
 
 The gene PF3D7_0611000 was identified as a candidate for encoding the ATP synthase 
subunit a, on the basis that it contains a large hydrophobic section with six transmembrane 
domains and conserves the essential arginine residue to interact with the c ring. The candidate 
proposed by Mogi and Kita displays four transmembrane domains but lacks the crucial Arg210 
which asks a question on the possible functionality of this proposed subunit (Mogi and Kita, 
2009). For ATP synthase subunit b, no distinct gene could be determined among 5 candidates in 
absence of motif patterns and based only on the secondary structure profile. A recent release of 
the Pfam database found a "mitochondrial ATP synthase B chain precursor family" domain for the 
gene PF3D7_1125100. Indeed, the gene has predicted attributes expected for the subunit b, such 
as two transmembrane domains near the N-terminus, an α-helical secondary structure in the C-
terminal domain, and a mitochondrial targeting peptide. However, this subunit-b like protein has 
not been selected by the bioinformatic filtering presented here due to an excessive molecular 
weight (59.2 kDa) which makes this subunit unconventional if its function is confirmed in future 
studies.   
3.4.2. Proteomic attempts to validate complex II candidate genes. 
2D gradient BNE/SDS-Page and non-gradient BNE/SDS-Page were performed to establish 
a proteomic cataloguing of all subunits that constitute the P. falciparum complex II.  A polyclonal 
antibody detecting the P. falciparum SdhA under denaturing conditions was successfully 
generated but attempts to generate an anti-ATP synthase subunit α failed. Attempts to identify 
and characterise SdhC and SdhD subunits in P. falciparum by using the conventional gradient 
BNE/SDS-Page were unsuccessful. The protein PF3D7_1117300, detected via our proteomics 
analysis, was not selected by the proceeding bioinformatic analyses due to its lack of SdhC or 
SdhD conserved motifs.  A highly divergent or unconventional subunit C or D is conceivable, and it 
Reference SdhC SdhD 
ATP synthase 
subunit a 
ATP synthase 
subunit b 
(Mogi and Kita, 
2009) 
PF3D7_0611100 PF3D7_1010300 PF3D7_1005800 PF3D7_0703600 
The present 
study 
PF3D7_1212600.2 PF3D7_0611100 PF3D7_0611000 
PF3D7_0107400 
PF3D7_0931500 
PF3D7_0933400 
PF3D7_1214000 
PF3D7_1223000 
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will be interesting in future studies to investigate whether this protein can be associated with the 
complex II. 
 
3.4.3. Critical assessment of the adopted methodologies 
The low number of structural fingerprints available to refine the bioinformatics filtering is a 
major limitation to correctly assign a unique candidate for the protein searched. Because the 
proteomic strategy exposed in this chapter failed to confirm predicted candidates, experimental 
data are still needed to evaluate the robustness of this bioinformatic approach. Thus, candidate 
genes proposed in this work have to be considered carefully. Additionally, this method requires 
manual bioinformatic processing and can be considered as a low throughput way to identify 
proteins. However, new bioinformatic approaches are needed to help the identification of highly 
divergent proteins. Indeed, BLAST or Hidden Markov Models search programs are too limited to 
identify those poorly-conserved proteins as well as no Pfam domains being detected in nearly 
50% of P. falciparum proteins (Terrapon et al., 2009). 
With better resolution and visualization, the non-gradient BNE/SDS-Page makes possible 
the identification of complex II subunits from enriched extracts. Unfortunately, no complex II 
subunits could be identified via this approach. This method worked well with preparation of 
isolated mitochondria of high purity but remains limited with poorly-expressed mitochondrial 
proteins included in a large membrane proteins mixture such as the P. falciparum membranes 
extract used here. Hence, a major failure of the methodological approach used was the failure to 
dissociate the mitochondria from other organelles (e.g. apicoplast and ER) and parasite 
membranes.  
The subunit identification of the unusual succinate dehydrogenase in Trypanosoma cruzi 
was carried out by purifying the enzyme from isolated mitochondrial preparations before it was 
resolved by a classical two dimensional technique (Morales et al., 2009).  To determine the seven 
subunits composing the unconventional complex II in plant Arabidopsis thaliana, the 
mitochondria were isolated and solubilised before being applied a 2D BNE/SDS-Page (Eubel et al., 
2003). It should be noted that the different Plasmodium mitochondrial preparations or the 
purification of the enzyme by FPLC published previously could not be reproduced with our 
parasite strains and our laboratory conditions (Kawahara et al., 2009; Mather et al., 2010; 
Suraveratum et al., 2000). 
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3.4.4. Future potential strategies. 
 The identification of the lacking subunits in succinate dehydrogenase or ATP synthase remain 
important objectives to achieve. Alternative future experimental strategies may include:  
 
 Determine standardized techniques to isolate the mitochondrion from malaria parasites 
as a routine procedure with a sufficient yield and purity, and with intact enzyme activities. 
For example, mitochondria isolation techniques used in other protists can be a source of 
inspiration. Hypotonic lysis coupled with Percoll gradient, as well as N2 cavitation 
followed by Nycodenz gradient centrifugation, are common approaches to purify 
mitochondria from T. brucei parasites (Schneider et al., 2007). In the protozoan parasite 
Blastocystis hominis, the mitochondria-like organelle is isolated and purified using a 
sucrose gradient (Nasirudeen and Tan, 2004).  
 
 Generate and characterise antibodies against full length SdhA or SdhB, ATPase subunit α 
(ATPα) or β antigens. Peptide-based antibodies, used in this study, worked predominantly 
in applications where the target protein was denatured whereas antibodies raised against 
full length protein antigens perform well against both denatured and native target (Brown 
et al., 2011). It may be possible to capture the whole complex II or ATP synthase from P. 
falciparum by immunoprecipitation in non-denaturing conditions with an antibody able to 
recognize folded antigens. Then, the subunit composition of the complex could be 
resolved by SDS-Page. The subunit composition of mammalian NADH dehydrogenase, F1F0 
ATP synthase, complex II or III has been shown using one-step immunopurification with 
monoclonal antibodies (Aggeler et al., 2002; Murray et al., 2003; Schilling et al., 2006). To 
acquire the antigens needed, a recombinant subunit should be cloned, over-expressed 
and purified before generating polyclonal or monoclonal antibodies by immunization. 
However, recombinant synthesis and purification of full length proteins can be 
complicated tasks with uncertain success. 
 
 Attempt a similar two-dimensional proteomic approach using gametocytes or sporozoites 
as source of mitochondrial enzymes instead of blood stage parasites. The expression of 
ETC-related genes such as type II NADH dehydrogenase, glycerol-3-phosphate 
dehydrogenase or cytochrome c were showed to be up-regulated for parasite stages 
having cristate mitochondria (Boysen and Matuschewski, 2011; Vontas et al., 2005). 
Those cristae are internal compartments of the inner membrane increasing the surface 
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for ETC complexes allowing for a higher rate of oxidative phosphorylation. Cristae 
morphology of the mitochondrion was reported for sexual and mosquito stages whereas 
acristate mitochondria were found for asexual erythrocytic stages (Langreth et al., 1978). 
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Chapter 4 
Electron contribution and membrane potential generation 
in Plasmodium falciparum mitochondria 
 
4.1.  Introduction 
4.1.1. Dehydrogenase contribution to the electron flow and membrane 
potential generation 
 As described in Chapter 1 section 1.2.4.3, the Plasmodium respiratory chain is composed of 
five dehydrogenases: type II NADH dehydrogenase (PfNDH2), succinate dehydrogenase (SDH), 
dihydroorotate dehydrogenase (DHODH), glycerol-3-phosphate dehydrogenase (G3PDH) and 
malate:quinone oxidoreductase (MQO). These five membrane-bound dehydrogenases convert 
ubiquinone (UQ) to ubiquinol (UQH2) which in turn is re-oxidised by the bc1 complex (complex III), 
feeding the electron transport chain (ETC). Thus, these enzymes contribute to the maintenance of 
the membrane potential generated by the vectorial translocation of protons (H+) from complex III 
and IV, and are essential for parasite survival. However, little is known about their relative 
contribution to the overall electron-flow at a given reduction state of the UQ-pool, and to the 
membrane potential generation. Furthermore, data regarding the presence and turnover of the ETC 
dehydrogenases have been reported in different studies but are fragmented and contradictory (Fry 
and Beesley, 1991; Kawahara et al., 2009; Krungkrai, 1995; Mather et al., 2010; Takashima et al., 
2001). 
 The most accurate method to determine the activity of those five dehydrogenases is to 
measure the oxidation of their substrate (NADH, succinate, dihydroorotate, malate and glycerol-3-
phosphate) or the reduction of their native electron acceptor (ubiquinone 8 (UQ8)). Because UQ8 is 
too hydrophobic and cannot be used as an exogenous substrate, dehydrogenase assays are 
commonly assayed with more hydrophilic analogues such as the artificial short-chain ubiquinone 
UQ1. Dehydrogenase substrate-product pairs cannot be detected spectrophotometrically in a 
reaction mixture, except for NADH which strongly absorbs ultraviolet light at 340 nm (ε340nm = 6.22 
mM.cm-1). With a maximal absorption at 283 nm (ε280nm = 8.10 mM.cm
-1), UQ is thus the most 
reliable indicator for monitoring dehydrogenase activities but can be impaired by the presence of 
opaque hemozoin pigments. Contained within Plasmodium membrane compartments, hemozoins 
are dark brown particles with a high propensity for light scattering.  They significantly affect the 
absorbance spectra between the UV region and 625 nm with a peak around 400 nm. The hemozoin 
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particles represent a challenge to spectrophotometric measurements of enzyme activities in malaria 
parasites (Biagini et al., 2006; Mather et al., 2010). To overcome this problem, employment of 
colorimetric linked assays is an alternative way to measure dehydrogenase activities in Plasmodium 
species. Each ubiquinone reductase can be determined by two types of UQ-pool linked assays 
measuring either (i) the reduction of exogenous cytochrome c through the bc1 complex activity 
which uses the generated UQH2 as substrate (ii) or the artificial electron acceptor 
dichlorophenolindophenol (DCPIP) reduced by released UQH2 in the lipid bilayer  (Fig. 4.1).  The 
PMS/MTT system is another approach to evaluate the substrate oxidation from flavoproteins by 
reduction of the artificial electron acceptor MTT (methylthiazolyldiphenyl-tetrazolium bromide) via 
the artificial electron mediator PMS (phenazine methosulfate). 
 
Figure 4.1. Schematic representation of different types of electron acceptors used to determine the 
dehydrogenase activity in Plasmodium species. Their peak absorptions are indicated in brackets. 
Abbreviations: PMS, phenazine methosulfate; MTT, methylthiazolyldiphenyl-tetrazolium bromide; DCPIP, 
dichlorophenolindophenol; UQ, ubiquinone; UQH2, ubiquinol, bc1; bc1 complex. 
 Fry and Beesley were the first to indirectly measure different dehydrogenases by following 
the cytochrome c reduction induced by NADH, succinate, glycerol-3-phopshate and dihydroorotate 
from P. falciparum and P. yoelii crude mitochondria (Fry and Beesley, 1991). Several studies have 
since reported specific activities of the five dehydrogenases from different Plasmodium species. 
Shown in Table 4.1, values obtained vary depending on the type of assay used, the procedure 
employed to prepare the parasite extract and the Plasmodium species cultivated. In this study, 
activities from all dehydrogenases are compared for the first time with an identical type of 
enzymatic assay and from the same malaria parasite preparation. This homogeneity of assays allows 
determination of the contribution of each dehydrogenase to the oxidative phosphorylation. 
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Table 4.1. Summary of Plasmodium dehydrogenase activities determined by different studies. Abbreviations: SDH, succinate dehydrogenase; DHODH, dihydroorotate 
dehydrogenase; MQO, malate:quinone oxidoreductase; G3PDH, glycerol-3-phosphate dehydrogenase; N.D., Not determined; CM, Crude mitochondria. 
Reference Assay 
Plasmodium 
species 
Type II NADH 
(NADH) 
SDH 
(Succinate) 
DHODH 
(Dihydroorotate) 
MQO 
(Malate) 
G3PDH 
(Glycerol-3-
phosphate) 
Specific activity (nmol.min-1.mg protein-1) 
(Fry and 
Beesley, 1991) 
Substrate:cytochrome c 
reductase (550 nm) 
P. falciparum (CM) 
P. yoelii (CM) 
385 ± 37 
470 ± 45 
112 ± 13 
150 ± 24 
11 ± 3 
18 ± 3 
N.D. 
N.D. 
176 ± 24 
230 ± 31 
(Kawahara et 
al., 2009) 
Substrate:DCPIP reductase 
assay (600 nm) 
P. yoelii (CM) 
N.D. 2.66 ± 0.02 10.5 ± 1.3 N.D. N.D. 
Substrate:cytochrome c 
reductase (550 nm) 
18.6 ± 1.6 N.D. N.D. N.D. N.D. 
NADH:UQ1 reductase assay 
(340 nm) 
42.2 ± 0.3 N.D. N.D. N.D. N.D. 
(Takashima et 
al., 2001) 
Succinate:PMS/MTT 
reductase (570 nm) 
P. falciparum (CM) 
N.D. 3.05 ± 0.8 N.D. N.D. N.D. 
Succinate:DCPIP reductase 
assay (600 nm) 
N.D. 4.18 ± 0.0 N.D. N.D. N.D. 
(Mather et al., 
2010) 
Substrate:DCPIP reductase 
assay (600 nm) 
P. falciparum (CM) N.D. 13.8 9.73 11.1 N.D. 
(Krungkrai, 
1995) 
Dihydroorotate:DCPIP 
reductase assay (600 nm) 
P. berghei (CM) N.D. N.D. 0.72 N.D. N.D. 
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 Because dehydrogenase activities are relatively low in blood-stage parasites (Mather et 
al., 2010; Vaidya and Mather, 2009), if the samples are not rich in mitochondria, it is important to 
use a relatively large amount of cell-free parasite extract per assay (e.g. 50 µg of parasite protein).  
This however can lead to relatively high levels of hemozoin in the reaction mixture. By monitoring 
the enzyme activity at 283 nm in the presence of malaria pigment, the light is scattered and a high 
signal background can be measured when using conventional 1 cm pathlength cuvette. To 
minimize the hemozoin absorbance and interference, assays were performed in a 1 mm 
pathlength quartz cuvettes, reducing the high signal-to-noise ratio (Fig. 4.2). 
 
Figure 4.2. Schematic representation of 1 cm and 1 mm pathlength quartz cuvettes. With less distance of 
hemozoin-containing solution (indicated by a beige colour) to be crossed by the spectrophotometer beam, 
the 1 mm pathlength cell exhibits a lower background signal and therefore a lower signal-to-noise ratio 
compared to 1 cm pathlength cuvette. 
 With 1 mm pathlength cuvettes, quinone reduction activities (283 nm) from each 
dehydrogenase were assayed in P. falciparum cell free extract to establish their specific turnover 
and determine their relative contribution to the electron flow. Steady state kinetics from complex 
III and IV were also established in this study to determine the relative electron flux driven by both 
enzymes. The main providers of electrons for downstream generation of the electrochemical 
membrane potential were finally evaluated by monitoring the mitochondrial membrane potential 
in response to dehydrogenase inhibitors. 
 Recently, it was reported that P. berghei lacking the type II NADH dehydrogenase 
(PbNDH2(-)) maintains a mitochondrial membrane potential, highlighting the hypothesis of 
mutual complementation among ETC enzymes (Boysen and Matuschewski, 2011). Kindly provided 
by Dr. Kai Matuschewski, PbNDH2(-) parasites were cultivated and NADH dehydrogenase activities 
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were measured by direct quinone reduction and Q-pool cytochrome c linked assays. Compared 
with NADH dehydrogenase activities from P. berghei ANKA wild-type (WT), this work attempts to 
determine if the dehydrogenase complementation exists in the rodent parasite and might 
extrapolate to P. falciparum. 
4.1.2. Menaquinone: an alternative electron carrier? 
 Menaquinone (MQ) is an alternative electron carrier of the respiratory chain mainly used 
by bacterial species. It is the predominant lipoquinone consumed by respiratory enzymes in 
Gram-positive bacteria such as Mycobacterium species (Collins and Jones, 1981; Pandya and King, 
1966). Facultative anaerobic organisms such as E. coli may employ both MQ and ubiquinone (UQ) 
whereas mammals use only UQ (Fig. 4.3). In E. coli, the ratio MQ/UQ is regulated depending on 
the oxygen supply in the environment (Bekker et al., 2007; Shestopalov et al., 1997). UQ, which 
has a high midpoint potential (E0′ = + 110 mV), is primarily involved in aerobic respiration whereas 
MQ, having a low midpoint potential (E0′ = - 80 mV), is mainly consumed in anaerobic conditions. 
 
Figure 4.3. Chemical structure of ubiquinone and menaquinone. 
 Recently, Tonhosolo and colleagues demonstrated an active pathway for biosynthesis of 
menaquinone-4 (MQ4) during the blood stage of P. falciparum parasites (Tonhosolo et al., 2010). 
This new insight suggests that MQ4 could replace the endogenous ubiquinone as electron 
acceptor under anaerobic conditions. During intraerythrocytic stages, the malaria parasite might 
be considered as microaerophilic (Trager, 1994). Due to variations of the O2 concentration in deep 
capillaries, parasites might be sequestered in an oxygen-depleted environment. Tonhosolo et al. 
confirmed that the P. falciparum parasite changes the content of its quinone pool depending on 
aeration conditions (Tonhosolo et al., 2010). Thus, parasites increase their MQ concentration by 
50% and decrease their UQ counterpart by 15% after 48h of cultivation in anaerobic conditions. 
Additionally, they revealed that PfNDH2 harvested from free parasite extracts can use MQ as an 
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electron carrier to oxidize NADH with an apparent Km of 72 ± 15 µM and Vmax of 3 ± 0.8 µmol.min
-
1.mg-1. 
 In mycobacteria, the menaquinol (MQH2) produced by both type II NADH dehydrogenase 
and succinate dehydrogenase is directly re-oxidized by the supercomplex cytochrome bc1 / 
cytochrome aa3 or the cytochrome bd-type terminal oxidase (Matsoso et al., 2005). However, no 
data are available on the capacity of P. falciparum bc1 complex to utilize MQH2 as a coenzyme.  
 To determine if menaquinone might be used as an alternative electron carrier by the P. 
falciparum ETC, PfNDH2 and bc1 complex activities were measured in presence of MQ and MQH2, 
respectively. These experiments were performed in anaerobic conditions to minimise possible 
non-enzymatic redox reactions. 
4.2.  Material & Methods 
4.2.1. Preparation of decylubiquinol 
 The artificial quinol electron donor was prepared based on a previously described method 
(Fisher et al., 2004b).  Briefly, 2,3-dimethoxy-5-methyl-n-decyl-1,4-benzoquinone 
(decylubiquinone), an analogue of ubiquinone (Sigma, St-Louis, USA), was dissolved (10 mg) in 
400 µl of nitrogen-saturated hexane.  An equal volume of aqueous 1.15 M sodium dithionite was 
added, and the mixture shaken vigorously until colourless. The upper, organic phase was 
collected, and the decylubiquinol recovered by evaporating off the hexane under N2.  The 
decylubiquinol was dissolved in 100 µl of 96 % ethanol (acidified with 10 mM HCl) and stored in 
aliquots at -80 °C.  Decylubiquinol concentration was determined spectrophotometrically from 
absolute spectra, using ε288-320  =  4.14 mM
-1.cm-1 (Figure 4.4).  
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Figure 4.4. Absorption spectra of decylubiquinol. The concentration of decylubiquinol was 
determined by measuring the absorbance difference between 288 and 320 nm using an extinction 
coefficient of 4.14 mM-1.cm-1. 
4.2.2.  Preparation of recombinant P. falciparum type II NADH 
dehydrogenase (PfNDH2). 
 Crude membranes containing the recombinant PfNDH2 were prepared from the E. coli 
heterologous expression strain F571 according to the method described by Fisher et al. (Fisher et 
al., 2009). E. coli F571 cells were prepared from LB broth containing 100 µg.ml-1 ampicillin, 50 
µg.ml-1 kanamycin and 10 µg.ml-1 tetracycline. 10 ml of bacterial cells were grown overnight at 
37°C in a shaking incubator (200 rpm). The following day these cultures were propagated in 400 
ml LB broth containing appropriate antibiotics and grown at 37°C with shaking at 200 rpm. When 
the culture reached the point of inoculation (OD600 = 0.6), 1 mM IPTG was added to the bacterial 
cultures to induce expression and maximize the yield of the recombinant PfNDH2. The cells were 
grown at 37°C for 16 h, with shaking at 200 rpm. After growth, the cells were harvested by 
centrifugation at 4,000 x g for 20 min. Cells were resuspended in ice-cold buffer containing 50 mM 
KPi pH 7.4, 2 mM EDTA and a cocktail of protease inhibitors (Roche). The resuspended cells were 
disrupted by two passes through a French press at a pressure of 25,000 psi.  The cell lysate was 
centrifuged at 10,000 rpm for 20 min at 4°C to remove unbroken cells. Membranes were 
recovered from the supernatant after ultracentrifugation (1 h at 100,000 x g and 4°C). The 
membranes were resuspended via a homogenizer in 500 µl of ice-cold buffer with 50 mM KPi pH 
7.4, 2 mM EDTA and protease inhibitors. Membranes were aliquoted and stored at -80°C. 
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4.2.3.  Measurement of ubiquinone reduction induced by NADH, 
succinate, glycerol-3-phosphate, malate and dihydroorotate. 
 NADH, SDH, G3PDH, MQO and DHODH activities were measured spectrophotometrically 
by following the reduction of ubiquinone-1 (UQ1) at 283 nm (ε283 = 8.1 mM
-1.cm-1) with a Cary 
4000 spectrophotometer (Varian Inc, USA). Enzyme activities were measured in a buffered 
solution (final volume 120 µl) containing 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 
mM KCN (1 M stock solution, pH adjusted to 7.5) and 50 µM coenzyme Q1 at room temperature. 
P. falciparum enzymes were present as a cell-free P. falciparum extract (preparation described in 
section 2.2) at a total protein concentration of 30-60 µg.ml-1. Inhibitors were added prior the 
addition of substrate. The reaction volume was 120 µl and assays were performed in a 1 mm 
pathlength quartz cuvette (Varian, USA). Inhibitors were added prior to initiation of the reaction 
by addition of 200 µM NADH, 10 mM succinate, 10 mM malate, 10 mM glycerol-3-phosphate or 1 
mM dihydroorotate.  
4.2.4. Measurement of ubiquinol:fumarate oxidoreductase activity 
 The ubiquinol:fumarate reductase (QFR) reaction was assayed by following the oxidation 
of decylubiquinol (dQH2) at 283 nm (ε283 = 8.1 mM
-1.cm-1). QFR activity was initiated by addition of 
10 mM fumarate in a buffered solution (final volume of 120 µl in a 1 mm pathlength quartz 
cuvette) containing 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN, 50 µM dQH2 
and P. falciparum cell-free extract (concentration between 30 to 60 µg.ml-1). Malonate inhibitor 
was added prior the addition of fumarate. 
4.2.5.  Measurement of Q-pool cytochrome c linked assay induced by 
dehydrogenase substrates 
 Cytochrome c reductase activity of complex III was monitored by following the reduction 
of cytochrome c at 550-542 nm (ε550-542 = 18.1 mM
-1.cm-1). The reaction buffer consisted of 50 mM 
potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN and 30 µM horse heart cytochrome c 
(Sigma, USA). The reaction volume was 700 µl and assays were performed at room temperature 
with a 1 cm pathlength quartz cuvette (Varian, USA). P. falciparum dehydrogenases were present 
as a cell-free P. falciparum extract (preparation described in section )at a total protein 
concentration of 30 to 60 µg.ml-1. Cytochrome c reductase activities were initiated by the addition 
of 50 µM dQH2 (to measure bc1 complex activity), 200 µM NADH, 10 mM succinate, 10 mM 
malate, 10 mM glycerol-3-phosphate or 1 mM dihydroorotate.  
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4.2.6.  Measurement of succinate:PMS/MTT oxidoreductase activity. 
 The ability of complex II to pass electrons from succinate to methylthiazolyldiphenyl-
tetrazolium bromide (MTT) was assayed by monitoring the absorbance increase at 570 nm (ϵ570 = 
17 mM-1.cm-1) in the presence of phenazine methosulfate (PMS) (Tran et al., 2006). The reaction 
volume was 700 µl and assays were performed at room temperature with a 1 cm pathlength 
quartz cuvette. The reaction mixture contained a reaction buffer (50 mM potassium phosphate, 2 
mM EDTA, pH 7.5), 750 μM PMS, 75 μM MTT and 30 to 60 µg.ml-1 of cell-free P. falciparum 
extract. Malonate was added prior the initiation of the reaction by addition of 10 mM succinate. 
IC50 value was calculated by fitting data to a four-parameter logistic fit function using 
Kaleidagraph software (Synergy Software, USA). 
4.2.7.  Measurement of bc1 protein and complex IV activities 
 Decylubiquinol:cytochrome c oxidoreductase (bc1 protein) and cytochrome c oxidase 
(complex IV) activities were measured by monitoring the increase and decrease of cytochrome c 
reduced concentration at 550-542 nm (ε550-542 = 18.1 mM
-1.cm-1), respectively. The bc1 reaction 
buffer consisted of 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN and 30 µM 
equine cytochrome c oxidised (Sigma, USA) (Fisher et al., 2004b). The complex IV mixture was 
composed of 50 mM potassium phosphate (pH 7.5), 2 mM EDTA and 5 µM antimycin A. Antimycin 
A is added to inhibit the bc1 complex downstream activity and stop the production of endogenous 
reduced cytochrome c. The reaction volume was 700 µl and assays were performed at room 
temperature with a 1 cm pathlength quartz cuvette. P. falciparum bc1 and complex IV were 
present as a cell-free P. falciparum extract at a total protein concentration of 30-60 µg.ml-1. 
Cytochrome c reductase (bc1) and oxidase (complex IV) activities were initiated respectively by the 
addition of 50 µM decylubiquinol (dQH2) and 30 µM reduced equine cytochrome c. The horse 
heart cytochrome c was reduced by adding a pinch of sodium dithionite and then passed through 
a PD-10 desalting column (Pharmacia, USA). Kinetic constants, Km and Vmax, were determined by 
fitting data to a Michaelis-Menton function using Kaleidagraph software. 
4.2.8. Measurement of dehydrogenases and bc1 complex activities with 
menaquinone in anaerobic conditions. 
 All measurements were collected on a Cary 50 scanning spectrophotometer (Varian Inc., 
USA) in a glove box (Belle Technology, UK) under a nitrogen atmosphere and with oxygen 
concentration maintained at less than 2 ppm. All buffers and solutions were degassed by bubbling 
with argon prior to entry into the glove box to ensure removal of O2. 
Chapter 4 
100 
 
 P. falciparum NDH2 (cell-free P. falciparum extract) and recombinant PfNDH2 (at a total 
protein concentration of 10 to 20 μg/ml) were assayed in a reaction medium consisting of 50 mM 
potassium phosphate (pH 7.5), 2 mM EDTA, 200 μM NADH and 10 mM KCN. NADH:menaquinone 
and NADH:ubiquinone oxidoreductase activities were initiated respectively by the addition of 100 
μM MQ4 and 50 μM UQ1. Their reduction was monitored at 286 nm and 283 nm, respectively.  
 Malate, glycerol-3-phosphate, succinate and DHO dehydrogenase activities were 
monitored at 286 nm and 283 nm in presence of MQ4 and UQ1, respectively. The reaction was 
prepared in a 120 µl final volume as described previously (section 4.2.5) and was induced by 
addition of 10 mM malate, 10 mM G-3-P, 10 mM succinate or 1 mM DHO in presence of cell-free 
P. falciparum extract (30-60 µg.ml-1). 
 Menaquinol:cytochrome c oxidoreductase and ubiquinol:cytochrome c oxidoreductase 
activities were measured as described previously (section 4.2.9). The reaction mixture was 
composed of 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN and 30 µM oxidised 
equine cytochrome c. The reaction was initiated by the addition of 100 µM menaquinol (MQH2) or  
50 µM decylubiquinone (dQH2) in presence of cell-free P. falciparum extract (30-60 µg.ml
-1). 
Menaquinol (MQH2) was generated from an aqueous solution of menaquinone-4 by reduction 
with an aqueous solution of sodium dithionite in the anaerobic environment. Artificial 
decylubiquinol (dQH2) was prepared as previously described (section 4.2.3) and degassed. 
4.2.9.  Real-time single-cell monitoring of membrane potential  
 The rhodamine derivative TMRE (tetramethyl rhodamine ethyl ester) was used to monitor 
the membrane potential of the cytoplasm and mitochondria from malaria-infected red blood 
cells. TMRE is cationic and reversibly accumulates inside energized membranes according to the 
Nernst equation. For the experiment, suspensions (5-8% parasiteamia, 1% haematocrit) of 
infected erythrocytes in HEPES-buffered RPMI medium (no serum) were loaded with 250 nM 
TMRE (Molecular Probes, USA) for 10 min at 37°C. For imaging, malaria parasite-infected 
erythrocytes were immobilized using polylysine-coated coverslips in a Bioptechs FCS2 perfusion 
chamber (Bioptechs, USA) and maintained at 37°C in growth medium (no serum). Before each 
assay, cells were treated with 200 nM concanamycin A for 5 minutes in order to remove the 
fluorescent contribution of the plasma membrane potential (Δψp) and measure only the 
mitochondrial membrane potential (Δψm). Inhibitors were added to the perfusate, and the 
membrane potential-dependent fluorescence responses were monitored in real time. During all 
manipulations, the concentration of TMRE in the perfusate was kept at 250 nM. The fluorescence 
signals from malaria-infected erythrocytes were collected on a Zeiss Pascal confocal laser 
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scanning microscope (Zeiss, Germany) through a Plan-Apochromat 63x 1.2 numerical aperture 
water objective. Excitation of TMRE was performed using the HeNe laser line at 543 nm. Emitted 
light was collected through a 560-nm long pass filter from a 543-nm dichroic mirror. For all assays, 
the fluorescence dynamic range was set up so that untreated TMRE-loaded cells were regarded as 
having complete fluorescence (100%), whereas the baseline (0%) was set by addition of 10 µM H+ 
ionophore FCCP (carbonyl cyanide p-(trifluoromethyl) phenylhydrazone). Photobleaching (the 
irreversible damage of TMRE producing a less fluorescent species) was assessed by continuous 
exposure (5 min) of loaded cells to laser illumination. For each experiment, the laser illumination 
and microscope settings (laser power, scan speed, pinhole diameter, number of scan sweeps and 
degree of magnification) that gave no reduction in signal were used. Data capture and extraction 
were carried out with Zeiss Pascal software and plot design were performed with Kaleidagraph 
(Synergy Software, Reading, USA). 
4.2.10. In vivo cultivation and cell-free extracts of wild-type and 
PbNDH2-depleted rodent malaria parasites 
 In vivo parasite cultivation was performed under UK Home Office Animals (Scientific 
Procedures) Act 1986, approved by the appropriate institutional animal care and use committee, 
and conducted in accordance with the International Conference on Harmonization safety 
guidelines. P. berghei ANKA-GFP (WT) and PbNDH2(−) parasite strains were kindly provided by Dr. 
Kai Matuschewski (Max Planck Institute for Infection Biology, Berlin, Germany). Blood stage P. 
berghei ANKA-GFP (WT) and PbNDH2(−) parasites were injected via the peritoneal cavity into 
male CD-1 mice and the developmental stage and parasitaemia were monitored by microscopic 
examination of Giemsa-stained blood smears. When a parasitaemia of asynchronous blood stage 
parasites reached a value greater than 10% (between 120 to 170 h after infection), about 5 to 8 
ml of blood was collected from 10 mice by cardiac puncture for both parasite strains. To remove 
serum and buffy coat, blood was washed three times in 25 mM HEPES-buffered RPMI 1640 by 
centrifugation at 4°C at 2,500 x g for 5 min. Preparation of cell-free parasites from mouse 
erythrocytes was performed by treatment with 0.15% (w/v) saponin in phosphate-buffered saline. 
The free parasite pellets were washed four times in 25 mM HEPES-buffered RPMI 1640 by 
centrifugation for 5 min at 6,000 x g and 4 °C. Before carrying out the enzymatic assays, both cell-
free parasites corresponding to WT and PbNDH2(−) strains, were disrupted with a probe sonicator 
in assay buffer (50 mM potassium phosphate, 2 mM EDTA, pH 7.5) including protease inhibitor 
cocktail (Complete Mini, Roche Applied Science, Germany). 
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4.3. Results 
4.3.1. Direct and Q-pool linked dehydrogenase activities 
 For the first time, the five dehydrogenases were assayed from P. falciparum cell-free 
extract by directly observing the reduction of UQ1 (Table 4.2). Enzyme assays measured 
dehydrogenase activity values in the same range (between 2 to 9 nmol UQ1 reduced. min
-1 .mg 
protein-1) and similar to those reported by Mather et al. using DCPIP UQ-pool linked assays 
(Mather et al., 2010). PfNDH2 is the most active dehydrogenase with a specific activity value of 
8.80 ± 0.64 nmol UQ1 reduced.min
-1.mg protein-1. DHODH, MQO and G3PDH seem two- to three-
fold less active than PfNDH2. Interestingly, no succinate:UQ1 oxidoreductase activity could be 
measured despite several attempts with different parasite preparations.  
 
Table 4.2. Specific activities of P. falciparum dehydrogenases by measuring directly the ubiquinone 
reduction. The quinone reduction rate was spectrophotometrically monitored at 283 nm with a 1 mm 
pathlength cuvette and P. falciparum cell-free extract. 
Dehydrogenase Assay 
Specific Activity1 
(nmol UQ1 red/mg protein/min ± SE) 
PfNDH2 NADH:UQ1 reductase 8.80 ± 0.64 
SDH Succinate:UQ1 reductase 0.00 ± 0.00 
DHODH Dihydroorotate:UQ1 reductase 4.41 ± 0.68 
MQO Malate:UQ1 reductase 3.91 ± 0.64 
G3PDH Glycerol-3-phosphate:UQ1 reductase 2.73 ± 0.29 
Values are expressed as mean ± standard error from at least 3 independent experiments.  
1 
Specific activity superior to the detection limit of the substrate:UQ1 reductase assay (= 0.05 nmol UQ1 
red/mg protein/min). 
 
 Subsequently, the capacity of each dehydrogenase substrate to provide UQH2 to the bc1 
complex was reported by performing UQ-Pool cytochrome c linked assays (Table 4.3). As 
previously observed by Fry and Beesley (Fry and Beesley, 1991), the induction by NADH provided 
the more important cytochrome c reduction with a Vmax superior to the bc1 turnover (assayed by 
induction with dQH2). Other dehydrogenases, including the succinate dehydrogenase, showed 
between six to seventeen-fold less cytochrome c reduction than PfNDH2. While induction with 
dHQ2 and NADH exhibited Michaelis-Menten kinetics, linear steady-state kinetics were obtained 
after addition of the other substrates, indicative of slower cytochrome c reductase activities. 
Interestingly, a low succinate:cytochrome c reductase activity was measured whereas no 
succinate:ubiquinone oxidoreductase activity has been clearly detected. First, this variation can 
be explained by a basal activity from the Q-pool behaviour and independent to any succinate 
dehydrogenase activity. On the other hand, the succinate:ubiquinone reduction activity could be 
underestimated due to the properties of the UQ analogue used (UQ1) as acceptor which may 
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diffuse less in the lipid  bilayer than the natural ubiquinone (UQ8). Used instead of native 
substrates, UQ1 is more water-soluble than the native substrate and may not diffuse correctly in 
the membranes which might cause different interactions with the quinone-binding site of the 
enzyme. 
Table 4.3. Cytochrome c reductase activities induced by different substrates. The cytochrome c reductase 
activity was measured spectrophotometrically at 550 - 542 nm with a 1 cm pathlength cuvette and with P. 
falciparum cell-free extract  Abbreviations: dQH2, decylubiquinol; Cyt c, cytochrome c. 
ETC enzyme Assay 
Specific Activity 
(nmol cyt c red/mg protein/min ± SE) 
bc1 complex dQH2: Cyt c reductase 97.40 ± 5.10 
PfNDH2 NADH:Cyt c reductase 112.15 ± 6.96 
SDH Succinate:Cyt c reductase 6.57 ± 3.87 
DHODH Dihydroorotate:Cyt c reductase 13.53 ± 10.44 
MQO Malate: Cyt c reductase 16.02 ± 9.53 
G3PDH Glycerol-3-phosphate:Cyt c reductase 19.33 ± 11.60 
Values are expressed as mean ± standard error from at least 3 independent experiments. 
 
 Surprisingly, the cytochrome c reductase activity initiated by NADH is extremely high and 
not comparable with the rate of quinone reduction measured from PfNDH2 (8.85 ± 0.64 nmol UQ1 
red/mg protein/min). Thus, another pathway is suspected to reduce exogenous cytochrome c by 
induction with NADH. The rotenone insensitive NADH:cytochrome b5 reductase (PlasmoDB entry 
PF3D7_1367500) located on the mitochondrial outer membrane is able to reduce exogenous 
cytochrome c in presence of NADH (Sottocasa et al., 1967). Both quinone reductase and UQ-pool 
cytochrome c linked assays were performed with P. berghei ANKA Wild Type (WT) and a mutant 
strain lacking the type II NADH dehydrogenase (PbNdh2 (-)) (Fig. 4.5) (Boysen and Matuschewski, 
2011). As expected, the mutant strain did not show any quinone reduction induced by NADH 
whereas WT parasites exhibited a full PbNDH2 activity inhibitable by ∼95% with 100 nM hydroxy-
2-dodecyl-4-(1H)-quinolone (HDQ). However, the NADH:cytochrome c reduction activity in the WT 
strain was inhibited by only ∼10% when using the same amount of HDQ inhibitor. Thus, this 
inhibited fraction can be speculated to be the cytochrome c reduced via the contribution of 
PbNDH2 only. The HDQ-uninhibited activity could be reduced by ∼85% and ∼90% in the WT and 
PbNdh2 (-) strains respectively using p-hydroxymercuribenzoate (pHMB), an inhibitor of the 
NADH:cytochrome b5 reductase (Barham et al., 1996). The residual activity remaining, accounting 
for up to 15% of the total reduction of cytochrome c in the WT strain, may be due to the partial 
inhibition of NADH:cytochrome b5 reductase or from another enzyme such as the NADPH-
cytochrome P450 reductase. Exogenous cytochrome c could be also spontaneously reduced by 
Reactive Oxygen Species (ROS) generated through the electron transport chain.  The sonication 
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step during the P. falciparum and P. berghei cell-free extract preparations may mix enzymes from 
different membrane compartments. In consequence, the cytochrome c reduction activity 
attributed to PbNDH2 was overestimated due to activities from NADH:cytochrome b5 reductase, 
maybe NADPH-cytochrome P450 reductase or ROS formation. 
 
Figure 4.5. Direct quinone reduction and Q-pool cytochrome c linked assays with P. berghei ANKA wild-
type (WT) and PbNDH2(-). (A) Cell-free extract NADH:ubiquinone-1 reductase assay was 
spectrophotometrically monitored at 283 nm. (B) Cell-free extract NADH:cytochrome c reductase assay was 
spectrophotometrically monitored at 542-550 nm.  Bars are expressed as mean ± standard error from at 
least 3 measurements. Abbreviations: HDQ, hydroxy-2-dodecyl-4-(1H)-quinolone; pHMB, p-
hydroxymercuribenzoate. 
 
 
4.3.2. Depolarization of the membrane potential by bc1 and 
dehydrogenase inhibitors 
 To determine the consequences of inhibiting dehydrogenase activities on the 
mitochondrial membrane potential (Δψm)  real-time single-cell imaging assays were performed as 
described by Biagini et al. (Biagini et al., 2006). The measurement of mitochondrial Δψm is based 
on the accumulation of the cationic ﬂuorescent probe TMRE according to the Nernst equation. 
The novel CK-2-68 compound, 5-fluoroorotic acid and thenoyltrifluoroacetone (TTFA) were used 
as selective inhibitors of PfNDH2, dihydroorotate dehydrogenase and complex II, respectively (Fig. 
4.6). To date, no specific inhibitors for the malate:quinone oxidoreductase and the glycerol-3-
phosphate dehydrogenase have been identified. 
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Figure 4.6. Structure and P. falciparum growth inhibition of bc1 complex and dehydrogenase inhibitors. 
(A) Chemical structure of mitochondrial inhibitors used in this study. (B) Plasmodium falciparum growth 
inhibition IC50 values. Values indicated are means ± SE of results from three independent experiments. N.D.: 
Not determined. 
 
  In line with previous studies (Biagini et al., 2006; Srivastava and Vaidya, 1999), the 
inhibition of the bc1 complex with a selective inhibitor like stigmatellin was shown to collapse the 
Δψm of P. falciparum parasites (Fig. 4.7. A). Trophozoite-stage parasites were perfused with 100 
nM CK-2-68 and showed a rapid and partial depolarization (Fig. 4.7. B). CK-2-68 is amongst a new 
generation of PfNDH2 inhibitors developed by a recent drug discovery project (Biagini et al., 
2012). This result is consistent with the previous observation made by Biagini et al. where DPI, 
another type II NADH:dehydrogenase inhibitor, was shown to significantly reduce the TMRE 
fluorescence signal (Biagini et al., 2006). The Δψm-dependent ﬂuorescence of concanamycin-
treated infected erythrocytes was shown to be insensitive to 5-fluoroorotic (10 µM) acid and TTFA 
(10 µM) (Fig. 4.7. C and D). These results demonstrate clearly that PfNDH2 contributes to the 
formation of the electrochemical gradient in our in vitro conditions. Although DHODH 
dehydrogenase is essential for pyrimidine biosynthesis, its contribution to the mitochondrial Δψm 
formation seems negligible due to a slower turnover. Interestingly, the conventional succinate 
dehydrogenase inhibitor also has no effect on the membrane potential highlighting a slow 
turnover or absence of the enzyme. 
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Figure 4.7. Effect of bc1 complex and dehydrogenase inhibitors on mitochondrial membrane potential 
(Δψm). Time course of TMRE-dependent ﬂuorescence of P. falciparum-infected erythrocytes after the 
addition of (A) stigmatellin (100 nM), (B) CK-2-68 (100 nM), (C) 5-fluoroototic acid (10 µM) and (D) TTFA (10 
µM). Inhibitors were tested against concanamycin-treated cells. The baseline (0%) was set by addition of 10 
µM carbonyl cyanide p-(trifluoromethyl) phenylhydrazone (FCCP). Data were normalized to 100% 
concanamycin-treated cells and to 0% in FCCP (10 µM)-treated cells. Graphs show means from experiments 
performed independently ± standard errors (n ≥ 7). 
 
4.3.3. Kinetic constants of P. falciparum complex III and IV. 
 Kinetic data from both the bc1 complex and the cytochrome c oxidase are reported for the 
first time (Fig. 4.8). Using the exogenous horse heart cytochrome c as electron acceptor, the bc1 
complex from P. falciparum cell-free parasites was shown to have a Km value of ∼5.5 µM for 
dQH2. By monitoring the oxidation of reduced cytochrome c, the Km and Vmax of the cytochrome c 
oxidase were determined as ∼20 µM and 2.85 nmol cytochrome c oxidised.min-1.mg protein-1, 
respectively. The relative high Km for complex IV means a lower affinity between the enzyme and 
reduced cytochrome c than between the bc1 complex and oxidised cytochrome c. The low Vmax 
measured may depend on the relatively low content of cytochrome c oxidase in the parasite or a 
poor reactivity between the enzyme and the exogenous cytochrome c used for the assay. 
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C   
Enzyme 
Apparent Km 
(µM ± SE) 
Vmax 
(nmol/mg/min ± SE) 
dQH2:cythochrome c oxidoreductase 
(complex III) 
5.5 ± 1.1 97.4 ± 5.1 
Cytochrome c oxidase 
(complex IV) 
20.3 ± 2.5 2.8 ± 0.1 
 
Figure 4.8. Kinetics of bc1 complex (complex III) and cytochrome c oxidase (complex IV) from cell-free P. 
falciparum extract. (A) Steady-state decylubiquinol:cytochrome c oxidoreductase activity of P. falciparum 
3D7. (B) Steady-state cytochrome c oxidase activity of P. falciparum 3D7. (C) Kinetic constants of bc1 
complex and cytochrome c oxidase in P. falciparum 3D7.  
 
4.3.4. Catalytic properties of P. falciparum complex II 
 As mentioned previously, no direct succinate:quinone oxidoreductase activity (SQR 
activity) could be detected in P. falciparum despite having used both ubiquinone-1 and 
decylubiquinone  (UQ10 or dQ) as electron acceptors (Table 4.4). Both assays showed low activities 
(∼0.05 nmol.mg protein-1.min-1) corresponding to the signal background from the succinate:UQ1 
reduction. However, oxidation of succinate to fumarate (SDH activity) was detected with an 
activity of 4.87 ± 0.18 nmol.mg protein-1.min-1 by monitoring the reduction of the artificial 
electron acceptor MTT. The succinate:PMS/MTT activity was shown to be sensitive to malonate, a 
complex II inhibitor, with an IC50 value of 4.3 ± 0.45 mM (Fig. 4.9). A clear activity could be also 
identified (5.37 ± 0.50 nmol dQH2 oxidized.min
-1.mg protein-1) by monitoring the dQH2:fumarate 
oxidoreduction, highlighting the presence of a ubiquinol:fumarate oxidoreductase (QFR) in 
malaria parasites. The QFR activity was also shown to be sensitive to a complex II inhibitor by 
showing 83% inhibition in presence of 10 mM malonate. 
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Table 4.4. The specific activities of succinate dehydrogenase (SDH) and fumarate reductase (QFR) assays 
from P. falciparum cell-free extract.  
Type of assay 
Specific Activity 
(nmol/mg protein/min ± SE) 
SQR activity (succinate:UQ1 reductase) 0.05 ± 0.03 
SQR activity (succinate:dQ reductase) 0.04 ± 0.02 
SDH activity (succinate:PMS/MTT reductase) 4.87 ± 0.18 
QFR activity (dQH2:fumarate reductase) 5.37 ± 0.50 
QFR activity + 10 mM malonate 0.95 ± 0.40 
   Values indicated are means ± SE of results from three independent experiments. 
 
 
 
Figure 4.9. Concentration-dependent malonate inhibition of succinate:PMS/MTT activity in crude cell-free 
extracts. IC50 value was calculated by fitting of four-parameter logistic curves (Kaleidagraph software). 
 
4.3.5. Anaerobic measurement of ETC enzymes with menaquinone as 
electron carrier 
 To determine whether menaquinone is an alternative electron carrier of the electron 
transport chain, NADH:quinone oxidoreductase activities induced by 100 µM menaquinone-4 
(MQ) or 50 µM ubiquinone-1 (UQ) were compared in anaerobic conditions to minimise possible 
non-enzymatic redox reactions. With the bacterial recombinant PfNDH2, depleted of hemozoin 
and overexpressed, no MQ reduction could be measured whereas a biphasic UQ reductase 
activity was obtained with an initial linear fast phase before reaching a stationary phase (Fig.  
4.10. A). A similar result was observed with PfNDH2 from cell-free parasite extract (Fig. 4.10. B). 
No reduction of menaquinone could be measured while a slow steady-state kinetic of ubiquinone 
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consumption was monitored after its addition. Nonenzymatic assays demonstrated the chemical 
stability of MQ in the presence of NADH. The glycerol-3-phosphate:menaquinone and 
malate:menaquinone oxidoreductase activities were also assayed by addition of 10 mM G-3-P or 
10 mM malate. (Fig. 4.10 C and D). No MQ reductase activity was detected after initiation of the 
reaction with both substrates and in the presence of cell-free parasites, whereas slow steady-
state kinetics were monitored using UQ as electron acceptor. In a similar manner, no 
DHO:menaquinone or succinate:menaquinone oxidoreductase activities were measured. 
Although carried out in an anaerobic environment, these results report that menaquinone is not 
an alternative coenzyme able to interact with P. falciparum dehydrogenases of the respiratory 
chain. 
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Figure 4.10. Kinetics of P. falciparum dehydrogenases in presence of menaquinone (MQ) or ubiquinone 
(UQ). (A) Recombinant PfNDH2 NADH:ubiquinone (●) or NADH:menaquinone (●) oxidoreductase kinetic 
data monitored at 283 nm or 286 nm, respectively. The reaction was initiated by the addition of 50 µM UQ 
or 100 µM MQ respectively. In comparison, the nonenzymatic rate of menaquinone reduction (○, 286 nm). 
(B) Free parasites NADH:ubiquinone (●) or NADH:menaquinone (●) oxidoreductase kinetic data monitored 
at 283 nm or 286 nm, respectively. The reaction was initiated by the addition of 50 µM UQ or 100 µM MQ 
respectively. In comparison, the nonenzymatic rate of menaquinone reduction (○, 286 nm). (C) Free 
parasites malate:ubiquinone (●) or malate:menaquinone (●) oxidoreductase kinetic data monitored at 283 
nm or 286 nm, respectively. The reaction was initiated by the addition of 10 mM malate. (D) Free parasites 
G-3-P:ubiquinone (●) or G-3-P:menaquinone (●) oxidoreductase steady data monitored at 283 nm or 286 
nm, respectively. The reaction was initiated by the addition of 10 mM G-3-P. Abbreviations: UQ, 
ubiquinone-1; MQ, menaquinone-4; QH2, ubiquinol-1; MQH2, menaquinol-4; G-3-P, glycerol-3-phoshapte; 
DHAP, dihydroxyacetone phosphate; rec. PfNDH2, recombinant PfNDH2. 
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 Furthermore, the reduction of cytochrome c induced by menaquinol via the P. 
falciparum bc1 complex has been tested. For this assay, menaquinol-4 (MQH2) was used as 
substrate and the reduction of exogenous cytochrome c was monitored in strictly anaerobic 
conditions and with sonicated cell-free parasites. A fast cytochrome c reduction initiated by 100 
µM MQH2 was detected (Fig. 4.11. A). However, similar kinetics were observed without parasite 
enzymes present in the reaction mixture. This suggests that MQH2 directly and spontaneously 
reduces cytochrome c without enzymatic catalysis in our assay conditions. To confirm the 
properties of MQH2 to be oxidised spontaneously, the reduction of NAD
+ induced by 100 µM 
menaquinol (PfNDH2 in reverse) was assayed with and without cell-free parasite enzymes (Fig. 
4.11. B). High NAD+ reduction activity initiated by MQH2 was measured in the enzymatic and 
nonenzymatic assays. It suggests that menaquinol-4 (MQH2) leads to an unspecific NAD
+ reductase 
activity. To conclude, electrons from MQH2 are not used by the P. falciparum bc1 complex to 
reduce cytochrome c. In anaerobic conditions, MQH2 is stable but can be spontaneously re-
oxidised to MQ in the presence of an oxidant such as cytochrome c oxidised or NAD+. To note, no 
PfNDH2 working in reverse, which reduces UQH2 or MQH2 in the presence of NAD
+, has been 
reported in the literature. In line with this, ubiquinol and NAD+ were added together and no 
formation of UQ or NADH has been noted, indicative of stability between both components. 
 
 
Figure 4.11. Kinetics of P. falciparum bc1 complex and the reversible reaction in the presence of 
menaquinone. (A) Menaquinol:cytochrome c oxidoreductase (●) kinetic data monitored at 550-542 nm and 
initiated by the addition of 100 µM MQH2. For comparison, the nonenzymatic rate of MQH2 oxidation (●). 
(B) Electron transfer ability between MQH2 and NAD
+
 in the presence of cell-free parasites (●) or without 
enzymes (●). 
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4.4. Discussion 
4.4.1. PfNDH2 appears to be the main electron donor 
 For the first time, direct quinone reductase activities were measured for all 
dehydrogenases. The apparent activities of those enzymes remain low due to their low expression 
in the blood stages of malaria parasites (Vaidya and Mather, 2009). Those minimal dehydrogenase 
activities are consistent with an energy metabolism based on the glycolytic pathway during 
asexual stages (Fry et al., 1990).  
 Despite their relative low activity, dehydrogenases are the primary electron source of the 
mitochondrial membrane potential (Δψm), which is indispensible to mitochondrial function 
(Srivastava et al., 1997). In this study, a robust assay developed for real-time, single-cell 
measurement of mitochondrial electrochemical gradient in P. falciparum-parasitized erythrocytes 
was used (Biagini et al., 2006).  The inhibition of certain ETC enzymes such as bc1 complex and 
PfNDH2 were confirmed to collapse the Δψm of P. falciparum mitochondria. Thus, a partial 
collapse of mitochondrial Δψm was observed upon addition of CK-2-68, a novel PfNDH2 inhibitor 
(IC50 = 16 ± 2 nM against the parasite enzyme).  Because CK-2-68 is a moderate inhibitor of the bc1 
complex (IC50 = 500 ± 120 nM against the parasite enzyme bc1), part of the depolarization 
observed (with 100 nM CK-2-68) may be caused by this inhibition. However, the contribution of 
PfNDH2 inhibition to the collapse has been recently confirmed by demonstrating depolarization at 
concentration as low as 1 nM CK-2-68, 500-fold below the IC50 against bc1 (Biagini et al., 2012). On 
the other hand, attempts to depolarize the membrane potential with inhibitors of complex II or 
DHODH failed. It suggests that PfNDH2 is a key electron donor for downstream generation of the 
electrochemical membrane potential, although at this stage a contribution by G3PDH and MQO 
cannot be ruled out. 
 By monitoring the absence of NADH:ubiquinone oxidoreductase activity in the mutant 
PbNdh2(-), this study confirms that P. berghei lacking the type II NADH dehydrogenase can 
develop normally in asexual stages. However, Boysen et al. revealed that PbNdh2 (-) parasites 
were transformed into aberrant immature oocyst in the mosquito midgut highlighting the 
necessity of that enzyme for the sexual stage development (Boysen and Matuschewski, 2011). 
Recently, the succinate dehydrogenase has also been reported to be dispensable for the sexual 
blood stage of P. berghei parasites, via a deletion of the gene encoding the flavoprotein subunit 
(mutant strain termed PbSdhA (-)) (Hino et al., 2012). As for PbNDH2 (-), PbSdhA (-) ookinetes 
failed in oocyst formation, leading to complete malaria transmission blockade. NDH2, complex II 
and maybe other dehydrogenases are not essential for P. falciparum blood stages which rely 
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mainly on cytoplasmic glycolysis raher than oxidative phosphorylation for their energy 
metabolism (Fry et al., 1990). Nevertheless, these enzymes seem indispensable for the parasite 
survival during mosquito stages. At the beginning of sexual maturation, parasites may switch their 
energy metabolism to oxidative phosphorylation which can explain the high number of cristate 
mitochondria present in gametocytes and mosquito stage parasites (Krungkrai et al., 2000). 
During those stages, parasites may need a large amount of ATP which could be generated by 
oxidative phosphorylation via a complete respiratory chain. 
 Furthermore, both PbNdh2 (-) and PbSdhA (-) maintain a mitochondrial membrane 
potential, supporting the hypothesis of mutual complementation among dehydrogenases (Boysen 
and Matuschewski, 2011; Hino et al., 2012). This parasite adaptation highlights the crucial 
function of ETC enzymes to maintain the electrochemical gradient during the blood stages. It is 
also important to note that essentiality of genes expressing the same function are not always 
conserved between the human and murine malaria species, and it remains to be determined 
whether this is the case for mitochondrial ETC genes. 
4.4.2. The bc1 complex is the main proton pump 
 In P. falciparum, the bc1 complex and the cytochrome c oxidase are the only two enzymes 
pumping protons from the mitochondrial matrix to the intermembrane space, in order to 
generate the mitochondrial electrochemical gradient (Vaidya and Mather, 2009). Both bc1 
complex and cytochrome c oxidase catalytic constants were determined in P. falciparum cell-free 
extract. By using substrates in excess, bc1 complex displays a 35-fold higher Vmax rate than 
complex IV. In human mitochondria, the complex IV has an activity only 1.4 ± 0.2 higher than 
complex III (Valnot et al., 1999). Such differences in Vmax could be explained by a variable content 
in respiratory chain complexes and/or a difference in the enzyme turnover. Under the reaction 
conditions in the cuvette with uncoupled (i.e damaged) mitochondria, the complex III is pumping 
more protons than complex IV. In vivo, that situation remains quite unknown. However, it could 
be interesting to observe the behaviour of both enzymes from P. berghei mitochondria. 
4.4.3. P. falciparum complex II: an ubiquinol:fumarate reductase? 
 The complex II belongs to the succinate:quinone oxidoreductases superfamily that 
includes succinate:quinone reductases (SQRs) and quinol:fumarate reductases (QFR). SQR oxidizes 
succinate to produce fumarate as a TCA cycle and respiratory chain member (Saraste, 1999). In 
facultative anaerobic bacteria or lower eukaryotes, QFR catalyzes the reverse reaction of SQR by 
reducing fumarate with ubiquinol as an electron donor (Sakai et al., 2012). SQR and QFR are 
Chapter 4 
114 
 
homologous proteins evolved from a common ancestor and have been shown to catalyze both 
reactions (Guest, 1981; Maklashina et al., 1998). 
 The catalytic properties of the P. falciparum complex II were examined using various 
electron donors and acceptors. By directly following quinone reduction at 283 nm, no SQR activity 
could be detected. This result can be explained by the lack of a suitable binding site for the 
ubiquinone coenzyme. This result opposes previous studies which demonstrated the presence of 
a SQR activity by using the DCPIP Q-pool linked assay (Kawahara et al., 2009; Mather et al., 2010; 
Takashima et al., 2001). The succinate oxidation (SDH activity) were only detected by using the 
malonate sensitive succinate:PMS/MTT assay. This enzymatic approach does not require the 
reduction of the ubiquinone at its binding site located into the anchoring subunits (Hagerhall, 
1997). This SDH activity confirms the enzymatic functionality of the SdhA/SdhB dimer in P. 
falciparum parasites but the lack of ubiquinone reduction highlights the absence of a conventional 
SQR enzyme. This may be explained by the lack of SdhC and SdhD subunits or a dissociation 
between the SdhA/SdhB dimer and their anchor domain (SdhC/SdhD dimer). Genes encoding for 
SdhA and SdhB may have been annotated too soon as subunits for an SQR enzyme whereas they 
might be components of a QFR dehydrogenase. 
 The detection of a malonate sensitive QFR activity in presence of decylubiquinol as 
electron donor indicates that Plasmodium complex II functions as a quinol-fumarate reductase in 
intraerythrocytic parasites. Earlier, Fry and Beesley found that fumarate inhibits the reduction of 
cytochrome c, implicating the presence of a fumarate reductase activity in P. falciparum (Fry and 
Beesley, 1991). Furthermore, no succinate dependent oxygen consumption has been observed in 
P. falciparum blood or sexual stages (Krungkrai et al., 1999; Takashima et al., 2001). Recently, 
Tanaka et al, showed that P. falciparum parasites possessing the disrupted SdhA subunit present 
growth retardation and can be rescued by addition of succinate, and not fumarate, suggesting the 
presence of a QFR as complex II (Tanaka et al., 2012). 
 To conclude, P. falciparum complex II appears to function as a QFR, incapable of SQR 
activity. As in malaria parasites, the QFR from Wolinella succinogenes was shown to not catalyze 
the reversible SQR reaction (Juhnke et al., 2009). However, these results contrast with the 
branched TCA cycle metabolism proposed in the parasites (hypothesis recently retracted), which 
display a functional succinate:quinone oxidoreductase (Olszewski et al., 2010). Therefore, further 
enzymatic and biochemical analysis are essential to confirm the nature of this enzyme and its 
physiological role.  
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4.4.4. Menaquinone in not an alternative ETC redox exchanger 
 In their study, Tonhosolo et al. demonstrate that type II NADH dehydrogenase from P. 
falciparum extracts can use menaquinone-4 to oxidize NADH (Tonhosolo et al., 2010). This work 
presented contradictory results concerning the involvement of menaquinone in the P. falciparum 
respiratory chain. On one hand, dehydrogenases such as PfNDH2, malate:quinone oxidoreductase 
or glycerol-3-phosphate dehydrogenase from cell-free parasite extracts has been shown to not 
use menaquinone-4 as an electron acceptor. On another hand, those activities performed in 
identical conditions in presence of ubiquinone were clearly detected which argues that it is the 
only electron carrier used by ETC dehydrogenases. Additionally, no menaquinol:cytochrome c 
oxidoreductase activity catalyzed by the bc1 complex could be detected due to a certain instability 
of the MQH2 which reduced cytochrome c or NAD
+ spontaneously. The midpoint redox potential 
(termed E0′ at pH 7.0) of the MQ/MQH2 couple is around − 80 mV, thus making MQH2 a strong 
reductant (Unden and Bongaerts, 1997). By contrast, the E0′ of the UQ/UQH2 couple is around + 
110 mV. The more negative midpoint potential of menaquinone, compared to ubiquinone, may 
contribute to its sensitivity to auto-oxidation in presence of electron acceptors such as NAD+ or 
cytochrome c oxidised. In the line with this, an unspecific menaquinol-4:cytochrome c 
oxidoreductase activity has already been observed due to the high temperature at which the 
assays were performed (Refojo et al., 2012). In this study, experiments were carried out in an 
anaerobic glove box maintained at room temperature (between 20 to 25°C). NADH which is highly 
reductant with an E0′ around -320 mV, has also been demonstrated to reduce cytochrome c at a 
rate of 20 nmol.cyt c reduced. mg protein-1.min-1, in the absence of Plasmodium enzymes (Fisher 
et al., 2009). Moreover, no fumarate reduction induced by menaquinol could be measured (data 
not show). This implies that the putative QFR detected is not able to employ lower potential 
quinones. 
 To conclude, the menaquinone pool was demonstrated to not be involved in the 
respiratory chain and only the ubiquinone pool interacts with ETC enzymes. By inhibiting 
menaquinone biosynthesis with a 1,4-dihydroxy-2-naphthoate prenyltransferase inhibitor (Ro 48-
8071 compound), Tonhosolo et al. showed a decrease of the parasitic growth (Tonhosolo et al., 
2010). However, a reversal of growth inhibition by adding menaquinone failed indicating either an 
insufficient uptake of exogenous menaquinone by the parasites or that menaquinone is not 
essential for parasite growth. Further metabolomic and biochemical studies are need to clarify the 
physiological role of menaquinone in malaria parasites and to validate if its biosynthesis may be 
regarded as a potential new drug target.  
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 The Figure 4.12. represents an updated picture of the electron transport chain in P. 
falciparum including new insights proposed in this chapter. 
 
Figure 4.12. Schematic representation of the electron transport chain in P. falciparum parasites. The 
thickness of arrows represents the relative importance of the electron or proton flux catalyzed by the 
enzyme. 
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Chapter 5 
 
Rapid Fe2+-chelatable depolarization of plasma and 
mitochondrial membrane potential by artemisinin and 
semi-synthetic endoperoxides 
 
5.1. Introduction 
5.1.1. Chemical structures and characteristics of endoperoxide 
compounds 
 Artemisinin is a unique tetracyclic 1,2,4-trioxane containing an endoperoxide bridge (C-O-
O-C) but lacking the nitrogen-containing ring system which is found in most antimalarial drugs 
(Meshnick et al., 1996; Van Geldre et al., 1997). In 1985, the endoperoxide bridge was identified 
as the key pharmacophore of the drug (Klayman, 1985). To improve the solubility and the 
pharmacological activity of artemisinin, a first series of semi-synthetic compounds was 
synthesized with a similar backbone but with modifications at the C10 position generating ester or 
ether derivatives like dihydroartemisinin (DHA), artemether and artesunate (Fig. 5.1). 
Artemisinins are efficient against malaria parasites at low nanomolar concentrations while 
micromolar ranges are needed for toxicity in mammalian cells (O'Neill and Posner, 2004). This 
selectivity can be explained by a higher uptake of the trioxane drug by the parasite. Indeed by 
using isotopic labelled [3H]-dihydroartemisinin and [14C]-artemisinin, different studies showed a 
>100-fold higher concentration in P. falciparum infected erythrocytes than in uninfected red 
blood cells (Gu et al., 1984; Kamchonwongpaisan et al., 1994).  
 Based on the structure of the endoperoxide bridge, extensive studies have been devoted 
to the synthesis of different classes of synthetic novel compounds leading to the emergence of 
drug development candidates such as the trioxolane OZ439 and the tetraoxane RKA-182 with high 
antimalarial activities in vitro and in rodent models of malaria (Fig. 5.1) (Charman et al., 2011; 
O'Neill et al., 2010a). 
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Figure 5.1. Chemical structures of artemisinin, its semi-synthetic derivatives (dihydroartemisinin, 
artemether and artesunate) and synthetic trioxane (compound OZ439) and tetraoxane (compound RKA-
182). The endoperoxide bridge is highlighted in red. 
  
5.1.2. Mode of activation of endoperoxide compounds  
 Initial studies deduced that the antimalarial activity of artemisinin, is mediated by the 
endoperoxide bridge. Located in the core of the structure, its cleavage generates cytotoxic 
oxygen-centred or alkoxyl radicals in presence of heme iron or free iron Fe2+ (Meshnick et al., 
1991; Meshnick et al., 1993). From this premise of "endoperoxide bioactivation", two different 
mechanisms have been proposed. 
 By using [18O]-labeled trioxane analogues the Posner group revealed that the oxygen-
centred radicals produced were rearranged to more stable carbon-centred radicals (Posner et al., 
1994; Posner et al., 1995). In this "reductive scission" model, a ferrous ion binds to either O1 or 
O2 cleaving the endoperoxide bond and providing respectively, an oxy radical intermediate or an 
oxygen-centred radical (Fig. 5.2. B). Both are rearranged to primary or secondary carbon-centred 
radicals via a β-scission or a [1,5]-H shift which cause irreversible damage to parasite proteins. In 
line with this, strong evidence of the formation of these carbon-centred radical intermediates has 
Chapter 5 
119 
 
been raised by using electron paramagnetic resonance (EPR) spin-trapping techniques (Butler et 
al., 1998; O'Neill et al., 2000; Wu et al., 1998).  
 In the second model proposed, iron acts as a Lewis acid to facilitate ionic activation of 
antimalarial trioxanes generating downstream reactive oxygen species (ROS) (Haynes et al., 2007; 
Haynes et al., 1999). The ring opening is driven by a heterolytic cleavage of the endoperoxide 
bridge followed by interaction with water generating an open unsaturated hydroperoxide, 
capable of direct oxidation of protein residues. Fenton degradation of the oxygen-centred radical 
intermediate can provide hydroxyl radicals (●OH) highly reactive against amino acids, lipids or 
nucleic acids.  
  
 
Figure 5.2. Open peroxide (A) and reductive scission (B) models of bioactivation of the endoperoxide 
bridge of artemisinin and its derivatives (O'Neill et al., 2010b). Radicals generated that are able to oxidise 
protein residues are highlighted in purple. 
 
 An alternative pathway of artemisinin activation has been suggested via the electron 
transport chain (ETC) components causing downstream ROS production and membrane 
depolarization in isolated malarial mitochondria (Li et al., 2005; Wang et al., 2010). However, the 
proposal of a reductive activation of the endoperoxide bridge chemically mediated by ETC activity 
remains unclear. Recently, the conservation of cytotoxic effects induced by artesunate in cells 
lacking a functional ETC has been demonstrated, contradicting the previous hypothesis proposed 
(Mercer et al., 2011). 
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 Another study proposed a non iron-mediated mechanism of activation where artemisinins 
have a dual role. In the absence of ferrous ions, endoperoxides are proposed to oxidize FADH2 
contained in flavoenzymes and initiate the autoxidation of dihydroflavin coupled with ROS 
generation (Haynes et al., 2010). Although additional biological support is needed to validate this 
new hypothesis, it confirms that the activation mechanism of endoperoxide compounds remains 
controversial. 
5.1.3. Role of heme and non heme iron in the mechanism of activation 
 Although the mechanism of activation involving cellular ferrous ions to produce radical 
intermediates is largely accepted, the origin of the iron available for bioactivation is a point of 
debate. Supported by experimental evidence, heme and non-heme iron were suggested to be the 
trigger (Golenser et al., 2006; Olliaro, 2001).  
 The involvement of heme in the activation of endoperoxide compounds was first 
proposed following isolation of heme-artemisinin in P. falciparum cultures (Meshnick et al., 1991). 
By using [14C]artemisinin, Maeno and colleagues showed its accumulation in the digestive vacuole 
(DV) where hemoglobin degradation leads to the release of soluble heme (Maeno et al., 1993). 
Moreover heme has been observed to enhance the oxidising effects of endoperoxide drugs 
(Berman and Adams, 1997). The reaction between heme and artemisinin has been confirmed in 
vitro and in vivo (Kannan et al., 2002; Pandey et al., 1999; Robert et al., 2005). A recent study 
proposed that heme is the primary activator of artemisinin by reacting with it more efficiently 
than other iron-containing molecules (ferrous ions, hemin or hemoglobin) (Zhang and Gerhard, 
2008). It has also been suggested that antimalarial trioxanes accumulated in the digestive vacuole 
are activated by neutral-lipid associated heme and induce oxidative membrane damage (Hartwig 
et al., 2009; Pisciotta et al., 2007). 
 Although the impact of heme on the activation of endoperoxide antimalarials has been 
demonstrated, alternative evidence shows that free ferrous ions can play a similar role. First, by 
using radio- or fluorescent-labeled artemisinins and high resolution microscopy, two studies 
contest the accumulation of trioxane drugs in the digestive vacuole and their possible interaction 
with heme (Eckstein-Ludwig et al., 2003; Ellis et al., 1985). Additionally, Haynes and colleagues 
proposed that artemisinins do not inhibit hemozoin formation and cannot react with heme 
according to conventional chemistry models (Haynes et al., 2004; Haynes et al., 2003). Even 
though 90% of iron is contained in the digestive vacuole in the form of heme, free iron is involved 
in free radical formation and might interact with artemisinin (Kamchonwongpaisan and Meshnick, 
1996; Meshnick et al., 1993; Scholl et al., 2005; Sibmooh et al., 2001). Several studies have shown 
Chapter 5 
121 
 
that iron chelation antagonizes the effect of endoperoxide antimalarials in vitro and can prevent 
their toxic effects in mice (Eckstein-Ludwig et al., 2003; Meshnick et al., 1993; Pradines et al., 
2002). Because iron chelators are selective to non-heme source of iron, it has been suggested that 
intracellular ferrous ions may have a role in artemisinins activation (Golenser et al., 2003; 
Golenser et al., 2006). Recent work demonstrated that three classes of endoperoxide drugs 
(trioxane, trioxolane and tetraoxane) have a common free-iron dependent mechanism of 
activation in malaria parasites (Stocks et al., 2007). 
5.1.4. Proposed modes of action 
 Once activated, endoperoxide antimalarials were hypothesised to have several mode of 
action by impairing the heme detoxification pathway (Pandey et al., 1999), alkylating different 
proteins including the translationally controlled tumor protein (PfTCTP) (Bhisutthibhan et al., 
1998), inhibiting the sarco/endoplasmic reticulum membrane calcium PfATPase6 (Eckstein-Ludwig 
et al., 2003) and disrupting mitochondrial functions (Li et al., 2005; Wang et al., 2010).  
 In the first hypothesis proposed, free radicals are produced after activation, alkylate 
intracellular heme in the digestive vacuole and interfere with its detoxification by inhibiting its 
polymerization to non toxic hemozoin (Cazelles et al., 2001; Robert et al., 2005; Robert et al., 
2006). The iron centre of heme plays the dual role of trigger and target of the endoperoxide 
bridge of artemisinins as well as causing also membrane damage to the DV (del Pilar Crespo et al., 
2008; Hartwig et al., 2009). Supplementary studies suggested the same mode of action for 
synthetic trioxolanes and tetraoxanes (Bousejra-El Garah et al., 2011; Creek et al., 2008). 
 The alkylation of different malarial proteins by artemisinin has been established for many 
years (Asawamahasakda et al., 1994; Yang et al., 1994). Radiolabeled artemisinins were observed 
to form covalent bonds with several proteins and may alter their function. PfTCTP, a 
translationally controlled tumour protein probably involved in cell growth, has been shown to 
react with artemisinin in the presence of hemin and bind to heme itself  (Bhisutthibhan and 
Meshnick, 2001; Bhisutthibhan et al., 1998). Nevertheless, the importance of this potential 
artemisinin target remains doubtful due to the lack of data about its role and essentiality in the 
malaria parasite. 
 
 It has been proposed that artemisinins inhibit the sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) orthologue of P. falciparum (PfATPase6) which reduce cytosolic free calcium 
concentrations, an essential activity for parasite survival (Eckstein-Ludwig et al., 2003). Due to 
their structural similarities with thapsigargin, a specific inhibitor of PfATPase6, artemisinins 
Chapter 5 
122 
 
display an iron-dependent inhibition of PfATPase6 expressed in Xenopus laevis oocytes. However, 
this hypothesis has been contradicted by demonstrating no antagonistic effect between 
thapsigargin and artemisinin like mentioned in the original work (del Pilar Crespo et al., 2008). 
Additionally, the first-generation trioxolane OZ277 showed week inhibition of PfATPase6 
(Uhlemann et al., 2007). Recently, no correlation between the affinity of various antimalarial 
drugs toward PfATPase6 was predicted in silico, yet their antimalarial activity has been 
established (Garah et al., 2009). 
 Finally, it has been suggested that artemisinin and its derivatives may interfere with the 
mitochondrial functions of P. falciparum after being activated by the ETC components. The 
administration of artemisinin to S. cerevisiae cultures using non-fermentable carbon sources 
inhibits yeast growth (Li et al., 2005). This indicates the impact of the drug on the mitochondrial 
membrane potential leading to a loss of mitochondrial functions, essential for the growth 
conditions used. This proposal has been correlated by a further study showing a mitochondrial 
membrane depolarization in P. berghei in presence of trioxane drugs (Wang et al., 2010). The 
observation of an artesunate distribution inside the mitochondria of infected erythrocytes 
support the theory of reactive oxygen species (ROS) generated by artemisinins in the organelle. 
The accumulation of ROS is suspected to collapse the mitochondrial membrane potential affecting 
the pyrimidine biosynthesis, a crucial metabolic process for parasite life. However, additional 
supporting data are needed to clarify the molecular mechanisms involved in this mode of action. 
5.1.5. Production of radical oxygen species and lipid peroxidation 
 Reactive oxygen species (ROS) like superoxide anions (●O2
−), hydroxyl radicals (●OH) or  
hydrogen peroxide (H2O2) are produced when electrons are liberated by oxidation and combine 
with molecular oxygen (Atamna and Ginsburg, 1993). In Plasmodium species, the oxidative stress 
is mainly generated during the haemoglobin degradation (Vennerstrom and Eaton, 1988). Parasite 
mitochondrion is also a source of ROS, produced by different components of the ETC via electrons 
transfer to O2 but its production was considered not quantitatively significant (Atamna and 
Ginsburg, 1993). To control the ROS accumulation, detoxification systems are essential. Thus, the 
malaria parasite relies on antioxidant defences to survive such as an isoform of superoxide 
dismutase (SOD) and thioredoxin-dependent peroxidases (reviewed in(Muller, 2004). However, 
an excess of ROS induced by artemisinin can overcome the oxidative defences of the parasite and 
initiate cell damage leading to irreversible injury (Haynes and Krishna, 2004). 
 Addition of artemisinins generating ROS has been demonstrated in both yeast and 
mammalian tumor cells (Disbrow et al., 2005; Li et al., 2005). The association between oxidant 
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stress and endoperoxide compounds was suggested by using ROS scavengers (tiron, N,N'-
diphenyl-1,4-phenylenediamine, catalase, α-tocopherol, etc) which increase cell survival in the 
presence of artemisinins (Krungkrai and Yuthavong, 1987; Mercer et al., 2011; Meshnick et al., 
1993; Wang et al., 2010). 
 The oxidative phospholipid bilayer deterioration and mitochondrial dysfunction have 
been demonstrated to be caused by carbon and oxygen radical species (Gardner, 1989; Richter, 
1987; Zhang et al., 1990). Shown in Figure 5.3, O'Neill and Posner proposed a possible mechanism 
of parasite membrane damage induced by artemisinins via lipid peroxidation coupled by 
generation of reactive oxygen species (ROS) (O'Neill and Posner, 2004). After iron-induced 
cleavage of their endoperoxide bridge, carbon-centred radicals (R●) interact with polyunsaturated 
fatty acids and initiate lipid peroxidation (Porter, 1986; Yin and Porter, 2005). The free-radical 
mediated lipid peroxidation mechanism has been intensely studied. The initiation step starts with 
the loss of hydrogen from polyunsaturated fatty acids to generate carbon-centred radicals. By 
addition of oxygen, lipid radicals are rearranged in lipid peroxyl radicals (ROO-). The chain 
propagation step begins with the transfer of hydrogen from unsaturated lipids to lipid peroxyl 
radicals producing lipid hydroperoxide (ROOH) and new lipid radicals which will initiate other 
chain reaction. Lipid hydroperoxides are degraded according to the superoxide-driven Fenton 
reaction (reaction 2) to hydroxyl radicals (●OH) which cause oxidative damage to receptors, 
enzymes or polyunsaturated lipids decreasing membrane fluidity and resulting in parasite 
membrane potentials depolarization (Chen and Yu, 1994; Marshansky et al., 1983; O'Neill and 
Posner, 2004). In the first step (reaction 1), Fe3+ is reduced by superoxide anions (●O2
-) to Fe2+, 
which is necessary for the latter (Fenton) reaction (Gutteridge and Bannister, 1986). 
Fe3+ + •O2
– → Fe2+ + O2  (reaction1) 
Fe2+ + H2O2 → Fe
3+ + HO• + HO–  (reaction 2) 
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Figure 5.3. Proposition of the membrane potential depolarization pathway induced by endoperoxides. 
This mechanism model has been adapted from(O'Neill and Posner, 2004). Inhibitors of chemical reactions 
used in this study are indicated in grey. 
 
5.1.6. The plasma and mitochondrial membrane potential  
 Plasmodium species have a negative electric potential (ΔΨp) across the plasma membrane 
of approximately -95 mV (Allen and Kirk, 2004; Izumo et al., 1988). It is generated by V-type H+-
ATPases which transfer protons out of the parasite cytosol (Hayashi et al., 2000; Saliba and Kirk, 
1999). Localised in the plasma membrane, the V-type H+-ATPase also plays a role in regulating a 
neutral cytosolic pH (near 7.3), crucial for enzyme function, incorporation of the vitamin B5 and 
generation of pH gradient across membranes of internal organelles (Saliba and Kirk, 1999; van 
Schalkwyk et al., 2010). The maintenance of the plasma membrane potential (ΔΨp) is also 
important in mediating the influx of K+ in the parasite cytosol and the uptake of nutrients such as 
inorganic phosphates and choline (Allen and Kirk, 2004; Biagini et al., 2004; Lehane et al., 2004; 
Saliba et al., 2006). The direct inhibition of the V-type H+-ATPase by specific inhibitors such as 
bafilomycin A1 or concanamycin A has been demonstrated to depolarize the plasma membrane 
potential and disturb the physiology of the parasite leading to its death (Allen and Kirk, 2004; 
Biagini et al., 2006; van Schalkwyk et al., 2010). 
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 It was generally accepted that the maintenance of mitochondrial membrane potential 
(ΔΨm), generated by the electron transport chain (ETC), is essential for mitochondrial functions 
and malaria parasite survival (Biagini et al., 2008; Vaidya and Mather, 2009). In asexual parasites, 
the pyrimidine biosynthesis is an essential function of the mitochondrion via the activity of the 
dihydroorotate dehydrogenase (DHODH) (Painter et al., 2007). This function is dependent on the 
integrity of the ETC enzymes generating the protonmotive ‘Q-cycle’ and the mitochondrial 
membrane potential. The inhibition of cytochrome bc1 (Complex III) of the ETC by atovaquone, an 
antimalarial drug, depolarizes malaria mitochondria resulting in parasite death (Srivastava et al., 
1997). The Ca2+ homeostasis is another vital mitochondrial function driven by the mitochondrial 
membrane potential and modulated by a Ca2+ uniporter (Gazarini and Garcia, 2004). 
  Mitochondrial membrane potential depolarization has been noticed to be an early effect 
of artemisinin in isolated mitochondria of P. berghei  (Wang et al., 2010). Moreover the induction 
of apoptotic cell death via the loss of membrane potential has been observed in endoperoxide 
treated HeLa cells (Mercer et al., 2011; Mercer et al., 2007). However, a contradictory report 
suggested that the lost of membrane potential is a downstream effect of cell death caused by 
artemisinin (del Pilar Crespo et al., 2008). 
5.1.7. In vivo dynamic monitoring of membrane potential in malaria 
parasites 
 As described, there have been several studies that have measured the effect of 
artemisinin on membrane potential depolarization (Mercer et al., 2011; Mercer et al., 2007; Wang 
et al., 2010). In these cases, depolarization has been noted at more than 30 min after 
endoperoxide induction. Using rhodamine 123 and confocal microscopy, del Pilar Crespo and 
colleagues showed no obvious effect on mitochondrial integrity after 4 hours of treatment with 
artemisinin, suggesting that mitochondrial dysfunction is not an early event of endoperoxide 
action (del Pilar Crespo et al., 2008). However, using light and electron microscopy to 
demonstrate morphological changes of the mitochondrion after incubation with artemisinins, 
other studies have observed significant mitochondrial damage/dysfunction (Jiang et al., 1985; 
Kawai et al., 1993; Maeno et al., 1993). The precise involvement of the mitochondrial membrane 
potential in the lost of the organelle functions and induction of cell apoptosis remains a point of 
debate and the results obtained in these different studies may differ depending on the cell types, 
the monitoring techniques and the fluorochromes used. 
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 In this chapter a highly sensitive method monitoring in vivo mitochondrial (ΔΨm) and 
plasma membrane potential (ΔΨp) is described. Their measurement is based on the accumulation 
of the fluorescent probe TMRE, a rhodamine 123 derivative. This dye is a lipophilic cation which 
can be accumulated in plasma and mitochondrial membranes of living cells according to the 
Nernst equation (Farkas et al., 1989; Loew, 1998; Loew et al., 1993). Combined with confocal 
imaging, this approach allows a rapid observation of fast changes (< 5 min) of both membrane 
potential in single parasite-infected erythrocytes (Biagini et al., 2008; Biagini et al., 2006) 
 
 The presented study was set out to investigate the potential of endoperoxide compounds 
to affect both plasma and mitochondrial electrochemical gradient. This established technique was 
applied to monitor the global membrane potential of P. falciparum infected erythrocytes treated 
with different endoperoxide compounds. The investigation was carried out by measuring 
independently the collapse of mitochondrial (ΔΨm) and plasma membrane potential induced by 
two inhibitors : a trioxolane, artemisinin and a tetraoxane, the drug-development candidate RKA-
182. The role of ferrous-iron, ROS generation and the ETC in the artemisinin action pathway is 
also reported. 
5.2. Results 
5.2.1. Endoperoxide compounds collapse both plasma and 
mitochondrial membrane potential in P. falciparum infected 
erythrocytes 
 To determine the effect of endoperoxides on membrane potential, a real-time single-cell 
imaging approach was used (see section 4.2.9). The endoperoxide compounds used were shown 
to inhibit the parasite growth in a low nanomolar range (Fig. 5.4). Their addition at a 
concentration of 100 nM was observed to reduce the total parasite fluorescence by 55 to 60% in 
<3 min (Fig. 5.5 C to F). Atovaquone, the bc1 complex inhibitor was used as a control, decreased 
the fluorescence by 30% (Fig. 5.5 A),  confirming previous observations performed by Biagini and 
colleagues (Biagini et al., 2006). Deoxyartemisinin is an artemisinin derivative lacking the 
endoperoxide bridge, the key pharmacophore of the anti-plasmodial activity of this class of 
compound (Fig. 5.4 B). In contrast to other derivatives, deoxyartemisinin is an ineffective inhibitor 
of P. falciparum growth with an IC50 higher than 10 µM. The addition of deoxyartemisinin 
decreased the TMRE fluorescence to 10% (Fig. 5.5 B). However, this relatively low reduction in 
signal could be accounted for by photobleaching and was not considered to be due to the direct 
effect of the drug. 
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Figure 5.4. Structures of endoperoxide compounds and their P. falciparum growth inhibition. Chemical 
structures of (A) artemisinins and its semisynthetic derivatives, (B) the deoxyartemisinin and (C) the 
synthetic 1,2,4,5-tetraoxane drug-development candidate RKA-182 used in this study. The endoperoxide 
bridge is highlighted in red. (D) Plasmodium falciparum growth inhibition IC50 values of endoperoxide 
antimalarials. Values indicated are means ± SE of results from three independent experiments. 
Chapter 5 
128 
 
 
Figure 5.5. Effect of endoperoxide antimalarials on both plasma and mitochondrial membrane potential 
of P. falciparum. Time course of TMRE-dependent fluorescence of P. falciparum-infected erythrocytes after 
the addition of (A) 100 nM atovaquone, (B) 100 nM deoxyartemisinin, (C) 100 nM artemisinin, (D) 100 nM 
tetraoxane (compound RKA-182), (E) 100 nM artesunate (F) and 100 nM didhydroartemisinin. The data 
were normalized to 100% in untreated cells and to 0% in FCCP (10µM)-treated cells. Graphs show means ± 
standard errors from three independent experiments monitoring ≥ 7 single cells. 
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 Because both plasma and mitochondrial membrane potentials participate to the TMRE 
accumulation in their respective lipid bilayer, their independent contribution to the global 
depolarization cannot be accurately quantified in this assay. However, pre-treatment with 
atovaquone or concanamycin A before addition of the inhibitor allows the contribution from each 
membrane to be monitored separately.  
 
5.2.2. Depolarization of the mitochondrial membrane potential (ΔΨm) 
by artemisinin and tetraoxane. 
 To evaluate the impact of endoperoxides on the mitochondrial ΔΨm, cells were pre-
treated with concanamycin A, a V-type H+ ATPase inhibitor. Upon addition of concanamycin A 
(200 nM), the fluorescent intensity from the cytosol decreases approximately of 70 to 80% 
(Biagini et al., 2006), leaving a local and strong signal originating from the parasite mitochondrion 
(Fig. 6.6 1b, 2b and 3b). The morphology of the mitochondrion differs in function of the stage in 
the parasite life cycle (see Chapter 1, section 1.2.1).  
 
 
Figure 5.6. Effect of atovaquone, artemisinin and tetraoxane (RKA-182) on fluorescent mitochondria from 
P. falciparum trophozoites. The panel shows (a) bright-field fluorescence and TMRE fluorescence images of 
canconomycin pre-treated infected erythrocytes (b) before and (c) 300 seconds after induction with (1) 100 
nM atovaquone, (2) 100 nM artemisinin and (3) 100 nM tetraoxane. The green in these images is a 
pseudocolor. TMRE was excited at 543 nm and emission was collected with a 560 nm long pass filter. 'M' 
label indicates the parasite mitochondrion and 'FV' the food vacuole. 
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 To measure the mitochondrial-dependent fluorescence, concanamycin A-treated 
parasites were normalized to 100% and the baseline (0%) was set by FCCP. Known to widely 
collapse the mitochondrial membrane potential (ΔΨm) via the inhibition of the respiratory chain, 
atovaquone was shown to reduce quickly (~ 3 min) the TMRE fluorescence by 70% (Fig. 5.7 A). For 
the same short period of time, addition of artemisinin and tetraoxane decreased the fluorescence 
by 60% and 50% respectively (Fig. 5.7 B and C). In Figure 5.6, confocal microscopy pictures show a 
significant reduction of mitochondrially-derived fluorescence after 5 min of drug treatment 
(atovaquone, artemisinin or tetraoxane). 
 
 
Figure 5.7. Effect of artemisinin and tetraoxane on mitochondrial membrane potential only. Plasma 
membrane potential is depolarized by treatment of P. falciparum-infected erythrocytes with 200 nM 
concanamycin A before induction of inhibitors. Time course of TMRE-plasma independent fluorescence is 
followed after addition of (A) 10 nM atovaquone, (B) 100 nM artemisinin and (C) 100 nM tetraoxane. Data 
were normalized to 100% in untreated cells and to 0% in FCCP (10µM)-treated cells. Graphs show means ± 
standard errors from three independent experiments monitoring ≥ 7 single cells. 
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5.2.3. Depolarization of the plasma membrane potential by artemisinin 
and tetraoxane. 
 The mitochondrial ΔΨm was demonstrated to represent between 20% to 30% of the total 
cellular TMRE fluorescence, leaving a homogenous cytosolic signal originating from the plasma 
membrane only (Biagini et al., 2006). To evaluate the plasma-dependent fluorescence, parasites 
were pre-treated with 100 nM atovaquone for 5 min before addition of the endoperoxide 
inhibitor. Then, atovaquone-treated parasites were normalized to 100% and the baseline (0%) 
was set by FCCP. The vacuolar H+ ATPase is involved in transforming the energy of ATP hydrolysis 
to generate the electrochemical potential at the surface of the malaria parasite through the 
transport of H+ across the plasma membrane (Allen and Kirk, 2004). The inhibition by 
concanamycin A, a well known V-type ATPases inhibitor, was shown to reduce rapidly the plasma-
dependent fluorescence by 60% (Fig. 5.8 A). In a similar manner, artemisinin and tetraoxane were 
observed to decrease the fluorescent signal by 40 to 60% respectively (Fig. 5.8 B and C). 
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Figure 5.8. Effect of artemisinin and tetraoxane on plasma membrane potential only. Mitochondrial 
membrane potential is depolarized by treatment of P. falciparum-infected erythrocytes with 100 nM 
atovaquone before induction of inhibitors. Time course of TMRE-mitochondrial independent fluorescence is 
followed after addition of  (A) 200 nM concanamycin A, (B) 100 nM artemisinin and (C) 100 nM tetraoxane. 
Data were normalized to 100% in untreated cells and to 0% in FCCP (10 µM)-treated cells. Graphs show 
means ± standard errors from three independent experiments monitoring ≥ 7 single cells. 
 
 
5.2.4. Effect of Fe2+-chelators desferrioxamine (DFO) and deferipone 
(DFP) on the membrane potential depolarization by artemisinin 
and tetraoxane.  
 The fixed-dose effect of iron chelators on membrane potential depolarization were 
observed to determine the involvement of free iron on the activity of endoperoxides by using 
desferrioxamine (DFO) and deferipone (DFP), two chelating agents selective for non-heme iron 
such as intracellular Fe2+ (Stocks et al., 2007). 
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 Both iron-chelators have in vitro antimalarial activities with a 48h IC50-dose-responsed 
against 3D7 P. falciparum growth of 17.3 ± 2 µM (DFO) and 111.8 ± 1.8 µM (DFP). However, under 
the short time period of this assay (< 6 min), 100 µM DFO and 100 µM DFP have not been 
observed to diminish the fluorescent signal coming from both membrane potentials. P. 
falciparum-infected erythrocytes were treated with 100 µM DFO and 100 µM DFP before and 
during induction of artemisinin (100 nM) or tetraoxane (100 nM) in order to study the impact of 
iron chelators on depolarization events. In presence of DFO and DFP, artemisinin was observed to 
reduce TMRE fluorescence only by 15 and 35%, respectively within 3 min after induction, whereas 
the drug diminished by 60% the fluorescent signal in absence of iron-chelators (Fig. 5.9 A). In a 
similar manner, tetraoxane was monitored to decrease by 15 and 40% the TMRE fluorescence 
from pre-treated parasites with DFO and DFP respectively, while the inhibitor diminished by 55% 
the TMRE signal from untreated parasites (Fig. 5.9 B). DFO presents a high  antagonistic effect 
inhibiting by 75 and 73% the collapse of transmembrane potential induced by artemisinin and 
tetraoxane, respectively. To a lesser extent, DFP prevents by 41 and 27% the action of artemisinin 
and tetraoxane respectively, on the membrane potential. 
 
Figure 5.9. Effect of artemisinin and tetraoxane on membrane potential in presence of iron-chelators. 
Time course of TMRE-dependent fluorescence of P. falciparum-infected erythrocytes after addition of (A) 
100 nM artemisinin and (B) 100 nM tetraoxane. Cells are not treated (○) or subjected to iron-chelator 
treatment with 100 µM desferrioxamine (●) and 100 µM deferiprone (♦). Data were normalized to 100% in 
untreated cells and to 0% in FCCP (10 µM)-treated cells. Graphs show means ± standard errors from three 
independent experiments monitoring ≥ 7 single cells. 
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5.2.5. Effect of the superoxide scavenger Tiron on the membrane 
potential depolarization induced by artemisinin and tetraoxane.  
 To gain further insights into the mechanism of action of artemisinin, the contribution of 
oxidative stress to the depolarizing activity of endoperoxides was investigated by treating malaria 
parasites with Tiron, a cell membrane permeable superoxide scavenger (Greenstock and Miller, 
1975). In a similar manner to iron-chelators, parasite-infected erythrocytes were incubated with 
100 µM Tiron before and during induction with artemisinin and tetraoxane. It was noted that no 
reduction of TMRE fluorescence was observed during treatment with the superoxide scavenger 
only. In the presence of Tiron, artemisinin and tetraoxane were monitored to decrease by 35 and 
25% the fluorescent signal respectively, whereas in the absence of the scavenger, a reduction of 
55% to 70% was observed (Fig. 5.10). Therefore, in our in vitro system, ROS scavenging by Tiron 
significantly reduced the endoperoxide-induced depolarisation by 50 to 55%.  
 
Figure 5.10. Effect of artemisinin and tetraoxane on membrane potential in presence of ROS scavenger. 
Time course of TMRE-dependent fluorescence of P. falciparum-infected erythrocytes after addition of (A) 
100 nM artemisinin and (B) 100 nM tetraoxane. Cells are not treated (○) or subjected to ROS scavenger 
treatment with 100 µM Tiron (●). Data were normalized to 100% in untreated cells and to 0% in FCCP 
(10µM)-treated cells. Graphs show means ± standard errors from three independent experiments 
monitoring ≥ 7 single cells. 
 
5.2.6. Direct inhibitory effect of endoperoxides on the respiratory chain 
components 
 Because previous studies have reported the involvement of the ETC in the activation of 
artemisinin (Li et al., 2005), here, the direct inhibitory activities of endoperoxides on major 
components of the ETC were investigated. Activities from three main ETC enzymes (PfNDH2, bc1 
complex and cytochrome c oxidase) were monitored spectrophotometrically. Because PfDNH2 
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was demonstrated to be the main provider of electrons among all dehydrogenases (as described 
in Chapter 4), effects of artemisinin and its derivates on its enzyme activity were determined on 
recombinant PfNDH2. Free parasite extracts were used to evaluate the inhibitory effect on the bc1 
protein (complex III) and cytochrome c oxidase (complex IV), essential for downstream generation 
of the electrochemical membrane potential. The results indicate that at up to 1 µM (final 
concentration) of endoperoxides, relatively weak inhibition of the individual respiratory 
components was observed (Table 5.1). The maximum inhibition values obtained were 17.1% of 
PfNDH2 activity by artemisinin, 23.2% of bc1 activity by tetraoxane and between 18.4% to 23.0% 
of complex IV activity for all endoperoxides. The inhibitory effects of endoperoxides are widely 
inferior to those obtained with HDQ, atovaquone and cyanide which are specific inhibitors of 
PfNDH2, bc1 complex and cytochrome c oxidase respectively. 
 
Table 5.1. Inhibitory profiles of endoperoxide compounds on three majors components of the electron 
transport chain of Plasmodium falciparum (3D7 strain). Specific inhibitors of PfNDH2 (HDQ), bc1 protein 
(atovaquone) and complex IV (cyanide) are used as positive controls. Direct activity assays have been 
performed on recombinant PfNDH2 enzymes whereas bc1 protein and Complex IV have been assayed with 
free parasites extract.  
Inhibitor 
% inhibition of 
PfNDH2 bc1 protein Complex IV 
Artemisinin (1 µM) 17.1 ± 4.2 3.2 ± 3.7 18.4 ± 4.3 
Tetraoxane  (1 µM) 12.3 ± 4.9 23.2 ± 4.2 19.1 ± 2.0 
Dihydroartemisinin ( 1µM) 5 ± 4.3 6.7 ± 4.1 21.1 ± 7.9 
Artesunate (1 µM) 3.7 ± 2.9 2.3 ± 0.4 21.1 ± 3.9 
Artemether (1 µM) 4.1 ± 3.3 1.8 ± 1.9 23.0 ± 2.0 
HDQ (100 nM) 88.1 ± 0.5 N.D. N.D. 
Atovaquone (50 nM) N.D. 89.0 ± 1.0 N.D. 
Cyanide (15 mM) N.D. N.D. 100 ± 0.0 
 Inhibitor concentration used are indicated in bracket. Values are means ± SE. n=3. 
 
5.3. Discussion 
5.3.1. Endoperoxides induce a rapid depolarization of both plasma and 
mitochondrial membrane potentials  
 In this work, a robust assay has been used for the real-time single-cell measurement of 
plasma (Δψp) and mitochondrial (Δψm) membrane potentials in P. falciparum infected 
erythrocytes. It has been proposed that both membrane potentials are the two major 
components driving the accumulation of cationic fluorescent dyes like rhodamine 123 or TMRE 
(Biagini et al., 2006; Izumo et al., 1988). First, by monitoring a global membrane potential, the 
selective mitochondrial inhibitor atovaquone (100 nM) was shown to collapse only the 
Chapter 5 
136 
 
contribution attributed to the organelle, in line with a previous study (Biagini et al., 2006). With 
therapeutically relevant concentrations (100 nM), different trioxanes (artemisinin, artesunate and 
dihydroartemisinin) and a tetraoxane (drug-development candidate RKA-182) display a two-fold 
higher depolarization activity than atovaquone on the overall membrane electrochemical 
potential. This observation indicated a probable dual action of the drug on mitochondrial and 
plasma membranes of the malaria parasite (Fig. 5.5). To confirm this hypothesis, the relative 
contributions of plasma and mitochondrial membrane potentials were monitored using selective 
pre-treatments of parasites (Biagini et al., 2006).  
 Pre-treatment of parasite-infected erythrocytes with 100 nM atovaquone enables the 
removal of the fluorescent signal emitted by the mitochondrial membrane potential without 
affecting the plasma membrane counterpart. The Figure 5.8 shows that two structurally different 
endoperoxides, artemisinin and tetraoxane, were able to mimic the action of the V-type ATPase 
inhibitor concanamycin A, by collapsing rapidly and partially the plasma membrane potential. 
Although the inhibitory effect of endoperoxides on V-type ATPases remains to be investigated, an 
indirect mode of action via the oxidative damage of cell membranes seems most plausible (O'Neill 
and Posner, 2004). In line with this, ROS generation may trigger the depolarization of the plasma 
membrane (Δψp) whose the maintenance has been linked to the uptake of K
+, inorganic 
phosphate and choline (Allen and Kirk, 2004; Lehane et al., 2004; Saliba et al., 2006). Thus, the 
collapse of the electrochemical gradient can stop the incorporation of these ions and nutrients 
inside the cytosol but also deregulate the pH gradient maintained across the plasma membrane 
provoking a cascade of reactions affecting rapidly the physiological integrity of the parasite. For 
instance, inhibition of the V-type ATPase activity was reported to drop the neutral cytosolic pH 
(around 7.3) by 0.4 pH unit in less than 3 min and 0.5 to 0.6 units within 20 min (Saliba and Kirk, 
1999; van Schalkwyk et al., 2010). It has also been revealed that pH regulation inhibitors prevent 
the parasite proliferation in 30 min to 4 h depending of their concentration (van Schalkwyk et al., 
2010). Therefore, the inability of the parasite to maintain its cytosolic pH has been established to 
cause rapid parasite death. However, further investigations are necessary to define the exact 
mechanisms linking the plasma membrane depolarization induced by endoperoxides to the 
parasite physiological disturbance. 
         By pre-treating cells with concanamycin A, the fluorescent contribution of the plasma 
membrane can be drastically reduced to monitor the single mitochondrial membrane potential 
(Δψm). It also allows to reveal the shape and size of the mitochondrion (Fig. 5.6). The Figure 5.7 
reports that artemisinin and tetraoxane depolarize rapidly the mitochondrial Δψm in the same 
manner as atovaquone. This result supports the hypothesis of a role of endoperoxide compounds 
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disturbing the mitochondrial functions of the malaria parasite by a fast collapse of its membrane 
potential via formation of radical oxygen species. A strong link between loss of mitochondrial 
membrane potential and parasite death has been demonstrated by the mode of action of bc1 
complex inhibitors such as atovaquone or antimycin A (Biagini et al., 2008). 
5.3.2. The endoperoxide bridge is the essential pharmacophore for drug 
activity 
 In line with previous studies (Brossi et al., 1988; Kaiser et al., 2007; Wang et al., 2010), the 
presented results confirm the inefficiency of deoxyartemisinin to inhibit parasite growth and 
demonstrate its inability to collapse both plasma and mitochondrial membrane potentials (Fig. 
5.5 B). The endoperoxide bridge is deduced to be the key pharmacophore for the membrane 
depolarization activity of this class of compounds. Additionally, the analogous disrupting effects of 
artemisinin and tetraoxane on membrane potentials despite their important structural 
differences highlight the role of their only common feature: the endoperoxide bond. 
5.3.3. Non heme iron Fe2+ is involved in artemisinin-induced membrane 
depolarization activity. 
 The reductive cleavage of the endoperoxide bridge is widely accepted to be due to a 
cellular source of ferrous iron. However, its origin from either hemin (ferrous heme) and/or 
exogenous non-heme iron (II) is still not well established and remains under debate (O'Neill et al., 
2010b). Different iron chelators, selective for non-heme free iron, have been previously observed 
to strongly antagonize the antimalarial activity of this class of drugs in vitro and to prevent the 
toxic effects of artemisinin in mice (Eckstein-Ludwig et al., 2003; Meshnick et al., 1993; Pradines 
et al., 2002). It was shown that two different iron-chelators, desferrioxamine (DFO) and 
deferiprone (DFP) reduce at different degrees the collapse of the plasma and mitochondrial 
membrane potential. Chelating ferric iron as part of 1:1 molecular complex, DFO displays the 
strongest antagonistic effect by decreasing 67% and 84% the depolarization effect induced by 
artemisinin and tetraoxane respectively. Despite being more lipophilic, DFP reports a weaker 
chelating activity which can be explained by a 1:2 molar ratio with Fe2+ and by its higher complex-
formation affinity with Fe3+ (Manzoori et al., 2011). Inhibition by DFO or DFP demonstrates the 
involvement of non-heme iron Fe2+ in the process of depolarization induced by artemisinin. 
According to the mechanism proposed by O'Neill and Posner (Fig. 5.3), Fe2+ can step in the 
pathway during the bioactivation of endoperoxide and mediates the Fenton reaction to generate 
hydroxyl radical (●OH) (O'Neill and Posner, 2004). Assays performed in this study cannot precise if 
free Fe2+ is only involved as cofactor for ROS generation or is also involved in endoperoxide 
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activation. However, recent work with fluorescent-tagged artemisinin showed that DFO and DFP 
inhibit the formation of stable adducts and their irreversible accumulation in the malaria parasite 
(Stocks et al., 2007). Stocks et al. concluded that non-heme chelatable-iron can mediate activation 
of endoperoxides confirming its involvement at both steps of the membrane potential 
depolarization pathway. 
5.3.4. Hydroxyl radical generation is the final factor of global membrane 
depolarization 
 The partial inhibition of depolarization obtained with Tiron indicates clearly the 
implication of superoxide anions (●O2
−) in a process of global membrane depolarization in P. 
falciparum (Fig. 5.10). Superoxide anions are speculated to mediate the generation of hydroxyl 
radicals by regenerating Fe2+ from Fe3+ to accelerate Fenton chemistry. Involvement of superoxide 
and non-heme iron Fe2+ validates the pathway suggested by linking lipid peroxidation with 
membrane depolarization via generation of hydroxyl radicals. Due to their reactive nature, most 
of ROS are acting where they are produced (Brosché et al., 2010). Thus, effect of hydroxyl radicals 
on membrane-bound proteins (enzymes, receptors, pores, etc.) and lipids may be located near 
their site of formation via lipid peroxidation induced by artemisinin carbon-centred radicals 
(O'Neill and Posner, 2004). A large ROS formation, not controllable by anti-oxidant defences, has 
been demonstrated to collapse the plasma membrane potential in the protozoon Giardia 
intestinalis (Lloyd et al., 2000). The oxidative stress damaging mitochondrial membranes may also 
lead to a dissipation of proton gradient and consequent membrane depolarization (Chinopoulos 
et al., 1999; Rogalska et al., 2008; Sen et al., 2006).  
 
 A collapse of the mitochondrial electrochemical gradient (Δψm) could also be explained by 
a direct inhibition of key enzymes constituting the respiratory chain such as complex I (by 
rotenone), III (by antimycin A) or IV (by cyanide) (Duchen and Biscoe, 1992; Moon et al., 2005; 
Wyatt and Buckler, 2004). In P. falciparum, bc1 inhibition by atovaquone has been demonstrated 
to collapse the mitochondrial membrane potential (Biagini et al., 2006; Srivastava et al., 1997). 
However, endoperoxide compounds showed weak inhibitory effects (< 25% inhibition at 1µM) on 
the three main components of the P. falciparum ETC (Table 6.1). Because endoperoxides kill 
malaria parasites in a low nanomolar range, this class of compounds follow an indirect pathway 
via ROS generation to affect the mitochondrial membrane potential instead of targeting a specific 
component of the respiratory chain. Recently, artemisinins cytotoxicity in human cell lines has 
also been confirmed to be independent of the ETC functionality (Mercer et al., 2011). 
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 In summary, this study confirms the effect of endoperoxide compounds on mitochondrial 
membrane potential and presents the first evidence of their impact on the cytoplasmic barrier of 
the malaria parasite. Artemisinin and its derivatives act as a generator of additional reactive 
oxygen species that overcome the oxidative defenses of the malaria parasite and cause a 
widespread and rapid membrane potential depolarization leading to mitochondrial dysfunction. 
Some further studies will be essential to clarify details of the depolarization mechanisms, to 
confirm the cytotoxic effect of plasma membrane depolarization and to determine the weight of 
this mode of action on parasite death. 
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Chapter 6 
 
Reduced cytochrome bc1 complex expression in the 
Plasmodium falciparum atovaquone-resistance field 
isolate TM90C2B 
 
6.1. Introduction 
 In this chapter, the bc1 protein expression is studied to investigate the stability of the 
enzyme in the P. falciparum atovaquone-resistance field isolate TM90C2B. This work has been 
recently published in "Cytochrome b Mutation Y268S Conferring Atovaquone Resistance 
Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein 
Expression" by Fisher et al., 2012. 
6.1.1. Atovaquone, a bc1 complex inhibitor 
 Atovaquone, a hydroxynapthoquinone, is a competitive inhibitor of ubiquinone, specially 
inhibiting Plasmodium falciparum (Fry and Pudney, 1992). Combined with proguanil in a fixed-
dose tablet (MalaroneTM), atovaquone is a potent and effective antimalarial drug for the 
treatment of children and adults with uncomplicated P. falciparum malaria (Osei-Akoto et al., 
2005; Painter et al., 2007). However, because of its expensive manufacturing and price, the drug 
is mainly used by international travellers and overseas-stationed military personnel from 
developed countries (Lalloo and Hill, 2008; Petersen, 2003).  
 Since the early stage of drug development, the bc1 complex has been suspected to be the 
primary site of action of atovaquone in the parasite (Kessl et al., 2007). Because a crystal structure 
of the P. falciparum cytochrome bc1 is not available, the details of the binding between 
atovaquone and the enzymatic complex has been studied on model organisms (Bos taurus, 
Saccharomyces cerevisiae, Rhodobacter capsulatus and Rb sphaeroides) and using molecular 
modelling. Site-directed mutagenesis of model organism cytochrome b, gene sequencing of 
atovaquone-resistant Plasmodium species or EPR spectroscopy of the Rieske [2Fe2S] cluster have 
demonstrated that atovaquone compete with quinol at the Qo site of the cytochrome bc1 
(reviewed in(Barton et al., 2010).  As described in the Chapter 1 (section 1.2.4.3.6), the 
cytochrome bc1 complex is a dimeric multi-subunit complex located in the inner membrane of the 
mitochondrion. This enzyme is a key element of the electron transport chain (ETC) by transferring 
electrons from ubiquinol, produced by different dehydrogenases, to cytochrome c (Crofts, 2004; 
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Hunte et al., 2003). This electron transfer is coupled to a vectorial translocation of protons across 
the inner membrane generating an electrochemical (and pH) gradient. The loss of bc1 activity 
results in mitochondrial dysfunction due to the collapse of the membrane potential (ΔΨm) and is 
lethal to the malaria parasite (Biagini et al., 2006; Srivastava et al., 1997). In the erythrocyte 
stages of the malaria parasite, one of the essential functions of the bc1 is the maintenance of the 
Q cycle in order to provide ubiquinone to act as electron acceptor for dihydroorotate 
dehydrogenase (DHODH). The formation of orotate by DHODH for the pyrimidine biosynthesis has 
been demonstrated to be an essential mitochondrial function for the malaria parasite by the 
generation of an atovaquone-resistant phenotype in transgenic P. falciparum parasites expressing 
ubiquinone-independent yeast DHODH (Painter et al., 2010). In line with this, inhibition of the bc1 
complex by atovaquone results in an increase in carbamoyl-aspartate and a reduction in UTP, CTP 
and dTTP (Hammond et al., 1985; Seymour et al., 1997). 
6.1.2. Cytochrome b mutation Y268S conferring the atovaquone 
resistance phenotype 
 Different resistance mutations associated with atovaquone have been detected in isolates 
of Plasmodium species (Kessl et al., 2007). However, a common mutation in P. falciparum 
atovaquone-resistant isolates following MalaroneTM treatment failure have been observed in 
infected patients returning from Thailand or African countries (David et al., 2003; Farnert et al., 
2003; Korsinczky et al., 2000; Wichmann et al., 2004). This atovaquone-resistance is associated 
with a point mutation at position 268 in cytochrome b exchanging tyrosine for serine (Y268S), or 
less frequently, asparagine (Y268N) (Berry et al., 2006; Fisher and Meunier, 2008; Fivelman et al., 
2002; Musset et al., 2006). The P. falciparum strain TM90C2B used in this work, is a field isolate 
associated to this mutation and was detected during a clinical phase 2 study to determine 
atovaquone efficacy in Thailand (Fig. 6.1) (Looareesuwan et al., 1996). Highly conserved across all 
species, the tyrosine 268, is located within the "ef" helix component of the Qo site. Its side chain 
participates in a stabilizing hydrophobic interaction with bound ubiquinol (Barton et al., 2010). 
Compared with parasite sensitive strains (IC50 = 0.8 ±0.1 nM), the resultant atovaquone-resistant 
phenotype displays a 1000-fold higher growth IC50 (Fisher et al., 2012).  
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Figure 6.1. Sequence alignments of the cytochrome b proteins from human, bovine, yeast  and P. 
falciparum sensitive- (Pf_3D7) and resistant-atovaquone (Pf_TM90C2B) strains around the Qo site. In red 
is highlighted the mutated Tyrosine 268 in P. falciparum  (at position 279 in yeast). Below the alignment, □ 
indicates residues interacting with atovaquone and ● those associated with atovaquone-resistance 
mutations in Plasmodium species. 
 
 Displaying a high degree of sequence identity with its P. falciparum homologue, the S. 
cerevisiae cytochrome b were used as a model to study the molecular aspect of the atovaquone 
resistance (Fisher and Meunier, 2005; Kessl et al., 2007; Mather et al., 2005). Because atovaquone 
is also an inhibitor of the yeast bc1 complex with a Ki of 9 nM (Kessl et al., 2003), their interaction 
were studied by using molecular modelling based on the crystal structure of S. cerevisiae 
cytochrome bc1 (Kessl et al., 2007). The presence of a similar stable interaction between Tyr
268 of 
cytochrome b (at position 279 in yeast) and atovaquone have been reported (Fig. 6.2). To stabilize 
the binding of atovaquone to the Qo site, additional interactions are believed to take place, 
namely hydrogen bonding between the His181 of the Rieske subunit and the Glu272 of the 
cytochrome b via a bridging water molecule. A hydrophobic pocket is formed from the side chain 
of Phe121 (transmembrane helix C) and Phe278 (ef loop) (Fisher et al., 2012). A hydrophobic 
interaction is predicted with the side chain of Leu275. The introduction of the Y268S mutation in 
yeast (Y279S) results in an increase in IC50 for atovaquone inhibition of bc1 enzymatic activity from 
60 nM to 4000 nM (Fisher and Meunier, 2005). By using mutant of bc1 from the bacterium 
Rhodobacter spharoides, Crofts et al. reported that a large or aromatic hydrophobic side chain 
residue like tyrosine is essential at the position 268 for an efficient catalytic activity (Crofts et al., 
2000). 
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Figure 6.2. Molecular model of atovaquone (Atv) docked into the Qo site of yeast cytochrome bc1 complex 
(Fisher et al., 2012). Yeast residues are labeled in white, with the corresponding P. falciparum residues 
labeled in orange. The cytochrome b polypeptide backbone is represented in green, with the Rieske protein 
backbone in brown. The [2Fe-2S] cluster of the Rieske protein is represented in CPK form (sulfur, yellow; 
iron, pink). Hydrogen bonds are indicated by yellow dotted lines. A 1.4 Å radius CPK dotted surface has been 
added around the docked atovaquone molecule to aid visual clarity. The Protein Database (PDB) accession 
number used for the cytochrome bc1 complex structure is 3CX5. 
 
6.1.3. Effect of the mutation Y268S on the parasite bc1 enzyme 
 Although the steady-state turnover activity of the yeast Y279S mutant has previously 
been measured with a reduction of 70% in comparison with the wild-strain, the effect of 
atovaquone resistant mutation Y268S on the parasite bc1 enzyme has just recently been 
elucidated (Fisher et al., 2012).  
 First, growth inhibition assays confirmed the phenotypic profiles of the wild type (3D7) 
and atovaquone-resistant strains (TM90C2B and 3D7-yDHODH·GFP) to therapeutic drugs and 
various specific electron transport inhibitors (Table 6.1). As expected, TM90C2B with the Y268S 
mutation in bc1 displayed high levels of resistant to atovaquone (~12,000 fold). TM90C2B was also 
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shown to have an increased resistance to other bc1 inhibitors including the Qo site inhibitors 
myxothiazol (~20-fold) and stigmatellin (~5-fold), as well as the Qi site inhibitor antimycin (≈20-
fold). The Qi site being located at the opposite side of the inner mitochondrial membrane within 
cytochrome b (separated by ~25 Å with the Qo site), the increase in IC50 for antimycin in TM90C2B 
compared with the control 3D7 strain is at first sight surprising. However, regulatory interactions 
between the Qo and Qi sites have been observed in yeast bc1 in which the binding of stigmatellin 
affected the interaction of antimycin in a complex manner, with one half of the (dimeric) enzyme 
binding antimycin in a slow, concentration-independent way. Antimycin was observed to bind 
rapidly and in a concentration-dependent manner in the presence of myxothiazol (a “b-proximal” 
Qo site inhibitor) (Covian and Trumpower, 2006). The structural mechanism for this apparent 
communication pathway between the quinone-binding sites within cytochrome b remains to be 
determined. The other atovaquone-resistant strain 3D7-yDHODH·GFP was also highly resistant to 
atovaquone and other bc1-targeting inhibitors (antimycin and stigmatellin), in line with the 
original work performed by Painter et al. (Painter et al., 2007). 
 
Table 6.1. Growth inhibition profiles of P. falciparum 3D7, TM90C2B and 3D7-yDHODH·GFP parasites 
(Fisher et al., 2012).   
Drug Target 
 IC50 (nM)  
3D7 TM90C2B 3D7-yDHODH·GFP 
Artesunate  1.6 ± 0.4 0.45 ± 0.09 1.1 ± 0.13 
Chloroquine  11.4 ± 0.4 70.6 ± 9.6 10.4 ± 0.4 
Atovaquone bc1 (Qo) 0.8 ± 0.1 12,418 ± 1,6 55 5,823 ± 2,254 
Stigmatellin bc1 (Qo) 23 ± 4.2 106.95 ± 13.66 4,145 ± 425 
Myxothiazol bc1 (Qo) 33± 6 564.2 ± 11.7 ND 
Antimycin bc1 (Qi) 13± 2 300.7 ± 34.67 ND 
Data are expressed as mean ± S.E., acquired from multiple replicates performed on at least 3 independent occasions.  
IC50 values were calculated by fitting of four-parameter logistic curves (Kaleidagraph software). ND, Not Determined. 
 
 To determine the impact of Y268S mutation on the catalytic activity of P. falciparum bc1, 
steady-state kinetics were performed on both wild type (3D7) and atovaquone-resistant 
(TM90C2B) strains. First, TM902CB bc1 displayed a 100-fold decrease in IC50 value against 
atovaquone (600 ± 90 nM) in comparison with the enzyme from the sensitive strain 3D7 (6 ± 1 
nM) (Fig. 6.3) (Fisher et al., 2012). 
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P. falciparum 
strain 
Atovaquone (nM) 
IC50 Ki 
3D7 6 ± 1 0.6 
TM90C2B 600 ± 90 162 
Values are mean ± standard errors from independent 
experiment. The Ki values for atovaquone inhibition 
were calculated using the Cheng-Prusoff equation 
(Cheng and Prusoff, 1973).  
 
Figure 6.3. ‘Cell-free extract’ cytochome bc1 complex inhibition by atovaquone in P. falciparum sensitive- 
(3D7) and resistant-atovaquone strains (TM902CB) (Fisher et al., 2012). Inhibition of steady-state 
decylubiquinol:cytochrome c oxidoreductase activity of P. falciparum 3D7 (○) and TM90C2B (●) bc1 in crude 
cell-free extracts by atovaquone. 
 
 Steady-state studies measured a decrease in Vmax in crude preparations of TM90C2B bc1 
(60.2 ± 3.2 nmol cyt c reduced/min/mg protein) compared with the control 3D7 strain (97.4 ± 5.1 
nmol cyt c reduced/min/mg protein) (Fig. 6.4) (Fisher et al., 2012). A three-fold increase in Km 
observed for decylubiquinol in TM90C2B bc1 were notified in comparison with the enzyme in 3D7.  
This increase in Km for decylubiquinol coupled with the decrease in Vmax observed in TM90C2B bc1 
suggests that the binding and/or positioning of the substrate ubiquinol within the Qo site is 
impaired in the atovaquone-resistant strain. A similar observation has been made for the yeast 
Y279C and Y279S mutants (turnover numbers of 47 and 30 s-1, respectively, compared with the 
wild type value of 80 s-1) (Fisher et al., 2004b; Fisher and Meunier, 2005; Wibrand et al., 2001), 
although it should be noted that more deleterious effects on the yeast enzyme activity have been 
noted in Y279S preparations in other laboratories (Kessl et al., 2005). 
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P. falciparum 
strain 
Vmax 
(nmol cyt c reduced 
/min/mg protein) 
Km 
(dQH2, 
µM) 
3D7 97.4 ± 5.1 5.5 ± 1.1 
TM90C2B 60.2 ± 3.2 18.5 ± 2.6 
Values are mean ± standard errors from 
independent experiment. 
Figure 6.4. ‘Cell-free extract’ steady-state cytochome bc1 complex activity in P. falciparum sensitive- (3D7) 
and resistant-atovaquone strains (TM902CB) (Fisher et al., 2012). Steady-state decylubiquinol:cytochrome 
c oxidoreductase activity of P. falciparum 3D7 (●) and TM90C2B (○) bc1 in crude cell-free extracts.  
6.1.4. Comparison of bc1 gene expression in sensitive and resistant-
atovaquone strains 
 Analysis of expression levels of genes composing the respiratory chain from the TM902CB 
strain revealed significant differences with the 3D7 atovaquone-sensitive strain. Then a ~2 fold 
increase in expression of some bc1 complex genes including cytochromes b, c1, and the Rieske 
(ISP) subunit of bc1 were observed in the atovaquone-resistant strain (Fig. 6.5) (Fisher et al., 
2012). Additionally a similar overexpression were reported for cytochrome c and two subunits of 
the cytochrome c oxidase (subunit 1 and 2). 
 
 
Figure 6.5. Fold changes in gene expression of electron transport chain components between P. 
falciparum  sensitive- (3D7) and resistant-atovaquone (TM90C2B) strains (Fisher et al., 2012). Dashed blue 
box indicates genes encoding for components of mitochondrial Complex III and IV.   
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 Point mutations of mitochondrial genes leading to residue substitutions impairs in some 
cases the stability of assembled respiratory chain complexes in mice model (Edgar et al., 2009). A 
protein deficiency due to instability or non-assembly can upregulate the tRNAs level of genes 
concerned via a compensatory mechanism (Ylikallio and Suomalainen, 2012). 
 In this chapter, the effect of the Y268S mutation on the stability of P. falciparum bc1 has 
been investigated. First, a new specific polyclonal antibody against the Rieske (ISP) subunit of the 
P. falciparum cytochrome bc1 was raised and characterized via immunoprecipitation and 
NanoLC/MS-MS.  Furthermore, using Western Blot analyses, protein expression levels were 
compared between atovaquone sensitive and resistant P. falciparum and yeast strains. The results 
are discussed in the context of the impact of the Y268S mutation on the ISP stability and bc1 
complex assembly. 
6.2. Material and methods 
6.2.1. Synthesis of an anti-bc1 polyclonal antibody  
 The peptide 322SHYDNSGRIRQGPA335 of the ubiquinol-cytochrome c reductase Rieske iron-
sulfur subunit (Swissprot accession # Q8IL75) of the Plasmodium falciparum bc1 protein was 
selected (Fig. 6.6), synthesized, and used for immunization in the rabbit and generation of an 
affinity-purified polyclonal antibody (GenScript Corp., Piscataway, NJ). The rabbit anti-Pfbc1 
polyclonal antibodies were lyophilized in phosphate-buffered saline (pH 7.4) with 0.02% sodium 
azide as preservative. Lyophilized antibodies were reconstituted with MilliQ water, and aliquots 
were stored at -20 °C until use. 
 
 
Figure 6.6. Sequence alignments of C-terminal ubiquinol-cytochrome c reductase Rieske iron-sulfur (ISP 
subunit) from human, bovine, yeast and P. falciparum 3D7 strain (Pf_3D7). In red is highlighted the 
peptide chosen in P. falciparum for the antibody synthesis. Below the alignment, * indicates conserved 
residues across all species. 
 
6.2.2. Immunoprecipitation of parasite membrane proteins 
 For immunoprecipitation studies, cell-free parasite membrane proteins were boiled (5 
min at 95 °C) in denaturing lysis buffer (50mMTris-HCl, 5mMEDTA, 2% (w/v) SDS, 10mM DTT) and 
diluted (10-fold) with nondenaturing lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% 
(v/v) Triton X-100, pH 7.5). Following centrifugation (17,000 x g for 30 min), denatured proteins 
were collected in the supernatant and incubated overnight with 2 µg of anti-bc1 antibody, rotating 
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at 4°C, followed by 50 µl of protein A-Sepharose slurry for 3 h at 4 °C. Immunoprecipitates were 
washed, gently eluated with an acidic buffer (pH 2.8), and then separated by 10% (w/v) SDS-PAGE 
gel electrophoresis before proceeding to immunoblotting, in gel-trypsin digestion and mass 
spectrometry. 
6.3. Results 
6.3.1. Characterization of the anti-Rieske subunit antibody 
 To measure bc1 protein expression in the parasite, a custom polyclonal antibody against 
the Rieske subunit of the P. falciparum bc1 complex was raised using a commercial supplier 
(GenScript Corp., USA). Due to its high conservation across species, the peptide 
322SHYDNSGRIRQGPA335 located near the C-terminal of the P. falciparum Rieske subunit was 
chosen for antibody generation. The anti-bc1 polyclonal antibody was raised by immunizing 
rabbits with the specific peptide (as peptide–KLH conjugate) and purified by affinity. 
  To validate this customized antibody by analysis of its antigens with NanoLC-MS/MS, an 
immunoprecipitation experiment was performed on the membrane proteins obtained from 3D7 
free-parasite extracts. The result of the immunocapture (separated by 10% SDS-PAGE) was 
observed by Western blot and silver staining (Fig. 6.7). The immunoblot revealed a protein 
captured at approxiamtely 41 kDa, consistent with the size of the Rieske subunit in the malaria 
parasite. The band corresponding to the protein was excised from the silver-stained gel, digested 
with trypsin, and analyzed by NanoLC-MS/MS to obtain the peptide sequence data. The Rieske 
subunit was identified by 28 peptide mass fingerprints with sequence coverage of 60.0% (Table 
6.2). An example of the NanoLC-MS/MS fragmentation pattern of the peptide 
101YAHYNQTAEPVPR114 is shown in Figure 6.8. Immunofluorescence localization of the bc1 complex 
inside the parasite-infected erythrocytes has been tempted by using the anti-Rieske antibody but 
results showed that it is unable to bind the subunit folded and can be used in denatured 
conditions only. Attempts to generate polyclonal antibodies specific to P. falciparum cytochrome 
b were unsuccessful.  
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Figure 6.7. Western Blot and silver staining of the Rieske subunit (41 kDa) immunocapture from 3D7 free 
parasites. HC indicate the heavy chain (50 kDa) of the polyclonal antibody used for the 
immunoprecipitation. Western blot was performed with customized anti-bc1 polyclonal antibodies (1/500 
dilution). 
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Table 6.2. List of 10 first hits obtained by NanoLC-MS/MS analysis and Sequest algorithm search of the immunoprecipitated 41 kDa band. In yellow is highlighted the 
most significant hit with the highest score.  
Hits Accession Coverage # Peptides # AAs 
MW 
[kDa] 
calc. pI Score Description 
1 PF14_0373 60.00% 28
a
 355 41.0 7.58 53.93 
organism=Plasmodium_falciparum_3D7 | product=ubiquinol-cytochrome c reductase 
iron-sulfur subunit, putative | location=Pf3D7_14:1600876-1601943(-) | length=355 
2 PF10_0379 25.07% 14 359 41.7 6.87 11.41 
organism=Plasmodium_falciparum_3D7 | product=phospholipase, putative | 
location=Pf3D7_10:1562808-1563887(+) | length=359 
3 PFB0480w 7.96% 3 314 37.1 7.53 6.71 
organism=Plasmodium_falciparum_3D7 | product=syntaxin, Qa-SNARE family | 
location=Pf3D7_02:436050-436994(+) | length=314 
4 MAL13P1.339 13.08% 8 367 44.6 9.23 5.46 
organism=Plasmodium_falciparum_3D7 | product=conserved Plasmodium protein, 
unknown function | location=Pf3D7_13:2679915-2681301(+) | length=367 
5 PF13_0004 15.45% 11 343 38.4 9.28 5.33 
organism=Plasmodium_falciparum_3D7 | product=rifin | location=Pf3D7_13:47686-
48872(+) | length=343 
6 MAL7P1.118 8.19% 8 403 47.0 8.69 5.30 
organism=Plasmodium_falciparum_3D7 | product=PelOta protein homologue, putative | 
location=Pf3D7_07:999399-1000610(+) | length=403 
7 PFF0025w 17.20% 6 372 41.5 9.01 4.79 
organism=Plasmodium_falciparum_3D7 | product=rifin | location=Pf3D7_06:26557-
27830(+) | length=372 
8 PFI0035c 22.31% 9 381 42.1 9.06 4.51 
organism=Plasmodium_falciparum_3D7 | product=rifin | location=Pf3D7_09:49612-
50971(-) | length=381 
9 PF14_0266 6.93% 8 433 51.4 8.21 4.11 
organism=Plasmodium_falciparum_3D7 | product=conserved protein, unknown function 
| location=Pf3D7_14:1129412-1130713(-) | length=433 
10 MAL13P1.43 22.50% 11 360 42.3 8.03 3.98 
organism=Plasmodium_falciparum_3D7 | product=conserved Plasmodium protein, 
unknown function | location=Pf3D7_13:416120-417202(-) | length=360 
a 
The list of 28 peptides identified are indicated in Appendix 2. 
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Figure 6.8. (A) Fragmentation spectra of the precursor ion with m/z = 846.90 Da (charge of +2) identified 
as peptide YAHYNQTAEPVPR (residues 101-114 of Rieske subunit). #1 = y4 (517.3738); #2 = y6 (744.0631); 
#3 = b6 (777.4517); #4 = b7 (878.6395); #5 = y12 (1459.2450). (B) Peptide sequence consensus obtained 
after matching of y- and b-fragment ions. 
 
6.3.2. Cytochrome bc1 protein expression in sensitive- and resistant-
atovaquone parasites  
 Using the characterized anti-ISP antibody, the extent to which the Y268S mutation 
affected protein expression was determined by performing Western blots of cell-free extracts 
prepared from TM90C2B compared with the atovaquone-sensitive 3D7 strain. As shown in Figure 
6.9, a decrease in ISP content was observed in Western blots prepared from TM90C2B compared 
with the 3D7 control strain. This experiment was performed on three separate occasions using 
different membrane preparations. For all experiments, aldolase was used to control for any 
potential differences in protein loading (Fig. 6.9).  
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Figure 6.9. Immunoblot analysis of the 3D7 and TM90C2B membrane proteins fractions with the 
customized anti-Rieske antibody. Aldolase is used as a loading control and detected from their respective 
soluble proteins fractions. 
6.3.3. Cytochrome bc1 protein expression in yeast wild type and 
Y279S mutant 
 Further Western blot analysis was carried out to observe the same mutation effect on 
yeast model. In contrast to the parasite data, no such loss in the ISP signal was observed using 
crude mitochondrial membranes prepared from yeast containing the Y279S cytochrome b 
mutation, relative to wild type control (WT) (Fig. 6.10 A). An identical SDS-Page stained with 
coomassie blue were performed as a loading control (Fig. 6.10 B). Bovine mitochondrial 
membrane preparation were used as a positive control. 
 
Figure 6.10. (A) Immunoblot analysis of the yeast wild type and Y279S membrane proteins fractions with 
the customized anti-Rieske antibody. WT indicates Wild Type strain and BH the Bovine mitochondrial 
membrane preparation. (B) Coomassie blue staining of an identical SDS-PAGE with similar protein loading. 
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6.4. Discussion 
 In this study the effect of the Y268S mutation in TM90C2B parasites was investigated at 
the bc1 expression level and compared to the wild type strain 3D7. This mutation causes a 3-fold 
increase in Km observed for decylubiquinol in TM90C2B bc1 coupled with the decrease in Vmax 
(Fisher et al., 2012). It suggests that the binding and/or positioning of the substrate ubiquinol 
within the Qo site is impaired in TM90C2B compared with the wild type, consistent with mutation 
studies of this residue in yeast model (Fisher and Meunier, 2005). To investigate if the loss of bc1 
activity in the resistant strain is linked to a change of its expression at a proteomic level, a specific 
polyclonal antibody was raised and further characterization revealed it to be specific to the P. 
falciparum Rieske subunit (a component of the bc1 complex) via immunoprecipitation and 
NanoLC-MS/MS analysis. The choice of a conserved peptide as antigen allocates a cross-species 
feature to the polyclonal antibody able to bind the protein from yeast and beef. 
 Western blot analysis of the Rieske subunit (ISP) content in free parasite extracts from 
resistant-atovaquone strain TM90C2B revealed a decreased level of the bc1 subunit in comparison 
with the sensitive strain 3D7 (Fig. 6.9). Although a ~2-fold increasing at the gene expression level 
has been observed in the resistant strain (Fig. 6.6), a reduced quantity of Rieske in TM90C2B 
membranes might be due to a protein instability. However, a similar procedure showed no 
distinguishable difference in ISP expression between yeast mutant (Y279S) and wild type (WT) 
(Fig. 6.10). In line with this, no loss of ISP content was observed in the yeast Y279A and Y279C 
mutants, although the Y279W mutation was found to be structurally destabilizing (Fisher et al., 
2004b; Kessl et al., 2005). These data further highlight the differences between parasite and yeast 
cytochrome b and the need for performing biochemical analyses on parasite material irrespective 
of the technical difficulties. 
 The instability of Rieske subunit has been previously suggested to be a cause of loss (or 
decrease) of bc1 activity. Early, some replacement of aromatic residues to non-aromatic in yeast 
mutant exhibited a reduced ISP level and cytochrome bc1 activity (Snyder et al., 1999). Mutations 
in the hinge region of the bacterium Rhodobacter sphaeroides bc1 complex reduced the flexibility 
of the neck region, increasing the sensitivity of the enzyme to detergent and leading to a 
destabilization of ISP and a loss of activity (Tian et al., 1998). Multiple-alanine substitutions of the 
extra fragment of the ISP in Rhodobacter sphaeroides decreased (or removed) the bc1 activity 
because of an instable mutant ISP protein despite an unaffected mutant mRNA (Xiao et al., 2004). 
A specific mutations in yeast ISP increase its sensitivity to proteolytic cleavage, destabilizing the 
bc1 complex and resulting in a lower QH2-cytochrome c reductase activity (Fisher et al., 2004a). 
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 The apparent instability of the ISP in TM90C2B as revealed by Western blotting suggests a 
weakened interaction between this subunit and cytochrome b. This instability of the Rieske 
subunit may be due to perturbation of the ef helix and surrounding protein structure at the Qo 
site caused by the introduced serinyl side chain. A potential consequence of structural 
perturbation around the Qo site would be a perturbation of the docking or positioning of the ISP 
ecto-domain at Qo, weakening the hydrogen bonding association and/or an increase in the 
electron transfer distance between bound ubiquinol and the ISP [2Fe-2S] cluster, or lowering the 
occupancy of bound ubiquinol. Such perturbations have been observed in Qo site mutants of the 
yeast bc1 complex (Brasseur et al., 2001; Brasseur et al., 2004; Fisher et al., 2004b). The 
differences in bc1 complex integrity observed in TM90C2B and the yeast Y279S mutant may arise 
from the potentially unusual structure of the Qo site and ISP docking surface in Apicomplexa (i.e. 
the four residue deletion in the N-terminal region of the cd2 helix (Biagini et al., 2008)). This 
potential structural perturbation affecting electron transfer may also account for the apparent 
increased tolerance (~20-fold) that the TM902CB parasite has for heme-proximal Qo inhibitors as 
well as Qi inhibitors. It will be important to further understand this phenomenon because the 
TM902CB strain is widely used to assess the suitability of novel bc1 inhibitors (Cross et al., 2011), 
and an apparent cross-resistance of novel chemotypes may be mistakenly interpreted as deriving 
from atovaquone-like binding. 
 
 In conclusion, this study gives the first description of the effect of the Y268S mutation on 
parasite bc1 catalytic turnover and stability. Results obtained indicate that the reduced enzyme 
activity affects protein stability and should incur a fitness penalty to the parasite, features that 
were not fully discernable using the yeast model alone.  
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Chapter 7 
Import and processing of mitochondrial proteins in 
Plasmodium falciparum and other apicomplexan parasites 
 
7.1.  Introduction 
 Apicomplexan parasites are causative agents of various diseases including human malaria, 
toxoplasmosis or cryptosporidiosis. The mitochondrion of apicomplexan species is an essential 
organelle and differs from the mitochondria in other eukaryotes. In the malaria parasite P. 
falciparum, the maintenance of a mitochondrial integrity is required for different functions such 
as [Fe-S] cluster assembly and heme and pyrimidine biosynthesis, which have become attractive 
targets for antimalarial drugs (Bonday et al., 1997; Lange et al., 2000; Painter et al., 2007). 
Apicomplexan mitochondrial genomes (mtDNAs) are extremely reduced by encoding only three 
components of the mitochondrial electron transport chain (ETC): the cytochrome c oxidase 
subunits I and III (Cox1 and Cox3) and the cytochrome b (Cytb) (reviewed in(Gray et al., 2004; 
Vaidya and Mather, 2009). Among apicomplexan parasites, the human pathogen Cryptosporidium 
does not have a mtDNA and thus the organelle is completely  dependent on nuclear-encoded 
proteins (Henriquez et al., 2005). Consequently, the great majority of mitochondrial proteins are 
imported post-translationally from the cytosol into the organelle. Those mitochondrial precursors 
contain N-terminal or internal targeting peptides recognized by surface receptors which induce 
their translocation. In P. falciparum, proteins targeting the mitochondrion have been predicted to 
represent around 7% (~380 proteins) of the total nuclear-encoded proteins (Bender et al., 2003).  
 The protein uptake into mitochondria has been demonstrated to be crucial for cell 
viability and at least four different pathways have been identified depending on the final 
destination of these precursors: the presequence pathway to the inner membrane or matrix, 
carrier pathway to the inner membrane, β-barrel pathway to the outer membrane and the 
intermembrane space assembly (reviewed in (Chacinska et al., 2009; Neupert and Herrmann, 
2007; Schmidt et al., 2010). To be sorted into mitochondrial membranes or transported across, 
mitochondrial precursors are assisted by multi-subunits membrane bound translocases and 
soluble chaperones located in the cytosol, intermembrane space and matrix. After import into the 
mitochondria, precursors are proteolytically processed by proteases to become functional. The 
proteolytic machinery is distributed in different mitochondrial compartments and cleaves 
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presequences or additional peptides to ensure the maturation, localization and assembly of 
mitochondrial proteins (recently reviewed in(Mossmann et al., 2011).  
 In the last 10 years, our understanding of the mitochondrial proteins import machinery 
has been accelerated with the identification of new components through the use of genetic 
approaches in model organisms such as baker's yeast Saccharomyces cerevisiae or fungi 
Neurospora crassa (Neupert and Herrmann, 2007). The sequencing of all apicomplexan genomes 
allowed a first description of the mitochondrial protein import apparatus in Plasmodium 
falciparum or Toxoplasma gondii based on yeast and plant homologues (Sheiner and Soldati-
Favre, 2008; van Dooren et al., 2006). However, the description of the apicomplexan model is still 
fragmented and no general overview has been proposed.  
 This work presents an updated picture of the whole protein import and processing 
machinery in apicomplexa, as well as, reveals novel putative components in this pathway. Hereby, 
all pathways and components in Plasmodium falciparum are described in detail and five different 
apicomplexan species homologues (Toxoplasma gondii, Cryptosporidium muris, Theileria parva, 
Babesia bovis and Neospora caninum) have been determined. The comparison with yeast, 
mammalians or plants exhibits certain similarities but also major distinctions that highlight an 
apicomplexan model distinct to other organisms. 
7.2. Mitochondrial targeting signals 
 Mitochondrial precursors are synthesized in the cytosol and target this organelle though 
specific signal peptides encoded in their amino acid sequences. There are two main groups of 
targeting signals using different importation pathways. The most common signal is the cleavable 
N-terminus of mitochondrial leading peptides (Horwich et al., 1985; Hurt et al., 1984). The pre-
sequence forms amphipathic α-helices with two faces, one which is hydrophilic and the other 
positively charged, these are recognized by import receptors of the mitochondrial outer and inner 
membranes (Neupert and Herrmann, 2007). Proteins with a pre-sequence are released into the 
matrix or inserted into the inner membrane if a hydrophobic sorting peptide follows the targeting 
signal (Fig. 7.1).  
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Figure 7.1. Signal profiles of proteins targeting mitochondrial compartments or other apicomplexan 
cellular locations. Extracellular and apicoplastical proteins display an N-terminal signal peptide that targets 
the endoplasmic reticulum (ER) where it is cleaved. Then proteins traffic via a secretory pathway but are 
not secreted if a transit peptide is exposed. In this case these proteins are transferred to the apicoplast 
where they become mature after processing of their transit sequence (Waller et al., 1998; Yung et al., 
2001). N-terminal pre-sequences designated for the mitochondrion are cleaved by the mitochondrial 
processing peptidase (MPP) located inside the matrix.  
 
 Among apicomplexans, the properties of mitochondrial N-terminal signal peptides have 
only been studied in Plasmodium falciparum leading to the development of two bioinformatic 
tools for predicting mitochondrial proteins in malaria parasites: PlasMit in 2003 
(gecco.org.chemie.uni-frankfurt.de/plasmit) followed by PFMpred in 2009 
(www.imtech.res.in/raghava/pfmpred) (Bender et al., 2003; Verma et al., 2010). In Plasmodium 
species, the length of targeting peptides can vary between 23 to 169 amino acids, with an average 
of 48 residues, and presents specific features compared to the N-terminal signals of apicoplast or 
secretory proteins. They display the highest content of positively charged residues and the lowest 
amount of hydrophobic amino acids, as well as a distinct abundance of glutamic acid (E), 
isoleucine (I) and tyrosine (T). For the rest of apicomplexans, two other in silico methods are 
commonly used for mitochondrial signal prediction, TargetP (www.cbs.dtu.dk/services/TargetP) 
and MitoProt II (ihg.gsf.de/ihg/mitoprot.html) developed for eukaryotic proteins, but the use of 
Plasmodium dedicated algorithms can also be possible (Cai et al., 2005; Zhou et al., 2005).  
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 The second group contains proteins with internal targeting signals, these are uncleavable 
and remain as part of the mature proteins (Brix et al., 1999; Egan et al., 1999; Schmidt et al., 
2010). These include β-barrel proteins of the outer membrane, hydrophobic carrier proteins of 
the inner membrane and intermembrane space (IMS) proteins. For β-barrel and carrier proteins, 
several internal signals can be exposed at different positions within their amino acid sequence, 
while only one internal signal peptide coupled to a cysteine-rich motif is needed to target the 
intermembrane space. The nature of these internal signals remains unclear and is difficult to 
identify. Furthermore, to date, there are no bioinformatic tools able to predict their localization in 
amino acid sequences. 
7.3. In silico identification of protein import and processing 
machinery components in Apicomplexan 
 Sequencing of apicomplexan genomes (for Plasmodium, Cryptosporidium, Theileri and 
Babesia species) or large-scale expressed sequence tag (EST) (for Toxoplasma or Neospora 
species) have become a  widely used technique in order to get a deeper understanding of many of 
their biological processes (Abrahamsen et al., 2004; Ajioka et al., 1998; Brayton et al., 2007; 
Carlton et al., 2002; Gardner et al., 2005; Gardner et al., 2002; Pain et al., 2005; Xu et al., 2004). 
The apparatus of protein translocation into the mitochondria and their subsequent processing has 
been mainly studied in P. falciparum and T. gondii through the identification of their putative 
components by homology searching of model organisms such as yeast, mammalian or plant 
mitochondrial (Dowse and Soldati, 2005; Gangwar et al., 2009; Maćašev et al., 2004; Sheiner and 
Soldati-Favre, 2008; van Dooren et al., 2006; van Dooren et al., 2002). However, our knowledge of 
those machineries in malaria parasite remains unclear in some areas mainly due to a lack of 
certain components. This can be explained by either their absence in the nuclear genome or their 
high divergence which makes their identification more difficult. Recently Dolezal et al. identified 
Sam50, a component of the outer membrane SAM complex, in different apicomplexan species by 
using a Hidden Markov Model approach (Dolezal et al., 2006). Compared to BLAST algorithms, 
profile Hidden Markov Models (HMMs) enhances the sensitivity for protein homology 
identification (Hofmann, 2000). New putative genes involved into the translocation and 
processing machineries of P. falciparum and five other apicomplexan species have been identified 
in this study by employing HMMER (hmmer.janelia.org), a sequence homology search software 
based on profile HMMs  (Finn et al., 2011). 
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7.4. Protein import into apicomplexan mitochondria 
 Based on component homologues from yeast (Saccharomyces cerevisiae), mammalian 
(Homo sapiens) and plant (Arabidopsis thaliana) models, an in silico inventory of the 
apicomplexan mitochondrial protein import apparatus was established (Table 7.1). 
 
Table 7.1. Components of the mitochondrial importation machinery in apicomplexan species and comparison 
with fungi, mammalian and plant representatives. Pf indicates Plasmodium falciparum, Tg: Toxoplasma 
gondii, Cm: Cryptosporidium muris, Tp: Theileria parva, Bb: Babesia bovi and Nc: Neospora caninum. 
Saccharomyces cereviae (Sc), Homo sapiens (Hs) and Arabidopsis thaliana (At) represent fungi, mammalian and 
plant kingdoms respectively. '•' indicates novel candidate genes. '■' indicates components demonstrated 
essential for yeast viability. Uniprot accession number of each component are available in Appendix 3. 
 
 Protein Function Pf Tg Cm Tp Bb Nc  Sc Hs At 
Cytosolic  
chaperones  
and factors 
cHsp70 Bind precursors and maintain them soluble and 
unfolded (import-competent conformation) 
          
Hsp90           
MSF Bind precursor/chaperone complexes to maintain 
preproteins in import-competent conformation 
          
AIP •          
NAC 
Bind nascent polypeptides and assist their 
mitochondrial importing 
          
RAC (hDnaJ)           
RAC (cHSP70)           
TOM 
complex  
Tom40 Channel of the translocation complex        ■   
Tom22 
Receptor of preproteins (cytosol side) and Tim50 (IMS 
side) 
      
 
   
mtOM64 
(TOM70) 
Initial receptor for internal signals proteins, functional 
homolog of TOM70 
      
 
   
Tom20 Initial receptor for N-terminal signal proteins            
Tom7 Delays TOM complex assembly •          
Tom6 Favours TOM complex assembly           
Tom5 Guides preproteins from receptors to Tom40 channel             
SAM 
complex 
Sam50 
Main component of the insertion in the outer 
membrane 
      
 
■   
Sam37 
Stabilizes SAM complex and/or promotes release of β-
barrel proteins in the outer membrane 
      
 
   
Sam35 Receptor of β-barrel proteins          ■   
Mdm10 Assists β-barrel proteins assembly           
Tiny 
TIMs 
Tim8 
Transfer of internal signals proteins to SAM or TIM22 
complexes through the IMS 
Assembly in chaperone complexes Tim8-Tim13 and 
Tim9-Tim10 
          
Tim13           
Tim9        ■   
Tim10        ■   
MIA 
pathway 
Mia40 Transfers disulfide bonds to IMS proteins        ■   
Erv1 
Generates disulphide bonds and transfers them to 
Mia40 
      
 
■   
Cytochrome c Oxidizes reduced Erv1        ■   
TIM22 
complex 
Tim22 
Twin-pore channel of the translocation 
 complex 
      
 
■   
Tim12 
Guides carrier proteins to the complex by forming a 
complex with Tim9-Tim10 
      
 
■   
Tim18 
Receptor of Tim9-Tim10-Tim12  
complex 
      
 
   
Tim54 Assists TIM22 complex assembly           
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TIM23 
complex  
+  
PAM 
motor 
 
Tim23 Channel of the translocation complex        ■   
Tim50 
Receptor of precursors and regulator of channel 
opening 
      
 
■   
Tim21 Modulates TIM23 assembly with PAM motor           
Tim17 Assists sorting of preproteins into the inner membrane        ■   
mtHsp70 
Mitochondrial chaperone transferring precursors to 
the matrix 
      
 
■   
Pam18 (Tim14) Stimulates transfer activity of mtHsp70        ■   
Pam16 (Tim16) Regulates transfer activity of mtHSp70        ■   
Pam17 
Involves in the association of TIM23 complex with PAM 
motor 
      
 
   
Tim44 
Membrane-bound receptor of mtHsp70 which guides 
preproteins to the matrix 
      
 
■   
GrpE Assists mtHsp70 in its transfer activity        ■   
 Oxa1 
complex 
mtDNA Mitochondrial genome yes yes no yes yes yes  yes yes yes 
Oxa1 Core of the insertion into the inner membrane           
Letm1/Mdm38 
Receptor of ribosomes and assists mitochondrial 
encoded proteins translation 
• • • • • • 
 
■   
Mba1 Promotes interaction with mitochondrial ribosomes           
  
7.4.1. Cytosolic chaperones and factors 
 All proteins required for mitochondrial functions, except for three (Cox1, Cox2 and Cytb), 
are encoded in the nuclear chromosomes. They are imported into the mitochondria after 
translation in the cytosol as precursor proteins with a pre- or internal sequence signals. However, 
the emerging polypeptide chain is prone to potential aggregation with other unfolded proteins by 
exposure of their hydrophobic domains. Cytosolic chaperones heat shock protein 70 and 90 
(Hsp70 and Hsp90) are essential to maintain these preproteins soluble through the interaction 
with their hydrophobic segments and  subsequent guidance  into the mitochondrial surface (Fig. 
7.2) (Deshaies et al., 1988; Murakami et al., 1988; Young et al., 2003). Hsp70 and Hsp90 amino 
acid sequences are highly conserved between species and several homologues were identified in 
every apicomplexans. However, only one cytosolic Hsp70 and Hsp90 is able to bind preproteins 
through their N-terminal ATPase domain which is followed by a peptide binding domain and 
terminated by the COOH-terminal sequence EEVD (Freeman et al., 1995). 
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Figure 7.2.  Transport of mitochondrial precursors at the organelle's surface in P. falciparum. Black dotted 
arrow indicates a novel pathway involving the new putative component AIP. OM indicates the 
mitochondrial outer membrane, IMS:  the intermembrane space, IM: the inner membrane and M: the 
matrix. 
 
 In mammalian or yeast, additional factors can facilitate the formation of 
precursor/chaperone complexes or their interaction with outer membrane receptors such as the 
mitochondrial import stimulation factor (MSF) or the aryl hydrocarbon receptor-interacting 
protein (AIP) (Hachiya et al., 1993; Yano et al., 2003). In mammalian cytosol, MSF is composed of 
two subunits MSFL and MSFS (isoforms ε and ζ of 14-3-3 proteins respectively) and can act alone 
or in complex with Hsp70 to maintain or restore precursors in a import-competent conformation 
(Alam et al., 1994; Hachiya et al., 1994). In apicomplexan species, only one or two putative 14-3-3 
proteins show over 30 % of similarities with human homologues (from 37% to 62% identities with 
the seven human ε, ζ, σ, η, ϑ, γ and β isoforms, Table 7.2). Due to the high degree of sequence 
conservation of these mammalian 14-3-3 proteins, apicomplexan homologues could not be 
assigned with confidence to a specific isoform. However, only an ε isoform has been clearly 
identified in Cryptosporidium (Brokx et al., 2011) and therefore, the presence of an MSP-
supported import in apicomplexa cannot be established.  
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Table 7.2. Similarities between putative 14-3-3 proteins from Apicomplexan species and the seven human 
isoforms (ε, ζ, σ, η, ϑ, γ and β). Percentage identities have been determined by using ClustalW2 
(www.ebi.ac.uk/Tools/msa/clustalw2) and highlighted in grey if over 30 % sequence identity is observed. 
Protein sequences are indicated by their Uniprot accession number. 
1
 B6AAH7 has been identified as a 14-3-
3 ε isoform in Cryptosporidium (Brokx et al., 2011). 
Apicomplexan 
species 
Putative 
14-3-3 proteins 
Human isoforms 
ε (MSFL) 
(P62258) 
ζ (MSFS) 
(P63104) 
σ 
(P31947) 
η 
(Q04917) 
ϑ 
(P27348) 
γ 
(P61981) 
β 
(P31946) 
P. falciparum 
(str. 3D7) 
C0H4V6 60% 59% 52% 56% 56% 56% 57% 
C0H5K0 21% 22% 21% 20% 23% 21% 20% 
T. gondii 
(str. GT1) 
B9Q0N7 60% 60% 55% 55% 56% 57% 58% 
B9PHG0 44% 44% 43% 44% 44% 45% 46% 
B9PHN5 25% 21% 24% 22% 21% 24% 21% 
C. muris 
(str.RN66) 
B6AAH7 62%
1
 57% 55% 55% 55% 55% 58% 
B6AI61 23% 24% 23% 25% 27% 24% 25% 
B6AFS7 24% 23% 21% 24% 23% 24% 24% 
T. parva (str. Muguga) Q4N4N3 57% 58% 53% 55% 55% 56% 58% 
B. bovis (str.T2Bo) A7AUI2 55% 57% 52% 54% 55% 54% 56% 
N. caninum 
(str. Liverpool) 
F0VG50 60% 60% 55% 55% 56% 57% 58% 
F0VJK0 37% 38% 39% 38% 40% 38% 39% 
F0VLI4 18% 17% 16% 12% 17% 14% 17% 
F0VJH0 20% 22% 22% 20% 20% 21% 23% 
 
  AIP (also termed FKBP37 or ARA9) is a 38 kDa peptidyl-prolyl cis/trans isomerase which 
has abilities to interact with Hsp70 and therefore mediate the binding between preproteins and 
the mitochondrial receptor Tom20 (Yano et al., 2003). A putative AIP homologue was identified 
only in P. falciparum with 19 % sequence identity with its human homologue, but exhibiting 
asimilar domain architecture with a N-terminal peptidylprolyl cis-trans isomerase domain (or 
FKBD domain) followed by three tetratricopeptide repeats (TPR) motifs (Fig. 7.3). The putative P. 
falciparum AIP has been previously characterised as a 35 kDa FKBP family chaperone (referred as 
PfPKBP35) with rotamase and protein folding activities (Kumar et al., 2005; Monaghan and Bell, 
2005). It has been structurally demonstrated that TPR motifs of PfPKBP35 can be associated with 
the C-terminal pentapeptide of the P. falciparum cytosolic Hsp90 (PlasmoDB accession number 
PF07_0029) and may also interact with the cytosolic PfHsp70 (Pf08_0054) which emphases a 
possible involvement of PfPKB35 in the importation of precursors into mitochondria (Alag et al., 
2009; Kumar et al., 2005).  
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Figure 7.3. Schematic representation of domains contained in human AIP and putative homologues in 
plant and malaria parasite. The 42 kDa peptidyl-prolyl isomerase has been suggested to be a Arabidopsis 
thaliana homologue of AIP by displaying 27 % of sequence identities (45 % similarity) to the human AIP 
(Glaser and Whelan, 2007). Sequences used were AIP in Homo sapiens (Uniprot accession # O00170), a 
putative AIP in Arabidopsis thaliana (Q9LDC0) and Plasmodium falciparum PKBP35 (Q8I4V8). 
Tetratricopeptide repeat motifs indicated by red 'TPR' boxes were predicted with SMART (smart.embl.de). 
 
 The preprotein import can also be initiated through the presence of two ribosome-
associated factors, both identified in apicomplexans: the nascent-associated polypeptide complex 
(NAC) and the ribosome-associated complex (RAC) (Beddoe and Lithgow, 2002; Gautschi et al., 
2001; Wiedmann et al., 1994). NAC is a heterodimer protein while RAC is constituted by a DnaJ 
homologue and one of the cytosolic Hsp70s (Gautschi et al., 2002; Otto et al., 2005). Both 
complexes contact the ribosome near the tunnel exit and interact with the nascent polypeptide in 
order to control protein folding, preventing aggregation and degradation or initiating the 
importation to the mitochondrial compartment (Beddoe and Lithgow, 2002; Koplin et al., 2010; 
Wang et al., 1995). Further studies are necessary to clarify if a co-translational import exists in 
apicomplexa via mitochondrion-bound polysomes, as it has previously been observed in yeast 
(Marc et al., 2002). 
7.4.2. Mitochondrial outer membrane 
All imported proteins have to traffic through the Translocase of the Outer Membrane 
complex (TOM) (Fig. 7.4). Although TOM complex can be composed of six to seven subunits in 
fungi, animal or plant species, only the subunit Tom40 is conserved among all apicomplexans. 
Tom40, a β-barrel protein, is the central pore for translocation of proteins into the 
intermembrane space (Maćašev et al., 2004). The subunit Tom22 is, on the other hand, a receptor 
present at the surface of the mitochondria which recognizes presequence proteins through the 
binding of the positively charged surface of the amphipathic α-helices formed by the N-terminal 
signal (Maćašev et al., 2004). Except for T. gondii, apicomplexan parasites conserve a functional 
but truncated form of Tom22 (referred as Tom22') whereby the N-terminal cytosolic receptor 
domain is absent.  
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Figure 7.4. Schematic view of protein import routes in Plasmodium falciparum. Black dotted lines  indicate 
the new putative components (Tom7, Tim12 and Mdm38).  
  
 The receptor Tom70 promotes the recruitment of proteins owning hydrophobic internal 
targeting peptides. However, no fungi or mammalian Tom70 homologues with significant 
sequence similarities could be identified in apicomplexan genomes. Although also absent in 
plants, an alternative Tom70 has been detected in Arabidopsis thaliana, this 64 kDa mitochondrial 
outer membrane protein (mtOM64) displays high sequence homology with a chloroplast protein 
import receptor from Pisum sativum (the translocase of the outer chloroplast envelope 64 - 
toc64) (Chew et al., 2004; Qbadou et al., 2006). Located on the mitochondrial surface, mtOM64 
has proven to be rate-limiting for the import of a plant specific subunit of the mitochondrial ATP 
synthase, highlighting its possible role in the initial stages of the import process (Lister et al., 
2007). Furthermore, recently it has been speculated that the gene PFL2015w (PlasmoDB 
accession number)  could be a putative mitochondrial OM64 receptor in Plasmodium falciparum 
(Sheiner and Soldati-Favre, 2008). This 80 kDa protein possesses both mtOM64/toc64 features: 
three tetratricopeptide repeat (TPR) motifs on its C-terminal section and a short N-terminal 
transmembrane domain (Fig. 7.5) (Wu and Sha, 2006). The three predicted TPR motifs of the P. 
falciparum OM64 homologue (PfOM64) are located at a similar position than that of mtOM64 or 
toc64 TPR domains, which are exposed on the cytosolic part of the protein and may mediate the 
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association of chaperones affiliated preproteins (Young et al., 2003). Furthermore, PfOM64 has an 
N-terminal transmembrane domain essential to anchor the mitochondrial outer membrane. 
However, orthologues of the putative PfOM64 have not been detected in other apicomplexan 
species. T. gondii seems to be devoid of both Tom70 and Tom20 receptors. Therefore, a 
minimised TOM complex without conventional receptors may be possible in apicomplexan 
parasites unless highly divergent homologues or apicomplexa-specific receptors have not been 
yet identified.  
 
 
Figure 7.5. Schematic representation of domains contained in plant toc64, mtOM64 and putative 
homologue in P. falciparum. Sequences used were toc64 in Pisum sativum (Uniprot accession # Q9MUK5), 
mitochondrial OM64 in Arabidopsis thaliana (F4KCL7) and the putative Plasmodium falciparum OM64 
(Q8I510). Transmembrane helix indicated by green 'TM' boxes were predicted by using THMMH algorithm 
(www.cbs.dtu.dk/services/TMHMM). Tetratricopeptide repeat motifs indicated by red 'TPR' boxes were 
predicted with SMART (smart.embl.de). 
 
 Tom5, Tom6 and Tom7 constitute a set of small proteins associated with Tom40 and 
stimulating the formation of the mature TOM complex. Tom7 regulates the oligomeric assembly 
of the TOM complex nevertheless it  could not be identified in apicomplexan genomes due to low 
sequence conservation across species (Johnston et al., 2002). However, the amino acid motif 
aGax1Px5G (with "a" for aromatic residues) was identified as a conserved pattern within Tom7 
homologues and having an essential role in targeting the mitochondrial outer membrane (Allen et 
al., 2002; Johnston et al., 2002). Consequently, encoded proteins below the 10 kDa size range and 
displaying the Tom7 motif were searched in apicomplexa. An 8 kDa putative Tom7 gene was 
identified in the P. falciparum genome only, displaying the aGax1Px5G pattern and a single 
transmembrane domain for anchoring the lipid bilayer (Fig. 7.6). Tom7, together with Tom40 and 
Tom22, are the only three TOM components commonly found in earlier eukaryotes including 
protists (Dolezal et al., 2006) and may constitute the minimal functional translocon in malaria 
parasites. To date, no gene candidates for both Tom5 and Tom6 could be identified within the 
apicomplexan family which may lack all small Tom proteins or that may remain undetected 
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through conventional homology searching due to high divergence across species and absence of 
conserved motifs. 
 
A 
 
B 
 
Figure 7.6. (A) Amino acid alignment of putative Tom7 in Plasmodium species along with Tom7 identified 
in other species. The sequences were aligned with ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2). 
Residues are displayed with dark boxes for full conservation and grey boxes for strong similarities. In red is 
highlighted the Tom7 motif aGaxPxxxxxG conserved. (B) Transmembrane helix are indicated by green 'TM 
helix' boxes were predicted using THMMH algorithm (www.cbs.dtu.dk/services/TMHMM). The Tom7 
sequences used were from Homo sapiens (Uniprot accession # 9P0U1), Drosophila melanogaster (Q7K036), 
Saccharomyces cerevisiae (P53507), Chlamydomonas reinhardtii (A8IG88), Caenorhabditis elegans (P34660) 
and the Plasmodium falciparum candidate (GeneDB accession # PF3D7_0823700). 
 The outer membrane contains two types of anchored proteins, α-helical proteins and β-
barrel proteins, which use different ways of insertion. Along with the TOM complex, the 
additional Sorting and Assembly Machinery (SAM complex) are necessary for adequate import, 
folding and insertion into the outer membrane of β-barrel proteins such as porins or Tom40  
(Kozjak et al., 2003; Wiedemann et al., 2003). In the yeast model, β-barrel proteins are 
translocated through the TOM complex and transferred to a four subunits-SAM complex via small 
intermembrane space chaperones Tim9-Tim10 or Tim8-Tim13 (Hoppins and Nargang, 2004; 
Wiedemann et al., 2004). Only the core component Sam50 was identified among apicomplexan 
species (Dolezal et al., 2006), whereas other subunits of the complex such as Sam35, Sam37 and 
Mdm10 seem absent. With only a single subunit conserved the insertion of α-helical via the SAM 
complex remains to be clarified in apicomplexa. 
7.4.3. Mitochondrial intermembrane space 
 The mitochondrial intermembrane space (IMS) contains a variety of small proteins, less 
than 20 kDa, with characteristic cysteine-rich motifs Cx3C, Cx9C or Cx2C (Gabriel et al., 2007). The 
four "Tiny TIMs" members (Tim 8, Tim9, Tim10 and Tim13) are ~10 kDa homologous proteins 
conserving the cysteine-rich motif Cx3Cx11-16Cx3C (where x is not a cysteine) and assembled in two 
types of hexamers: Tim83-Tim103 and Tim93-Tim103. Both hexameric chaperones are involved in 
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protein transfer of carrier and β-barrel proteins through the IMS  previously released by the TOM 
complex and designated to the SAM and TIM22 complexes respectively (Curran et al., 2002; 
Hoppins and Nargang, 2004; Koehler et al., 1998b; Wiedemann et al., 2004). All Tiny TIMs 
members family have been previously identified in P. falciparum and T. gondii (Gentle et al., 2007; 
Sheiner and Soldati-Favre, 2008; van Dooren et al., 2006). A full set of Tiny Tims has also been 
identified in N. caninum but no Tim13 homologues could be found in C. muris, T. parva and B. 
bovis suggesting a unique functional small Tim complex. In accordance to these results, Tim9-
Tim10 complex has proven to be essential and the main IMS chaperone in yeast whereas Tim8-
Tim13 can be unnecessary in cell growth (Koehler et al., 1999).  
 Precursors of small intermembrane space proteins (IMS proteins) are translocated via the 
TOM complex in a reduced and unfolded conformation. In most of eukaryotes, the reducing and 
folding of IMS proteins through disulphide bond exchange are mediated by two components: the 
mitochondrial intermembrane space assembly protein Mia40 (Mitochondrial intermembrane 
space import and assembly protein 40) and the sulphydryl oxidase Erv1 (Essential for respiration 
and viability 1). In P. falciparum, a Erv1 homologue has been identified however, Mia40 seems to 
be lacking in the human malaria parasite (Senkevich et al., 2000). Although Erv1 orthologues were 
detected in other apicomplexans, no Mia40 homologues could be detected due to limitations in 
gene prediction or possibly due to these organisms using another model of cysteine-rich proteins 
folding. Inactivation of A. thaliana Mia40 does not affect the import and/or assembly of small Tim 
proteins into plant mitochondria while Erv1 plays an essential role (Carrie et al., 2010). 
Additionally, a Mia40-independent pathway has been suggested in Trypanosoma parasites where 
IMS proteins require only Erv1 for a disulphide bond exchange (Allen et al., 2008). This model can 
also be applied to apicomplexans (Fig. 7.7). Erv1 acts as a disulphide bonds carrier to the IMS 
proteins through the formation of a transient disulphide bond prior to its transfer. Erv1 oxidation 
is mediated by cytochrome c which generates the disulphide bond by transferring the electrons 
from Erv1 to O2 via the cytochrome c oxidase (complex IV) of the respiratory chain (Allen et al., 
2005). Cryptosporidium species lack the cytochrome c oxidase and it was then proposed that Erv1 
could be oxidised through the low-affinity physiological oxidant O2 that may be facilitated by an 
enzyme alternative oxidase (AOX) which promotes electron transfer to O2 (Allen et al., 2008). To 
transfer several disulphide bonds, Erv1 shuttle between the protein precursor and the source of 
oxidation until the mature form of the IMS protein is reached.  
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Figure 7.7. Mia40-independent oxidative folding of intermembrane space proteins in apicomplexan 
(adapted from(Allen et al., 2008). (1) The IMS protein is translocated across the outer membrane via the 
TOM complex. (2) Erv1 binds the IMS protein forming a transient disulphide bond (S-S). (3) Erv1 becomes 
reduced by transferring the disulphide bond to the unfolded IMS protein. (4) Erv1 is oxidised though its 
interaction with cytochrome c. Electrons are transferred from reduced cytochrome c to O2 via the 
cytochrome c oxidase (complex IV). An alternative pathway with the physiological oxidant O2 and 
generating ROS (H2O2) have been hypothesised if the cytochrome c-dependent respiration is absent. (5) To 
transfer several disulphide bonds, the previous cycle is repeated with a shuttle of Erv1 between the IMS 
precursor and cytochrome c (or O2) until the protein is entirely oxidized. 
 
7.4.4. Mitochondrial inner membrane 
 The inner membrane is the host of three different translocase complexes: (i) the TIM23 
complex which translocates inner membrane-sorted or matrix-targeted proteins with N-terminal 
presequences (coupled with the PAM machinery), (ii) the TIM22 complex inserting carrier proteins 
with internal targeting signals and (iii) Oxa1 that imports proteins synthesised in the 
mitochondrial matrix into the inner membrane (Fig. 7.4).  
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 Nearly all components of TIM23 complex and presequence translocase-associated motor 
(PAM) have clear homologues in apicomplexan species (van Dooren et al., 2006). Tim23, Tim50 
and Tim17 form the core of the complex (Tim23CORE) inserted in the inner membrane (Neupert 
and Herrmann, 2007). Furthermore, subunit Tim23 and its partner Tim17, form the translocation 
channel which transports α-helical presequence proteins across the inner membrane. The N-
terminal section of the yeast Tim23 has been demonstrated to bind the outer membrane to 
improve the protein import efficiency into the mitochondria (Donzeau et al., 2000). However, 
Tim23 in apicomplexans may lack the outer membrane anchoring function due to a deletion of 
the first 28 to 52 residues in comparison with its yeast homologue. Moreover, the leucine zipper 
motif 61Lx6Lx6L
83, a motif  identified only in yeast which facilitates a membrane potential-
dependent Tim23 dimer formation, is not conserved in apicomplexan species (Bauer et al., 1996). 
Tim50 plays a triple role by (i) acting as a receptor for the precursors destined to the inner 
membrane or the matrix, (ii) interacting with the trans domain of Tom22 to enhance the protein 
transfer between TOM and TIM23 complexes and (iii) regulating the channel opening and closing 
to avoid ions leaking through the inner membrane and reduction of the membrane potential ΔΨm 
(Maćašev et al., 2004; Meinecke et al., 2006; Yamamoto et al., 2002). Only the component Tim21 
is still not identified in apicomplexans, but its role of preproteins sorting switch to the matrix or 
the inner membrane, have been demonstrated to be non-essential (Mokranjac et al., 2005; 
Wiedemann et al., 2007). 
 When preproteins are destined to the mitochondrial matrix, a PAM motor is coupled to 
the TIM23 complex. Five essential components of the PAM machinery (mtHsp70, Pam18, Pam16, 
Tim44 and GrpE) have been annotated in P. falciparum genome (Brehelin et al., 2010; Slapeta and 
Keithly, 2004; van Dooren et al., 2006). Their orthologues in other apicomplexans were easily 
identified and revealed a complete PAM motor in every species. Tim44 interacts with the 
emerging preprotein from the Tim23 channel and recruits the mitochondrial Hsp70 (mtHsp70) 
which drives the polypeptide chain into the matrix, a mechanism which requiries ATP hydrolysis 
(Kang et al., 1990; Liu et al., 2003; Schneider et al., 1994b). The nucleotide exchange factor GrpE 
stimulates the release of ADP from mtHsp70 to promote a new cycle of ATP binding and continue 
the presequence protein translocation (Neupert and Herrmann, 2007; Schneider et al., 1996). 
Furthermore, two membrane-bound co-chaperones Pam18 and Pam16 regulate the activity of 
mtHsp70. As a J-protein family member, Pam18 stimulates the ATP hydrolysis from its partner 
mtHsp70 (Mokranjac et al., 2003; Truscott et al., 2003). Additionally, Pam16, a J-like protein, acts 
as an antagonist by binding Pam18 and regulating its stimulating function (Kozany et al., 2004; Li 
et al., 2004). The Pam17 component is involved in the association between TIM23 complex and 
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PAM motor (Hutu et al., 2008; van der Laan et al., 2005). Only identified in yeast and C. elegans, 
Pam17 could not be detected in apicomplexan species. 
 The TIM22 complex inserts carrier proteins with non-cleavable mitochondrial targeting 
signals into the inner membrane. The carrier import pathway in apicomplexan differs from other 
known models as it has only two crucial components Tim22 and Tim12 (Gentle et al., 2007; van 
Dooren et al., 2006). The absence of yeast-specific components Tim18 and Tim54 suggests a 
minimised complex, with the twin-pore translocase Tim22 as the central element, releasing 
precursors into the lipid membrane in a functional form (Koehler et al., 2000; Rehling et al., 2003; 
Sirrenberg et al., 1996). All apicomplexans seem to have acquired a supplementary Tim12-type 
protein due to a recent gene duplication event from a Tiny TIMs member (Gentle et al., 2007). 
Tim12 has a crucial role, as it establishes a membrane bound complex with Tim9-Tim10 at the 
surface of Tim22 which guides carrier proteins to the pore (Koehler et al., 1998a; Koehler et al., 
1999). 
 Oxa1 (also termed YidC in bacteria) facilitates the insertion into the inner membrane of 
mitochondrially coded membrane proteins and binds mitochondrial ribosomes to facilitate co-
translational protein translocation (Hell et al., 2001; Kohler et al., 2009). Although Trypanosoma 
and Leishmania species display two Oxa1 homologues, only one has been detected in 
apicomplexan parasites which can mediate the insertion of the three mitochondrial encoded 
proteins (Cox1, Cox3 and Cytb) (Schneider et al., 2008; van Dooren et al., 2006). Interestingly, 
Cryptosporidium lost Oxa1 most likely due to the lack of mitochondrial genome (Henriquez et al., 
2005). A Letm1-like protein, conserved across all apicomplexans, displays similarities with Letm1 
in human or yeast (termed Mdm38) (Fig. 7.8). Mdm38/Letm1 is a mitochondrial inner membrane 
receptor essential for respiratory chain biogenesis. Hereby Mdm38/Letm1 interacts with a large 
ribosomal subunit and therefore supporting the translation of mitochondrial proteins destined to 
the inner membrane (Lupo et al., 2011; Piao et al., 2009). A similar role can be speculated for the 
apicomplexan Letm1 through the promotion of the ribosomes recruitment near Oxa1 and 
supporting the translation of three mitochondrial-encoded ETC subunits. The yeast-specific 
component Mba1 which is known to cooperate with Oxa1 through  favouring protein translation, 
doesn't seem to have homologues in apicomplexa (Ott et al., 2006). 
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Figure 7.8. Schematic representation of domains contained in human Letm1, yeast Mdm38 and putative 
homologue in P. falciparum. Sequences used were LETM1 in Homo sapiens (Uniprot accession # O95202), 
Mdm38 in Saccharomyces cerevisiae (Q08179) and the putative Plasmodium falciparum Mdm38 (Q8I1R5). 
Transmembrane helixes indicated in green 'TM' boxes were predicted by using THMMH algorithm 
(www.cbs.dtu.dk/services/TMHMM). LETM1 domains indicated by blue boxes were predicted with InterPro 
(www.ebi.ac.uk/Tools/pfa/iprscan). P. falciparum mitochondrial transit peptide were predicted with PlasMit 
(gecco.org.chemie.uni-frankfurt.de/plasmit).The 'RBD' arrow indicates an essential ribosome binding site in 
yeast Mdm38 (Lupo et al., 2011). 
 
 
7.5. Mitochondrial processing and protein stability  
 In mitochondria, a proteolytic machinery participates in the processing and stability of the 
imported preproteins. Several proteases have been identified in apicomplexan species which can 
be categorised according to their location in either the matrix or inner membrane (Table 7.3). 
 
Table 7.3.  Components of the mitochondrial processing and stability machinery in apicomplexan species 
and comparison with fungi, mammalian and plant representatives. '•' indicates putative candidates. '■' 
indicates components demonstrated essential for yeast viability. Uniprot accession number of apicomplexan 
components are available in Appendix 4. 
 Protein Function Pf Tg Cm Tp Bb Nc  Sc Hs At 
Matrix 
processing 
MPP (α subunit) Cleaves N-terminal presequences of matrix and inner 
membrane proteins 
       ■   
MPP (β subunit)        ■   
MIP Cleaves octapeptide in MPP downstream • • • • • •     
Icp55 Cleaves a single amino acid in MPP downstream           
FCN (PreP/Cym1) Degrades presequence peptides           
mtHsp60 
Assist folding of matrix proteins 
          
Hsp10           
Inner  
membrane 
processing 
 
m-AAA Cleaves matrix peptides of matrix proteins  • • • • • •     
i-AAA Cleaves matrix peptides of inner membrane proteins • •  • • •     
Atp23            
Rom6 Cleaves transmembrane domain peptides     Ta       
Imp1 
 
• • • • • •     
Imp2           
Ta: Theileria annulata 
 
Chapter 7 
172 
 
7.5.1. Processing and stability of matrix preproteins 
 After their transfer into the matrix, most of the precursor proteins undergo a proteolytic 
cleavage of their N-terminal presequences by a mitochondrial processing peptidase (MPP) 
(reviewed in(Gakh et al., 2002). Composed of two subunits (α-MPP and β-MPP), the soluble 
heterodimer is highly conserved across species including apicomplexans (Table 7.3) (van Dooren 
et al., 2006). The apicomplexan MPP contains an inverted zinc-binding motif (Hx2EHx71-77E) located 
on its β subunit which constitutes the catalytic binding site (Gakh et al., 2002; Taylor et al., 2001). 
The cleavage site near an arginine has been analysed in several species and categorised in four 
classes: R-none motif (X↓X-(S/X)), R-2 motif (R-X↓X), R-3 motif (R-X-(Y/F/L)↓(S/A/X)) and R-10 
motif (R-X↓(F/L/I)-X2-(T/S/G)-X4↓X) (Gavel and von Heijne, 1990). Demonstrated to be essential 
for yeast viability, MPP cleaves matrix proteins entirely translocated and also preproteins in 
transit to the inner membrane (Fig. 7.9) (Gakh et al., 2002). 
 
Figure 7.9. Schematic view of processing for inner membrane and matrix proteins in Plasmodium 
falciparum. Black dotted lines indicate new putative components (MIP, Imp1, i-AAA and m-AAA).  
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 Following the MPP cleavage, two matrix proteases - the mitochondrial intermediate 
peptidase (MIP) and the yeast-specific Icp55 - have been shown to perform a second proteolytic 
event. MIP is a soluble monomeric metalloprotease known to cleave an octapeptide from the N-
terminal of proteins previously processed by MPP (reviewed in(Gakh et al., 2002). A yeast study 
(Chew et al., 1996) demonstrated that a deletion of MIP is not lethal but may cause a respiratory 
deficiency. Each apicomplexan genome contains a M3 family peptidase with the conserved zinc-
binding motif HEx2H essential to cleave N-termini. This cleavage is mainly performed at a R-3 
motif site (Isaya et al., 1994). This protease has been shown to be the most significant MIP 
homologue in apicomplexa, according to the HMM searching performed in this study using 
human or yeast MIP as templates. Additionally, transit peptide analysis of the putative P. 
falciparum MIP predicted its localisation in the mitochondria. Further localisation studies of the 
MIP homologue in apicomplexans could confirm its involvement in mitochondrial processing. 
Recently, the novel protease Icp55, which cleaves a single amino acid from an intermediate 
generated by MPP, has been identified in yeast but seems absent in mammalian plant or 
apicomplexan genomes (Naamati et al., 2009; Vogtle et al., 2009).   
 Once cleaved, mitochondrial presequences and free peptides may cause mitochondrial 
damages by penetrating the lipid bilayer and subsequently reducing membrane potential and 
uncouple respiration (Lu and Beavis, 1997; Nicolay et al., 1994; Roise et al., 1986). Thus, both  
peptide sequences are degraded within the mitochondria by the matrix protease Cym1 in yeast 
(known as PreP in human and plants) (Alikhani et al., 2011; Bhushan et al., 2003; Falkevall et al., 
2006; Kambacheld et al., 2005; Mzhavia et al., 1999; Stahl et al., 2002). No evident homologues of 
PreP/Cym1 aminopeptidases were identified in apicomplexan species. However, the P. falciparum 
falcilysin (FCN) has been speculated to be a possible substitute. FCN is a zinc metalloprotease 
member of the M16 family mainly involve in haemoglobin removal into the food vacuole through 
the degradation of 10-20 amino acid globin peptides (Eggleson et al., 1999; Goldberg, 2005). 
However, its localisation in mitochondria as well as in the apicoplast of the malaria parasite 
suggests an additional function, such as cleavage of targeting peptides in the P. falciparum 
mitochondrion (Ponpuak et al., 2007). It is important to mention that except for C. muris, all other 
apicomplexan parasites possess a FCN orthologue.  
 To reach their mature form, the folding process of matrix proteins can be spontaneous or 
assisted by two chaperones Hsp10 and Hsp60, early identified in human cells and rat liver 
(Hartman et al., 1992; Jindal et al., 1989). These chaperones are highly conserved across species 
and one Hsp10 and two Hsp60 homologues were found in apicomplexans. Their characterisation 
in P. falciparum revealed that only one Hsp60 is a mitochondrial resident (mtHsp60), the other 
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being affected to the apicoplast (apHsp60) (Sato et al., 2003; Sato and Wilson, 2004). PfHsp10 is 
only located in the mitochondrion, although its mammalian homologue can be found in other cell 
compartments (Sadacharan et al., 2001; Sato and Wilson, 2005). In mammals, Hsp60 forms a 
tetradecamer complex consisting of two ring barrels of seven subunits which form two defined 
cavities. If capped by a Hsp10 heptamer and associated with ATP, each cavity becomes a suitable 
environment for protein folding (Ranson et al., 1998; Rye et al., 1997). 
7.5.2. Inner membrane processing machinery 
 AAA proteases (ATPases Associated with diverse cellular Activities, also termed Ftsh 
peptidases) are ATP-dependent metalloproteases anchored to the inner membrane participating 
in assembly, proteolytic maturation and degradation of misfolded or unassembled mitochondrial 
membrane proteins (Langer, 2000). Found in fungi, mammals or plants, m-AAA and i-AAA are two 
oligomeric complexes exposing their catalytic centre in the matrix or the intermembrane space 
respectively. The m-AAA protease is a hetero- or homo-hexamer constituted of one or two 
different subunits (Yta12 and Yta10 in S. cerevisiae, Ftsh10 and Ftsh3 in A. thaliana) (Arlt et al., 
1996; Piechota et al., 2010). Only one component (Yme1) forms the i-AAA complex in yeast while 
two homologues have been found to constitute two independent i-AAA in plants (Ftsh4 and 
Ftsh11) (Leonhard et al., 1996; Urantowka et al., 2005).  In P. falciparum, three metalloproteases 
(PlasmoDB accession number PF11_0203, PFL1925w and PF14_0616), belonging to the M41 
family peptidase, have been identified and their domain analysis revealed certain m-AAA/i-AAA 
features: one or two transmembrane regions in their N-terminal followed by two domains, a P-
loop ATPase and a peptidase M41 (with a zinc-binding motif HEx2H in its active centre) (Fig. 7.10 
and 7.11) (Gangwar et al., 2009). The P. falciparum AAA isoform PF11_0203 displays a high 
sequence similarity with Yta10/Ftsh3 and Yta12/Ftsh10 indicating its probable involvement in an 
m-AAA complex. Two other malaria parasite isoforms show higher identities with subunits of the 
i-AAA complex in yeast (Yme1) or plants (Ftsh4/Ftsh11). Identification of apicomplexan 
orthologues showed that each parasite has two subunits to compose i-AAA complexes and only 
one to form a homo-oligomeric m-AAA structure, except for Cryptosporidium species with no 
putative i-AAA components found. 
 
Chapter 7 
175 
 
 
Figure 7.10. Schematic representation of domains contained in yeast, plant and putative P. falciparum m-
AAA. Sequences used were m-AAA in Saccharomyces cerevisiae (Uniprot accession # P40341 for Yta12; 
P39925 for Yta10), in Arabidopsis thaliana (Q84WU8 for Ftsh3; Q8VZI8 for Ftsh10) and putative Plasmodium 
falciparum m-AAA (Q8IIH1 and Q8I526). Transmembrane helix, AAA domain and Peptidase M41 indicated in 
green 'TM' boxes, orange 'AAA' boxes and blue 'Peptidase M41' respectively as predicted by Pfam 
(pfam.sanger.ac.uk).  
 
 
 
Figure 7.11. Schematic representation of domains contained in yeast, plant and putative P. falciparum i-
AAA. Sequences used were i-AAA in Saccharomyces cerevisiae (Uniprot accession # P32795  for Yme1), in 
Arabidopsis thaliana (O80983 for Ftsh4; Q9FGM0  for Ftsh11) and the putative Plasmodium falciparum m-
AAA (Q8IKI9). Transmembrane helix, AAA domain and Peptidase M41 indicated by green 'TM' boxes, orange 
'AAA' boxes and blue 'Peptidase M41' respectively were predicted by Pfam (pfam.sanger.ac.uk).  
 Rhomboid-like proteins are a family of integral membrane serine proteases which assist 
protein assembly by cleaving transmembrane domains of inserted proteins. First characterised in 
the Golgi apparatus of Drosophila melanogaster (Urban et al., 2001), it has been established that 
rhomboids are ubiquitous and were classified according to their cell compartment localisation 
(Koonin et al., 2003). The only rhomboid located in mitochondria (Pcp1 in yeast) in all 
apicomplexan parasites has been named as Rom6 (Dowse and Soldati, 2005; M. Santos et al., 
2012). Surprisingly, no Rom6 homologue has been found in Theileria parva despite its presence in 
Theileria annulata. Rom6 contains a putative catalytic dyad within their transmembrane domains 
indicating a proteolytic activity into the lipid bilayer (Lemberg et al., 2005). Located in the inner 
membrane, the yeast Pcp1 has been demonstrated to mediate a second cleavage of the 
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cytochrome c peroxidase Ccp1 and the dynamin-like GTPase Mgm1 while its mammalian 
homologue (PARL) is involved in processing of the mitochondrial protease Omi/HhtrA2 and kinase 
PINK1. (Esser et al., 2002; Herlan et al., 2003; Whitworth et al., 2008).  
 The mitochondrial inner membrane protease (IMP) is an hetero-oligomer composed of 
two catalytic subunits Imp1 and Imp2 (Schneider et al., 1994a). IMP cleaves the hydrophobic 
sorting signal from proteins which expose an active site in the IMS (Nunnari et al., 1993). Five 
mitochondrial proteins (Cox2, Cyb2, Mcr1, DIABLO and Gut2) are matured by Imp1 and only one 
by Imp2 (Cyc1) (Burri et al., 2005; Esser et al., 2004; Gasser et al., 1982; Haucke et al., 1997; 
Nunnari et al., 1993; Pratje et al., 1983). Both Imp subunits have a peptidase S26 domain and are 
classified in the type-I signal peptidase family of proteases which includes the bacterial signal 
peptidase I or the chloroplastic thylakoid processing peptidase (Dalbey, 1991). According to the 
bioinformatic search presented in this study, only one Imp1 homologue seems encoded in each 
apicomplexan genome. Furthermore, evolutionary analysis reveals that eukaryotic IMPs appear to 
be the nearest neighbour to the P. falciparum candidate (Wu et al., 2003). The presence of a 
single IMP subunit is not unusual, for example, Imp2 is the only component identified in the other 
protist Trypanosoma (Schneider et al., 2008).    
 Atp23 is a metalloprotease localized in the IMS which plays a unique role of processing 
and assisting the assembly of the subunit a (atp6) of the mitochondrial ATPase (Michon et al., 
1988; Zeng et al., 2007). To date, Atp23 has been identified in fungi, mammals and/or plants but 
remains unknown in protists including apicomplexa. Atp6 is an essential subunit of the 
mitochondrial ATP synthase Fo sector but it is still undetected in apicomplexan species 
(Balabaskaran Nina et al., 2011). 
7.6. Conclusion 
 As shown by the mode of action of atovaquone, the P. falciparum mitochondrion is a 
validated drug target as the mitochondrial protein import and processing machineries are 
expected to be indispensable for parasite survival. Throughout this chapter, an extensive 
evaluation of the current knowledge on the mitochondrial importation and processing in P. 
falciparum has been described.  To date, studies on mitochondrial protein import in apicomplexa 
has been rather limited to bioinformatic analysis (Sheiner and Soldati-Favre, 2008; van Dooren et 
al., 2006). Comparative genomics have therefore given crucial insights into the importation and 
processing mechanisms in apicomplexan mitochondria as availability of experimental studies are 
scarce.  
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 Although the mitochondrial protein import and processing is expected to be conserved 
among eukaryotes, the composition of those pathways is relatively heterogeneous between 
species (Eckers et al., 2012; Hewitt et al., 2011). In line with this, apicomplexan mitochondria 
display reduced machineries due to the lack of several components such as Tom20, Tom5, Tom6, 
Sam35, Mia40, Tim18, Tim54, etc. Thus, several major questions remain to be clarified, such as; 
how nuclear-encoded mitochondrial proteins are recognized without any TOM receptors in T. 
gondii? How the folding of IMS proteins can be functional without the essential component 
Mia40? How β-barrel proteins are recognized and incorporated into the outer membrane in the 
absence of Sam35? And how proteins can be embedded in the innner membrane without the 
receptor (Tim18) and assisting component (Tim54) of TIM22?  
 Future research studies should be directed towards finding missing components using 
novel bioinformatic algorithms as well as on the experimental study of the functionality of these 
restricted machineries. Subcellular localisation of components, in vivo protein import kinetics or 
the determination of essential genes by knockout analyses will aid to understand how 
apicomplexan parasites have adapted and minimized import and processing systems to perform 
an equivalent role to other more extensive pathways in mitochondria. 
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Chapter 8 
Concluding remarks and perspectives 
 This chapter presents the main findings of this thesis and their contribution to our 
understanding of processes of the Plasmodium electron transport chain, the mode of action of 
endoperoxide compounds and parasite resistance to atovaquone. Limitations of the studies are 
also presented and potential future research directions are explored. 
8.1. The Plasmodium complex II, a dehydrogenase which remains to be 
elucidated 
 In Chapters 3, the characterization of complex II components from P. falciparum was 
attempted towards understanding the observed catalytic properties measured in Chapter 4. This 
enzyme remains the only dehydrogenase of the electron transport chain which is neither clearly 
annotated nor well defined. Although the complex II has been established as a 
succinate:ubiquinol oxidoreductase (SQR) by previous studies, results in this thesis and recent 
new findings (Tanaka et al., 2012) argue that the enzyme could instead be a quinol:fumarate 
oxidoreductase (QFR). Indeed, the absence of SQR activity was demonstrated whereas a clear QFR 
activity inhibitable by malonate, a well known complex II inhibitor, was detected. Additionally, 
whereas most bacterial QFRs can use the low-potential menaquinone as an electron donor 
(Miyadera et al., 2003), the Plasmodium QFR has the unusual feature to have a single substrate 
with ubiquinone. This new insight into complex II activity is mainly due to a new type of enzymatic 
assay used. A direct measurement of dehydrogenase activity has been favoured instead of using 
linked assays which can be interfered with by nonspecific activities of competing enzymes able to 
reduce DCPIP or cytochrome c. However, direct measurement of quinone reduction may have a 
limit of detection when using free-cell parasite extract, which is rich in hemozoin, instead of clear 
mitochondrial enrichment. The possibility that dehydrogenase activities obtained could be 
underestimated should not be exclude and that SQR activity or menaquinone consumption could 
be below that limit of detection. Thus, the QFR identified may be reversible as observed in 
Escherichia coli or Wolinella succinogenes. Further work is required to examine the physiological 
role of this enzyme in the Plasmodium respiratory chain. It is crucial to understand why the 
Plasmodium complex II seems to favour fumarate respiration. The Plasmodium QFR could be part 
of an alternative metabolic pathway which remains yet to be determined. 
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 With a bioinformatic approach based on specific fingerprints, gene candidates were 
identified for subunits SdhC and SdhD, and ATP synthase subunits a and b. These putative 
candidates present all structural properties and motif patterns required to achieve particular 
subunit functions. However, gene candidates obtained in this study are different to those 
proposed by Mogi et al. who used a similar in silico method (Mogi and Kita, 2009). The type of 
fingerprints, their cutoffs and the motif patterns chosen explain why this approach found 
different candidate genes. In light of this divergence, a proteomic validation is essential to confirm 
those bioinformatic predictions. Although the development of a complex II antibody has been 
successful, the identification of both anchor subunits from P. falciparum extract failed despite 
using gradient or non-gradient 2D BNE-SDS-Page gels. By comparison, with a mitochondrial 
bovine 2D pattern, it could be speculated that complex II in malaria parasites has a similar size of 
approximately 130 kDa, confirming the presence of both membrane anchor subunits. While 2D 
BNE/SDS-Page followed by mass spectrometry enabled the complex II characterization in several 
species, this approach revealed itself as extremely complex with malaria parasites. The low-level 
expression of complex II in blood stages and the difficulties to prepare a clean extract of isolated 
mitochondria were both important limitations for the proteomic method. In future, subunit 
identification might be achieved by an optimization strategy such as an improvement of 
mitochondrial extraction to obtain a higher yield and purity and/or to work with sexual stage 
parasites where expression of ETC enzymes may be more important than in blood stages. The 
capture of the complex II by immunoprecipitation and identification of its subunits by mass 
spectrometry will be the best alternative proteomic method when a specific antibody able to bind 
the Plasmodium enzyme in native conditions is available. 
8.2.  A conventional ATP synthase but a limited oxidative phosphorylation? 
 A recent study confirmed that the Plasmodium ATP synthase should be conventionally 
assembled as a large dimeric complex (Balabaskaran Nina et al., 2011). As previously mentioned, 
potential gene candidates for the missing ATP synthase subunits a and b were identified. 
However, specific anti-ATPα antibody could not be generated and thus attempt to validate the 
bioinformatic predictions via the proteomic approach. Thereby, many questions regarding the F0 
section remain: characterization of subunits a and b, number of c-subunits composing the 
rotational ring, presence of additional subunits (e.g. subunits d or F6)? 
 Oxidative phosphorylation is likely essential for parasite survival and relies on the 
electrochemical gradient. As mentioned in Chapter 4, only complex III and IV pump protons across 
the mitochondrial inner membrane to generate the membrane potential. Under conditions of 
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active ATP synthesis, the H+/2 e- ratio is 2 and 4 for complex III and IV respectively. The lack of 
conventional complex I results in a loss of 3 protons translocated per NADH oxidised (2 e-) 
(Wikstrom and Hummer, 2012). The protonmotive complex I is a large and complex enzyme 
whose synthesis requires considerable cellular resources and is also a source of cell-damaging 
ROS. It can be speculated that the parasite is better off without it if its energetic demands can be 
met in other ways (e.g. the glycolysis pathway). 
 However, the replacement of complex I by non-protonmotive PfNDH2 has two possible 
consequences for Plasmodium oxidative phosphorylation. On one hand, the parasite ETC has to 
"work harder" to pump protons and generate an electrochemical gradient comparable to those 
observed in mammalian mitochondria possessing complex I. In that case, the respiratory chain 
tries to maximise the rate of ATP production. On the other hand, the protonmotive force may be 
lower in Plasmodium which has consequences for ATP synthesis. The difference in proton 
potential needed to maintain the ATP/ADP ratio required for parasite life is dependent on the 
number of protons translocated for each synthesized ATP molecule (termed H+/ATP ratio) 
(Steigmiller et al., 2008). A straightforward interpretation of rotational ATP synthesis predicts that 
the H+/ATP ratio coincides with the ratio of proton-binding subunits c to the three catalytic ADP-
binding β-subunits, implying that for mammalian ATP synthases (with 10 subunits c) an H+/ATP 
ratio of 3.3 is expected. If the protonmotive force is lower in Plasmodium parasites then the 
H+/ATP ratio should be higher and the ATPase might be expected to have more c-subunits. Having 
a low electrochemical proton potential, thermoalkaliphilic bacteria present a large oligomeric c 
ring and thus a high stoichiometry of protons per ATP synthesized (Meier et al., 2007). The 
phosphate/oxygen ratio (also called the P/O ratio), which refers to the amount of ATP produced 
from two electrons donated by reduction of an oxygen atom, is dependent on the amount of H+ 
pumped across the inner membrane and returned inward through the ATP synthase. Because the 
parasite produces plenty of ATP via the glycolysis pathway during the erythrocytic stage and does 
not need an optimal respiratory chain with respect to ATP synthesis, this P/O ratio could also be 
lower in Plasmodium. A limited rate of oxidative phosphorylation could not make significant 
contributions to the cytosolic energetic demands but could provide sufficient ATP for the local 
energy requirements of the mitochondrion. 
8.3.  ETC dehydrogenases: their contribution to the membrane potential 
 Although expression of dehydrogenases remains low in asexual stages, their basal 
activities are essential to maintain the electrochemical gradient across the inner membrane of the 
mitochondria. Data obtained suggests that PfNDH2 is the main electron provider to the bc1 
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complex whilst other dehydrogenases (i.e. DHODH, MQO and G3PDH) make minimal 
contributions in in vitro conditions. A similar experiment with cell-free extract from P. berghei 
parasites will confirm the situation in vivo. In absence of PfNDH2 or complex II, recent studies 
showed that the electrochemical gradient can be maintained by the contribution of the others 
(Boysen and Matuschewski, 2011; Hino et al., 2012). 
8.4. Possible strategies to inhibit the Plasmodium ETC 
 The development of atovaquone as an antimalarial drug validated the malaria parasite's 
mitochondrial electron transport chain (ETC) as an exploitable drug target. However, with the 
emergence of atovaquone resistance there is an urgent need for new antimalarial drugs with 
novel mechanisms of action. The differences between host and parasite mitochondria hold 
promising targets for development of malaria chemotherapy. Because the cytochrome bc1 
complex revealed itself as an excellent target, the development of a novel generation of 
quinolone inhibitors targeting the Qo site remains a realistic strategy (Fig. 8.1, strategy A). Thus, 
quinolone esters or acridinediones are new types of selective and potent inhibitors of the 
mitochondrial bc1 complex (Biagini et al., 2008; Cowley et al., 2012). The generation of inhibitors 
that are active against two key enzymes in the respiratory pathway - PfNDH2 and bc1 complex - is 
a recently developed multi-target approach (Biagini et al., 2012) (Fig. 8.1, strategy B). As 
mentioned previously, PfNDH2 may be considerate as the main drug target through which to 
block electron transfer upstream of bc1. This type of pharmacology should be an advantage both 
in potency across a wide range of malaria parasite strains and in protection against the rapid 
evolution of resistance. Specific inhibitors for both enzymes have been controlled by manipulation 
of the privileged quinolone core at the 2 or 3 position and displayed nanomolar activity against 
atovaquone-resistant P. falciparum parasites. 
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Figure 8.1. Chemotherapeutic strategies targeting the Plasmodium electron transport chain. The different 
enzymes targeted are indicated from strategy A to E. Yellow stars indicate enzymes which have been 
demonstrated to be essential for parasite development.  
 
 It is believed that in asexual parasites, one of the essential functions of the mitochondrion 
is to provide orotate for the biosynthesis of pyrimidine through the activity of dihydroorotate 
dehydrogenase (DHODH) (Fig. 8.1, strategy C). Thus, several studies have chosen to target the 
dihydroorotate dehydrogenase with novel inhibitors (Baldwin et al., 2005; Booker et al., 2010; 
Coteron et al., 2011; Phillips et al., 2008; Skerlj et al., 2011). Complex II and ATP synthase have 
been recently demonstrated to be essential for the sexual stage development suggesting that 
they could be new targets for transmission blocking (Balabaskaran Nina et al., 2011; Hino et al., 
2012) (Fig. 8.1, strategies D and E). However, the development of Plasmodium complex II 
inhibitors will only be conceivable if the 3D structure of its ubiquinone-binding site is distinct from 
its mammalian counterpart. In line with this, previous work revealed that the mammalian 
complex II inhibitor Atpenin A5 lost its potency against the parasitic complex II, indicating a 
possible divergence of their respective ubiquinol binding site (Kawahara et al., 2009). In the same 
manner, the parasitic ATPase activity is highly insensitive to well-known complex V inhibitors such 
as oligomycin and azide, suggesting the possibility of an alternative F0 structural section (Mather 
et al., 2010). In light of this divergence, further studies would be necessary to investigate the 
potential of Plasmodium complex II and V as therapeutic targets. 
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8.5. Global membrane depolarization via ROS generation: a new mode of 
action for artemisinins? 
 In Chapter 5, endoperoxide drugs are revealed to provoke a rapid collapse of both 
membrane potentials (and not only mitochondrial) essential for parasite survival. Addition of the 
iron chelator desferrioxamine or the superoxide scavenger Tiron drastically reduces the 
depolarization, highlighting the role of ferrous ions and oxidant stress in the artemisinins 
activation process and the membrane damaging activity. 
 Artemisinin-induced mitochondrial membrane depolarization has long been established 
as a possible cause of malaria parasite death (Li et al., 2005; Wang et al., 2010). In line with this, 
recent investigations confirm the initiation of human cell death by artesunate via mitochondrial 
membrane depolarization and ROS generation (Mercer et al., 2011). For Leishmania parasites, 
artemisinin has been demonstrated to cause induction of apoptosis associated with 
depolarization of the mitochondria (Sen et al., 2007).  Therefore, an alternative cytotoxic mode of 
action of endoperoxides has been suggested whereby mitochondrial dysfunction is triggered by a 
collapse of electrochemical gradient via reactive oxygen species. Data obtained supports the 
theory previously proposed but globalises it to all parasite membranes. Indeed, the plasma 
membrane depolarization observed adjusts this mode of action to the global parasite lipid 
bilayers. 
 Mitochondrial depolarization has already been suspected to cause parasite death via a 
loss of its essential functions (Biagini et al., 2008; Srivastava et al., 1997). Although the damage of 
the plasma membrane seems cytotoxic, the role and impact of its depolarization on parasite 
death remains to be clearly established. Interestingly, oxidative stress was suggested to disrupt 
the plasma membrane potential of the parasitic protozoon Giardia intestinalis leading to its death 
(Lloyd et al., 2000). In line with the proposal of a global membrane disturbance induced by 
endoperoxide compounds, morphological observations of the food vacuole in malaria parasite 
showed early damage of its membrane in presence of artemisinin, which is suspected to alkylate 
its components (enzymes and lipids) (Bousejra-El Garah et al., 2011; del Pilar Crespo et al., 2008). 
 Those findings contribute to the understanding of the molecular mechanism of action of 
these drugs. To date, artemisinin and its derivatives might have several modes of action by 
directly inhibiting or alkylating specific proteins (e.g. PfATPase6 or PfTCTP) and interfering with 
vital organelle functions (e.g. heme detoxification, mitochondrial and plasma membrane 
potentials) (Fig. 8.2) However, more studies are needed to clarify the contribution of these 
multiple targets to parasite killing depending on the artemisinin derivative, the Plasmodium 
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strain, and the parasite stage investigated. Recently, clinical isolates of malaria that possess a  
artemisinin-tolerant phenotype (delayed parasite clearance), but that are not resistant in vitro, 
have been reported. This alteration of artemisinin sensitivity has been associated with several 
genes (e.g. PfMdr1, PfCrt and PfATPase6) but the difficulty for the parasite in developing a strong 
resistance is compatible with the hypothesis that several pathways are targeted by that class of 
compound. It can be supposed that the "inhibition pathway" could be the most susceptible to 
emerging resistances due to point mutations interfering with the non-covalent binding of 
artemisinin to specific proteins. However, the increased capacity of protein turnover and protein 
synthesis might also contribute to artemisinin resistance by withstanding the loss of active 
proteins caused by oxidative stress and/or protein alkylation effects of these drugs. In future, it 
will be interesting to measure the endoperoxide effects on global membrane potential from 
artemisinin-resistant strains in order to detect whether that pathway could be also source of 
emerging resistances. 
 
 
Figure 8.2. Proposed biological modes of action for artemisinin (ART) and its endoperoxide derivatives. 
 
 With several potential mechanisms of action slowing down the development of truly 
resistant strains, artemisinin and its derivatives remain powerful antimalarial drugs for 
combination treatments against uncomplicated malaria and widespread drug-resistant malaria. 
8.6.  An atovaquone resistance causing bc1 instability and fitness penalty to 
the parasite 
In Chapter 6, the point mutation harboured by the atovaquone-resistant strain TM90C2B 
was shown to affect both catalytic bc1 turnover and substrate affinity, as well as atovaquone 
binding. Extensively studied in model organisms, the effect of this mutation has been analyzed in 
the parasite itself. Western blotting analysis indicated reduced levels of ISP protein in the 
TM90C2B strain compared to the bc1 wild type 3D7 strain, suggestive of a weakened interaction 
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between this subunit and cytochrome b. The reduced enzyme turnover and the significant 
reduction in ISP content in parasite bc1 carrying the Y268S mutation may result in a significant 
fitness cost (manifested as a slower growth rate) to the parasite. In line with this hypothesis, a 
fitness cost has been demonstrated for atovaquone-resistant K1 clones of P. falciparum 
containing the M133I/G280D double mutation within cytochrome b (Peters et al., 2002). 
However, analysis of the fold change in gene expression of the atovaquone-resistant strain 
TM90C2B compared with the atovaquone-sensitive 3D7 strain revealed some significant 
differences between the two strains (Fisher et al., 2012). An approximate 2-fold increase in 
expression of complex III and complex IV genes, including the ISP Rieske subunit, has been 
observed for the resistant strain. Thus, it is also hypothesized that the observed differential 
expression of these and other key genes may offset the fitness cost resulting from reduced bc1 
activity.  
8.7. The unusual protein import in Apicomplexan mitochondria 
In all eukaryotes, the biogenesis and proper functionality of the mitochondrion is 
dependent on the import and processing machinery for nuclear-encoded proteins. In 
apicomplexa, the limitation of the mitochondrial genome (only three genes encoded) highlights 
the importance of understanding the importation pathways and identification of all their 
components. Due to the complete sequencing of apicomplexan genomes, noticeable progress has 
been achieved toward the in silico identification of involved proteins. New putative components 
complete an apicomplexan map which exposes all main importation pathways known in yeast, 
animal or plant models. However, essential components such as Mia40 or Sam35 may be missing 
or not yet annotated due to limitations of homology searching. The absence of receptors Tom20 
and Tom70 is another major difference compared to other eukaryotes. Despite the identification 
of a plant mtOM64 homologue in P. falciparum that might play a similar role than Tom70, the 
mechanism of precursor detection at the mitochondrial surface remains unclear in apicomplexa. 
The total absence of receptors in Toxoplasma gondii may lead to the hypothesis of apicomplexan-
specific proteins able to detect presequences or internal sequences. The discovery of a putative 
Tom6 subunit by studying plant homologues demonstrates specific affinities with the A. thaliana 
model. Because apicomplexan parasites possess an apicoplast similar to chloroplast, they may 
have acquired plant-specific proteins. Additionally, some apicomplexan components display a 
clear diversification with eukaryotic homologues being truncated or with a greater amino acid 
length. 
The identification of apicomplexan-specific subunits and the characterization of unusual 
homologue components will need experimental validation. Newly identified mitochondrial 
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proteases highlight the importance of remodelling mitochondrial proteins. Most studies on 
mitochondrial import and processing have been done in a baker's yeast model but the coverage 
of its mitochondrial proteome is not yet complete. The possible identification of new fungal 
components in future might give answers to the apicomplexan model gaps. 
8.8. Future challenges for mitochondrial research in malaria 
Today, the key role of malaria parasite mitochondria as drug target has been recognized 
due to extensive studies. Indeed, impressive progresses in the understanding of physiological 
processes in Plasmodium mitochondria have been made. However, important challenges remain 
to be raised: 
(i) Define the exact composition of the respiratory chain. To date, the cataloguing of the 
ETC in Plasmodium species is still uncompleted. It is critical to know all subunits 
composing the respiratory chain for our understanding of the function and evolution of 
the ETC in general. For example, the functionality of the ATP synthase in blood stages of 
malaria parasites has been debated for decades only due to incapacity for annotating two 
membrane anchor subunits (Balabaskaran Nina et al., 2011). Direct purification and 
characterization of Plasmodium ETC complexes facilitates the discovery of lacking and 
novel subunits, providing a functional context for certain hypothetical proteins identified 
in proteomic or genomic studies like presented in this thesis. 
(ii) Study the essentiality of ETC enzymes in P. falciparum. To know if an enzyme is a 
“druggable” target, determine its impact on parasite survival is a key step. Recently, NDH2 
and Complex II have been determined essential in sexual stages of the rodent malaria 
parasite (Boysen and Matuschewski, 2011; Hino et al., 2012). However, this conclusion 
has to be confirmed in its human counterpart. Therefore, those genes and other coding 
for ETC enzymes should be disrupted in the human malaria parasite P. falciparum and 
phenotypes of the disruptant should be observed in experimental infections in 
mosquitoes in order to investigate their role in parasite death. 
(iii) Determine the presence of supercomplexes. In eukaryote mitochondria, the electron 
transport chain was shown to be organized in multiple supercomplexes (Schagger and 
Pfeiffer, 2000). For example, in yeast which lacks the conventional complex I as in malaria 
parasites, complex III exists as a free dimer or in supercomplexes with one or two complex 
IV monomers (Schagger and Pfeiffer, 2000). The main role of these supramolecular 
assemblies, called also “respirasomes”, is thought to enhance the electron transfer and 
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regulation of these complexes (Dudkina et al., 2010). Except ATP synthase which was 
found to exist as a dimer (Balabaskaran Nina et al., 2011), little is known about 
supercomplex assembly in Plasmodium species which deserves further investigations in 
future. For example, it will be interesting to know if the cytochome bc1 and cytochome c 
oxidase can operate as supercomplexes and if repercussions due to bc1 mutations may 
exist. Threshold-effect studies (Rossignol et al., 2003) or two dimensional gels coupled 
with LC-MS/MS analysis (Gomez et al., 2009; Wittig et al., 2006) can be attempted to 
demonstrate presence of mitochondrial supercomplexes in malaria parasites. 
(iv) Solve the crystal structure of ETC enzymes in Plasmodium. Only two structures of ETC 
enzymes in P. falciparum are currently available (DHODH and G3PDH). To help the 
development of new antimalarial drugs targeting the respiratory chain, determine the 
structure of ETC enzymes appears to be an important step. Indeed, co-crystallization 
structures of P. falciparum DHODH with different inhibitors provide a good starting point 
for structure-based development of more potent drugs (Davies et al., 2009). In the same 
manner, resolution of the crystal structure for the Plasmodium bc1, which rely only on the 
yeast model, and PfNDH2 will be helpful for their respective drug discovery programs. To 
date, attempts to crystalize a recombinant PfNDH2 failed (personal communication). 
Then, purification of those enzymes directly from parasites cell free extracts seems the 
best alternative even though this is particularly challenging as the Plasmodium parasite 
has only one mitochondrion. Therefore, the major obstacle is obviously the insufficient 
amount of starting materials which is required to start crystallisation of the protein. But, 
with time – maybe several years –, it should be possible to collect enough mitochondrial 
membrane for such a preparation. 
(v) Determine new drug targets in mitochondria. Because many mitochondrial functions are 
critical for parasite survival as well as several mitochondrial proteins are enough divergent 
from their host counterparts, this organelle presents great opportunities for finding 
antimalarial drug targets. For example, the TCA cycle in malaria parasites has been 
revealed to be drastically different from the tricarboxylic acid metabolism in human 
mitochondria. Several of the TCA enzymes such as the malate:quinone oxidoreductase 
(MQO), absent in human, or the fumarate hydratase call for detail investigations to 
determine their properties as drug targets.   
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8.9. Conclusion 
 Although the malaria parasites appear to minimise the mitochondrial contributions to 
their physiology, the mitochondrion is nevertheless essential for their survival and a valid drug 
target. A better knowledge of the electron transport chain and its biochemical processes help us 
to understand how the existing drugs affect the parasite, but also to develop new drugs to target 
the disease. The several new insights presented in this thesis are a step towards achieving these 
objectives. Future research remains to be done to clarify knowledge gaps on certain enzymes and 
their roles in the metabolic pathways. Much existing works about P. falciparum mitochondria 
have been focused on the asexual stages due to the simplicity to obtain in vitro parasites, but the 
characterisation of other stages is likely to be rewarding. An important challenge remains to be 
taken up to complete this fascinating mitochondrial puzzle and develop new therapeutic methods  
against  the parasite. 
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Appendix 1. List of the 19 peptides covering the first hit identifying the Escherichia coli SdhA subunit. 
Sequence Protein Accession Modifications Probability m/z [Da] RT (min) 
LGGNSLLDLVVFGR P0AC43  65.36 730.41675 59.74 
EFDAVVIGAGGAGmR P0AC43 M14(Oxidation) 39.52 733.36273 36.26 
ATVLATGGAGR P0AC43  61.10 487.27557 19.74 
IYQRPFGGQSK P0AC43  14.71 640.83844 19.57 
EFDAVVIGAGGAGmR P0AC43 M14(Oxidation) 44.59 733.35651 36.00 
VTGQALTVNEK P0AC43  66.79 580.31848 21.28 
ATVLATGGAGR P0AC43  17.92 487.27603 19.23 
VTGQALTVNEK P0AC43  52.56 580.32086 21.07 
NGEDPVAIR P0AC43  33.37 485.74869 23.02 
GEGGYLLNK P0AC43  21.23 475.75095 25.54 
NGEDPVAIR P0AC43  23.83 485.75299 23.05 
LPGILELSR P0AC43  47.10 499.30646 41.89 
NFGGEQAAR P0AC43  8.31 475.22754 16.42 
LPGILELSR P0AC43  5.95 499.30945 42.39 
LPGILELSR P0AC43  19.93 499.30502 41.37 
SImIEIR P0AC43 M3(Oxidation) 2.07 439.24533 31.42 
NGEDPVAIR P0AC43  1.00 485.71313 22.33 
SImIEIR P0AC43 M3(Oxidation) 1.00 438.75085 30.99 
HGERFMER P0AC43  1.00 531.81787 48.96 
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Appendix 2. List of the 28 peptides covering the first hit identifying the P. falciparum Rieske subunit. 
Sequence Protein Accession Modifications Probability m/z [Da] RT (min) 
YAHYNQTAEPVFPR PF14_0373  77.00 846.90662 35.53 
TDVWHNPKEPAIVSIGK PF14_0373  23.63 631.00323 39.12 
YAHYNQTAEPVFPR PF14_0373  66.08 846.91394 35.02 
YAHYNQTAEPVFPR PF14_0373  28.91 564.94244 35.44 
KVEDLSELVEPSNHPHQYEGIFAR PF14_0373  48.58 699.34778 45.88 
DLVAGGTTELDmR PF14_0373 M12(Oxidation) 49.36 697.33398 37.99 
NFRPAGYAENcPNPESINSDHHPDFR PF14_0373 C11(Carbamidomethyl) 34.67 761.08417 36.55 
VEDLSELVEPSNHPHQYEGIFAR PF14_0373  38.28 667.32233 48.60 
NLFDHAEDIK PF14_0373  15.67 601.29681 37.27 
YAHYNQTAEPVFPR PF14_0373  8.09 564.94183 34.94 
TVNPGEHVVIK PF14_0373  26.68 596.83911 27.25 
YAHYNQTAEPVFPR PF14_0373  6.55 564.94177 35.97 
IPPASEDPSYK PF14_0373  8.83 602.29718 29.21 
SVHFFWISK PF14_0373  35.86 575.80487 47.66 
IPPASEDPSYK PF14_0373  42.21 602.29767 28.15 
NLFDHAEDIK PF14_0373  9.80 601.29956 37.86 
IPPASEDPSYK PF14_0373  31.06 602.29675 28.47 
QGPAPSNLEVPPYEFVDENTIK PF14_0373  1.00 1222.60071 52.86 
IPPASEDPSYK PF14_0373  35.96 602.29352 29.25 
IPPASEDPSYK PF14_0373  45.13 602.29761 28.66 
TVNPGEHVVIK PF14_0373  18.48 596.83600 27.77 
TDVWHNPK PF14_0373  26.70 498.74945 24.56 
EPAIVSIGK PF14_0373  1.00 457.27197 35.48 
IPPASEDPSYK PF14_0373  7.61 602.30524 27.66 
IPPASEDPSYK PF14_0373  1.00 602.29346 29.77 
LWEIEEKQNVSHK PF14_0373  1.00 547.67804 68.43 
TIKPEWLVNIGIcTHLGcVPAQGGNYSGYFcPcHGSHYDNSGR PF14_0373 
C13(Carbamidomethyl) 
C18(Carbamidomethyl) 
C31(Carbamidomethyl) 
C33(Carbamidomethyl) 
1.35 1220.39294 69.83 
EPAIVSIGK PF14_0373  1.00 457.26715 34.97 
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Appendix 3.  Uniprot accession numbers of components of the mitochondrial importation machinery in 
different apicomplexan species (www.uniprot.org).  
 Protein 
Plasmodium 
falciparum 
(str.3D7) 
Toxoplasma 
Gondii 
(str. GT1/ME49/VEG) 
Cryptosporidium 
muris 
(str.RN66) 
Theileria 
parva 
(str. Muguga) 
Babesia 
bovis 
(str.T2Bo) 
Neospora 
Caninum 
(str. Liverpool) 
Cytosolic  
chaperones 
and factors 
cHsp70 Q8IB24 Q9TW75 (GT1) B6AE62 Q27031 Q9U545 F0VIP7 
Hsp90 Q8IC05 Q7Z1F7 (GT1) B6AIL0 P24724 Q9NDI2 F0VBM9 
MSF - - - - - - 
AIP Q8I4V8 - - - - - 
NAC C6KT55 B9QF62 (VEG) B6ACH0 Q4N187 A7APM3 F0VET4 
RAC (hDnaJ) Q8I5N9 B9QFN4 (VEG) B6AH49 Q4N2E7 A7AT73 F0VF74 
RAC (cHSP70) 
Q8I2X4 
Q8IB24 
C0H5H0 
PF3D7_08317001 
Q9U540 (GT1) 
Q9TW75 (GT1) 
B9PMT2 (GT1) 
B6AHN5 
B6AE62 
B6AJW6 
Q27031 
Q4N3K7 
Q4N8J2 
A7AP56 
Q9U545 
A7AWL8 
F0VN28 
F0VIP7 
F0VLQ7 
TOM 
Complex  
Tom40 C6KT11 B9PQE1 (GT1) B6AI18 Q4N6X4 A7AQ94 F0VPX2 
Tom22' Q8I3L8 - B6AD33 Q4N6K1 A7AMW2 F0VH87 
OM64 (Tom70) Q8I510 - - - - - 
Tom20 - - - - - - 
Tom7 Q8IB71 - - - - - 
Tom6 - - - - - - 
Tom5 - - - - - - 
SAM 
Complex 
Sam50 PF3D7_0608310
1
 B6KIE3 (ME49) B6AE29 Q4MYN3 A7AM13 F0VET2 
Sam37 - - - - -  
Sam35 - - - - - - 
Mdm10 - - - - - - 
Tiny TIMs 
Tim8 Q8I500 B6KNU2 (GT1) B6AJ50 Q4MYV5 A7AM86 F0V9J5 
Tim13 Q8ILN5 B9PG40 (GT1) - - - F0VIL7 
Tim9 Q8ID24 B9PGF1 (GT1) B6AEM1 Q4N7M1 A7AS04 F0VIC8 
Tim10 Q8I5W2 B9PZS6 (GT1) B6AAF8 Q4N7D5 A7ARS5 F0VL53 
IMS 
machinery 
Mia40 - - - - - - 
Erv1 Q8I242 B9PVQ6 (GT1) B6ACM3 Q4N5T5 A7AUU4 F0VBQ0 
Cytochrome c Q8IM53 B9PQQ9 - Q4N594 A7ANI1 F0VPL5 
TIM22 
complex 
Tim22 C6KTB0 B9PMH5 (GT1) B6AHV7 Q4MZU8 A7AVL2 F0VM00 
Tim12 Q8I472 B9PN09 (GT1) B6ACI9 Q4N242 A7ASU8 F0VLJ2 
Tim18 - - - - - - 
Tim54 - - - - - - 
TIM23 
Complex 
+ 
PAM 
motor 
Tim23 Q8IDE0 B9PZG4 (GT1) B6AD68 Q4N7T7 A7ASA5 F0VKW2 
Tim50 Q8IBI8 B9PSW6 (GT1) B6AC38 Q4N713 A7AQ81 F0VCQ3 
Tim21 - - - - - - 
Tim17 Q8ILB7 B9PK67 (GT1) B6AJQ7 Q4N769 A7ARK7 F0VN60 
Pam18 
(Tim14) 
Q8IBK8 B9PUI0 (GT1) B6ACF8 Q4N5D4 A7AP77 F0VFC7 
Pam16 
(Tim16) 
Q8I3X2 B9PRA9 (GT1) B6AAU5 Q4N488 A7AVW7 F0VR30 
Pam17 - - - - - - 
Tim44 Q8IIA9 B9PN05 (GT1) B6AG36 Q4N770 A7ARK8 F0VLJ6 
mHSP70 Q8II24 B9PRL0 (GT1) B6AIR7 Q4N486 A7AVW9 F0VRB1 
GrpE Q8IIB6 B9Q1G8 (GT1) B6ACF7 Q4N773 A7ARL1 F0VBE5 
OXA  
complex 
Oxa1 Q8IBB5 B9PK92 - Q4MZ94 A7AVL5 F0VN78 
Mdm38 Q8I1R5 B9PU05 B6A9N6 Q4N224 A7ATX9 F0VBN1 
Mba1 - - - - - - 
Ylh47 - - - - - - 
      1 
GeneDB accession number (www.genedb.org). 
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Appendix 4. Uniprot accession numbers of components of the mitochondrial processing machinery in 
different apicomplexan species (www.uniprot.org).  
 Protein 
Plasmodium 
falciparum 
(str.3D7) 
Toxoplasma 
Gondii 
(str. GT1) 
Cryptosporidium 
muris 
(str.RN66) 
Theileria 
parva 
(str. Muguga) 
Babesia 
bovis 
(str.T2Bo) 
Neospora 
Caninum 
(str. Liverpool) 
Matrix 
processing 
MPP (α subunit) Q8MTV4 B9PUJ6  B6AFN5 Q4N5S2 A7AN14 F0VFD9 
MPP (β subunit) Q8MTV6 B9PW21  B6ACH4 Q4N9G3 A7AV97 F0VKL8 
MIP Q8IDW2 B9PFS9  B6AH36 Q4N8F6 A7AMP2 F0VIX1 
Icp55 - - - - - - 
FCN Q9U7N7 B9PN15  - Q4N5N0 A7AU33 F0VLI5 
mtHsp60 Q8IJN9 B9PPQ1  B6AJJ0 Q4N3C1 A7AR66 F0VQU9 
Hsp10 Q8I5Q3 B6KCB9  B6AFS0 Q4N9C4 A7AWV1 F0VG09 
Inner  
membrane 
processing 
m-AAA Q8IIH1 B9PUJ9  B6AIA1 Q4N560 A7ANF2 F0VFE8 
i-AAA 
Q8IKI9 
Q8I526 
B9Q2U6  
B9PKW2 
- 
Q4N3I7 
Q4N6P8 
A7ASY6 
A7ASM0 
F0VQP5 
F0VGU4 
Atp23 - - - - - - 
Rom6 Q8IDP3 Q2PP52 B6ADY7 
Q4UH21 
(T. annulata) 
A7AWM4 F0VQ63 
Imp1 Q8IEA9 B9PH52  B6AEI4 Q4N750 A7AWS9 F0VJQ1 
Imp2 - - - - - - 
 
 
 
 
 
 
 
 
 
 
 
 194 
  
References 
Abrahamsen, M.S., Templeton, T.J., Enomoto, S., Abrahante, J.E., Zhu, G., Lancto, C.A., Deng, M., 
Liu, C., Widmer, G., Tzipori, S., et al. (2004). Complete genome sequence of the 
apicomplexan, Cryptosporidium parvum. Science 304, 441-445. 
Aggeler, R., Coons, J., Taylor, S.W., Ghosh, S.S., Garcia, J.J., Capaldi, R.A., and Marusich, M.F. 
(2002). A functionally active human F1F0 ATPase can be purified by immunocapture from 
heart tissue and fibroblast cell lines. Subunit structure and activity studies. J Biol Chem 
277, 33906-33912. 
Agnandji, S.T., Lell, B., Soulanoudjingar, S.S., Fernandes, J.F., Abossolo, B.P., Conzelmann, C., 
Methogo, B.G., Doucka, Y., Flamen, A., Mordmuller, B., et al. (2011). First results of phase 
3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365, 1863-1875. 
Aide, P., Dobaño, C., Sacarlal, J., Aponte, J.J., Mandomando, I., Guinovart, C., Bassat, Q., Renom, 
M., Puyol, L., Macete, E., et al. (2011). Four year immunogenicity of the RTS,S/AS02A 
malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29, 6059-6067. 
Aikawa, M. (1966). The fine structure of the erythrocytic stages of three avian malarial parasites, 
Plasmodium fallax, P. lophurae, and P. cathemerium. Am J Trop Med Hyg 15, 449-471. 
Aikawa, M., Hepler, P.K., Huff, C.G., and Sprinz, H. (1966). The feeding mechanism of avian 
malarial parasites. J Cell Biol 28, 355-373. 
Ajioka, J.W., Boothroyd, J.C., Brunk, B.P., Hehl, A., Hillier, L., Manger, I.D., Marra, M., Overton, 
G.C., Roos, D.S., Wan, K.L., et al. (1998). Gene discovery by EST sequencing in Toxoplasma 
gondii reveals sequences restricted to the Apicomplexa. Genome Res 8, 18-28. 
Alag, R., Bharatham, N., Dong, A., Hills, T., Harikishore, A., Widjaja, A.A., Shochat, S.G., Hui, R., and 
Yoon, H.S. (2009). Crystallographic structure of the tetratricopeptide repeat domain of 
Plasmodium falciparum FKBP35 and its molecular interaction with Hsp90 C-terminal 
pentapeptide. Protein Sci 18, 2115-2124. 
Alam, R., Hachiya, N., Sakaguchi, M., Kawabata, S., Iwanaga, S., Kitajima, M., Mihara, K., and 
Omura, T. (1994). cDNA cloning and characterization of mitochondrial import stimulation 
factor (MSF) purified from rat liver cytosol. J Biochem 116, 416-425. 
Aldritt, S.M., Joseph, J.T., and Wirth, D.F. (1989). Sequence identification of cytochrome b in 
Plasmodium gallinaceum. Mol Cell Biol 9, 3614-3620. 
Alikhani, N., Berglund, A.K., Engmann, T., Spanning, E., Vogtle, F.N., Pavlov, P., Meisinger, C., 
Langer, T., and Glaser, E. (2011). Targeting capacity and conservation of PreP homologues 
localization in mitochondria of different species. J Mol Biol 410, 400-410. 
Allen, J.W., Ferguson, S.J., and Ginger, M.L. (2008). Distinctive biochemistry in the trypanosome 
mitochondrial intermembrane space suggests a model for stepwise evolution of the MIA 
pathway for import of cysteine-rich proteins. FEBS Lett 582, 2817-2825. 
Allen, R., Egan, B., Gabriel, K., Beilharz, T., and Lithgow, T. (2002). A conserved proline residue is 
present in the transmembrane-spanning domain of Tom7 and other tail-anchored protein 
subunits of the TOM translocase. FEBS Lett 514, 347-350. 
Allen, R.J., and Kirk, K. (2004). The membrane potential of the intraerythrocytic malaria parasite 
Plasmodium falciparum. J Biol Chem 279, 11264-11272. 
Allen, S., Balabanidou, V., Sideris, D.P., Lisowsky, T., and Tokatlidis, K. (2005). Erv1 mediates the 
Mia40-dependent protein import pathway and provides a functional link to the 
respiratory chain by shuttling electrons to cytochrome c. J Mol Biol 353, 937-944. 
Alonso, P.L., Sacarlal, J., Aponte, J.J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, 
B., Guinovart, C., Espasa, M., et al. (2004). Efficacy of the RTS,S/AS02A vaccine against 
Plasmodium falciparum infection and disease in young African children: randomised 
controlled trial. The Lancet 364, 1411-1420. 
References 
195 
 
Alonso, P.L., Smith, T., Schellenberg, J.R., Masanja, H., Mwankusye, S., Urassa, H., Bastos de 
Azevedo, I., Chongela, J., Kobero, S., Menendez, C., et al. (1994). Randomised trial of 
efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern 
Tanzania. Lancet 344, 1175-1181. 
Alonso, P.L., Smith, T.A., Armstrong-Schellenberg, J.R., Kitua, A.Y., Masanja, H., Hayes, R., Hurt, N., 
Font, F., Menendez, C., Kilama, W.L., et al. (1996). Duration of protection and age-
dependence of the effects of the SPf66 malaria vaccine in African children exposed to 
intense transmission of Plasmodium falciparum. J Infect Dis 174, 367-372. 
Andriantsoanirina, V., Menard, D., Rabearimanana, S., Hubert, V., Bouchier, C., Tichit, M., Bras, 
J.L., and Durand, R. (2010). Association of microsatellite variations of Plasmodium 
falciparum Na+/H+ exchanger (Pfnhe-1) gene with reduced in vitro susceptibility to 
quinine: lack of confirmation in clinical isolates from Africa. Am J Trop Med Hyg 82, 782-
787. 
Angevine, C.M., Herold, K.A., Vincent, O.D., and Fillingame, R.H. (2007). Aqueous access pathways 
in ATP synthase subunit a. Reactivity of cysteine substituted into transmembrane helices 
1, 3, and 5. J Biol Chem 282, 9001-9007. 
Arakawa, T., Komesu, A., Otsuki, H., Sattabongkot, J., Udomsangpetch, R., Matsumoto, Y., Tsuji, 
N., Wu, Y., Torii, M., and Tsuboi, T. (2005). Nasal immunization with a malaria 
transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in 
mice against field isolates of Plasmodium falciparum. Infect Immun 73, 7375-7380. 
Arlt, H., Tauer, R., Feldmann, H., Neupert, W., and Langer, T. (1996). The YTA10-12 complex, an 
AAA protease with chaperone-like activity in the inner membrane of mitochondria. Cell 
85, 875-885. 
Arnold, I., Pfeiffer, K., Neupert, W., Stuart, R.A., and Schagger, H. (1998). Yeast mitochondrial 
F1F0-ATP synthase exists as a dimer: identification of three dimer-specific subunits. EMBO 
J 17, 7170-7178. 
Asawamahasakda, W., Ittarat, I., Pu, Y.M., Ziffer, H., and Meshnick, S.R. (1994). Reaction of 
antimalarial endoperoxides with specific parasite proteins. Antimicrob Agents Chemother 
38, 1854-1858. 
Atamna, H., and Ginsburg, H. (1993). Origin of reactive oxygen species in erythrocytes infected 
with Plasmodium falciparum. Mol Biochem Parasitol 61, 231-241. 
Balabaskaran Nina, P., Dudkina, N.V., Kane, L.A., van Eyk, J.E., Boekema, E.J., Mather, M.W., and 
Vaidya, A.B. (2010). Highly divergent mitochondrial ATP synthase complexes in 
Tetrahymena thermophila. PLoS Biol 8, e1000418. 
Balabaskaran Nina, P., Morrisey, J.M., Ganesan, S.M., Ke, H., Pershing, A.M., Mather, M.W., and 
Vaidya, A.B. (2011). ATP synthase complex of Plasmodium falciparum: dimeric assembly in 
mitochondrial membranes and resistance to genetic disruption. J Biol Chem 286, 41312-
41322. 
Baldwin, J., Michnoff, C.H., Malmquist, N.A., White, J., Roth, M.G., Rathod, P.K., and Phillips, M.A. 
(2005). High-throughput screening for potent and selective inhibitors of Plasmodium 
falciparum dihydroorotate dehydrogenase. J Biol Chem 280, 21847-21853. 
Bannister, L.H., Hopkins, J.M., Fowler, R.E., Krishna, S., and Mitchell, G.H. (2000). A brief 
illustrated guide to the ultrastructure of Plasmodium falciparum asexual blood stages. 
Parasitol Today 16, 427-433. 
Bannister, L.H., and Mitchell, G.H. (2009). The malaria merozoite, forty years on. Parasitology 136, 
1435-1444. 
Barham, H.M., Inglis, R., Chinje, E.C., and Stratford, I.J. (1996). Development and validation of a 
spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase 
in human tumour cells. Br J Cancer 74, 1188-1193. 
Barnwell, J.W., and Galinski, M.R. (1998). Invasion of vertebrate cells: erythrocytes. Malaria: 
Parasite Biology, Pathogenesis and Protection, ASM Press, Washington, DC, 93-120. 
References 
196 
 
Barton, V., Fisher, N., Biagini, G.A., Ward, S.A., and O'Neill, P.M. (2010). Inhibiting Plasmodium 
cytochrome bc1: a complex issue. Curr Opin Chem Biol 14, 440-446. 
Bauer, M.F., Sirrenberg, C., Neupert, W., and Brunner, M. (1996). Role of Tim23 as voltage sensor 
and presequence receptor in protein import into mitochondria. Cell 87, 33-41. 
Beck, H.P., Felger, I., Huber, W., Steiger, S., Smith, T., Weiss, N., Alonso, P., and Tanner, M. (1997). 
Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the 
phase III trial of the malaria vaccine SPf66. J Infect Dis 175, 921-926. 
Beddoe, T., and Lithgow, T. (2002). Delivery of nascent polypeptides to the mitochondrial surface. 
Biochim Biophys Acta 1592, 35-39. 
Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, 
J., Dubois, M.C., et al. (2008). Efficacy of RTS,S/AS01E vaccine against malaria in children 5 
to 17 months of age. N Engl J Med 359, 2521-2532. 
Bekker, M., Kramer, G., Hartog, A.F., Wagner, M.J., de Koster, C.G., Hellingwerf, K.J., and de 
Mattos, M.J. (2007). Changes in the redox state and composition of the quinone pool of 
Escherichia coli during aerobic batch-culture growth. Microbiology 153, 1974-1980. 
Bender, A., van Dooren, G.G., Ralph, S.A., McFadden, G.I., and Schneider, G. (2003). Properties 
and prediction of mitochondrial transit peptides from Plasmodium falciparum. Mol 
Biochem Parasitol 132, 59-66. 
Berman, P.A., and Adams, P.A. (1997). Artemisinin enhances heme-catalysed oxidation of lipid 
membranes. Free Radic Biol Med 22, 1283-1288. 
Berry, A., Senescau, A., Lelievre, J., Benoit-Vical, F., Fabre, R., Marchou, B., and Magnaval, J.F. 
(2006). Prevalence of Plasmodium falciparum cytochrome b gene mutations in isolates 
imported from Africa, and implications for atovaquone resistance. Trans R Soc Trop Med 
Hyg 100, 986-988. 
Bhisutthibhan, J., and Meshnick, S.R. (2001). Immunoprecipitation of [(3)H]dihydroartemisinin 
translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-
infected erythrocytes by using anti-TCTP antibodies. Antimicrob Agents Chemother 45, 
2397-2399. 
Bhisutthibhan, J., Pan, X.Q., Hossler, P.A., Walker, D.J., Yowell, C.A., Carlton, J., Dame, J.B., and 
Meshnick, S.R. (1998). The Plasmodium falciparum translationally controlled tumor 
protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem 273, 
16192-16198. 
Bhushan, S., Lefebvre, B., Stahl, A., Wright, S.J., Bruce, B.D., Boutry, M., and Glaser, E. (2003). Dual 
targeting and function of a protease in mitochondria and chloroplasts. EMBO Rep 4, 1073-
1078. 
Biagini, G.A., Fisher, N., Berry, N., Stocks, P.A., Meunier, B., Williams, D.P., Bonar-Law, R., Bray, 
P.G., Owen, A., O'Neill, P.M., et al. (2008). Acridinediones: Selective and Potent Inhibitors 
of the Malaria Parasite Mitochondrial bc1 Complex. Molecular Pharmacology 73, 1347-
1355. 
Biagini, G.A., Fisher, N., Shone, A.E., Mubaraki, M.A., Srivastava, A., Hill, A., Antoine, T., Warman, 
A.J., Davies, J., Pidathala, C., et al. (2012). Generation of quinolone antimalarials targeting 
the Plasmodium falciparum mitochondrial respiratory chain for the treatment and 
prophylaxis of malaria. Proc Natl Acad Sci U S A. 
Biagini, G.A., Pasini, E.M., Hughes, R., De Koning, H.P., Vial, H.J., O'Neill, P.M., Ward, S.A., and 
Bray, P.G. (2004). Characterization of the choline carrier of Plasmodium falciparum: a 
route for the selective delivery of novel antimalarial drugs. Blood 104, 3372-3377. 
Biagini, G.A., Viriyavejakul, P., O'Neill P, M., Bray, P.G., and Ward, S.A. (2006). Functional 
characterization and target validation of alternative complex I of Plasmodium falciparum 
mitochondria. Antimicrob Agents Chemother 50, 1841-1851. 
Bisetto, E., Picotti, P., Giorgio, V., Alverdi, V., Mavelli, I., and Lippe, G. (2008). Functional and 
stoichiometric analysis of subunit e in bovine heart mitochondrial F(0)F(1)ATP synthase. J 
Bioenerg Biomembr 40, 257-267. 
References 
197 
 
Bonday, Z.Q., Taketani, S., Gupta, P.D., and Padmanaban, G. (1997). Heme biosynthesis by the 
malarial parasite. Import of delta-aminolevulinate dehydrase from the host red cell. J Biol 
Chem 272, 21839-21846. 
Booker, M.L., Bastos, C.M., Kramer, M.L., Barker, R.H., Jr., Skerlj, R., Sidhu, A.B., Deng, X., Celatka, 
C., Cortese, J.F., Guerrero Bravo, J.E., et al. (2010). Novel inhibitors of Plasmodium 
falciparum dihydroorotate dehydrogenase with anti-malarial activity in the mouse model. 
J Biol Chem 285, 33054-33064. 
Bosia, A., Ghigo, D., Turrini, F., Nissani, E., Pescarmona, G.P., and Ginsburg, H. (1993). Kinetic 
characterization of Na+/H+ antiport of Plasmodium falciparum membrane. J Cell Physiol 
154, 527-534. 
Bousejra-El Garah, F., Wong, M.H., Amewu, R.K., Muangnoicharoen, S., Maggs, J.L., Stigliani, J.L., 
Park, B.K., Chadwick, J., Ward, S.A., and O'Neill, P.M. (2011). Comparison of the reactivity 
of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron 
salts, heme, and ferrous iron salts/phosphatidylcholine. J Med Chem 54, 6443-6455. 
Boyer, P.D. (1997). The ATP synthase--a splendid molecular machine. Annu Rev Biochem 66, 717-
749. 
Boysen, K.E., and Matuschewski, K. (2011). Arrested oocyst maturation in Plasmodium parasites 
lacking type II NADH:ubiquinone dehydrogenase. J Biol Chem 286, 32661-32671. 
Bozdech, Z., Llinas, M., Pulliam, B.L., Wong, E.D., Zhu, J., and DeRisi, J.L. (2003). The transcriptome 
of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 1, E5. 
Bradford, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254. 
Brasseur, G., Di Rago, J.P., Slonimski, P.P., and Lemesle-Meunier, D. (2001). Analysis of suppressor 
mutation reveals long distance interactions in the bc(1) complex of Saccharomyces 
cerevisiae. Biochim Biophys Acta 1506, 89-102. 
Brasseur, G., Lemesle-Meunier, D., Reinaud, F., and Meunier, B. (2004). QO site deficiency can be 
compensated by extragenic mutations in the hinge region of the iron-sulfur protein in the 
bc1 complex of Saccharomyces cerevisiae. J Biol Chem 279, 24203-24211. 
Bray, P.G., Mungthin, M., Hastings, I.M., Biagini, G.A., Saidu, D.K., Lakshmanan, V., Johnson, D.J., 
Hughes, R.H., Stocks, P.A., O'Neill, P.M., et al. (2006). PfCRT and the trans-vacuolar proton 
electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. 
Mol Microbiol 62, 238-251. 
Brayton, K.A., Lau, A.O., Herndon, D.R., Hannick, L., Kappmeyer, L.S., Berens, S.J., Bidwell, S.L., 
Brown, W.C., Crabtree, J., Fadrosh, D., et al. (2007). Genome sequence of Babesia bovis 
and comparative analysis of apicomplexan hemoprotozoa. PLoS Pathog 3, 1401-1413. 
Brehelin, L., Florent, I., Gascuel, O., and Marechal, E. (2010). Assessing functional annotation 
transfers with inter-species conserved coexpression: application to Plasmodium 
falciparum. BMC Genomics 11, 35. 
Briolant, S., Pelleau, S., Bogreau, H., Hovette, P., Zettor, A., Castello, J., Baret, E., Amalvict, R., 
Rogier, C., and Pradines, B. (2011). In vitro susceptibility to quinine and microsatellite 
variations of the Plasmodium falciparum Na+/H+ exchanger (Pfnhe-1) gene: the absence 
of association in clinical isolates from the Republic of Congo. Malar J 10, 37. 
Brix, J., Rudiger, S., Bukau, B., Schneider-Mergener, J., and Pfanner, N. (1999). Distribution of 
binding sequences for the mitochondrial import receptors Tom20, Tom22, and Tom70 in a 
presequence-carrying preprotein and a non-cleavable preprotein. J Biol Chem 274, 16522-
16530. 
Brokx, S.J., Wernimont, A.K., Dong, A., Wasney, G.A., Lin, Y.H., Lew, J., Vedadi, M., Lee, W.H., and 
Hui, R. (2011). Characterization of 14-3-3 proteins from Cryptosporidium parvum. PLoS 
One 6, e14827. 
Brosché, M., Overmyer, K., Wrzaczek, M., Kangasjärvi, J., and Kangasjärvi, S. (2010). Stress 
Signaling III: Reactive Oxygen Species (ROS) 
References 
198 
 
Abiotic Stress Adaptation in Plants. In, A. Pareek, S.K. Sopory, and H.J. Bohnert, eds. (Springer 
Netherlands), pp. 91-102. 
Brossi, A., Venugopalan, B., Dominguez Gerpe, L., Yeh, H.J., Flippen-Anderson, J.L., Buchs, P., Luo, 
X.D., Milhous, W., and Peters, W. (1988). Arteether, a new antimalarial drug: synthesis 
and antimalarial properties. J Med Chem 31, 645-650. 
Brown, M.C., Joaquim, T.R., Chambers, R., Onisk, D.V., Yin, F., Moriango, J.M., Xu, Y., Fancy, D.A., 
Crowgey, E.L., He, Y., et al. (2011). Impact of immunization technology and assay 
application on antibody performance--a systematic comparative evaluation. PLoS One 6, 
e28718. 
Burke, P.V., and Poyton, R.O. (1998). Structure/function of oxygen-regulated isoforms in 
cytochrome c oxidase. J Exp Biol 201, 1163-1175. 
Burri, L., Strahm, Y., Hawkins, C.J., Gentle, I.E., Puryer, M.A., Verhagen, A., Callus, B., Vaux, D., and 
Lithgow, T. (2005). Mature DIABLO/Smac is produced by the IMP protease complex on the 
mitochondrial inner membrane. Mol Biol Cell 16, 2926-2933. 
Bustamante, P.J., Woodruff, D.C., Oh, J., Keister, D.B., Muratova, O., and Williamson, K.C. (2000). 
Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, 
Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol 22, 373-380. 
Butler, A.R., Gilbert, B.C., Hulme, P., Irvine, L.R., Renton, L., and Whitwood, A.C. (1998). EPR 
evidence for the involvement of free radicals in the iron-catalysed decomposition of 
qinghaosu (artemisinin) and some derivatives; antimalarial action of some polycyclic 
endoperoxides. Free Radic Res 28, 471-476. 
Cai, X., Herschap, D., and Zhu, G. (2005). Functional characterization of an evolutionarily distinct 
phosphopantetheinyl transferase in the apicomplexan Cryptosporidium parvum. Eukaryot 
Cell 4, 1211-1220. 
Canfield, C.J., Pudney, M., and Gutteridge, W.E. (1995). Interactions of atovaquone with other 
antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80, 373-381. 
Capaldi, R.A., and Aggeler, R. (2002). Mechanism of the F(1)F(0)-type ATP synthase, a biological 
rotary motor. Trends Biochem Sci 27, 154-160. 
Carlton, J.M., Angiuoli, S.V., Suh, B.B., Kooij, T.W., Pertea, M., Silva, J.C., Ermolaeva, M.D., Allen, 
J.E., Selengut, J.D., Koo, H.L., et al. (2002). Genome sequence and comparative analysis of 
the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 419, 512-519. 
Carrie, C., Giraud, E., Duncan, O., Xu, L., Wang, Y., Huang, S., Clifton, R., Murcha, M., Filipovska, A., 
Rackham, O., et al. (2010). Conserved and novel functions for Arabidopsis thaliana MIA40 
in assembly of proteins in mitochondria and peroxisomes. J Biol Chem 285, 36138-36148. 
Carter, R., Mendis, K.N., Miller, L.H., Molineaux, L., and Saul, A. (2000). Malaria transmission-
blocking vaccines--how can their development be supported? Nat Med 6, 241-244. 
Cazelles, J., Robert, A., and Meunier, B. (2001). Alkylation of heme by artemisinin, an antimalarial 
drug. Comptes Rendus de l'Académie des Sciences - Series IIC - Chemistry 4, 85-89. 
Chacinska, A., Koehler, C.M., Milenkovic, D., Lithgow, T., and Pfanner, N. (2009). Importing 
mitochondrial proteins: machineries and mechanisms. Cell 138, 628-644. 
Charman, S.A., Arbe-Barnes, S., Bathurst, I.C., Brun, R., Campbell, M., Charman, W.N., Chiu, F.C., 
Chollet, J., Craft, J.C., Creek, D.J., et al. (2011). Synthetic ozonide drug candidate OZ439 
offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 
108, 4400-4405. 
Chavchich, M., Gerena, L., Peters, J., Chen, N., Cheng, Q., and Kyle, D.E. (2010). Role of pfmdr1 
amplification and expression in induction of resistance to artemisinin derivatives in 
Plasmodium falciparum. Antimicrob Agents Chemother 54, 2455-2464. 
Chen, J.J., and Yu, B.P. (1994). Alterations in mitochondrial membrane fluidity by lipid 
peroxidation products. Free Radic Biol Med 17, 411-418. 
Chen, P.Q., Li, G.Q., Guo, X.B., He, K.R., Fu, Y.X., Fu, L.C., and Song, Y.Z. (1994). The infectivity of 
gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med 
J (Engl) 107, 709-711. 
References 
199 
 
Cheng, Y., and Prusoff, W.H. (1973). Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochem Pharmacol 22, 3099-3108. 
Chew, A., Rollins, R.A., Sakati, W.R., and Isaya, G. (1996). Mutations in a putative zinc-binding 
domain inactivate the mitochondrial intermediate peptidase. Biochem Biophys Res 
Commun 226, 822-829. 
Chew, O., Lister, R., Qbadou, S., Heazlewood, J.L., Soll, J., Schleiff, E., Millar, A.H., and Whelan, J. 
(2004). A plant outer mitochondrial membrane protein with high amino acid sequence 
identity to a chloroplast protein import receptor. FEBS Lett 557, 109-114. 
Chinopoulos, C., Tretter, L., and Adam-Vizi, V. (1999). Depolarization of in situ mitochondria due 
to hydrogen peroxide-induced oxidative stress in nerve terminals: inhibition of alpha-
ketoglutarate dehydrogenase. J Neurochem 73, 220-228. 
Chiodini, P.L., Conlon, C.P., Hutchinson, D.B., Farquhar, J.A., Hall, A.P., Peto, T.E., Birley, H., and 
Warrell, D.A. (1995). Evaluation of atovaquone in the treatment of patients with 
uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 36, 1073-1078. 
Collins, M.D., and Jones, D. (1981). Distribution of isoprenoid quinone structural types in bacteria 
and their taxonomic implication. Microbiological Reviews 45, 316-354. 
Coteron, J.M., Marco, M., Esquivias, J., Deng, X., White, K.L., White, J., Koltun, M., El Mazouni, F., 
Kokkonda, S., Katneni, K., et al. (2011). Structure-guided lead optimization of 
triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum 
dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem 
54, 5540-5561. 
Covian, R., and Trumpower, B.L. (2006). Regulatory interactions between ubiquinol oxidation and 
ubiquinone reduction sites in the dimeric cytochrome bc1 complex. J Biol Chem 281, 
30925-30932. 
Cowley, R., Leung, S., Fisher, N., Al-Helal, M., Berry, N.G., Lawrenson, A.S., Sharma, R., Shone, A.E., 
Ward, S.A., Biagini, G.A., et al. (2012). The development of quinolone esters as novel 
antimalarial agents targeting the Plasmodium falciparum bc1 protein complex. 
MedChemComm 3, 39-44. 
Cowman, A.F., and Crabb, B.S. (2006). Invasion of red blood cells by malaria parasites. Cell 124, 
755-766. 
Cox, F.E. (2010). History of the discovery of the malaria parasites and their vectors. Parasit Vectors 
3, 5. 
Creek, D.J., Charman, W.N., Chiu, F.C., Prankerd, R.J., Dong, Y., Vennerstrom, J.L., and Charman, 
S.A. (2008). Relationship between antimalarial activity and heme alkylation for spiro- and 
dispiro-1,2,4-trioxolane antimalarials. Antimicrob Agents Chemother 52, 1291-1296. 
Crofts, A.R. (2004). The cytochrome bc1 complex: function in the context of structure. Annu Rev 
Physiol 66, 689-733. 
Crofts, A.R., Guergova-Kuras, M., Kuras, R., Ugulava, N., Li, J., and Hong, S. (2000). Proton-coupled 
electron transfer at the Q(o) site: what type of mechanism can account for the high 
activation barrier? Biochim Biophys Acta 1459, 456-466. 
Cross, R.M., Maignan, J.R., Mutka, T.S., Luong, L., Sargent, J., Kyle, D.E., and Manetsch, R. (2011). 
Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-
activity and structure-property relationships. J Med Chem 54, 4399-4426. 
Curran, S.P., Leuenberger, D., Schmidt, E., and Koehler, C.M. (2002). The role of the Tim8p-Tim13p 
complex in a conserved import pathway for mitochondrial polytopic inner membrane 
proteins. J Cell Biol 158, 1017-1027. 
Dahlstrom, S., Veiga, M.I., Martensson, A., Bjorkman, A., and Gil, J.P. (2009). Polymorphism in 
PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 
associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents 
Chemother 53, 2553-2556. 
Dalbey, R.E. (1991). Leader peptidase. Mol Microbiol 5, 2855-2860. 
References 
200 
 
David, K.P., Alifrangis, M., Salanti, A., Vestergaard, L.S., Ronn, A., and Bygbjerg, I.B. (2003). 
Atovaquone/proguanil resistance in Africa: a case report. Scand J Infect Dis 35, 897-898. 
Davies, M., Heikkila, T., McConkey, G.A., Fishwick, C.W., Parsons, M.R., and Johnson, A.P. (2009). 
Structure-based design, synthesis, and characterization of inhibitors of human and 
Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem 52, 2683-2693. 
de Souza, W. (2008). An introduction to the structural organization of parasitic protozoa. Curr 
Pharm Des 14, 822-838. 
Deckers-Hebestreit, G., Greie, J.-C., Stalz, W.-D., and Altendorf, K. (2000). The ATP synthase of 
Escherichia coli: structure and function of F0 subunits. Biochimica et Biophysica Acta 
(BBA) - Bioenergetics 1458, 364-373. 
del Pilar Crespo, M., Avery, T.D., Hanssen, E., Fox, E., Robinson, T.V., Valente, P., Taylor, D.K., and 
Tilley, L. (2008). Artemisinin and a series of novel endoperoxide antimalarials exert early 
effects on digestive vacuole morphology. Antimicrob Agents Chemother 52, 98-109. 
Deshaies, R.J., Koch, B.D., Werner-Washburne, M., Craig, E.A., and Schekman, R. (1988). A 
subfamily of stress proteins facilitates translocation of secretory and mitochondrial 
precursor polypeptides. Nature 332, 800-805. 
Devenish, R.J., Prescott, M., and Rodgers, A.J. (2008). The structure and function of mitochondrial 
F1F0-ATP synthases. Int Rev Cell Mol Biol 267, 1-58. 
Dickson, V.K., Silvester, J.A., Fearnley, I.M., Leslie, A.G., and Walker, J.E. (2006). On the structure 
of the stator of the mitochondrial ATP synthase. EMBO J 25, 2911-2918. 
Disbrow, G.L., Baege, A.C., Kierpiec, K.A., Yuan, H., Centeno, J.A., Thibodeaux, C.A., Hartmann, D., 
and Schlegel, R. (2005). Dihydroartemisinin is cytotoxic to papillomavirus-expressing 
epithelial cells in vitro and in vivo. Cancer Res 65, 10854-10861. 
Dolezal, P., Likic, V., Tachezy, J., and Lithgow, T. (2006). Evolution of the molecular machines for 
protein import into mitochondria. Science 313, 314-318. 
Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., Lwin, K.M., Ariey, F., 
Hanpithakpong, W., Lee, S.J., et al. (2009). Artemisinin resistance in Plasmodium 
falciparum malaria. N Engl J Med 361, 455-467. 
Donzeau, M., Kaldi, K., Adam, A., Paschen, S., Wanner, G., Guiard, B., Bauer, M.F., Neupert, W., 
and Brunner, M. (2000). Tim23 links the inner and outer mitochondrial membranes. Cell 
101, 401-412. 
Dorn, A., Stoffel, R., Matile, H., Bubendorf, A., and Ridley, R.G. (1995). Malarial haemozoin/beta-
haematin supports haem polymerization in the absence of protein. Nature 374, 269-271. 
Dowse, T.J., and Soldati, D. (2005). Rhomboid-like proteins in Apicomplexa: phylogeny and 
nomenclature. Trends Parasitol 21, 254-258. 
Duchen, M.R., and Biscoe, T.J. (1992). Relative mitochondrial membrane potential and [Ca2+]i in 
type I cells isolated from the rabbit carotid body. J Physiol 450, 33-61. 
Dudkina, N.V., Kouril, R., Peters, K., Braun, H.P., and Boekema, E.J. (2010). Structure and function 
of mitochondrial supercomplexes. Biochim Biophys Acta 1797, 664-670. 
Eastman, R.T., and Fidock, D.A. (2009). Artemisinin-based combination therapies: a vital tool in 
efforts to eliminate malaria. Nat Rev Microbiol 7, 864-874. 
Eckers, E., Cyrklaff, M., Simpson, L., and Deponte, M. (2012). Mitochondrial protein import 
pathways are functionally conserved among eukaryotes despite compositional diversity of 
the import machineries. Biol Chem 393, 513-524. 
Eckstein-Ludwig, U., Webb, R.J., Van Goethem, I.D., East, J.M., Lee, A.G., Kimura, M., O'Neill, P.M., 
Bray, P.G., Ward, S.A., and Krishna, S. (2003). Artemisinins target the SERCA of 
Plasmodium falciparum. Nature 424, 957-961. 
Edgar, D., Shabalina, I., Camara, Y., Wredenberg, A., Calvaruso, M.A., Nijtmans, L., Nedergaard, J., 
Cannon, B., Larsson, N.G., and Trifunovic, A. (2009). Random point mutations with major 
effects on protein-coding genes are the driving force behind premature aging in mtDNA 
mutator mice. Cell Metab 10, 131-138. 
References 
201 
 
Egan, B., Beilharz, T., George, R., Isenmann, S., Gratzer, S., Wattenberg, B., and Lithgow, T. (1999). 
Targeting of tail-anchored proteins to yeast mitochondria in vivo. FEBS Lett 451, 243-248. 
Eggleson, K.K., Duffin, K.L., and Goldberg, D.E. (1999). Identification and characterization of 
falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria 
parasite Plasmodium falciparum. J Biol Chem 274, 32411-32417. 
Ekland, E.H., and Fidock, D.A. (2008). In vitro evaluations of antimalarial drugs and their relevance 
to clinical outcomes. Int J Parasitol 38, 743-747. 
Ekvall, H. (2003). Malaria and anemia. Curr Opin Hematol 10, 108-114. 
Ellis, D.S., Li, Z.L., Gu, H.M., Peters, W., Robinson, B.L., Tovey, G., and Warhurst, D.C. (1985). The 
chemotherapy of rodent malaria, XXXIX. Ultrastructural changes following treatment with 
artemisinine of Plasmodium berghei infection in mice, with observations of the 
localization of [3H]-dihydroartemisinine in P. falciparum in vitro. Ann Trop Med Parasitol 
79, 367-374. 
Esseiva, A.C., Naguleswaran, A., Hemphill, A., and Schneider, A. (2004). Mitochondrial tRNA 
import in Toxoplasma gondii. J Biol Chem 279, 42363-42368. 
Esser, K., Jan, P.S., Pratje, E., and Michaelis, G. (2004). The mitochondrial IMP peptidase of yeast: 
functional analysis of domains and identification of Gut2 as a new natural substrate. Mol 
Genet Genomics 271, 616-626. 
Esser, K., Tursun, B., Ingenhoven, M., Michaelis, G., and Pratje, E. (2002). A novel two-step 
mechanism for removal of a mitochondrial signal sequence involves the mAAA complex 
and the putative rhomboid protease Pcp1. J Mol Biol 323, 835-843. 
Eubel, H., Jansch, L., and Braun, H.P. (2003). New insights into the respiratory chain of plant 
mitochondria. Supercomplexes and a unique composition of complex II. Plant Physiol 133, 
274-286. 
Falkevall, A., Alikhani, N., Bhushan, S., Pavlov, P.F., Busch, K., Johnson, K.A., Eneqvist, T., 
Tjernberg, L., Ankarcrona, M., and Glaser, E. (2006). Degradation of the amyloid beta-
protein by the novel mitochondrial peptidasome, PreP. J Biol Chem 281, 29096-29104. 
Farkas, D.L., Wei, M.D., Febbroriello, P., Carson, J.H., and Loew, L.M. (1989). Simultaneous 
imaging of cell and mitochondrial membrane potentials. Biophys J 56, 1053-1069. 
Farnert, A., Lindberg, J., Gil, P., Swedberg, G., Berqvist, Y., Thapar, M.M., Lindegardh, N., Berezcky, 
S., and Bjorkman, A. (2003). Evidence of Plasmodium falciparum malaria resistant to 
atovaquone and proguanil hydrochloride: case reports. BMJ 326, 628-629. 
Feagin, J. (2000). Mitochondrial genome diversity in parasites. International Journal for 
Parasitology 30, 371-390. 
Feagin, J.E. (1992). The 6-kb element of Plasmodium falciparum encodes mitochondrial 
cytochrome genes. Mol Biochem Parasitol 52, 145-148. 
Feagin, J.E., and Drew, M.E. (1995). Plasmodium falciparum: alterations in organelle transcript 
abundance during the erythrocytic cycle. Exp Parasitol 80, 430-440. 
Feagin, J.E., Mericle, B.L., Werner, E., and Morris, M. (1997). Identification of additional rRNA 
fragments encoded by the Plasmodium falciparum 6 kb element. Nucleic Acids Res 25, 
438-446. 
Feagin, J.E., Werner, E., Gardner, M.J., Williamson, D.H., and Wilson, R.J. (1992). Homologies 
between the contiguous and fragmented rRNAs of the two Plasmodium falciparum 
extrachromosomal DNAs are limited to core sequences. Nucleic Acids Res 20, 879-887. 
Feng, Y., Li, W., Li, J., Wang, J., Ge, J., Xu, D., Liu, Y., Wu, K., Zeng, Q., Wu, J.W., et al. (2012). 
Structural insight into the type-II mitochondrial NADH dehydrogenases. Nature 491, 478-
482. 
Fidock, D.A., Nomura, T., Talley, A.K., Cooper, R.A., Dzekunov, S.M., Ferdig, M.T., Ursos, L.M., 
Sidhu, A.B., Naude, B., Deitsch, K.W., et al. (2000). Mutations in the P. falciparum digestive 
vacuole transmembrane protein PfCRT and evidence for their role in chloroquine 
resistance. Mol Cell 6, 861-871. 
References 
202 
 
Finn, R.D., Clements, J., and Eddy, S.R. (2011). HMMER web server: interactive sequence similarity 
searching. Nucleic Acids Res 39, W29-37. 
Fisher, N., Abd Majid, R., Antoine, T., Al-Helal, M., Warman, A.J., Johnson, D.J., Lawrenson, A.S., 
Ranson, H., O'Neill, P.M., Ward, S.A., et al. (2012). Cytochrome b mutation Y268S 
conferring the atovaquone resistance phenotype in the malaria parasite results in reduced 
parasite bc1 catalytic turnover and protein expression. J Biol Chem. 
Fisher, N., Bourges, I., Hill, P., Brasseur, G., and Meunier, B. (2004a). Disruption of the interaction 
between the Rieske iron-sulfur protein and cytochrome b in the yeast bc1 complex owing 
to a human disease-associated mutation within cytochrome b. Eur J Biochem 271, 1292-
1298. 
Fisher, N., Bray, P.G., Ward, S.A., and Biagini, G.A. (2007). The malaria parasite type II 
NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. Trends 
Parasitol 23, 305-310. 
Fisher, N., Castleden, C.K., Bourges, I., Brasseur, G., Dujardin, G., and Meunier, B. (2004b). Human 
disease-related mutations in cytochrome b studied in yeast. J Biol Chem 279, 12951-
12958. 
Fisher, N., and Meunier, B. (2005). Re-examination of inhibitor resistance conferred by Qo-site 
mutations in cytochrome b using yeast as a model system. Pest Manag Sci 61, 973-978. 
Fisher, N., and Meunier, B. (2008). Molecular basis of resistance to cytochrome bc1 inhibitors. 
FEMS Yeast Res 8, 183-192. 
Fisher, N., Warman, A.J., Ward, S.A., and Biagini, G.A. (2009). Chapter 17 Type II NADH: quinone 
oxidoreductases of Plasmodium falciparum and Mycobacterium tuberculosis kinetic and 
high-throughput assays. Methods Enzymol 456, 303-320. 
Fitch, C.D. (2004). Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline 
drugs. Life Sci 74, 1957-1972. 
Fivelman, Q.L., Butcher, G.A., Adagu, I.S., Warhurst, D.C., and Pasvol, G. (2002). Malarone 
treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate 
from Lagos, Nigeria. Malar J 1, 1. 
Fivelman, Q.L., McRobert, L., Sharp, S., Taylor, C.J., Saeed, M., Swales, C.A., Sutherland, C.J., and 
Baker, D.A. (2007). Improved synchronous production of Plasmodium falciparum 
gametocytes in vitro. Molecular and Biochemical Parasitology 154, 119-123. 
Foote, S.J., Thompson, J.K., Cowman, A.F., and Kemp, D.J. (1989). Amplification of the multidrug 
resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 57, 921-930. 
Foth, B.J., Stimmler, L.M., Handman, E., Crabb, B.S., Hodder, A.N., and McFadden, G.I. (2005). The 
malaria parasite Plasmodium falciparum has only one pyruvate dehydrogenase complex, 
which is located in the apicoplast. Mol Microbiol 55, 39-53. 
Francis, S.E., Sullivan, D.J., Jr., and Goldberg, D.E. (1997). Hemoglobin metabolism in the malaria 
parasite Plasmodium falciparum. Annu Rev Microbiol 51, 97-123. 
Freeman, B.C., Myers, M.P., Schumacher, R., and Morimoto, R.I. (1995). Identification of a 
regulatory motif in Hsp70 that affects ATPase activity, substrate binding and interaction 
with HDJ-1. EMBO J 14, 2281-2292. 
Friesen, J., Borrmann, S., and Matuschewski, K. (2011). Induction of antimalaria immunity by 
pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite 
resistance. Antimicrob Agents Chemother 55, 2760-2767. 
Fry, M., and Beesley, J.E. (1991). Mitochondria of mammalian Plasmodium spp. Parasitology 102 
Pt 1, 17-26. 
Fry, M., and Pudney, M. (1992). Site of action of the antimalarial hydroxynaphthoquinone, 2-
[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem 
Pharmacol 43, 1545-1553. 
Fry, M., Webb, E., and Pudney, M. (1990). Effect of mitochondrial inhibitors on 
adenosinetriphosphate levels in Plasmodium falciparum. Comp Biochem Physiol B 96, 
775-782. 
References 
203 
 
Gabriel, K., Milenkovic, D., Chacinska, A., Muller, J., Guiard, B., Pfanner, N., and Meisinger, C. 
(2007). Novel mitochondrial intermembrane space proteins as substrates of the MIA 
import pathway. J Mol Biol 365, 612-620. 
Gakh, O., Cavadini, P., and Isaya, G. (2002). Mitochondrial processing peptidases. Biochim Biophys 
Acta 1592, 63-77. 
Gangwar, D., Kalita, M.K., Gupta, D., Chauhan, V.S., and Mohmmed, A. (2009). A systematic 
classification of Plasmodium falciparum P-loop NTPases: structural and functional 
correlation. Malar J 8, 69. 
Garah, F.B., Stigliani, J.L., Cosledan, F., Meunier, B., and Robert, A. (2009). Docking studies of 
structurally diverse antimalarial drugs targeting PfATP6: no correlation between in silico 
binding affinity and in vitro antimalarial activity. ChemMedChem 4, 1469-1479. 
Gardner, H.W. (1989). Oxygen radical chemistry of polyunsaturated fatty acids. Free Radic Biol 
Med 7, 65-86. 
Gardner, M.J., Bishop, R., Shah, T., de Villiers, E.P., Carlton, J.M., Hall, N., Ren, Q., Paulsen, I.T., 
Pain, A., Berriman, M., et al. (2005). Genome sequence of Theileria parva, a bovine 
pathogen that transforms lymphocytes. Science 309, 134-137. 
Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A., 
Nelson, K.E., Bowman, S., et al. (2002). Genome sequence of the human malaria parasite 
Plasmodium falciparum. Nature 419, 498-511. 
Gasser, S.M., Ohashi, A., Daum, G., Bohni, P.C., Gibson, J., Reid, G.A., Yonetani, T., and Schatz, G. 
(1982). Imported mitochondrial proteins cytochrome b2 and cytochrome c1 are processed 
in two steps. Proc Natl Acad Sci U S A 79, 267-271. 
Gautschi, M., Lilie, H., Funfschilling, U., Mun, A., Ross, S., Lithgow, T., Rucknagel, P., and Rospert, 
S. (2001). RAC, a stable ribosome-associated complex in yeast formed by the DnaK-DnaJ 
homologs Ssz1p and zuotin. Proc Natl Acad Sci U S A 98, 3762-3767. 
Gautschi, M., Mun, A., Ross, S., and Rospert, S. (2002). A functional chaperone triad on the yeast 
ribosome. Proc Natl Acad Sci U S A 99, 4209-4214. 
Gavel, Y., and von Heijne, G. (1990). Cleavage-site motifs in mitochondrial targeting peptides. 
Protein Eng 4, 33-37. 
Gazarini, M.L., and Garcia, C.R. (2004). The malaria parasite mitochondrion senses cytosolic Ca2+ 
fluctuations. Biochem Biophys Res Commun 321, 138-144. 
Gentle, I.E., Perry, A.J., Alcock, F.H., Likic, V.A., Dolezal, P., Ng, E.T., Purcell, A.W., McConnville, M., 
Naderer, T., Chanez, A.L., et al. (2007). Conserved motifs reveal details of ancestry and 
structure in the small TIM chaperones of the mitochondrial intermembrane space. Mol 
Biol Evol 24, 1149-1160. 
Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R.F., Saul, A., Rare, L., Baisor, M., Lorry, K., 
Brown, G.V., et al. (2002). A recombinant blood-stage malaria vaccine reduces 
Plasmodium falciparum density and exerts selective pressure on parasite populations in a 
phase 1-2b trial in Papua New Guinea. J Infect Dis 185, 820-827. 
Ginger, M.L. (2006). Niche metabolism in parasitic protozoa. Philos Trans R Soc Lond B Biol Sci 
361, 101-118. 
Girard, M.P., Reed, Z.H., Friede, M., and Kieny, M.P. (2007). A review of human vaccine research 
and development: malaria. Vaccine 25, 1567-1580. 
Glaser, E., and Whelan, J. (2007). Import of Nuclear-Encoded Mitochondrial Proteins. In Annual 
Plant Reviews Volume 31: Plant Mitochondria (John Wiley & Sons, Inc.), pp. 97-140. 
Goldberg, D.E. (2005). Hemoglobin degradation. Curr Top Microbiol Immunol 295, 275-291. 
Golenser, J., Domb, A., Leshem, B., Kremsner, P., and Luty, A. (2003). Iron chelators as drugs 
against malaria pose a potential risk. Redox Rep 8, 268-271. 
Golenser, J., Waknine, J.H., Krugliak, M., Hunt, N.H., and Grau, G.E. (2006). Current perspectives 
on the mechanism of action of artemisinins. Int J Parasitol 36, 1427-1441. 
References 
204 
 
Gomez, L.A., Monette, J.S., Chavez, J.D., Maier, C.S., and Hagen, T.M. (2009). Supercomplexes of 
the mitochondrial electron transport chain decline in the aging rat heart. Arch Biochem 
Biophys 490, 30-35. 
Gosoniu, L., Vounatsou, P., Tami, A., Nathan, R., Grundmann, H., and Lengeler, C. (2008). Spatial 
effects of mosquito bednets on child mortality. BMC Public Health 8, 356. 
Graham, S.M., Molyneux, E.M., Walsh, A.L., Cheesbrough, J.S., Molyneux, M.E., and Hart, C.A. 
(2000). Nontyphoidal Salmonella infections of children in tropical Africa. Pediatr Infect Dis 
J 19, 1189-1196. 
Grassi, G. (1900). Studi di uno Zoologo Sulla Malaria. 
Gravitz, L. (2012). Vector control: The last bite. Nature 484, S26-S27. 
Gray, M.W., Lang, B.F., and Burger, G. (2004). Mitochondria of protists. Annu Rev Genet 38, 477-
524. 
Greenstock, C.L., and Miller, R.W. (1975). The oxidation of tiron by superoxide anion. Kinetics of 
the reaction in aqueous solution in chloroplasts. Biochim Biophys Acta 396, 11-16. 
Greenwood, B.M., Fidock, D.A., Kyle, D.E., Kappe, S.H., Alonso, P.L., Collins, F.H., and Duffy, P.E. 
(2008). Malaria: progress, perils, and prospects for eradication. J Clin Invest 118, 1266-
1276. 
Gregson, A., and Plowe, C.V. (2005). Mechanisms of Resistance of Malaria Parasites to Antifolates. 
Pharmacological Reviews 57, 117-145. 
Gu, H.M., Warhurst, D.C., and Peters, W. (1984). Uptake of [3H] dihydroartemisinine by 
erythrocytes infected with Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg 78, 
265-270. 
Guest, J.R. (1981). Partial replacement of succinate dehydrogenase function by phage- and 
plasmid-specified fumarate reductase in Escherichia coli. J Gen Microbiol 122, 171-179. 
Gujjar, R., El Mazouni, F., White, K.L., White, J., Creason, S., Shackleford, D.M., Deng, X., Charman, 
W.N., Bathurst, I., Burrows, J., et al. (2011). Lead optimization of aryl and aralkyl amine-
based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate 
dehydrogenase with antimalarial activity in mice. J Med Chem 54, 3935-3949. 
Gutman, J., Kachur, S.P., Slutsker, L., Nzila, A., and Mutabingwa, T. (2012). Combination of 
probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in 
pregnancy. Malar J 11, 39. 
Gutteridge, J.M., and Bannister, J.V. (1986). Copper + zinc and manganese superoxide dismutases 
inhibit deoxyribose degradation by the superoxide-driven Fenton reaction at two different 
stages. Implications for the redox states of copper and manganese. Biochem J 234, 225-
228. 
Gutteridge, W.E., Dave, D., and Richards, W.H. (1979). Conversion of dihydroorotate to orotate in 
parasitic protozoa. Biochim Biophys Acta 582, 390-401. 
Hachiya, N., Alam, R., Sakasegawa, Y., Sakaguchi, M., Mihara, K., and Omura, T. (1993). A 
mitochondrial import factor purified from rat liver cytosol is an ATP-dependent 
conformational modulator for precursor proteins. EMBO J 12, 1579-1586. 
Hachiya, N., Komiya, T., Alam, R., Iwahashi, J., Sakaguchi, M., Omura, T., and Mihara, K. (1994). 
MSF, a novel cytoplasmic chaperone which functions in precursor targeting to 
mitochondria. EMBO J 13, 5146-5154. 
Hagerhall, C. (1997). Succinate: quinone oxidoreductases. Variations on a conserved theme. 
Biochim Biophys Acta 1320, 107-141. 
Hammond, D.J., Burchell, J.R., and Pudney, M. (1985). Inhibition of pyrimidine biosynthesis de 
novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone 
in vitro. Mol Biochem Parasitol 14, 97-109. 
Hanssen, E., McMillan, P.J., and Tilley, L. (2010). Cellular architecture of Plasmodium falciparum-
infected erythrocytes. Int J Parasitol 40, 1127-1135. 
Hartgers, F.C., and Yazdanbakhsh, M. (2006). Co-infection of helminths and malaria: modulation 
of the immune responses to malaria. Parasite Immunol 28, 497-506. 
References 
205 
 
Hartman, D.J., Hoogenraad, N.J., Condron, R., and Hoj, P.B. (1992). Identification of a mammalian 
10-kDa heat shock protein, a mitochondrial chaperonin 10 homologue essential for 
assisted folding of trimeric ornithine transcarbamoylase in vitro. Proc Natl Acad Sci U S A 
89, 3394-3398. 
Hartwig, C.L., Rosenthal, A.S., D'Angelo, J., Griffin, C.E., Posner, G.H., and Cooper, R.A. (2009). 
Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium 
falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol 77, 322-
336. 
Hatch, L.P., Cox, G.B., and Howitt, S.M. (1995). The essential arginine residue at position 210 in 
the alpha subunit of the Escherichia coli ATP synthase can be transferred to position 252 
with partial retention of activity. J Biol Chem 270, 29407-29412. 
Haucke, V., Ocana, C.S., Honlinger, A., Tokatlidis, K., Pfanner, N., and Schatz, G. (1997). Analysis of 
the sorting signals directing NADH-cytochrome b5 reductase to two locations within yeast 
mitochondria. Mol Cell Biol 17, 4024-4032. 
Hawking, F., Wilson, M.E., and Gammage, K. (1971). Evidence for cyclic development and short-
lived maturity in the gametocytes of Plasmodium falciparum. Transactions of the Royal 
Society of Tropical Medicine and Hygiene 65, 549-559. 
Hay, S.I., Guerra, C.A., Gething, P.W., Patil, A.P., Tatem, A.J., Noor, A.M., Kabaria, C.W., Manh, 
B.H., Elyazar, I.R., Brooker, S., et al. (2009). A world malaria map: Plasmodium falciparum 
endemicity in 2007. PLoS Med 6, e1000048. 
Hayashi, M., Yamada, H., Mitamura, T., Horii, T., Yamamoto, A., and Moriyama, Y. (2000). 
Vacuolar H(+)-ATPase localized in plasma membranes of malaria parasite cells, 
Plasmodium falciparum, is involved in regional acidification of parasitized erythrocytes. J 
Biol Chem 275, 34353-34358. 
Haynes, R.K., Chan, W.C., Lung, C.M., Uhlemann, A.C., Eckstein, U., Taramelli, D., Parapini, S., 
Monti, D., and Krishna, S. (2007). The Fe2+-mediated decomposition, PfATP6 binding, and 
antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-
centered radicals as bioactive intermediates. ChemMedChem 2, 1480-1497. 
Haynes, R.K., Chan, W.C., Wong, H.N., Li, K.Y., Wu, W.K., Fan, K.M., Sung, H.H., Williams, I.D., 
Prosperi, D., Melato, S., et al. (2010). Facile oxidation of leucomethylene blue and 
dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial 
mechanism of action. ChemMedChem 5, 1282-1299. 
Haynes, R.K., Ho, W.Y., Chan, H.W., Fugmann, B., Stetter, J., Croft, S.L., Vivas, L., Peters, W., and 
Robinson, B.L. (2004). Highly antimalaria-active artemisinin derivatives: biological activity 
does not correlate with chemical reactivity. Angew Chem Int Ed Engl 43, 1381-1385. 
Haynes, R.K., and Krishna, S. (2004). Artemisinins: activities and actions. Microbes and Infection 6, 
1339-1346. 
Haynes, R.K., Monti, D., Taramelli, D., Basilico, N., Parapini, S., and Olliaro, P. (2003). Artemisinin 
antimalarials do not inhibit hemozoin formation. Antimicrob Agents Chemother 47, 1175. 
Haynes, R.K., Pai, H.H.-O., and Voerste, A. (1999). Ring opening of artemisinin (qinghaosu) and 
dihydroartemisinin and interception of the open hydroperoxides with Formation of N-
oxides — a chemical model for antimalarial mode of action. Tetrahedron Letters 40, 4715-
4718. 
Heinemeyer, J., Braun, H.P., Boekema, E.J., and Kouril, R. (2007). A structural model of the 
cytochrome C reductase/oxidase supercomplex from yeast mitochondria. J Biol Chem 282, 
12240-12248. 
Hell, K., Neupert, W., and Stuart, R.A. (2001). Oxa1p acts as a general membrane insertion 
machinery for proteins encoded by mitochondrial DNA. EMBO J 20, 1281-1288. 
Henriquez, F.L., Richards, T.A., Roberts, F., McLeod, R., and Roberts, C.W. (2005). The unusual 
mitochondrial compartment of Cryptosporidium parvum. Trends Parasitol 21, 68-74. 
Henry, M., Briolant, S., Zettor, A., Pelleau, S., Baragatti, M., Baret, E., Mosnier, J., Amalvict, R., 
Fusai, T., Rogier, C., et al. (2009). Plasmodium falciparum Na+/H+ exchanger 1 transporter 
References 
206 
 
is involved in reduced susceptibility to quinine. Antimicrob Agents Chemother 53, 1926-
1930. 
Herlan, M., Vogel, F., Bornhovd, C., Neupert, W., and Reichert, A.S. (2003). Processing of Mgm1 by 
the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial 
morphology and of mitochondrial DNA. J Biol Chem 278, 27781-27788. 
Hermsen, C.C., Verhage, D.F., Telgt, D.S., Teelen, K., Bousema, J.T., Roestenberg, M., Bolad, A., 
Berzins, K., Corradin, G., Leroy, O., et al. (2007). Glutamate-rich protein (GLURP) induces 
antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria 
vaccine trial. Vaccine 25, 2930-2940. 
Hewitt, V., Alcock, F., and Lithgow, T. (2011). Minor modifications and major adaptations: the 
evolution of molecular machines driving mitochondrial protein import. Biochim Biophys 
Acta 1808, 947-954. 
Hikosaka, K., Watanabe, Y., Kobayashi, F., Waki, S., Kita, K., and Tanabe, K. (2011). Highly 
conserved gene arrangement of the mitochondrial genomes of 23 Plasmodium species. 
Parasitol Int 60, 175-180. 
Hino, A., Hirai, M., Tanaka, T.Q., Watanabe, Y.I., Matsuoka, H., and Kita, K. (2012). Critical roles of 
the mitochondrial complex II in oocyst formation of rodent malaria parasite Plasmodium 
berghei. J Biochem. 
Hisaeda, H., Stowers, A.W., Tsuboi, T., Collins, W.E., Sattabongkot, J.S., Suwanabun, N., Torii, M., 
and Kaslow, D.C. (2000). Antibodies to malaria vaccine candidates Pvs25 and Pvs28 
completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68, 
6618-6623. 
Hofmann, K. (2000). Sensitive protein comparisons with profiles and hidden Markov models. Brief 
Bioinform 1, 167-178. 
Hoppins, S.C., and Nargang, F.E. (2004). The Tim8-Tim13 complex of Neurospora crassa functions 
in the assembly of proteins into both mitochondrial membranes. J Biol Chem 279, 12396-
12405. 
Horsefield, R., Iwata, S., and Byrne, B. (2004). Complex II from a structural perspective. Curr 
Protein Pept Sci 5, 107-118. 
Horsefield, R., Yankovskaya, V., Sexton, G., Whittingham, W., Shiomi, K., Omura, S., Byrne, B., 
Cecchini, G., and Iwata, S. (2006). Structural and computational analysis of the quinone-
binding site of complex II (succinate-ubiquinone oxidoreductase): a mechanism of 
electron transfer and proton conduction during ubiquinone reduction. J Biol Chem 281, 
7309-7316. 
Horwich, A.L., Kalousek, F., Mellman, I., and Rosenberg, L.E. (1985). A leader peptide is sufficient 
to direct mitochondrial import of a chimeric protein. EMBO J 4, 1129-1135. 
Howells, R.E. (1970). Cytochrome oxidase activity in a normal and some drug-resistant strains of 
Plasmodium berghei--a cytochemical study. II. Sporogonic stages of a drug-sensitive srain. 
Ann Trop Med Parasitol 64, 223-225. 
Howells, R.E., Peters, W., and Fullard, J. (1969). Cytochrome oxidase activity in a normal and some 
drug-resistant strains of Plasmodium berghei--a cytochemical study. I. Asexual 
erythrocytic stages. Mil Med 134, 893-915. 
Huang, L.-s., Sun, G., Cobessi, D., Wang, A.C., Shen, J.T., Tung, E.Y., Anderson, V.E., and Berry, E.A. 
(2006). 3-Nitropropionic Acid Is a Suicide Inhibitor of Mitochondrial Respiration That, 
upon Oxidation by Complex II, Forms a Covalent Adduct with a Catalytic Base Arginine in 
the Active Site of the Enzyme. Journal of Biological Chemistry 281, 5965-5972. 
Hudson, A.T., Dickins, M., Ginger, C.D., Gutteridge, W.E., Holdich, T., Hutchinson, D.B., Pudney, 
M., Randall, A.W., and Latter, V.S. (1991). 566C80: a potent broad spectrum anti-infective 
agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp 
Clin Res 17, 427-435. 
References 
207 
 
Hudson, A.T., Randall, A.W., Fry, M., Ginger, C.D., Hill, B., Latter, V.S., McHardy, N., and Williams, 
R.B. (1985). Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum 
anti-protozoal activity. Parasitology 90 ( Pt 1), 45-55. 
Hunte, C., Palsdottir, H., and Trumpower, B.L. (2003). Protonmotive pathways and mechanisms in 
the cytochrome bc1 complex. FEBS Lett 545, 39-46. 
Hurt, D.E., Widom, J., and Clardy, J. (2006). Structure of Plasmodium falciparum dihydroorotate 
dehydrogenase with a bound inhibitor. Acta Crystallogr D Biol Crystallogr 62, 312-323. 
Hurt, E.C., Pesold-Hurt, B., and Schatz, G. (1984). The cleavable prepiece of an imported 
mitochondrial protein is sufficient to direct cytosolic dihydrofolate reductase into the 
mitochondrial matrix. FEBS Lett 178, 306-310. 
Hutu, D.P., Guiard, B., Chacinska, A., Becker, D., Pfanner, N., Rehling, P., and van der Laan, M. 
(2008). Mitochondrial protein import motor: differential role of Tim44 in the recruitment 
of Pam17 and J-complex to the presequence translocase. Mol Biol Cell 19, 2642-2649. 
Hyde, J.E. (2007a). Drug-resistant malaria - an insight. FEBS J 274, 4688-4698. 
Hyde, J.E. (2007b). Targeting purine and pyrimidine metabolism in human apicomplexan 
parasites. Curr Drug Targets 8, 31-47. 
Isaya, G., Miklos, D., and Rollins, R.A. (1994). MIP1, a new yeast gene homologous to the rat 
mitochondrial intermediate peptidase gene, is required for oxidative metabolism in 
Saccharomyces cerevisiae. Mol Cell Biol 14, 5603-5616. 
Ishmukhametov, R.R., Pond, J.B., Al-Huqail, A., Galkin, M.A., and Vik, S.B. (2008). ATP synthesis 
without R210 of subunit a in the Escherichia coli ATP synthase. Biochim Biophys Acta 
1777, 32-38. 
Ittarat, I., Asawamahasakda, W., and Meshnick, S.R. (1994). The effects of antimalarials on the 
Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol 79, 50-56. 
Iwata, S., Lee, J.W., Okada, K., Lee, J.K., Iwata, M., Rasmussen, B., Link, T.A., Ramaswamy, S., and 
Jap, B.K. (1998). Complete structure of the 11-subunit bovine mitochondrial cytochrome 
bc1 complex. Science 281, 64-71. 
Izumo, A., Tanabe, K., and Kato, M. (1988). The plasma membrane and mitochondrial membrane 
potentials of Plasmodium yoelii. Comp Biochem Physiol B 91, 735-739. 
Jambou, R., Legrand, E., Niang, M., Khim, N., Lim, P., Volney, B., Ekala, M.T., Bouchier, C., Esterre, 
P., Fandeur, T., et al. (2005). Resistance of Plasmodium falciparum field isolates to in-vitro 
artemether and point mutations of the SERCA-type PfATPase6. Lancet 366, 1960-1963. 
Jensen, M.D., Conley, M., and Helstowski, L.D. (1983). Culture of Plasmodium falciparum: the role 
of pH, glucose, and lactate. J Parasitol 69, 1060-1067. 
Jiang, J.B., Jacobs, G., Liang, D.S., and Aikawa, M. (1985). Qinghaosu-induced changes in the 
morphology of Plasmodium inui. Am J Trop Med Hyg 34, 424-428. 
Jindal, S., Dudani, A.K., Singh, B., Harley, C.B., and Gupta, R.S. (1989). Primary structure of a 
human mitochondrial protein homologous to the bacterial and plant chaperonins and to 
the 65-kilodalton mycobacterial antigen. Mol Cell Biol 9, 2279-2283. 
Johnston, A.J., Hoogenraad, J., Dougan, D.A., Truscott, K.N., Yano, M., Mori, M., Hoogenraad, N.J., 
and Ryan, M.T. (2002). Insertion and assembly of human tom7 into the preprotein 
translocase complex of the outer mitochondrial membrane. J Biol Chem 277, 42197-
42204. 
Juhnke, H.D., Hiltscher, H., Nasiri, H.R., Schwalbe, H., and Lancaster, C.R. (2009). Production, 
characterization and determination of the real catalytic properties of the putative 
'succinate dehydrogenase' from Wolinella succinogenes. Mol Microbiol 71, 1088-1101. 
Kaiser, M., Wittlin, S., Nehrbass-Stuedli, A., Dong, Y., Wang, X., Hemphill, A., Matile, H., Brun, R., 
and Vennerstrom, J.L. (2007). Peroxide bond-dependent antiplasmodial specificity of 
artemisinin and OZ277 (RBx11160). Antimicrob Agents Chemother 51, 2991-2993. 
Kambacheld, M., Augustin, S., Tatsuta, T., Muller, S., and Langer, T. (2005). Role of the novel 
metallopeptidase Mop112 and saccharolysin for the complete degradation of proteins 
residing in different subcompartments of mitochondria. J Biol Chem 280, 20132-20139. 
References 
208 
 
Kamchonwongpaisan, S., Chandra-ngam, G., Avery, M.A., and Yuthavong, Y. (1994). Resistance to 
artemisinin of malaria parasites (Plasmodium falciparum) infecting alpha-thalassemic 
erythrocytes in vitro. Competition in drug accumulation with uninfected erythrocytes. J 
Clin Invest 93, 467-473. 
Kamchonwongpaisan, S., and Meshnick, S.R. (1996). The mode of action of the antimalarial 
artemisinin and its derivatives. Gen Pharmacol 27, 587-592. 
Kang, P.J., Ostermann, J., Shilling, J., Neupert, W., Craig, E.A., and Pfanner, N. (1990). Requirement 
for hsp70 in the mitochondrial matrix for translocation and folding of precursor proteins. 
Nature 348, 137-143. 
Kannan, R., Sahal, D., and Chauhan, V.S. (2002). Heme-artemisinin adducts are crucial mediators 
of the ability of artemisinin to inhibit heme polymerization. Chem Biol 9, 321-332. 
Karunajeewa, H. (2012). Artemisinins: Artemisinin, Dihydroartemisinin, Artemether and 
Artesunate. 
Kawahara, K., Mogi, T., Tanaka, T.Q., Hata, M., Miyoshi, H., and Kita, K. (2009). Mitochondrial 
dehydrogenases in the aerobic respiratory chain of the rodent malaria parasite 
Plasmodium yoelii yoelii. J Biochem 145, 229-237. 
Kawai, S., Kano, S., and Suzuki, M. (1993). Morphologic effects of artemether on Plasmodium 
falciparum in Aotus trivirgatus. Am J Trop Med Hyg 49, 812-818. 
Kerscher, S.J. (2000). Diversity and origin of alternative NADH:ubiquinone oxidoreductases. 
Biochim Biophys Acta 1459, 274-283. 
Kessl, J.J., Ha, K.H., Merritt, A.K., Lange, B.B., Hill, P., Meunier, B., Meshnick, S.R., and Trumpower, 
B.L. (2005). Cytochrome b mutations that modify the ubiquinol-binding pocket of the 
cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces 
cerevisiae. J Biol Chem 280, 17142-17148. 
Kessl, J.J., Lange, B.B., Merbitz-Zahradnik, T., Zwicker, K., Hill, P., Meunier, B., Palsdottir, H., Hunte, 
C., Meshnick, S., and Trumpower, B.L. (2003). Molecular basis for atovaquone binding to 
the cytochrome bc1 complex. J Biol Chem 278, 31312-31318. 
Kessl, J.J., Meshnick, S.R., and Trumpower, B.L. (2007). Modeling the molecular basis of 
atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol 23, 494-501. 
Kita, K., Miyadera, H., Saruta, F., and Miyoshi, H. (2001). Parasite Mitochondria as a Target for 
Chemotherapy. Journal of Health Science 47, 219-239. 
Klayman, D.L. (1985). Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 
1049-1055. 
Klodmann, J., Sunderhaus, S., Nimtz, M., Jansch, L., and Braun, H.P. (2010). Internal architecture 
of mitochondrial complex I from Arabidopsis thaliana. Plant Cell 22, 797-810. 
Koehler, C.M., Jarosch, E., Tokatlidis, K., Schmid, K., Schweyen, R.J., and Schatz, G. (1998a). Import 
of mitochondrial carriers mediated by essential proteins of the intermembrane space. 
Science 279, 369-373. 
Koehler, C.M., Leuenberger, D., Merchant, S., Renold, A., Junne, T., and Schatz, G. (1999). Human 
deafness dystonia syndrome is a mitochondrial disease. Proc Natl Acad Sci U S A 96, 2141-
2146. 
Koehler, C.M., Merchant, S., Oppliger, W., Schmid, K., Jarosch, E., Dolfini, L., Junne, T., Schatz, G., 
and Tokatlidis, K. (1998b). Tim9p, an essential partner subunit of Tim10p for the import of 
mitochondrial carrier proteins. EMBO J 17, 6477-6486. 
Koehler, C.M., Murphy, M.P., Bally, N.A., Leuenberger, D., Oppliger, W., Dolfini, L., Junne, T., 
Schatz, G., and Or, E. (2000). Tim18p, a new subunit of the TIM22 complex that mediates 
insertion of imported proteins into the yeast mitochondrial inner membrane. Mol Cell Biol 
20, 1187-1193. 
Kohler, R., Boehringer, D., Greber, B., Bingel-Erlenmeyer, R., Collinson, I., Schaffitzel, C., and Ban, 
N. (2009). YidC and Oxa1 form dimeric insertion pores on the translating ribosome. Mol 
Cell 34, 344-353. 
References 
209 
 
Koonin, E.V., Makarova, K.S., Rogozin, I.B., Davidovic, L., Letellier, M.C., and Pellegrini, L. (2003). 
The rhomboids: a nearly ubiquitous family of intramembrane serine proteases that 
probably evolved by multiple ancient horizontal gene transfers. Genome Biol 4, R19. 
Koplin, A., Preissler, S., Ilina, Y., Koch, M., Scior, A., Erhardt, M., and Deuerling, E. (2010). A dual 
function for chaperones SSB-RAC and the NAC nascent polypeptide-associated complex 
on ribosomes. J Cell Biol 189, 57-68. 
Korenromp, E.L., Williams, B.G., de Vlas, S.J., Gouws, E., Gilks, C.F., Ghys, P.D., and Nahlen, B.L. 
(2005). Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis 
11, 1410-1419. 
Korsinczky, M., Chen, N., Kotecka, B., Saul, A., Rieckmann, K., and Cheng, Q. (2000). Mutations in 
Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are 
located at a putative drug-binding site. Antimicrob Agents Chemother 44, 2100-2108. 
Kozany, C., Mokranjac, D., Sichting, M., Neupert, W., and Hell, K. (2004). The J domain-related 
cochaperone Tim16 is a constituent of the mitochondrial TIM23 preprotein translocase. 
Nat Struct Mol Biol 11, 234-241. 
Kozjak, V., Wiedemann, N., Milenkovic, D., Lohaus, C., Meyer, H.E., Guiard, B., Meisinger, C., and 
Pfanner, N. (2003). An essential role of Sam50 in the protein sorting and assembly 
machinery of the mitochondrial outer membrane. J Biol Chem 278, 48520-48523. 
Kremsner, P.G., and Krishna, S. (2004). Antimalarial combinations. Lancet 364, 285-294. 
Krishna, S., and Staines, H. (2012). Non-Antifolate Antibiotics: Clindamycin, Doxycycline, 
Azithromycin and Fosmidomycin. 
Krotoski, W.A., Collins, W.E., Bray, R.S., Garnham, P.C., Cogswell, F.B., Gwadz, R.W., Killick-
Kendrick, R., Wolf, R., Sinden, R., Koontz, L.C., et al. (1982). Demonstration of hypnozoites 
in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 31, 1291-1293. 
Krungkrai, J. (1995). Purification, characterization and localization of mitochondrial 
dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite. 
Biochim Biophys Acta 1243, 351-360. 
Krungkrai, J., Burat, D., Kudan, S., Krungkrai, S., and Prapunwattana, P. (1999). Mitochondrial 
oxygen consumption in asexual and sexual blood stages of the human malarial parasite, 
Plasmodium falciparum. Southeast Asian J Trop Med Public Health 30, 636-642. 
Krungkrai, J., Krungkrai, S.R., and Bhumiratana, A. (1993). Plasmodium berghei: partial purification 
and characterization of the mitochondrial cytochrome c oxidase. Exp Parasitol 77, 136-
146. 
Krungkrai, J., Krungkrai, S.R., and Phakanont, K. (1992). Antimalarial activity of orotate analogs 
that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol 43, 
1295-1301. 
Krungkrai, J., Krungkrai, S.R., Suraveratum, N., and Prapunwattana, P. (1997). Mitochondrial 
ubiquinol-cytochrome c reductase and cytochrome c oxidase: chemotherapeutic targets 
in malarial parasites. Biochem Mol Biol Int 42, 1007-1014. 
Krungkrai, J., Prapunwattana, P., and Krungkrai, S.R. (2000). Ultrastructure and function of 
mitochondria in gametocytic stage of Plasmodium falciparum. Parasite 7, 19-26. 
Krungkrai, S.R., and Yuthavong, Y. (1987). The antimalarial action on Plasmodium falciparum of 
qinghaosu and artesunate in combination with agents which modulate oxidant stress. 
Trans R Soc Trop Med Hyg 81, 710-714. 
Kublin, J.G., Dzinjalamala, F.K., Kamwendo, D.D., Malkin, E.M., Cortese, J.F., Martino, L.M., 
Mukadam, R.A., Rogerson, S.J., Lescano, A.G., Molyneux, M.E., et al. (2002). Molecular 
markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment 
of Plasmodium falciparum malaria. J Infect Dis 185, 380-388. 
Kuboyama, M., Yong, F.C., and King, T.E. (1972). Studies on cytochrome oxidase. 8. Preparation 
and some properties of cardiac cytochrome oxidase. J Biol Chem 247, 6375-6383. 
Kumar, R., Adams, B., Musiyenko, A., Shulyayeva, O., and Barik, S. (2005). The FK506-binding 
protein of the malaria parasite, Plasmodium falciparum, is a FK506-sensitive chaperone 
References 
210 
 
with FK506-independent calcineurin-inhibitory activity. Mol Biochem Parasitol 141, 163-
173. 
Kwiatkowski, D.P. (2005). How malaria has affected the human genome and what human genetics 
can teach us about malaria. Am J Hum Genet 77, 171-192. 
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227, 680-685. 
Laishram, D.D., Sutton, P.L., Nanda, N., Sharma, V.L., Sobti, R.C., Carlton, J.M., and Joshi, H. (2012). 
The complexities of malaria disease manifestations with a focus on asymptomatic malaria. 
Malar J 11, 29. 
Lakshmanan, V., Bray, P.G., Verdier-Pinard, D., Johnson, D.J., Horrocks, P., Muhle, R.A., Alakpa, 
G.E., Hughes, R.H., Ward, S.A., Krogstad, D.J., et al. (2005). A critical role for PfCRT K76T in 
Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 24, 2294-
2305. 
Lalloo, D.G., and Hill, D.R. (2008). Preventing malaria in travellers. BMJ 336, 1362-1366. 
Lambros, C., and Vanderberg, J.P. (1979). Synchronization of Plasmodium falciparum erythrocytic 
stages in culture. J Parasitol 65, 418-420. 
Lange, C., and Hunte, C. (2002). Crystal structure of the yeast cytochrome bc1 complex with its 
bound substrate cytochrome c. Proc Natl Acad Sci U S A 99, 2800-2805. 
Lange, H., Kaut, A., Kispal, G., and Lill, R. (2000). A mitochondrial ferredoxin is essential for 
biogenesis of cellular iron-sulfur proteins. Proc Natl Acad Sci U S A 97, 1050-1055. 
Langer, T. (2000). AAA proteases: cellular machines for degrading membrane proteins. Trends 
Biochem Sci 25, 247-251. 
Langreth, S.G., Jensen, J.B., Reese, R.T., and Trager, W. (1978). Fine structure of human malaria in 
vitro. J Protozool 25, 443-452. 
Laveran, A. (1881). Un nouveau parasite trouvé dans le sang de malades atteints de fièvre 
palustre. Origine parasitaire des accidents de l'impaludisme. Bull Mém Soc Méd Hôpitaux 
Paris 17, 158-164. 
Ledesma, A., de Lacoba, M.G., and Rial, E. (2002). The mitochondrial uncoupling proteins. 
Genome Biol 3, REVIEWS3015. 
Lehane, A.M., Saliba, K.J., Allen, R.J., and Kirk, K. (2004). Choline uptake into the malaria parasite 
is energized by the membrane potential. Biochem Biophys Res Commun 320, 311-317. 
Lemberg, M.K., Menendez, J., Misik, A., Garcia, M., Koth, C.M., and Freeman, M. (2005). 
Mechanism of intramembrane proteolysis investigated with purified rhomboid proteases. 
EMBO J 24, 464-472. 
Lengeler, C. (2000). Insecticide-treated bednets and curtains for preventing malaria. Cochrane 
Database Syst Rev, CD000363. 
Leonhard, K., Herrmann, J.M., Stuart, R.A., Mannhaupt, G., Neupert, W., and Langer, T. (1996). 
AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic 
system for the ATP-dependent degradation of inner membrane proteins in mitochondria. 
EMBO J 15, 4218-4229. 
Leung, S.C., Gibbons, P., Amewu, R., Nixon, G.L., Pidathala, C., Hong, W.D., Pacorel, B., Berry, N.G., 
Sharma, R., Stocks, P.A., et al. (2012). Identification, design and biological evaluation of 
heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone 
oxidoreductase (PfNDH2). J Med Chem 55, 1844-1857. 
Li, W., Mo, W., Shen, D., Sun, L., Wang, J., Lu, S., Gitschier, J.M., and Zhou, B. (2005). Yeast model 
uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet 1, e36. 
Li, Y., Dudek, J., Guiard, B., Pfanner, N., Rehling, P., and Voos, W. (2004). The presequence 
translocase-associated protein import motor of mitochondria. Pam16 functions in an 
antagonistic manner to Pam18. J Biol Chem 279, 38047-38054. 
Lingelbach, K., and Joiner, K.A. (1998). The parasitophorous vacuole membrane surrounding 
Plasmodium and Toxoplasma: an unusual compartment in infected cells. J Cell Sci 111 ( Pt 
11), 1467-1475. 
References 
211 
 
Lister, R., Carrie, C., Duncan, O., Ho, L.H., Howell, K.A., Murcha, M.W., and Whelan, J. (2007). 
Functional definition of outer membrane proteins involved in preprotein import into 
mitochondria. Plant Cell 19, 3739-3759. 
Liu, Q., D'Silva, P., Walter, W., Marszalek, J., and Craig, E.A. (2003). Regulated cycling of 
mitochondrial Hsp70 at the protein import channel. Science 300, 139-141. 
Lloyd, D., Harris, J.C., Maroulis, S., Biagini, G.A., Wadley, R.B., Turner, M.P., and Edwards, M.R. 
(2000). The microaerophilic flagellate Giardia intestinalis: oxygen and its reaction products 
collapse membrane potential and cause cytotoxicity. Microbiology 146 Pt 12, 3109-3118. 
Loew, L.M. (1998). Measuring membrane potential in single cells with confocal microscopy. In Cell 
Biology: A Laboratory Handbook, Vol 3 J E Celis, editor Academic Press, San Diego, 375-
379. 
Loew, L.M., Tuft, R.A., Carrington, W., and Fay, F.S. (1993). Imaging in five dimensions: time-
dependent membrane potentials in individual mitochondria. Biophys J 65, 2396-2407. 
Looareesuwan, S., Bunnag, D., and Harinasuta, T. (1990). The Textbook of Tropical Medicine. 
Ruamthasa Publishers 39-44. 
Looareesuwan, S., Viravan, C., Webster, H.K., Kyle, D.E., Hutchinson, D.B., and Canfield, C.J. 
(1996). Clinical studies of atovaquone, alone or in combination with other antimalarial 
drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54, 
62-66. 
Looareesuwan, S., Wilairatana, P., Chalermarut, K., Rattanapong, Y., Canfield, C.J., and 
Hutchinson, D.B. (1999). Efficacy and safety of atovaquone/proguanil compared with 
mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop 
Med Hyg 60, 526-532. 
Lu, Y., and Beavis, A.D. (1997). Effect of leader peptides on the permeability of mitochondria. J 
Biol Chem 272, 13555-13561. 
Lupo, D., Vollmer, C., Deckers, M., Mick, D.U., Tews, I., Sinning, I., and Rehling, P. (2011). Mdm38 
is a 14-3-3-like receptor and associates with the protein synthesis machinery at the inner 
mitochondrial membrane. Traffic 12, 1457-1466. 
M. Santos, J., Graindorge, A., and Soldati-Favre, D. (2012). New insights into parasite rhomboid 
proteases. Molecular and Biochemical Parasitology 182, 27-36. 
Maćašev, D., Whelan, J., Newbigin, E., Silva-Filho, M.C., Mulhern, T.D., and Lithgow, T. (2004). 
Tom22′, an 8-kDa trans-Site Receptor in Plants and Protozoans, Is a Conserved Feature of 
the TOM Complex That Appeared Early in the Evolution of Eukaryotes. Molecular Biology 
and Evolution 21, 1557-1564. 
Maeno, Y., Toyoshima, T., Fujioka, H., Ito, Y., Meshnick, S.R., Benakis, A., Milhous, W.K., and 
Aikawa, M. (1993). Morphologic effects of artemisinin in Plasmodium falciparum. Am J 
Trop Med Hyg 49, 485-491. 
Maier, A.G., Cooke, B.M., Cowman, A.F., and Tilley, L. (2009). Malaria parasite proteins that 
remodel the host erythrocyte. Nat Rev Microbiol 7, 341-354. 
Maklashina, E., Berthold, D.A., and Cecchini, G. (1998). Anaerobic expression of Escherichia coli 
succinate dehydrogenase: functional replacement of fumarate reductase in the 
respiratory chain during anaerobic growth. J Bacteriol 180, 5989-5996. 
Malkin, E.M., Diemert, D.J., McArthur, J.H., Perreault, J.R., Miles, A.P., Giersing, B.K., Mullen, G.E., 
Orcutt, A., Muratova, O., Awkal, M., et al. (2005a). Phase 1 clinical trial of apical 
membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. 
Infect Immun 73, 3677-3685. 
Malkin, E.M., Durbin, A.P., Diemert, D.J., Sattabongkot, J., Wu, Y., Miura, K., Long, C.A., Lambert, 
L., Miles, A.P., Wang, J., et al. (2005b). Phase 1 vaccine trial of Pvs25H: a transmission 
blocking vaccine for Plasmodium vivax malaria. Vaccine 23, 3131-3138. 
Malmquist, N.A., Gujjar, R., Rathod, P.K., and Phillips, M.A. (2008). Analysis of flavin oxidation and 
electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. 
Biochemistry 47, 2466-2475. 
References 
212 
 
Manzoori, J.L., Amjadi, M., Soleymani, J., Tamizi, E., Rezamand, A., and Jouyban, A. (2011). 
Determination of deferiprone in urine and serum using a terbium-sensitized luminescence 
method. Luminescence. 
Marc, P., Margeot, A., Devaux, F., Blugeon, C., Corral-Debrinski, M., and Jacq, C. (2002). Genome-
wide analysis of mRNAs targeted to yeast mitochondria. EMBO Rep 3, 159-164. 
Marshansky, V.N., Novgorodov, S.A., and Yaguzhinsky, L.S. (1983). The role of lipid peroxidation in 
the induction of cation transport in rat liver mitochondria. The antioxidant effect of 
oligomycin and dicyclohexylcarbodiimide. FEBS Lett 158, 27-30. 
Martin, R.E., and Kirk, K. (2004). The malaria parasite's chloroquine resistance transporter is a 
member of the drug/metabolite transporter superfamily. Mol Biol Evol 21, 1938-1949. 
Martin, R.E., Marchetti, R.V., Cowan, A.I., Howitt, S.M., Broer, S., and Kirk, K. (2009). Chloroquine 
transport via the malaria parasite's chloroquine resistance transporter. Science 325, 1680-
1682. 
Massey, V., and Singer, T.P. (1957). Studies on succinic dehydrogenase. III. The fumaric reductase 
activity of succinic dehydrogenase. J Biol Chem 228, 263-274. 
Mather, M.W., Darrouzet, E., Valkova-Valchanova, M., Cooley, J.W., McIntosh, M.T., Daldal, F., 
and Vaidya, A.B. (2005). Uncovering the molecular mode of action of the antimalarial drug 
atovaquone using a bacterial system. J Biol Chem 280, 27458-27465. 
Mather, M.W., Henry, K.W., and Vaidya, A.B. (2007). Mitochondrial drug targets in apicomplexan 
parasites. Curr Drug Targets 8, 49-60. 
Mather, M.W., Morrisey, J.M., and Vaidya, A.B. (2010). Hemozoin-free Plasmodium falciparum 
mitochondria for physiological and drug susceptibility studies. Molecular and Biochemical 
Parasitology 174, 150-153. 
Mather, M.W., and Vaidya, A.B. (2008). Mitochondria in malaria and related parasites: ancient, 
diverse and streamlined. Journal of Bioenergetics and Biomembranes 40, 425-433. 
Matsoso, L.G., Kana, B.D., Crellin, P.K., Lea-Smith, D.J., Pelosi, A., Powell, D., Dawes, S.S., Rubin, H., 
Coppel, R.L., and Mizrahi, V. (2005). Function of the cytochrome bc1-aa3 branch of the 
respiratory network in mycobacteria and network adaptation occurring in response to its 
disruption. J Bacteriol 187, 6300-6308. 
Mattevi, A., Obmolova, G., Sokatch, J.R., Betzel, C., and Hol, W.G. (1992). The refined crystal 
structure of Pseudomonas putida lipoamide dehydrogenase complexed with NAD+ at 2.45 
A resolution. Proteins 13, 336-351. 
McFadden, G.I. (2011). The apicoplast. Protoplasma 248, 641-650. 
Meier, T., Morgner, N., Matthies, D., Pogoryelov, D., Keis, S., Cook, G.M., Dimroth, P., and 
Brutschy, B. (2007). A tridecameric c ring of the adenosine triphosphate (ATP) synthase 
from the thermoalkaliphilic Bacillus sp. strain TA2.A1 facilitates ATP synthesis at low 
electrochemical proton potential. Mol Microbiol 65, 1181-1192. 
Meinecke, M., Wagner, R., Kovermann, P., Guiard, B., Mick, D.U., Hutu, D.P., Voos, W., Truscott, 
K.N., Chacinska, A., Pfanner, N., et al. (2006). Tim50 maintains the permeability barrier of 
the mitochondrial inner membrane. Science 312, 1523-1526. 
Mendis, K.N., and Carter, R. (1995). Clinical disease and pathogenesis in malaria. Parasitol Today 
11, PTI1-16. 
Mercer, A.E., Copple, I.M., Maggs, J.L., O'Neill, P.M., and Park, B.K. (2011). The role of heme and 
the mitochondrion in the chemical and molecular mechanisms of mammalian cell death 
induced by the artemisinin antimalarials. J Biol Chem 286, 987-996. 
Mercer, A.E., Maggs, J.L., Sun, X.M., Cohen, G.M., Chadwick, J., O'Neill, P.M., and Park, B.K. (2007). 
Evidence for the involvement of carbon-centered radicals in the induction of apoptotic 
cell death by artemisinin compounds. J Biol Chem 282, 9372-9382. 
Meshnick, S.R., Taylor, T.E., and Kamchonwongpaisan, S. (1996). Artemisinin and the antimalarial 
endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 60, 301-
315. 
References 
213 
 
Meshnick, S.R., Thomas, A., Ranz, A., Xu, C.M., and Pan, H.Z. (1991). Artemisinin (qinghaosu): the 
role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 
49, 181-189. 
Meshnick, S.R., Yang, Y.Z., Lima, V., Kuypers, F., Kamchonwongpaisan, S., and Yuthavong, Y. 
(1993). Iron-dependent free radical generation from the antimalarial agent artemisinin 
(qinghaosu). Antimicrob Agents Chemother 37, 1108-1114. 
Mi-Ichi, F., Takeo, S., Takashima, E., Kobayashi, T., Kim, H.S., Wataya, Y., Matsuda, A., Torrii, M., 
Tsuboi, T., and Kita, K. (2003). Unique properties of respiratory chain in Plasmodium 
falciparum mitochondria. Adv Exp Med Biol 531, 117-133. 
Michon, T., Galante, M., and Velours, J. (1988). NH2-terminal sequence of the isolated yeast ATP 
synthase subunit 6 reveals post-translational cleavage. Eur J Biochem 172, 621-625. 
Miller, L.H., Baruch, D.I., Marsh, K., and Doumbo, O.K. (2002). The pathogenic basis of malaria. 
Nature 415, 673-679. 
Miller, L.H., Good, M.F., and Milon, G. (1994a). Malaria pathogenesis. Science 264, 1878-1883. 
Miller, R.L., Ikram, S., Armelagos, G.J., Walker, R., Harer, W.B., Shiff, C.J., Baggett, D., Carrigan, M., 
and Maret, S.M. (1994b). Diagnosis of Plasmodium falciparum infections in mummies 
using the rapid manual ParaSight-F test. Trans R Soc Trop Med Hyg 88, 31-32. 
Mita, T., Tanabe, K., and Kita, K. (2009). Spread and evolution of Plasmodium falciparum drug 
resistance. Parasitology International 58, 201-209. 
Mitamura, T., and Palacpac, N.M. (2003). Lipid metabolism in Plasmodium falciparum-infected 
erythrocytes: possible new targets for malaria chemotherapy. Microbes Infect 5, 545-552. 
Mitchell, P. (1975). The protonmotive Q cycle: a general formulation. FEBS Lett 59, 137-139. 
Miyadera, H., Hiraishi, A., Miyoshi, H., Sakamoto, K., Mineki, R., Murayama, K., Nagashima, K.V., 
Matsuura, K., Kojima, S., and Kita, K. (2003). Complex II from phototrophic purple 
bacterium Rhodoferax fermentans displays rhodoquinol-fumarate reductase activity. Eur J 
Biochem 270, 1863-1874. 
Mogi, T., and Kita, K. (2009). Identification of mitochondrial Complex II subunits SDH3 and SDH4 
and ATP synthase subunits a and b in Plasmodium spp. Mitochondrion 9, 443-453. 
Mogi, T., Murase, Y., Mori, M., Shiomi, K., Omura, S., Paranagama, M.P., and Kita, K. (2009). 
Polymyxin B Identified as an Inhibitor of Alternative NADH Dehydrogenase and Malate: 
Quinone Oxidoreductase from the Gram-positive Bacterium Mycobacterium smegmatis. 
Journal of Biochemistry 146, 491-499. 
Mokranjac, D., Popov-Celeketic, D., Hell, K., and Neupert, W. (2005). Role of Tim21 in 
mitochondrial translocation contact sites. J Biol Chem 280, 23437-23440. 
Mokranjac, D., Sichting, M., Neupert, W., and Hell, K. (2003). Tim14, a novel key component of the 
import motor of the TIM23 protein translocase of mitochondria. EMBO J 22, 4945-4956. 
Molenaar, D., van der Rest, M.E., and Petrovic, S. (1998). Biochemical and genetic characterization 
of the membrane-associated malate dehydrogenase (acceptor) from Corynebacterium 
glutamicum. Eur J Biochem 254, 395-403. 
Monaghan, P., and Bell, A. (2005). A Plasmodium falciparum FK506-binding protein (FKBP) with 
peptidyl-prolyl cis-trans isomerase and chaperone activities. Mol Biochem Parasitol 139, 
185-195. 
Monzote, L., and Gille, L. (2010). Mitochondria as a promising antiparasitic target. Curr Clin 
Pharmacol 5, 55-60. 
Moon, Y., Lee, K.H., Park, J.H., Geum, D., and Kim, K. (2005). Mitochondrial membrane 
depolarization and the selective death of dopaminergic neurons by rotenone: protective 
effect of coenzyme Q10. J Neurochem 93, 1199-1208. 
Moorthy, V.S., Imoukhuede, E.B., Keating, S., Pinder, M., Webster, D., Skinner, M.A., Gilbert, S.C., 
Walraven, G., and Hill, A.V. (2004a). Phase 1 evaluation of 3 highly immunogenic prime-
boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in 
Gambian men. J Infect Dis 189, 2213-2219. 
References 
214 
 
Moorthy, V.S., Imoukhuede, E.B., Milligan, P., Bojang, K., Keating, S., Kaye, P., Pinder, M., Gilbert, 
S.C., Walraven, G., Greenwood, B.M., et al. (2004b). A randomised, double-blind, 
controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in 
Gambian adults. PLoS Med 1, e33. 
Morales, J., Mogi, T., Mineki, S., Takashima, E., Mineki, R., Hirawake, H., Sakamoto, K., Omura, S., 
and Kita, K. (2009). Novel mitochondrial complex II isolated from Trypanosoma cruzi is 
composed of 12 peptides including a heterodimeric Ip subunit. J Biol Chem 284, 7255-
7263. 
Mossmann, D., Meisinger, C., and Vogtle, F.N. (2011). Processing of mitochondrial presequences. 
Biochim Biophys Acta. 
Mu, J., Ferdig, M.T., Feng, X., Joy, D.A., Duan, J., Furuya, T., Subramanian, G., Aravind, L., Cooper, 
R.A., Wootton, J.C., et al. (2003). Multiple transporters associated with malaria parasite 
responses to chloroquine and quinine. Mol Microbiol 49, 977-989. 
Mu, J., Joy, D.A., Duan, J., Huang, Y., Carlton, J., Walker, J., Barnwell, J., Beerli, P., Charleston, 
M.A., Pybus, O.G., et al. (2005). Host switch leads to emergence of Plasmodium vivax 
malaria in humans. Mol Biol Evol 22, 1686-1693. 
Muller, I.B., and Hyde, J.E. (2010). Antimalarial drugs: modes of action and mechanisms of 
parasite resistance. Future Microbiol 5, 1857-1873. 
Muller, S. (2004). Redox and antioxidant systems of the malaria parasite Plasmodium falciparum. 
Mol Microbiol 53, 1291-1305. 
Murakami, H., Pain, D., and Blobel, G. (1988). 70-kD heat shock-related protein is one of at least 
two distinct cytosolic factors stimulating protein import into mitochondria. J Cell Biol 107, 
2051-2057. 
Murray, J., Zhang, B., Taylor, S.W., Oglesbee, D., Fahy, E., Marusich, M.F., Ghosh, S.S., and Capaldi, 
R.A. (2003). The subunit composition of the human NADH dehydrogenase obtained by 
rapid one-step immunopurification. J Biol Chem 278, 13619-13622. 
Musset, L., Bouchaud, O., Matheron, S., Massias, L., and Le Bras, J. (2006). Clinical atovaquone-
proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 
mutations. Microbes Infect 8, 2599-2604. 
Mzhavia, N., Berman, Y.L., Qian, Y., Yan, L., and Devi, L.A. (1999). Cloning, expression, and 
characterization of human metalloprotease 1: a novel member of the pitrilysin family of 
metalloendoproteases. DNA Cell Biol 18, 369-380. 
Naamati, A., Regev-Rudzki, N., Galperin, S., Lill, R., and Pines, O. (2009). Dual targeting of Nfs1 and 
discovery of its novel processing enzyme, Icp55. J Biol Chem 284, 30200-30208. 
Nasirudeen, A.M., and Tan, K.S. (2004). Isolation and characterization of the mitochondrion-like 
organelle from Blastocystis hominis. J Microbiol Methods 58, 101-109. 
Neupert, W., and Herrmann, J.M. (2007). Translocation of proteins into mitochondria. Annu Rev 
Biochem 76, 723-749. 
Nicolay, K., Laterveer, F.D., and van Heerde, W.L. (1994). Effects of amphipathic peptides, 
including presequences, on the functional integrity of rat liver mitochondrial membranes. 
J Bioenerg Biomembr 26, 327-334. 
Nosten, F., Phillips-Howard, P., and Kuile, F. (2012). Other 4-Methanolquinolines, Amyl Alcohols 
and Phentathrenes: Mefloquine, Lumefantrine and Halofantrine. 
Nosten, F., and White, N.J. (2007). Artemisinin-based combination treatment of falciparum 
malaria. Am J Trop Med Hyg 77, 181-192. 
Nunnari, J., Fox, T.D., and Walter, P. (1993). A mitochondrial protease with two catalytic subunits 
of nonoverlapping specificities. Science 262, 1997-2004. 
Nzila, A. (2012). Antifolates: Pyrimethamine, Proguanil, Sulphadoxine and Dapsone. 
O'Neill, P.M., Amewu, R.K., Nixon, G.L., Bousejra ElGarah, F., Mungthin, M., Chadwick, J., Shone, 
A.E., Vivas, L., Lander, H., Barton, V., et al. (2010a). Identification of a 1,2,4,5-tetraoxane 
antimalarial drug-development candidate (RKA 182) with superior properties to the 
semisynthetic artemisinins. Angew Chem Int Ed Engl 49, 5693-5697. 
References 
215 
 
O'Neill, P.M., Barton, V.E., and Ward, S.A. (2010b). The molecular mechanism of action of 
artemisinin--the debate continues. Molecules 15, 1705-1721. 
O'Neill, P.M., Bishop, L.P., Searle, N.L., Maggs, J.L., Storr, R.C., Ward, S.A., Park, B.K., and Mabbs, F. 
(2000). Biomimetic Fe(II)-mediated degradation of arteflene (Ro-42-1611). The first EPR 
spin-trapping evidence for the previously postulated secondary carbon-centered 
cyclohexyl radical. J Org Chem 65, 1578-1582. 
O'Neill, P.M., and Posner, G.H. (2004). A medicinal chemistry perspective on artemisinin and 
related endoperoxides. J Med Chem 47, 2945-2964. 
O’Neill, P., Barton, V., Ward, S., and Chadwick, J. (2012). 4-Aminoquinolines: Chloroquine, 
Amodiaquine and Next-Generation Analogues. In Treatment and Prevention of Malaria, 
H.M. Staines, and S. Krishna, eds. (Springer Basel), pp. 19-44. 
Okamoto, N., Spurck, T.P., Goodman, C.D., and McFadden, G.I. (2009). Apicoplast and 
mitochondrion in gametocytogenesis of Plasmodium falciparum. Eukaryot Cell 8, 128-132. 
Okombo, J., Kiara, S.M., Rono, J., Mwai, L., Pole, L., Ohuma, E., Borrmann, S., Ochola, L.I., and 
Nzila, A. (2010). In vitro activities of quinine and other antimalarials and pfnhe 
polymorphisms in Plasmodium isolates from Kenya. Antimicrob Agents Chemother 54, 
3302-3307. 
Olliaro, P. (2001). Mode of action and mechanisms of resistance for antimalarial drugs. 
Pharmacology & Therapeutics 89, 207-219. 
Olszewski, K.L., Mather, M.W., Morrisey, J.M., Garcia, B.A., Vaidya, A.B., Rabinowitz, J.D., and 
Llinas, M. (2010). Branched tricarboxylic acid metabolism in Plasmodium falciparum. 
Nature 466, 774-778. 
Osei-Akoto, A., Orton, L., and Owusu-Ofori, S.P. (2005). Atovaquone-proguanil for treating 
uncomplicated malaria. Cochrane Database Syst Rev, CD004529. 
Ott, M., Prestele, M., Bauerschmitt, H., Funes, S., Bonnefoy, N., and Herrmann, J.M. (2006). Mba1, 
a membrane-associated ribosome receptor in mitochondria. EMBO J 25, 1603-1610. 
Otto, H., Conz, C., Maier, P., Wolfle, T., Suzuki, C.K., Jeno, P., Rucknagel, P., Stahl, J., and Rospert, 
S. (2005). The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated 
complex. Proc Natl Acad Sci U S A 102, 10064-10069. 
Pagola, S., Stephens, P.W., Bohle, D.S., Kosar, A.D., and Madsen, S.K. (2000). The structure of 
malaria pigment beta-haematin. Nature 404, 307-310. 
Pain, A., Renauld, H., Berriman, M., Murphy, L., Yeats, C.A., Weir, W., Kerhornou, A., Aslett, M., 
Bishop, R., Bouchier, C., et al. (2005). Genome of the host-cell transforming parasite 
Theileria annulata compared with T. parva. Science 309, 131-133. 
Painter, H.J., Morrisey, J.M., Mather, M.W., and Vaidya, A.B. (2007). Specific role of mitochondrial 
electron transport in blood-stage Plasmodium falciparum. Nature 446, 88-91. 
Painter, H.J., Morrisey, J.M., and Vaidya, A.B. (2010). Mitochondrial Electron Transport Inhibition 
and Viability of Intraerythrocytic Plasmodium falciparum. Antimicrobial Agents and 
Chemotherapy 54, 5281-5287. 
Pandey, A.V., Tekwani, B.L., Singh, R.L., and Chauhan, V.S. (1999). Artemisinin, an endoperoxide 
antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in 
malarial parasite. J Biol Chem 274, 19383-19388. 
Pandya, K.P., and King, H.K. (1966). Ubiquinone and menaquinone in bacteria: a comparative 
study of some bacterial respiratory systems. Arch Biochem Biophys 114, 154-157. 
Pasvol, G. (2005). The treatment of complicated and severe malaria. Br Med Bull 75-76, 29-47. 
Patarroyo, G., Franco, L., Amador, R., Murillo, L.A., Rocha, C.L., Rojas, M., and Patarroyo, M.E. 
(1992). Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in 
children aged 1-14 years. Vaccine 10, 175-178. 
Patel, V., Booker, M., Kramer, M., Ross, L., Celatka, C.A., Kennedy, L.M., Dvorin, J.D., Duraisingh, 
M.T., Sliz, P., Wirth, D.F., et al. (2008). Identification and characterization of small 
molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J Biol 
Chem 283, 35078-35085. 
References 
216 
 
Peel, S.A. (2001). The ABC transporter genes of Plasmodium falciparum and drug resistance. Drug 
Resistance Updates 4, 66-74. 
Perkins, S.L., and Austin, C.C. (2009). Four new species of Plasmodium from New Guinea lizards: 
integrating morphology and molecules. J Parasitol 95, 424-433. 
Peters, J.M., Chen, N., Gatton, M., Korsinczky, M., Fowler, E.V., Manzetti, S., Saul, A., and Cheng, 
Q. (2002). Mutations in cytochrome b resulting in atovaquone resistance are associated 
with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 46, 2435-
2441. 
Petersen, E. (2003). The safety of atovaquone/proguanil in long-term malaria prophylaxis of 
nonimmune adults. J Travel Med 10 Suppl 1, S13-15; discussion S21. 
Petmitr, S., and Krungkrai, J. (1995). Mitochondrial cytochrome b gene in two developmental 
stages of human malarial parasite Plasmodium falciparum. Southeast Asian J Trop Med 
Public Health 26, 600-605. 
Phillips, M.A., Gujjar, R., Malmquist, N.A., White, J., El Mazouni, F., Baldwin, J., and Rathod, P.K. 
(2008). Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent 
and selective activity against the malaria parasite Plasmodium falciparum. J Med Chem 
51, 3649-3653. 
Piao, L., Li, Y., Kim, S.J., Byun, H.S., Huang, S.M., Hwang, S.K., Yang, K.J., Park, K.A., Won, M., Hong, 
J., et al. (2009). Association of LETM1 and MRPL36 contributes to the regulation of 
mitochondrial ATP production and necrotic cell death. Cancer Res 69, 3397-3404. 
Piechota, J., Kolodziejczak, M., Juszczak, I., Sakamoto, W., and Janska, H. (2010). Identification and 
characterization of high molecular weight complexes formed by matrix AAA proteases and 
prohibitins in mitochondria of Arabidopsis thaliana. J Biol Chem 285, 12512-12521. 
Pisciotta, J.M., Coppens, I., Tripathi, A.K., Scholl, P.F., Shuman, J., Bajad, S., Shulaev, V., and 
Sullivan, D.J., Jr. (2007). The role of neutral lipid nanospheres in Plasmodium falciparum 
haem crystallization. Biochem J 402, 197-204. 
Ponpuak, M., Klemba, M., Park, M., Gluzman, I.Y., Lamppa, G.K., and Goldberg, D.E. (2007). A role 
for falcilysin in transit peptide degradation in the Plasmodium falciparum apicoplast. Mol 
Microbiol 63, 314-334. 
Porter, N.A. (1986). Mechanisms for the autoxidation of polyunsaturated lipids. Accounts of 
Chemical Research 19, 262-268. 
Posner, G.H., Oh, C.H., Wang, D., Gerena, L., Milhous, W.K., Meshnick, S.R., and Asawamahasadka, 
W. (1994). Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-
methylated trioxanes structurally related to artemisinin: the importance of a carbon-
centered radical for antimalarial activity. J Med Chem 37, 1256-1258. 
Posner, G.H., Wang, D., Cumming, J.N., Oh, C.H., French, A.N., Bodley, A.L., and Shapiro, T.A. 
(1995). Further evidence supporting the importance of and the restrictions on a carbon-
centered radical for high antimalarial activity of 1,2,4-trioxanes like artemisinin. J Med 
Chem 38, 2273-2275. 
Pradines, B., Rolain, J.M., Ramiandrasoa, F., Fusai, T., Mosnier, J., Rogier, C., Daries, W., Baret, E., 
Kunesch, G., Le Bras, J., et al. (2002). Iron chelators as antimalarial agents: in vitro activity 
of dicatecholate against Plasmodium falciparum. J Antimicrob Chemother 50, 177-187. 
Pratje, E., Mannhaupt, G., Michaelis, G., and Beyreuther, K. (1983). A nuclear mutation prevents 
processing of a mitochondrially encoded membrane protein in Saccharomyces cerevisiae. 
EMBO J 2, 1049-1054. 
Qbadou, S., Becker, T., Mirus, O., Tews, I., Soll, J., and Schleiff, E. (2006). The molecular chaperone 
Hsp90 delivers precursor proteins to the chloroplast import receptor Toc64. EMBO J 25, 
1836-1847. 
Raabe, C.A., Sanchez, C.P., Randau, G., Robeck, T., Skryabin, B.V., Chinni, S.V., Kube, M., 
Reinhardt, R., Ng, G.H., Manickam, R., et al. (2010). A global view of the nonprotein-
coding transcriptome in Plasmodium falciparum. Nucleic Acids Res 38, 608-617. 
References 
217 
 
Radloff, P.D., Philipps, J., Nkeyi, M., Hutchinson, D., and Kremsner, P.G. (1996). Atovaquone and 
proguanil for Plasmodium falciparum malaria. Lancet 347, 1511-1514. 
Raj, D.K., Mu, J., Jiang, H., Kabat, J., Singh, S., Sullivan, M., Fay, M.P., McCutchan, T.F., and Su, X.Z. 
(2009). Disruption of a Plasmodium falciparum multidrug resistance-associated protein 
(PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem 
284, 7687-7696. 
Ranson, N.A., White, H.E., and Saibil, H.R. (1998). Chaperonins. Biochem J 333 ( Pt 2), 233-242. 
Refojo, P.N., Teixeira, M., and Pereira, M.M. (2012). The Alternative complex III: Properties and 
possible mechanisms for electron transfer and energy conservation. Biochim Biophys 
Acta. 
Rehling, P., Model, K., Brandner, K., Kovermann, P., Sickmann, A., Meyer, H.E., Kuhlbrandt, W., 
Wagner, R., Truscott, K.N., and Pfanner, N. (2003). Protein insertion into the 
mitochondrial inner membrane by a twin-pore translocase. Science 299, 1747-1751. 
Reyburn, H., Mbatia, R., Drakeley, C., Bruce, J., Carneiro, I., Olomi, R., Cox, J., Nkya, W.M., Lemnge, 
M., Greenwood, B.M., et al. (2005). Association of transmission intensity and age with 
clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 
293, 1461-1470. 
Rich, P.R. (2003). The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans 31, 
1095-1105. 
Richter, C. (1987). Biophysical consequences of lipid peroxidation in membranes. Chem Phys 
Lipids 44, 175-189. 
Richter, O.M., and Ludwig, B. (2003). Cytochrome c oxidase--structure, function, and physiology of 
a redox-driven molecular machine. Rev Physiol Biochem Pharmacol 147, 47-74. 
Ridley, R.G. (2002). Medical need, scientific opportunity and the drive for antimalarial drugs. 
Nature 415, 686-693. 
Robert, A., Benoit-Vical, F., Claparols, C., and Meunier, B. (2005). The antimalarial drug artemisinin 
alkylates heme in infected mice. Proc Natl Acad Sci U S A 102, 13676-13680. 
Robert, A., Bonduelle, C., Laurent, S.A.L., and Meunier, B. (2006). Heme alkylation by artemisinin 
and trioxaquines. Journal of Physical Organic Chemistry 19, 562-569. 
Robinson, K.M., and Lemire, B.D. (1996). Covalent attachment of FAD to the yeast succinate 
dehydrogenase flavoprotein requires import into mitochondria, presequence removal, 
and folding. J Biol Chem 271, 4055-4060. 
Rogalska, A., Koceva-Chyla, A., and Jozwiak, Z. (2008). Aclarubicin-induced ROS generation and 
collapse of mitochondrial membrane potential in human cancer cell lines. Chem Biol 
Interact 176, 58-70. 
Roise, D., Horvath, S.J., Tomich, J.M., Richards, J.H., and Schatz, G. (1986). A chemically 
synthesized pre-sequence of an imported mitochondrial protein can form an amphiphilic 
helix and perturb natural and artificial phospholipid bilayers. EMBO J 5, 1327-1334. 
Rosenthal, P.J., and Meshnick, S.R. (1996). Hemoglobin catabolism and iron utilization by malaria 
parasites. Mol Biochem Parasitol 83, 131-139. 
Ross, R. (1898). The role of the mosquito in the evolution of the malaria parasite. Lancet ii, 489. 
Rossignol, R., Faustin, B., Rocher, C., Malgat, M., Mazat, J.P., and Letellier, T. (2003). 
Mitochondrial threshold effects. Biochemical Journal 370, 751-762. 
Rudzinska, M.A. (1969). The fine structure of malaria parasites. Int Rev Cytol 25, 161-199. 
Rye, H.S., Burston, S.G., Fenton, W.A., Beechem, J.M., Xu, Z., Sigler, P.B., and Horwich, A.L. (1997). 
Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL. 
Nature 388, 792-798. 
Sachs, J., and Malaney, P. (2002). The economic and social burden of malaria. Nature 415, 680-
685. 
Sadacharan, S.K., Cavanagh, A.C., and Gupta, R.S. (2001). Immunoelectron microscopy provides 
evidence for the presence of mitochondrial heat shock 10-kDa protein (chaperonin 10) in 
red blood cells and a variety of secretory granules. Histochem Cell Biol 116, 507-517. 
References 
218 
 
Sadasivaiah, S., Tozan, Y., and Breman, J.G. (2007). Dichlorodiphenyltrichloroethane (DDT) for 
Indoor Residual Spraying in Africa: How Can It Be Used for Malaria Control? The American 
Journal of Tropical Medicine and Hygiene 77, 249-263. 
Sakai, C., Tomitsuka, E., Esumi, H., Harada, S., and Kita, K. (2012). Mitochondrial fumarate 
reductase as a target of chemotherapy: From parasites to cancer cells. Biochim Biophys 
Acta 1820, 643-651. 
Saliba, K.J., and Kirk, K. (1999). pH regulation in the intracellular malaria parasite, Plasmodium 
falciparum. H(+) extrusion via a v-type h(+)-atpase. J Biol Chem 274, 33213-33219. 
Saliba, K.J., Martin, R.E., Broer, A., Henry, R.I., McCarthy, C.S., Downie, M.J., Allen, R.J., Mullin, 
K.A., McFadden, G.I., Broer, S., et al. (2006). Sodium-dependent uptake of inorganic 
phosphate by the intracellular malaria parasite. Nature 443, 582-585. 
Saraste, M. (1999). Oxidative phosphorylation at the fin de siecle. Science 283, 1488-1493. 
Saruta, F., Kuramochi, T., Nakamura, K., Takamiya, S., Yu, Y., Aoki, T., Sekimizu, K., Kojima, S., and 
Kita, K. (1995). Stage-specific isoforms of complex II (succinate-ubiquinone 
oxidoreductase) in mitochondria from the parasitic nematode, Ascaris suum. J Biol Chem 
270, 928-932. 
Sato, S., Rangachari, K., and Wilson, R.J. (2003). Targeting GFP to the malarial mitochondrion. Mol 
Biochem Parasitol 130, 155-158. 
Sato, S., and Wilson, R.J. (2004). The use of DsRED in single- and dual-color fluorescence labeling 
of mitochondrial and plastid organelles in Plasmodium falciparum. Mol Biochem Parasitol 
134, 175-179. 
Sato, S., and Wilson, R.J. (2005). Organelle-specific cochaperonins in apicomplexan parasites. Mol 
Biochem Parasitol 141, 133-143. 
Schagger, H., and Pfeiffer, K. (2000). Supercomplexes in the respiratory chains of yeast and 
mammalian mitochondria. EMBO J 19, 1777-1783. 
Scheibel, L.W., Adler, A., and Trager, W. (1979). Tetraethylthiuram disulfide (Antabuse) inhibits 
the human malaria parasite Plasmodium falciparum. Proceedings of the National 
Academy of Sciences of the United States of America 76, 5303-5307. 
Scheibel, L.W., and Pflaum, W.K. (1970). Cytochrome oxidase activity in platelet-free preparations 
of Plasmodium falciparum. J Parasitol 56, 1054. 
Schilling, B., Murray, J., Yoo, C.B., Row, R.H., Cusack, M.P., Capaldi, R.A., and Gibson, B.W. (2006). 
Proteomic analysis of succinate dehydrogenase and ubiquinol-cytochrome c reductase 
(Complex II and III) isolated by immunoprecipitation from bovine and mouse heart 
mitochondria. Biochim Biophys Acta 1762, 213-222. 
Schlitzer, M. (2007). Malaria chemotherapeutics part I: History of antimalarial drug development, 
currently used therapeutics, and drugs in clinical development. ChemMedChem 2, 944-
986. 
Schmid, R., and Gerloff, D.L. (2004). Functional properties of the alternative NADH:ubiquinone 
oxidoreductase from E. coli through comparative 3-D modelling. FEBS Lett 578, 163-168. 
Schmidt, O., Pfanner, N., and Meisinger, C. (2010). Mitochondrial protein import: from proteomics 
to functional mechanisms. Nat Rev Mol Cell Biol 11, 655-667. 
Schneider, A., Bursac, D., and Lithgow, T. (2008). The direct route: a simplified pathway for 
protein import into the mitochondrion of trypanosomes. Trends Cell Biol 18, 12-18. 
Schneider, A., Charriere, F., Pusnik, M., and Horn, E.K. (2007). Isolation of mitochondria from 
procyclic Trypanosoma brucei. Methods Mol Biol 372, 67-80. 
Schneider, A., Oppliger, W., and Jeno, P. (1994a). Purified inner membrane protease I of yeast 
mitochondria is a heterodimer. J Biol Chem 269, 8635-8638. 
Schneider, H.C., Berthold, J., Bauer, M.F., Dietmeier, K., Guiard, B., Brunner, M., and Neupert, W. 
(1994b). Mitochondrial Hsp70/MIM44 complex facilitates protein import. Nature 371, 
768-774. 
References 
219 
 
Schneider, H.C., Westermann, B., Neupert, W., and Brunner, M. (1996). The nucleotide exchange 
factor MGE exerts a key function in the ATP-dependent cycle of mt-Hsp70-Tim44 
interaction driving mitochondrial protein import. EMBO J 15, 5796-5803. 
Scholl, P.F., Tripathi, A.K., and Sullivan, D.J. (2005). Bioavailable iron and heme metabolism in 
Plasmodium falciparum. Curr Top Microbiol Immunol 295, 293-324. 
Sen, R., Bandyopadhyay, S., Dutta, A., Mandal, G., Ganguly, S., Saha, P., and Chatterjee, M. (2007). 
Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani 
promastigotes. J Med Microbiol 56, 1213-1218. 
Sen, T., Sen, N., Tripathi, G., Chatterjee, U., and Chakrabarti, S. (2006). Lipid peroxidation 
associated cardiolipin loss and membrane depolarization in rat brain mitochondria. 
Neurochem Int 49, 20-27. 
Senkevich, T.G., White, C.L., Koonin, E.V., and Moss, B. (2000). A viral member of the ERV1/ALR 
protein family participates in a cytoplasmic pathway of disulfide bond formation. Proc 
Natl Acad Sci U S A 97, 12068-12073. 
Seymour, K.K., Yeo, A.E., Rieckmann, K.H., and Christopherson, R.I. (1997). dCTP levels are 
maintained in Plasmodium falciparum subjected to pyrimidine deficiency or excess. Ann 
Trop Med Parasitol 91, 603-609. 
Sheiner, L., and Soldati-Favre, D. (2008). Protein trafficking inside Toxoplasma gondii. Traffic 9, 
636-646. 
Shestopalov, A.I., Bogachev, A.V., Murtazina, R.A., Viryasov, M.B., and Skulachev, V.P. (1997). 
Aeration-dependent changes in composition of the quinone pool in Escherichia coli. 
Evidence of post-transcriptional regulation of the quinone biosynthesis. FEBS Lett 404, 
272-274. 
Shortt, H., and Garnham, P. (1948). Pre-erythrocytic stages in mammalian malaria parasites. 
Nature 161, 126. 
Sibmooh, N., Udomsangpetch, R., Kujoa, A., Chantharaksri, U., and Mankhetkorn, S. (2001). Redox 
reaction of artemisinin with ferrous and ferric ions in aqueous buffer. Chem Pharm Bull 
(Tokyo) 49, 1541-1546. 
Sidhu, A.B., Uhlemann, A.C., Valderramos, S.G., Valderramos, J.C., Krishna, S., and Fidock, D.A. 
(2006). Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens 
susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect 
Dis 194, 528-535. 
Simpson, A.G., and Roger, A.J. (2004). The real 'kingdoms' of eukaryotes. Curr Biol 14, R693-696. 
Sinden, R.E., and Billingsley, P.F. (2001). Plasmodium invasion of mosquito cells: hawk or dove? 
Trends in Parasitology 17, 209-211. 
Singh, B., Sung, L.K., Matusop, A., Radhakrishnan, A., Shamsul, S.S.G., Cox-Singh, J., Thomas, A., 
and Conway, D.J. (2004). A large focus of naturally acquired Plasmodium knowlesi 
infections in human beings. The Lancet 363, 1017-1024. 
Sirrenberg, C., Bauer, M.F., Guiard, B., Neupert, W., and Brunner, M. (1996). Import of carrier 
proteins into the mitochondrial inner membrane mediated by Tim22. Nature 384, 582-
585. 
Skerlj, R.T., Bastos, C.M., Booker, M.L., Kramer, M.L., Barker, R.H., Celatka, C.A., O’Shea, T.J., 
Munoz, B., Sidhu, A.B., Cortese, J.F., et al. (2011). Optimization of Potent Inhibitors of P. 
falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria. ACS Medicinal 
Chemistry Letters 2, 708-713. 
Slapeta, J., and Keithly, J.S. (2004). Cryptosporidium parvum mitochondrial-type HSP70 targets 
homologous and heterologous mitochondria. Eukaryot Cell 3, 483-494. 
Smilkstein, M., Sriwilaijaroen, N., Kelly, J.X., Wilairat, P., and Riscoe, M. (2004). Simple and 
inexpensive fluorescence-based technique for high-throughput antimalarial drug 
screening. Antimicrob Agents Chemother 48, 1803-1806. 
Smith, D.C., and Sanford, L.B. (1985). Laveran's germ: the reception and use of a medical 
discovery. Am J Trop Med Hyg 34, 2-20. 
References 
220 
 
Snyder, C.H., Denke, E., and Trumpower, B.L. (1999). Aromatic amino acids in the Rieske iron–
sulfur protein do not form an obligatory conduit for electron transfer from the iron–sulfur 
cluster to the heme of cytochrome c1 in the cytochrome bc1 complex. Biochimica et 
Biophysica Acta (BBA) - Bioenergetics 1410, 237-247. 
Sottocasa, G.L., Kuylenstierna, B., Ernster, L., and Bergstrand, A. (1967). An electron-transport 
system associated with the outer membrane of liver mitochondria. A biochemical and 
morphological study. J Cell Biol 32, 415-438. 
Srivastava, I.K., Rottenberg, H., and Vaidya, A.B. (1997). Atovaquone, a broad spectrum 
antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J 
Biol Chem 272, 3961-3966. 
Srivastava, I.K., and Vaidya, A.B. (1999). A mechanism for the synergistic antimalarial action of 
atovaquone and proguanil. Antimicrob Agents Chemother 43, 1334-1339. 
Stahl, A., Moberg, P., Ytterberg, J., Panfilov, O., Brockenhuus Von Lowenhielm, H., Nilsson, F., and 
Glaser, E. (2002). Isolation and identification of a novel mitochondrial metalloprotease 
(PreP) that degrades targeting presequences in plants. J Biol Chem 277, 41931-41939. 
Steigmiller, S., Turina, P., and Graber, P. (2008). The thermodynamic H+/ATP ratios of the H+-
ATPsynthases from chloroplasts and Escherichia coli. Proc Natl Acad Sci U S A 105, 3745-
3750. 
Stocks, P.A., Bray, P.G., Barton, V.E., Al-Helal, M., Jones, M., Araujo, N.C., Gibbons, P., Ward, S.A., 
Hughes, R.H., Biagini, G.A., et al. (2007). Evidence for a common non-heme chelatable-
iron-dependent activation mechanism for semisynthetic and synthetic endoperoxide 
antimalarial drugs. Angew Chem Int Ed Engl 46, 6278-6283. 
Stoute, J.A., Gombe, J., Withers, M.R., Siangla, J., McKinney, D., Onyango, M., Cummings, J.F., 
Milman, J., Tucker, K., Soisson, L., et al. (2007). Phase 1 randomized double-blind safety 
and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein 
FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 25, 176-184. 
Sullivan, D. (2012). Cinchona Alkaloids: Quinine and Quinidine. 
Sun F Fau - Huo, X., Huo X Fau - Zhai, Y., Zhai Y Fau - Wang, A., Wang A Fau - Xu, J., Xu J Fau - Su, 
D., Su D Fau - Bartlam, M., Bartlam M Fau - Rao, Z., and Rao, Z. Crystal structure of 
mitochondrial respiratory membrane protein complex II. 
Suraveratum, N., Krungkrai, S.R., Leangaramgul, P., Prapunwattana, P., and Krungkrai, J. (2000). 
Purification and characterization of Plasmodium falciparum succinate dehydrogenase. 
Mol Biochem Parasitol 105, 215-222. 
Swamy, M. (2006). Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) for the 
Identification and Analysis of Multiprotein Complexes. Science's STKE 2006, pl4-pl4. 
Symersky, J., Pagadala, V., Osowski, D., Krah, A., Meier, T., Faraldo-Gomez, J.D., and Mueller, D.M. 
(2012). Structure of the c(10) ring of the yeast mitochondrial ATP synthase in the open 
conformation. Nat Struct Mol Biol 19, 485-491. 
Takashima, E., Takamiya, S., Takeo, S., Mi-ichi, F., Amino, H., and Kita, K. (2001). Isolation of 
mitochondria from Plasmodium falciparum showing dihydroorotate dependent 
respiration. Parasitol Int 50, 273-278. 
Takeo, S., Kokaze, A., Ng, C.S., Mizuchi, D., Watanabe, J.I., Tanabe, K., Kojima, S., and Kita, K. 
(2000). Succinate dehydrogenase in Plasmodium falciparum mitochondria: molecular 
characterization of the SDHA and SDHB genes for the catalytic subunits, the flavoprotein 
(Fp) and iron-sulfur (Ip) subunits. Mol Biochem Parasitol 107, 191-205. 
Takken, W., and Knols, B.G. (2009). Malaria vector control: current and future strategies. Trends 
Parasitol 25, 101-104. 
Tanaka, T.Q., Hirai, M., Watanabe, Y.I., and Kita, K. (2012). Toward understanding the role of 
mitochondrial complex II in the intraerythrocytic stages of Plasmodium falciparum: Gene 
targeting of the Fp subunit. Parasitol Int. 
References 
221 
 
Taylor, A.B., Smith, B.S., Kitada, S., Kojima, K., Miyaura, H., Otwinowski, Z., Ito, A., and 
Deisenhofer, J. (2001). Crystal structures of mitochondrial processing peptidase reveal the 
mode for specific cleavage of import signal sequences. Structure 9, 615-625. 
Taylor, S.W., Warnock, D.E., Glenn, G.M., Zhang, B., Fahy, E., Gaucher, S.P., Capaldi, R.A., Gibson, 
B.W., and Ghosh, S.S. (2002). An alternative strategy to determine the mitochondrial 
proteome using sucrose gradient fractionation and 1D PAGE on highly purified human 
heart mitochondria. J Proteome Res 1, 451-458. 
ter Kuile, F., White, N.J., Holloway, P., Pasvol, G., and Krishna, S. (1993). Plasmodium falciparum: 
in vitro studies of the pharmacodynamic properties of drugs used for the treatment of 
severe malaria. Exp Parasitol 76, 85-95. 
ter Kuile, F.O., Terlouw, D.J., Phillips-Howard, P.A., Hawley, W.A., Friedman, J.F., Kariuki, S.K., Shi, 
Y.P., Kolczak, M.S., Lal, A.A., Vulule, J.M., et al. (2003). Reduction of malaria during 
pregnancy by permethrin-treated bed nets in an area of intense perennial malaria 
transmission in western Kenya. Am J Trop Med Hyg 68, 50-60. 
Terrapon, N., Gascuel, O., Marechal, E., and Breehelin, L. (2009). Detection of new protein 
domains using co-occurrence: application to Plasmodium falciparum. Bioinformatics 25, 
3077-3083. 
Theakston, R.D., Howells, R.E., Fletcher, K.A., Peters, W., Fullard, J., and Moore, G.A. (1969). The 
ultrastructural distribution of cytochrome oxidase activity in Plasmodium Berghei and P. 
Gallinaceum. Life Sci 8, 521-529. 
Tian, H., Yu, L., Mather, M.W., and Yu, C.A. (1998). Flexibility of the neck region of the rieske iron-
sulfur protein is functionally important in the cytochrome bc1 complex. J Biol Chem 273, 
27953-27959. 
Tonhosolo, R., Gabriel, H.B., Matsumura, M.Y., Cabral, F.J., Yamamoto, M.M., D’Alexandri, F.L., 
Sussmann, R.A.C., Belmonte, R., Peres, V.J., and Crick, D.C. (2010). Intraerythrocytic stages 
of Plasmodium falciparum biosynthesize menaquinone. FEBS Letters 584, 4761-4768. 
Torrentino-Madamet, M., Desplans, J., Travaille, C., James, Y., and Parzy, D. (2010). 
Microaerophilic respiratory metabolism of Plasmodium falciparum mitochondrion as a 
drug target. Curr Mol Med 10, 29-46. 
Trager, W. (1994). Cultivation of malaria parasites. Methods Cell Biol 45, 7-26. 
Trager, W., and Jensen, J.B. (1976). Human malaria parasites in continuous culture. Science 193, 
673-675. 
Tran, Q.M., Rothery, R.A., Maklashina, E., Cecchini, G., and Weiner, J.H. (2006). The quinone 
binding site in Escherichia coli succinate dehydrogenase is required for electron transfer 
to the heme b. J Biol Chem 281, 32310-32317. 
Truscott, K.N., Voos, W., Frazier, A.E., Lind, M., Li, Y., Geissler, A., Dudek, J., Muller, H., Sickmann, 
A., Meyer, H.E., et al. (2003). A J-protein is an essential subunit of the presequence 
translocase-associated protein import motor of mitochondria. J Cell Biol 163, 707-713. 
Tschan, S., Kremsner, P.G., and Mordmuller, B. (2012). Emerging drugs for malaria. Expert Opin 
Emerg Drugs 17, 319-333. 
Uhlemann, A.C., and Krishna, S. (2005). Antimalarial multi-drug resistance in Asia: mechanisms 
and assessment. Curr Top Microbiol Immunol 295, 39-53. 
Uhlemann, A.C., Wittlin, S., Matile, H., Bustamante, L.Y., and Krishna, S. (2007). Mechanism of 
antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob Agents 
Chemother 51, 667-672. 
Unden, G., and Bongaerts, J. (1997). Alternative respiratory pathways of Escherichia coli: 
energetics and transcriptional regulation in response to electron acceptors. Biochim 
Biophys Acta 1320, 217-234. 
Urantowka, A., Knorpp, C., Olczak, T., Kolodziejczak, M., and Janska, H. (2005). Plant mitochondria 
contain at least two i-AAA-like complexes. Plant Mol Biol 59, 239-252. 
Urban, S., Lee, J.R., and Freeman, M. (2001). Drosophila rhomboid-1 defines a family of putative 
intramembrane serine proteases. Cell 107, 173-182. 
References 
222 
 
Uyemura, S.A., Luo, S., Moreno, S.N., and Docampo, R. (2000). Oxidative phosphorylation, Ca(2+) 
transport, and fatty acid-induced uncoupling in malaria parasites mitochondria. J Biol 
Chem 275, 9709-9715. 
Uyemura, S.A., Luo, S., Vieira, M., Moreno, S.N., and Docampo, R. (2004). Oxidative 
phosphorylation and rotenone-insensitive malate- and NADH-quinone oxidoreductases in 
Plasmodium yoelii yoelii mitochondria in situ. J Biol Chem 279, 385-393. 
Vaidya, A. (2012). Naphthoquinones: Atovaquone, and Other Antimalarials Targeting 
Mitochondrial Functions. 
Vaidya, A.B. (2004). Mitochondrial and plastid functions as antimalarial drug targets. Curr Drug 
Targets Infect Disord 4, 11-23. 
Vaidya, A.B., Akella, R., and Suplick, K. (1989). Sequences similar to genes for two mitochondrial 
proteins and portions of ribosomal RNA in tandemly arrayed 6-kilobase-pair DNA of a 
malarial parasite. Mol Biochem Parasitol 35, 97-107. 
Vaidya, A.B., and Arasu, P. (1987). Tandemly arranged gene clusters of malarial parasites that are 
highly conserved and transcribed. Mol Biochem Parasitol 22, 249-257. 
Vaidya, A.B., and Mather, M.W. (2009). Mitochondrial evolution and functions in malaria 
parasites. Annu Rev Microbiol 63, 249-267. 
Vaidya, A.B., Morrisey, J., Plowe, C.V., Kaslow, D.C., and Wellems, T.E. (1993). Unidirectional 
dominance of cytoplasmic inheritance in two genetic crosses of Plasmodium falciparum. 
Mol Cell Biol 13, 7349-7357. 
Valnot, I., Kassis, J., Chretien, D., de Lonlay, P., Parfait, B., Munnich, A., Kachaner, J., Rustin, P., and 
Rotig, A. (1999). A mitochondrial cytochrome b mutation but no mutations of nuclearly 
encoded subunits in ubiquinol cytochrome c reductase (complex III) deficiency. Hum 
Genet 104, 460-466. 
van den Berg, H. (2009). Global status of DDT and its alternatives for use in vector control to 
prevent disease. Environ Health Perspect 117, 1656-1663. 
van der Laan, M., Chacinska, A., Lind, M., Perschil, I., Sickmann, A., Meyer, H.E., Guiard, B., 
Meisinger, C., Pfanner, N., and Rehling, P. (2005). Pam17 is required for architecture and 
translocation activity of the mitochondrial protein import motor. Mol Cell Biol 25, 7449-
7458. 
van Dooren, G.G., Marti, M., Tonkin, C.J., Stimmler, L.M., Cowman, A.F., and McFadden, G.I. 
(2005). Development of the endoplasmic reticulum, mitochondrion and apicoplast during 
the asexual life cycle of Plasmodium falciparum. Mol Microbiol 57, 405-419. 
van Dooren, G.G., Stimmler, L.M., and McFadden, G.I. (2006). Metabolic maps and functions of 
thePlasmodiummitochondrion. FEMS Microbiology Reviews 30, 596-630. 
van Dooren, G.G., Su, V., D'Ombrain, M.C., and McFadden, G.I. (2002). Processing of an apicoplast 
leader sequence in Plasmodium falciparum and the identification of a putative leader 
cleavage enzyme. J Biol Chem 277, 23612-23619. 
Van Geldre, E., Vergauwe, A., and Van den Eeckhout, E. (1997). State of the art of the production 
of the antimalarial compound artemisinin in plants. Plant Mol Biol 33, 199-209. 
van Schalkwyk, D.A., Chan, X.W., Misiano, P., Gagliardi, S., Farina, C., and Saliba, K.J. (2010). 
Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives 
results in rapid parasite death. Biochem Pharmacol 79, 1291-1299. 
Vander Jagt, D.L., Hunsaker, L.A., Campos, N.M., and Baack, B.R. (1990). D-lactate production in 
erythrocytes infected with Plasmodium falciparum. Mol Biochem Parasitol 42, 277-284. 
Vennerstrom, J.L., and Eaton, J.W. (1988). Oxidants, oxidant drugs, and malaria. J Med Chem 31, 
1269-1277. 
Verma, R., Varshney, G.C., and Raghava, G.P. (2010). Prediction of mitochondrial proteins of 
malaria parasite using split amino acid composition and PSSM profile. Amino Acids 39, 
101-110. 
References 
223 
 
Vibat, C.R., Cecchini, G., Nakamura, K., Kita, K., and Gennis, R.B. (1998). Localization of histidine 
residues responsible for heme axial ligation in cytochrome b556 of complex II 
(succinate:ubiquinone oxidoreductase) in Escherichia coli. Biochemistry 37, 4148-4159. 
Vogtle, F.N., Wortelkamp, S., Zahedi, R.P., Becker, D., Leidhold, C., Gevaert, K., Kellermann, J., 
Voos, W., Sickmann, A., Pfanner, N., et al. (2009). Global analysis of the mitochondrial N-
proteome identifies a processing peptidase critical for protein stability. Cell 139, 428-439. 
von Ballmoos, C., Cook, G.M., and Dimroth, P. (2008). Unique rotary ATP synthase and its 
biological diversity. Annu Rev Biophys 37, 43-64. 
Vontas, J., Siden-Kiamos, I., Papagiannakis, G., Karras, M., Waters, A.P., and Louis, C. (2005). Gene 
expression in Plasmodium berghei ookinetes and early oocysts in a co-culture system with 
mosquito cells. Mol Biochem Parasitol 139, 1-13. 
Walker, J.E., and Dickson, V.K. (2006). The peripheral stalk of the mitochondrial ATP synthase. 
Biochim Biophys Acta 1757, 286-296. 
Walker, K., and Lynch, M. (2007). Contributions of Anopheles larval control to malaria suppression 
in tropical Africa: review of achievements and potential. Medical and Veterinary 
Entomology 21, 2-21. 
Waller, R.F., Keeling, P.J., Donald, R.G., Striepen, B., Handman, E., Lang-Unnasch, N., Cowman, 
A.F., Besra, G.S., Roos, D.S., and McFadden, G.I. (1998). Nuclear-encoded proteins target 
to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc Natl Acad Sci U S A 
95, 12352-12357. 
Walther, M., Thompson, F.M., Dunachie, S., Keating, S., Todryk, S., Berthoud, T., Andrews, L., 
Andersen, R.F., Moore, A., Gilbert, S.C., et al. (2006). Safety, immunogenicity, and efficacy 
of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus 
Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect 
Immun 74, 2706-2716. 
Wang, J., Huang, L., Li, J., Fan, Q., Long, Y., Li, Y., and Zhou, B. (2010). Artemisinin directly targets 
malarial mitochondria through its specific mitochondrial activation. PLoS One 5, e9582. 
Wang, S., Sakai, H., and Wiedmann, M. (1995). NAC covers ribosome-associated nascent chains 
thereby forming a protective environment for regions of nascent chains just emerging 
from the peptidyl transferase center. J Cell Biol 130, 519-528. 
Waters, N., and Edstein, M. (2012). 8-Aminoquinolines: Primaquine and Tafenoquine. 
Weber, J. (2007). ATP synthase--the structure of the stator stalk. Trends Biochem Sci 32, 53-56. 
Weinstein, E.A., Yano, T., Li, L.S., Avarbock, D., Avarbock, A., Helm, D., McColm, A.A., Duncan, K., 
Lonsdale, J.T., and Rubin, H. (2005). Inhibitors of type II NADH:menaquinone 
oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci U S A 102, 
4548-4553. 
Wendel, W.B. (1946). The influence of napthoquinones upon the respiratory and carbohydrate 
metabolism of malarial parasites. Fed Proc 5, 406. 
White, N.J. (2008). Qinghaosu (artemisinin): the price of success. Science 320, 330-334. 
Whitworth, A.J., Lee, J.R., Ho, V.M., Flick, R., Chowdhury, R., and McQuibban, G.A. (2008). 
Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease 
factors Pink1 and Parkin. Dis Model Mech 1, 168-174; discussion 173. 
WHO (2010). World Health Organization - World Malaria Report 2010. 
Wibrand, F., Ravn, K., Schwartz, M., Rosenberg, T., Horn, N., and Vissing, J. (2001). Multisystem 
disorder associated with a missense mutation in the mitochondrial cytochrome b gene. 
Ann Neurol 50, 540-543. 
Wichmann, O., Muehlberger, N., Jelinek, T., Alifrangis, M., Peyerl-Hoffmann, G., Muhlen, M., 
Grobusch, M.P., Gascon, J., Matteelli, A., Laferl, H., et al. (2004). Screening for mutations 
related to atovaquone/proguanil resistance in treatment failures and other imported 
isolates of Plasmodium falciparum in Europe. J Infect Dis 190, 1541-1546. 
References 
224 
 
Wiedemann, N., Kozjak, V., Chacinska, A., Schonfisch, B., Rospert, S., Ryan, M.T., Pfanner, N., and 
Meisinger, C. (2003). Machinery for protein sorting and assembly in the mitochondrial 
outer membrane. Nature 424, 565-571. 
Wiedemann, N., Truscott, K.N., Pfannschmidt, S., Guiard, B., Meisinger, C., and Pfanner, N. (2004). 
Biogenesis of the protein import channel Tom40 of the mitochondrial outer membrane: 
intermembrane space components are involved in an early stage of the assembly 
pathway. J Biol Chem 279, 18188-18194. 
Wiedemann, N., van der Laan, M., Hutu, D.P., Rehling, P., and Pfanner, N. (2007). Sorting switch of 
mitochondrial presequence translocase involves coupling of motor module to respiratory 
chain. J Cell Biol 179, 1115-1122. 
Wiedmann, B., Sakai, H., Davis, T.A., and Wiedmann, M. (1994). A protein complex required for 
signal-sequence-specific sorting and translocation. Nature 370, 434-440. 
Wikstrom, M., and Hummer, G. (2012). Stoichiometry of proton translocation by respiratory 
complex I and its mechanistic implications. Proc Natl Acad Sci U S A 109, 4431-4436. 
Wilairatana, P., and Krudsood, S. (2009). Cerebral Malaria. In International Neurology (Wiley-
Blackwell), pp. 285-289. 
Wilkens, S., and Capaldi, R.A. (1998). Electron microscopic evidence of two stalks linking the F1 
and F0 parts of the Escherichia coli ATP synthase. Biochim Biophys Acta 1365, 93-97. 
Wilson, C.M., Serrano, A.E., Wasley, A., Bogenschutz, M.P., Shankar, A.H., and Wirth, D.F. (1989). 
Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium 
falciparum. Science 244, 1184-1186. 
Winstanley, P., and Ward, S. (2006). Malaria chemotherapy. Adv Parasitol 61, 47-76. 
Winter, R.W., Kelly, J.X., Smilkstein, M.J., Dodean, R., Hinrichs, D., and Riscoe, M.K. (2008). 
Antimalarial quinolones: synthesis, potency, and mechanistic studies. Exp Parasitol 118, 
487-497. 
Wirth, D.F. (2002). The parasite genome: Biological revelations. Nature 419, 495-496. 
Wittig, I., Braun, H.-P., and Schägger, H. (2006). Blue native PAGE. Nature Protocols 1, 418-428. 
Wittig, I., Meyer, B., Heide, H., Steger, M., Bleier, L., Wumaier, Z., Karas, M., and Schagger, H. 
(2010). Assembly and oligomerization of human ATP synthase lacking mitochondrial 
subunits a and A6L. Biochim Biophys Acta 1797, 1004-1011. 
Wittig, I., and Schagger, H. (2008). Structural organization of mitochondrial ATP synthase. Biochim 
Biophys Acta 1777, 592-598. 
Wongsrichanalai, C., Pickard, A.L., Wernsdorfer, W.H., and Meshnick, S.R. (2002). Epidemiology of 
drug-resistant malaria. Lancet Infect Dis 2, 209-218. 
Wu, W.-M., Wu, Y., Wu, Y.-L., Yao, Z.-J., Zhou, C.-M., Li, Y., and Shan, F. (1998). Unified 
Mechanistic Framework for the Fe(II)-Induced Cleavage of Qinghaosu and 
Derivatives/Analogues. The First Spin-Trapping Evidence for the Previously Postulated 
Secondary C-4 Radical. Journal of the American Chemical Society 120, 3316-3325. 
Wu, Y., and Sha, B. (2006). Crystal structure of yeast mitochondrial outer membrane translocon 
member Tom70p. Nat Struct Mol Biol 13, 589-593. 
Wu, Y., Wang, X., Liu, X., and Wang, Y. (2003). Data-mining approaches reveal hidden families of 
proteases in the genome of malaria parasite. Genome Res 13, 601-616. 
Wyatt, C.N., and Buckler, K.J. (2004). The effect of mitochondrial inhibitors on membrane currents 
in isolated neonatal rat carotid body type I cells. J Physiol 556, 175-191. 
Xia, D., Yu, C.A., Kim, H., Xia, J.Z., Kachurin, A.M., Zhang, L., Yu, L., and Deisenhofer, J. (1997). 
Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science 
277, 60-66. 
Xiang, H., McSurdy-Freed, J., Moorthy, G.S., Hugger, E., Bambal, R., Han, C., Ferrer, S., Gargallo, D., 
and Davis, C.B. (2006). Preclinical drug metabolism and pharmacokinetic evaluation of 
GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. J Pharm Sci 
95, 2657-2672. 
References 
225 
 
Xiao, K., Liu, X., Yu, C.-A., and Yu, L. (2004). The Extra Fragment of the Iron−Sulfur Protein 
(Residues 96-107) of Rhodobacter sphaeroides Cytochrome bc1 Complex Is Required for 
Protein Stability†. Biochemistry 43, 1488-1495. 
Xu, P., Widmer, G., Wang, Y., Ozaki, L.S., Alves, J.M., Serrano, M.G., Puiu, D., Manque, P., Akiyoshi, 
D., Mackey, A.J., et al. (2004). The genome of Cryptosporidium hominis. Nature 431, 1107-
1112. 
Yamamoto, H., Esaki, M., Kanamori, T., Tamura, Y., Nishikawa, S., and Endo, T. (2002). Tim50 is a 
subunit of the TIM23 complex that links protein translocation across the outer and inner 
mitochondrial membranes. Cell 111, 519-528. 
Yang, Y.Z., Little, B., and Meshnick, S.R. (1994). Alkylation of proteins by artemisinin. Effects of 
heme, pH, and drug structure. Biochem Pharmacol 48, 569-573. 
Yankovskaya, V., Horsefield, R., Tornroth, S., Luna-Chavez, C., Miyoshi, H., Leger, C., Byrne, B., 
Cecchini, G., and Iwata, S. (2003). Architecture of succinate dehydrogenase and reactive 
oxygen species generation. Science 299, 700-704. 
Yano, M., Terada, K., and Mori, M. (2003). AIP is a mitochondrial import mediator that binds to 
both import receptor Tom20 and preproteins. J Cell Biol 163, 45-56. 
Yeates, C.L., Batchelor, J.F., Capon, E.C., Cheesman, N.J., Fry, M., Hudson, A.T., Pudney, M., 
Trimming, H., Woolven, J., Bueno, J.M., et al. (2008). Synthesis and structure-activity 
relationships of 4-pyridones as potential antimalarials. J Med Chem 51, 2845-2852. 
Yin, H., and Porter, N.A. (2005). New insights regarding the autoxidation of polyunsaturated fatty 
acids. Antioxid Redox Signal 7, 170-184. 
Ylikallio, E., and Suomalainen, A. (2012). Mechanisms of mitochondrial diseases. Ann Med 44, 41-
59. 
Young, J.C., Hoogenraad, N.J., and Hartl, F.U. (2003). Molecular chaperones Hsp90 and Hsp70 
deliver preproteins to the mitochondrial import receptor Tom70. Cell 112, 41-50. 
Yung, S., Unnasch, T.R., and Lang-Unnasch, N. (2001). Analysis of apicoplast targeting and transit 
peptide processing in Toxoplasma gondii by deletional and insertional mutagenesis. Mol 
Biochem Parasitol 118, 11-21. 
Zara, V., Conte, L., and Trumpower, B.L. (2009). Evidence that the assembly of the yeast 
cytochrome bc1 complex involves the formation of a large core structure in the inner 
mitochondrial membrane. FEBS J 276, 1900-1914. 
Zeng, X., Neupert, W., and Tzagoloff, A. (2007). The metalloprotease encoded by ATP23 has a dual 
function in processing and assembly of subunit 6 of mitochondrial ATPase. Mol Biol Cell 
18, 617-626. 
Zhang, J., Krugliak, M., and Ginsburg, H. (1999). The fate of ferriprotorphyrin IX in malaria infected 
erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol Biochem 
Parasitol 99, 129-141. 
Zhang, S., and Gerhard, G.S. (2008). Heme activates artemisinin more efficiently than hemin, 
inorganic iron, or hemoglobin. Bioorg Med Chem 16, 7853-7861. 
Zhang, Y., Marcillat, O., Giulivi, C., Ernster, L., and Davies, K.J. (1990). The oxidative inactivation of 
mitochondrial electron transport chain components and ATPase. J Biol Chem 265, 16330-
16336. 
Zhang, Z., Huang, L., Shulmeister, V.M., Chi, Y.I., Kim, K.K., Hung, L.W., Crofts, A.R., Berry, E.A., and 
Kim, S.H. (1998). Electron transfer by domain movement in cytochrome bc1. Nature 392, 
677-684. 
Zhou, X.W., Kafsack, B.F., Cole, R.N., Beckett, P., Shen, R.F., and Carruthers, V.B. (2005). The 
opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and 
survival proteins. J Biol Chem 280, 34233-34244. 
 
 
